From June 2017, all EULAR education offers under a new and individual membership.

EULAR will combine all its educational offers, from live courses and online courses to books or webinars, under the roof of the EULAR School of Rheumatology. You will find it to be an exciting novel approach to EULAR education.

The EULAR School of Rheumatology enables you to enjoy enhanced access to educational programmes.
# Table of Contents

Welcome Message  
Organising Committees  
General Information  
  - Information about your participation  
  - EULAR Corporate Social Responsibility Statement  
  - Networking opportunities  
  - Scientific information  
  - Information on industry related activities  
Scientific Programme  
  Congress at a Glance:  
    - Wednesday, 14 June 2017  
    - Thursday, 15 June 2017  
    - Friday, 16 June 2017  
    - Saturday, 17 June 2017  
  Wednesday, 14 June 2017  
    - Scientific Programme  
  Thursday, 15 June 2017  
    - Scientific Programme  
    - Guided Poster Tours  
    - Scientific Poster Session 1  
  Friday, 16 June 2017  
    - Scientific Programme  
    - Guided Poster Tours  
    - Scientific Poster Session 2  
  Saturday, 17 June 2017  
    - Scientific Programme  
    - Guided Poster Tours  
    - Scientific Poster Session 3  
Health Professionals in Rheumatology Programme and Posters  
PARE Programme and Posters  
EULAR Related Meetings  
Partner Programme  
  Satellite Symposia  
  Company Profiles  
  Acknowledgements  
Congress Venue General Plan  
Exhibitors’ List  
Exhibition Plan

The acronym “PARE” used in the programme stands for “People with Arthritis/Rheumatism in Europe”

The acronym “HPR” used in the programme stands for “Health Professionals in Rheumatology”

All information listed in this programme is at the status of 1 May 2017
13 - 16 June 2018
Amsterdam, Netherlands

EULAR 2018
Annual European Congress of Rheumatology

For more information visit congress.eular.org
Dear Colleagues,

Welcome to this EULAR Annual European Congress of Rheumatology in Madrid!

Welcome to the 70th anniversary of EULAR!
The annual EULAR Congresses, which began in 2000, are today a major event in the calendar of world rheumatology. This meeting, which marks the 70th anniversary of our very active society, will once again provide a unique occasion for the exchange of scientific and clinical information. It will facilitate interaction between patients, medical doctors, scientists, health professionals and professionals representing the pharmaceutical industry from Europe and from around the world. Participating in the congress is just one element of the annual educational package provided by EULAR: almost all oral presentations will be available online after signing up and participants will be provided with a complimentary, one-year subscription to the latest developments and publications in the field of rheumatic and musculoskeletal diseases (RMDs). This is in line with a new, exciting event taking place in Madrid this year - the launch of the EULAR School of Rheumatology, which will be unique in providing education in rheumatology throughout the world.

EULAR has grown rapidly in terms of the number of participants and the quality of the submissions. A record number of more than 4'850 abstracts have been submitted to this year’s congress in Madrid, and 180 sessions and poster tours are offered. This tremendous success continues to reflect the increasing interest in RMDs: it also reflects the availability of increased information on the size, burden and cost of these diseases for society - and a significantly improved ability to diagnose and treat them. The incorporation of health professional and patient organisations within EULAR has been a considerable stimulus for these advances.

The EULAR Congress 2017 in Madrid will provide a wide range of topics including clinical innovations, clinical translational and basic science. In addition, there will be significant contributions made by People with Arthritis and Rheumatism (PARE), by Health Professionals in Rheumatology (HPR) and by the health care industry. The core science and central activity of the congress will be the poster presentations and poster tours with their highly interactive exchanges between participants. The Madrid meeting will further promote the reputation of the EULAR Congress as a most innovative and informative venue for clinical research for the practising physician and health professionals. Meanwhile, the EULAR EMEUNET organisation of young rheumatologists aims to attract young colleagues to the meeting and will disseminate the message that rheumatology is one of the most attractive and successful disciplines of medicine.

We are back in the vibrant city of Madrid with its remarkable history, architecture, galleries, museums and ambience, all of which will once again provide an excellent background for clinical exchanges, international collaborations and renewal of friendships. “No pierdas tu tren” and in international language “Don’t Delay, Connect Today!” marks the first general EULAR Campaign to be launched in Madrid aiming at early recognition and treatment of RMDs.

It is our great pleasure and a real joy in welcoming medical doctors, patients, health professionals and representatives of the pharmaceutical industry and we hope their stay in Madrid will be delightful, informative, and educational. We wish you a great time, good science, good discussions, good meetings and most of all good memories to take home when you are heading back from Madrid and from our 70th anniversary congress.

Gerd R. Burmester
President of EULAR
Organising Committees

**EULAR EXECUTIVE COMMITTEE**

- President
  Prof. Gerd R. Burmester, Germany
- President-elect
  Prof. Johannes W. J. Bijlsma, Netherlands
- Past President
  Prof. Maurizio Cutolo, Italy
- Vice President representing national PARE organisations
  Marios Kouloumas, Cyprus
- Vice President representing the Health Professionals in Rheumatology
  Prof. Christina H. Opava, Sweden
- Vice President-elect Health Professionals in Rheumatology
  Prof. Tanja Stamm, Austria
- Treasurer
  Prof. Iain B. McInnes, United Kingdom
- General Secretary
  Prof. Ruxandra Ionescu, Romania
- Editor in Chief of the “Annals of the Rheumatic Diseases - The EULAR Journal”
  Prof. Tore K. Kvien, Norway
- * Editor in Chief of “RMD Open”
  Prof. Bernard Combe, France
- Liaison Officer EMEUNET
  Dr Sofia Ramiro, Netherlands
- Liaison Officer elect EMEUNET
  Dr Elena Nikiphorou, United Kingdom
- * Liaison to the American College of Rheumatology ACR
  Prof. Désirée van der Heijde, Netherlands
- * Liaison Officer, EU Public Affairs
  Mr Neil Betteridge, United Kingdom
- * Liaison Officer FOREUM
  Prof. Steffen Gay, Switzerland
- * President UEMS Section of Rheumatology
  Prof. Nada Cikes, Croatia
- * Executive Director
  Dr Julia Rautenstrauch, Switzerland

**EULAR STANDING COMMITTEE CHAIRPERSONS**

(ex officio members of the EULAR Executive Committee)

- Investigative Rheumatology
  Prof. Xavier Mariette, France
- Clinical Affairs
  Prof. Ronald van Vollenhoven, Sweden
- Education and Training
  Prof. Annamaria Iagnocco, Italy
- Epidemiology and Health Services Research
  Prof. Axel Finckh, Switzerland
- Musculoskeletal Imaging
  Dr Lene Terslev, Denmark
- Paediatric Rheumatology
  Prof. Tadej Avcin, Slovenia
- PARE
  Mr Dieter Wiek, Germany
- Health Professionals in Rheumatology
  Dr Annette de Thurah, Denmark

**CONGRESS PROGRAMME COMMITTEE**

**Scientific, Health Professionals, PARE**

- The EULAR Executive Committee Members
  (excluding functions marked with “*”)
- The EULAR Standing Committee Chairs
- Prof. João Eurico Fonseca, Portugal
  Chair of the Scientific Programme Committee
- Prof. Robert Landewé, Netherlands
  Chair of the Abstract Selection Committee
- Prof. Dirk Elewaaut, Belgium
  Past-Chair of the Scientific Programme Committee

- Prof. Maxime Breban, France
- Prof. Leonard Calabrese, United States
- Prof. Thomas Dörner, Germany
- Prof. Martin Herrmann, Germany
- Prof. Margreet Kloppenburg, Netherlands
- Prof. Anne-Marie Malfait, United States
- Prof. Christian Mallen, United Kingdom
- Prof. Stephen McMahon, United Kingdom
- Prof. Ulf Müller-Ladner, Germany
- Dr Elena Neumann, Germany
- Prof. Ingemar Petersson, Sweden
- Prof. Gabriela Riemekasten, Germany
- Prof. Alexander So, Switzerland
- Prof. Zoltán Szekanecz, Hungary
- Prof. Leonie Taams, United Kingdom
- Prof. Tsutomu Takeuchi, Japan
- Prof. Lai-Shan Tam, China
- Prof. Angela Tincani, Italy
- Dr Yeliz Prior, United Kingdom
- Prof. Francesco Zulian, Italy

* These functions are not included in the Congress Programme Committee
CONGRESS VENUE: DATES AND LOCATION

The Annual European Congress of Rheumatology EULAR 2017 is held at:

IFEMA
Feria de Madrid
Avenida del Partenón
28042 Madrid, Spain
Website: www.ifema.es

The congress opens on Wednesday, 14 June 2017 - 12:00 and closes on Saturday, 17 June 2017 - 15:00.

The EULAR Congress Opening Plenary session, followed by a Networking Platform, is held in the evening of Wednesday, 14 June 2017, at the congress venue itself.

Set next to one of the most important business centres in the city, the Feria de Madrid is linked to major arteries, which makes it easily accessible for EULAR 2017 participants.

The Adolfo Suaréz Madrid-Barajas airport is just a few kilometres away from the IFEMA. Delegates can also make use of public transport, particularly thanks to the vast underground network, which links the venue to every point in the city.

The architecture of Feria de Madrid’s facilities and the versatile capacity of its various spaces make this complex one of the most modern, technologically best-designed and equipped venues in Europe.

REGISTRATION AREA OPENING HOURS

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>13 June 2017</td>
<td>17:00 - 20:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>14 June 2017</td>
<td>08:00 - 20:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>15 June 2017</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Friday</td>
<td>16 June 2017</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Saturday</td>
<td>17 June 2017</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

SCIENTIFIC SECRETARIAT

EULAR Secretariat
Seestrasse 240
CH-8802 Kilchberg/Zurich
Switzerland
Tel: +41 44 716 3030
Fax: +41 44 716 3039
E-mail: eular@eular.org
Website: www.eular.org / www.congress.eular.org

ORGANISING SECRETARIAT

In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations

EULAR 2017
c/o MCI SUISSE SA
Rue du Pré-Bouvier 9
CH-1242 Satigny, Geneva
Switzerland
Tel: +41 22 33 99 590
Fax: +41 22 33 99 601
Email: eular@mci-group.com
Website: www.mci-group.com

LOCAL ORGANISING AGENCY

For social events, excursions, transfers, company events

MCI Group Spain SA
MCI Madrid
Alcalde Sainz de Baranda 45
28009 Madrid
Spain
Tel: +34 914 009 384
Fax: +34 914 504 3774
Email: eular17.soc@mci-group.com
Website: www.mci-group.com/spain

General Information
Information about your Participation

ADMITTANCE TO THE EULAR CONGRESS

In respect of Spanish and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR Congress shall be limited solely to participants who are 18 years of age or older. Registration by anyone who is under 18 is unauthorized and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time.

This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision.

CANCELLATION OF CONGRESS

It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages.

EULAR CONGRESS MOBILE APP

Since 2003 EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In the last six years, we have also offered a planning tool, the internet based itinerary planner. Schedules made in the planner can be transferred easily to your smartphone or tablet on iOS, Android or WindowsPhone. Apart from general information, the app contains the complete congress programme with all sessions and lectures, all abstracts in full text and all symposia. Links between these elements allow for changes to content to be made easily. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place.

A support desk for mobile devices is located in the EULAR Village.

DATA SCANNING SYSTEM

Congress badges will contain a barcode acting as an electronic business card and thus enable visitors to leave their contact details for exhibitors quickly and easily.

DRESS CODE

Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates.

General Information

CERTIFICATE OF ATTENDANCE

A certificate of attendance is included in the congress bag given to each participant.

CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES

Charging stations for smartphones and other mobile devices are available in the registration area and exhibition halls.

CLOAKROOM

A cloakroom service for coats and reasonable-sized luggage is available during the opening hours of the congress in Hall 2, near the south entrance. For security reasons, electrical items cannot be kept in the cloakroom.

CONTINUING MEDICAL EDUCATION (CME) CREDITS

EULAR 2017 Madrid has been accredited for a maximum of 21 European CME credits. This is an equivalent of 21 hours Continued Medical Education. CME points are recognized by the American Medical Association towards the Physician’s Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

CYBER CAFÉ

Two Cyber Cafés are located in the exhibition halls.

CONGRESS DOCUMENTS AND BADGES

Name badges can be printed at the self-service stations, located at the registration area in Hall 2 for participants accessing IFEMA from the south entrance. Participants accessing IFEMA from the north entrance can use the shuttle service to commute to the south entrance. Alternatively, congress documents (including name badges) can be collected at the registration desks in Hall 2. Name badges must be worn visibly at all time during the congress and in the exhibition area.

CONGRESS EVALUATION

We would be grateful if you could take a few minutes to support the onsite staff member who may approach you to gain your opinion about the congress and the scientific programme. This will help us to continue to improve the congress in the future.

CLIMATE

Madrid and its metropolitan area have a Mediterranean climate that borders on the continental climate with mild, cool winters and warm to hot summers. The average temperature in June is 21°C (70F). During summer, days are longer and the city really begins to come alive in the evening.

CREDIT CARDS

Major credit cards (Visa, American Express, Eurocard/Mastercard, Diners Club) are accepted in most hotels, restaurants and shops. ATM/cash machines are available at the congress venue.
CURRENCY
The Spanish currency is the Euro (1 Euro = 100 cents).

ELECTRICITY
The electricity power supply in Spain is 220 Volts with a European standard plug.

FOOD AND BEVERAGE
During official coffee breaks, complimentary coffee and tea will be served in the EULAR Village and exhibition/poster area, Hall 10. Lunch will be provided on Thursday and Friday and will also be served in the EULAR Village and exhibition/poster areas. Various self-service restaurants and sandwich bars are located in the congress venue.

HELP POINT FOR SMARTPHONES AND MOBILE DEVICES
A help point for phones and other mobile devices as well as charging options for such devices will be located in the congress venue. The EULAR Mobile Congress App can also be downloaded there.

MADRID & SPAIN (FACTS ABOUT)
Madrid is the capital of Spain. Such a self-evident statement has a much wider-ranging, underlying significance, the multiple implications of which have moulded the city’s singular personality. Madrid is the decision-making centre of the Spanish government, the place where the different de-facto national powers have their headquarters and where major companies, multinationals, banks and financial markets are located. It is also the geographic centre of the Iberian Peninsula (the exact centre is Cerro de los Angeles, 14 km outside of Madrid), and the hub of all of Spain’s national highways and international throughways.

The diversity of its neighbourhoods and buildings reminds us at every step of the city’s dual role in politics and economics. Its historic monuments are the heritage of a city that has wielded administrative power for more than four centuries. Alongside them, skyscrapers clad with glass and concrete encase the heartbeat of an increasingly important local economy, whose weight is growing both at the Spanish and international levels.

Within the territory of the Madrid region, which has a total surface area of approximately 8000 km², two other major local powers live side-by-side: the government of the autonomous region and the capital’s city council. Madrid is one of Spain’s 17 autonomous regions, which were created under the Spanish Constitution of 1978; unlike most of the autonomous regions of Spain, Madrid has only one province. Its population tops 5 million, or 12% of the national total. Its surroundings and its location have shaped Madrid’s development.

It is a city in the centre not only of the region, but also of the country. Perhaps this location is one of the determining factors in its status as the capital - as the political, business, economic and transport centre - all which help to explain why this city has always been a potpourri of different people and interests, both historically and in modern times.
Geographically, the Madrid region has a diversity that might astonish someone who only knows the city and its outskirts. The nearby Sierra de Guadarrama offers a variety of landscapes that break up the monotony of the Castilian meseta, and make Madrid a region of forests, hidden valleys and peaks more than 2500m high, a surprising contrast to the great city and its far-flung suburbs.

Madrid boasts a unique historic and artistic heritage that co-exists in harmony with creativity, embracing culture and gastronomy. The modern and cosmopolitan flare of the Spanish capital offers guests a variety of things to discover. The passionate and friendly character of the Madrileños also enhances any visitor's experience.

GETTING AROUND IN MADRID

Metro
The underground (metro) is the fastest, most efficient and most affordable way to move around Madrid. The city has a vast metropolitan network, one of the most comprehensive in Europe, and covers almost all the points in the capital and many of the neighbouring areas.

Currently, there are twelve metro lines and three metro Ligero (tramway) lines.

The metro line number 8 or pink line (Nuevos Ministerios - Airport T4) connects the city to the Adolfo Suarez Madrid-Barajas airport, in approximately 12 minutes and to Madrid’s Trade Fair grounds (IFEMA). The metro stop at IFEMA is called “Campos de las Naciones”, located at the South Entrance of the IFEMA.

Bus
Madrid has an extensive city bus network, run by the company Empresa Municipal de Transporte (EMT), which covers the whole city. All the vehicles are air-conditioned and equipped with WiFi. Madrid’s buses have special facilities for disabled access. Although main streets have dedicated bus lanes, buses can be slowed down during rush hours.

Line number 112 running from Mar de cristal to Barrio aeropuerto stops at the IFEMA. Get off at “Partenon - Campo de la Naciones”.

Taxis
Taxis in Madrid are white with a diagonal red band on their front door bearing the emblem of the city. They have a green light that is on when they are free. To hail a taxi all you need to do is raise your hand.

There are also several taxi ranks around the city, indicated by a blue sign with a white letter ‘T’. Taxis must be taken from the corresponding ranks at railway and bus stations and at the airport. Throughout the rest of the city they can be easily stopped on the street.

With over 15,600 taxis in Madrid, finding a free one on any of the city’s main streets is rarely difficult. Journeys are usually paid for in cash although more and more taxis accept credit cards.

Prices are quite reasonable, considering that a one-way trip from the city centre to the airport costs around 20-25 Euros.

INSURANCE AND LIABILITY

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EULAR and MCI as organisers accept no liability or responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants.

LANGUAGES/OFFICIAL LANGUAGE

The official language in Madrid is Spanish, however English is spoken in tourist areas. Catalan, Galician and Basque are frequently spoken in some areas. The official congress language is English. No simultaneous translation is provided.

PRESS CENTRE

The press and media area is located in room Goya, next to Hall 4. Facilities such as computers, telephone, photocopier, and internet access are available for registered press representatives.

SECURITY

Please pay special attention to your personal belongings, especially when walking in the city centre or using the public transportation system, but also inside the congress venue. Any security problems or concerns within the congress venue should be reported to a member of the EULAR or MCI staff.

Security staff will handle any emergency situation and everyone is required to follow instructions announced via the public information system.

Emergency exits are marked with green exit signs.

SERVICES FOR THE DISABLED

All session rooms at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.
GENERAL INFORMATION / 9

SCIENTIFIC SESSIONS (ACCESS TO)
The meeting rooms for scientific sessions vary in size. Should the room be full, we invite you to use the overflow facilities located in Hall 9 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session. The maximum capacities of the rooms are determined by the local safety and security regulations must be respected by law.

PRINTING
EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. No abstract book and no preliminary programme for EULAR 2018 will be printed. All abstracts will be available online as well as the preliminary programme. This will save printing about 24,000,000 pages.

LOCAL SUPPLIERS
EULAR wishes to have a positive local impact. When sourcing materials and supplies, EULAR gives priority to local partners to avoid a negative transportation impact and to positively impact the local economy.

SMOKING POLICY
Smoking is not permitted at the congress venue.

TRANSPORTATION
EULAR provides transportation passes to duly registered delegates who booked the accommodation through MCI, the official congress housing bureau, enabling them to travel on the public transportation network during the EULAR Congress within zone A.

SHOPPING IN MADRID
Madrid is a very interesting city for shopping. International brands mix with local shops which are open (normally from 10:00 to 22:00), where you can find almost everything: clothing, shoes, food, wines, souvenirs... in very different styles, at very different prices.

TELEPHONES
Please respect your fellow colleagues and friends by operating your mobile devices in silent mode in all session rooms and poster areas.

TIME
Spain follows Central European Time (CET) which is UTC +1 hour in winter and UTC + 2 in summer.

TIPPING
Locals in Madrid usually tip when they have received good service. In general, people tend to tip 10% in restaurants (restaurants do not charge extra on the bill). Tipping taxicab drivers and hotel personnel is also customary in Madrid.

EULAR Corporate Social Responsibility Statement
EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place.
For the Madrid Congress EULAR has made the following sustainable arrangements:

HEALTHY FOOD
All buffets for lunches and coffee breaks offer healthy options meaning that there is always a choice of fresh fruit or vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritized.

Networking Opportunities

OPENING PLENARY SESSION AND NETWORKING PLATFORM
Wednesday, 14 June 2017 - 18:45-22:00 - Hall 6
The Opening Plenary Session is followed by the Networking Platform in Hall 6. All registered participants are cordially invited to these two events which take place in the congress venue.

EULAR CONGRESS DINNER
Friday, 16 June 2017 - 20:30-00:00 - Castle of Viñuelas
Price: EUR 95 per person (not included in the registration fee)
Over the years, the EULAR Annual European Congress of Rheumatology has set the Congress Dinner as a traditional event offering a unique opportunity to meet and network with friends and colleagues from around the world in a relaxed atmosphere, enjoying the unmatched charm of the different venues and artistic performances selected.
In this special anniversary year, the EULAR Congress Dinner will take place in a special location, the historical Castle of Viñuelas, located in the north of the city of Madrid. You will enjoy a wonderful experience full of local flavours in this incredible venue surrounded by meadow-oak forest within a protected natural area allowing for the observation of wild animals and birds at close range.
Come and celebrate EULAR's 70th anniversary with us and enjoy the impressive grounds of this property taking you back to the 17th century.
Don't miss this exceptional chance to experience the culture of Madrid and Spain and get to know other attendees!
Scientific Information

CERTIFICATE OF ATTENDANCE
A certificate of attendance is included in the congress bag given to each participant.

CONTINUING MEDICAL EDUCATION (CME) CREDITS
EULAR 2017 Madrid has been accredited for a maximum of 21 European CME credits. This is an equivalent of 21 hours Continuing Medical Education. CME points are recognized by the American Medical Association towards the Physician’s Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

POSTERS
The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in the exhibition halls from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed permanently near the EULAR PARE booth, located in the EULAR Village. Delegates interested in the EULAR Projects have the possibility to browse posters of the different projects and working groups in the poster area.

Official poster viewing will take place at the following hours:
- Thursday 15 June 2017 11:45 - 13:30
- Friday 16 June 2017 11:45 - 13:30
- Saturday 17 June 2017 10:15 - 12:00

Guided poster tours on selected topics will take place during the official poster viewing times.

SPEAKERS’ PREVIEW ROOM
The Speakers’ Preview Room, located in the Business Centre on the Mezzanine level above Hall 7, is open at the following hours:
- Wednesday 14 June 2017 08:00 - 20:00
- Thursday 15 June 2017 08:00 - 19:00
- Friday 16 June 2017 08:00 - 19:00
- Saturday 17 June 2017 08:00 - 14:30

The preview room is equipped with computers. All speakers are required to check in their presentation at least 2 hours before their session, or on the day before, for the early morning sessions.

Information on Industry Related Activities

EXHIBITION
During the congress, EULAR will present an attractive exhibition to the congress participants.

The abstract poster presentation areas are built within the exhibition. Coffee and other refreshments are available within the exhibition during official breaks.

The exhibition hours are as follows:
- Wednesday 14 June 2017 12:00 - 18:30
- Thursday 15 June 2017 08:00 - 17:15
- Friday 16 June 2017 08:00 - 17:15
- Saturday 17 June 2017 08:15 - 14:00

EXHIBITION ACCESS (RESTRICTED)
Based on “DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2011 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE” and on information received from the Spanish Association for Pharmaceutical Industry in Spain (Farmaindustria), the EULAR Board has decided to restrict the access for congress participants registered as PARE representative or as patient to the non-commercial part of the exhibition hall. The access to all other parts of the congress is unrestricted.

We ask the participants involved to follow the specific instructions they will receive together with the congress documents. Onsite staff and special signs are there to help participants navigate inside the exhibition halls.

PRIVATE EVENTS POLICY
All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat.

SATELLITE SYMPOSIA (ACCESS TO)
The meeting rooms for satellite symposia vary in size. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a satellite symposium. The maximum capacities of the rooms are determined by the local safety and security regulations and must be respected by law.

SATELLITE SYMPOSIA (TIMINGS)
A number of satellite symposia are organised during EULAR 2017 at the following times:
- Wednesday 14 June 2017 13:00 - 14:30
- Thursday 15 June 2017 08:15 - 09:45
- 15 June 2017 17:30 - 19:00
- Friday 16 June 2017 08:15 - 09:45
- 16 June 2017 17:30 - 19:00

Further information is available in the satellite booklet, included in your congress bag and on pages 217 to 226 of this programme.

Satellite symposia are governed by EULAR Guidelines. All symposia and special events must be approved by EULAR. Other symposia are strictly prohibited during the official programme, as outlined in the EULAR Code of Practice.
### ALL DATES AND TIMES

<table>
<thead>
<tr>
<th>DATE</th>
<th>REGISTRATION AREA</th>
<th>SPEAKERS PREVIEW</th>
<th>POSTERS VIEWING</th>
<th>NETWORKING OPPORTUNITIES</th>
<th>EXHIBITION</th>
<th>SATELLITE SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday 13 June 2017</td>
<td>17:00 - 20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday 14 June 2017</td>
<td>08:00 - 20:00</td>
<td>08:00 - 20:00</td>
<td>18:45 - 22:00</td>
<td>12:00 - 18:30</td>
<td></td>
<td>13:00 - 14:30</td>
</tr>
<tr>
<td>Thursday 15 June 2017</td>
<td>07:45 - 19:15</td>
<td>08:00 - 19:00</td>
<td>11:45 - 13:30</td>
<td>08:00 - 17:15</td>
<td></td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17:30 - 19:00</td>
</tr>
<tr>
<td>Friday 16 June 2017</td>
<td>07:45 - 19:15</td>
<td>08:00 - 19:00</td>
<td>11:45 - 13:30</td>
<td>20:30 - 00:00</td>
<td>08:00 - 17:15</td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EULAR Congress Dinner</td>
<td></td>
<td>17:30 - 19:00</td>
</tr>
<tr>
<td>Saturday 17 June 2017</td>
<td>08:00 - 15:00</td>
<td>08:00 - 14:30</td>
<td>10:15 - 12:00</td>
<td></td>
<td>08:15 - 14:00</td>
<td></td>
</tr>
</tbody>
</table>

### Future Congresses

- **Annual European Congress of Rheumatology 2018**
  - Amsterdam, Netherlands, 13-16 June 2018
KEEP IN TOUCH WITH RHEUMATOLOGY

UPDATE YOUR CONTACT DETAILS!

Receive your access codes to the recorded sessions*

Receive your free subscription**

Annals of the Rheumatic Diseases - the EULAR Journal (ARD)**

Go to any Yellow Tower to update your contact information to secure delivery of the EULAR Journal and access to view the recorded presentations

*if purchased

** the patient and exhibitor registration categories do not include the complimentary subscription
### Congress at a Glance

**WEDNESDAY, 14 JUNE 2017**

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
<th>N101/N102</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session</td>
<td>HPR Welcome session</td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>Basic and Translational Science session</td>
<td>HPR session</td>
</tr>
<tr>
<td></td>
<td>WIN: Axial and peripheral spondyloarthritis</td>
<td>Moving towards new criteria in SLE, SpA and APS</td>
<td>The differential diagnosis of diffuse skin sclerosis and Raynaud’s phenomenon</td>
<td>Controlling the balance between cancer and autoimmunity</td>
<td>Fibromyalgia: a disease of the peripheral or central nervous system?</td>
<td>Channeling the chondrocyte</td>
<td>Wearable technologies in 21st century healthcare</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>HPR session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Still breaking news on TNF inhibitors in rheumatoid arthritis</td>
<td>Progress in management of SpA</td>
<td>Early diagnosis of systemic sclerosis and myositis: biomarkers and diagnostic tool</td>
<td>SLE, SpA, APS - clinical aspects</td>
<td>Osteoporosis treatment gap, new options and new strategies</td>
<td>Rehabilitation and modern drug treatment - needs and challenges</td>
<td></td>
</tr>
<tr>
<td>18:45-20:00</td>
<td><strong>EULAR 2017 Opening Plenary session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00-22:00</td>
<td><strong>NETWORKING PLATFORM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Clinical Science session</td>
<td>The Young Rheumatologist</td>
<td>Clinical/ HPR/ PARE Joint session</td>
<td>EULAR Projects in Paediatric Rheumatology</td>
<td>Practical skills session*</td>
<td>Practical skills session*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment and management of osteoporosis</td>
<td>Systematic literature review: the link from science to clinical practice</td>
<td>EULAR Campaign: Don’t Delay, Connect Today</td>
<td>Standing Committee on paediatric rheumatology</td>
<td>Crystals I</td>
<td>Ultrasound basic I</td>
<td></td>
</tr>
<tr>
<td>16:30-17:00</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>Paediatric Rheumatology Abstract session</td>
<td>Abstract session</td>
<td>PARE session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic and clinical science in paediatric rheumatology</td>
<td>Impact of rheumatic diseases</td>
<td>Comorbidities: having one RMD is enough - we don’t need anything else</td>
<td>Risk factors for developing diseases or comorbidities</td>
<td>Scleroderma, myositis and related syndromes, etiology, pathogenesis</td>
<td>Novel insights in inflammatory mediators</td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** See detailed satellite symposia programme on pages 217 to 226
### Congress at a Glance

**THURSDAY, 15 JUNE 2017**

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:15-09:45</strong></td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td><strong>09:45-10:15</strong></td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>WIN: What is the use of imaging for regional pain syndromes?</td>
<td>Progress in biological treatment of RA</td>
<td>PsA: a fascinating disease</td>
<td>More or less imaging in axial SpA?</td>
<td>Clinical and therapeutical news in systemic sclerosis</td>
<td>Vasculitis clinical and pathogenic highlights</td>
</tr>
<tr>
<td></td>
<td>WIN: Fibromyalgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-13:30</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50-13:30</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>WIN: Antiphospholipid syndrome</td>
<td>Treat-to-target in axSpA: reality or utopia?</td>
<td>What choice after failure of the first anti-TNF</td>
<td>Calcium crystal deposition in rheumatic diseases</td>
<td>Fifty shades of remission in RA</td>
<td>Innate immunity</td>
</tr>
<tr>
<td></td>
<td>HOT: Vasculitis treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>WIN: Disease registers and electronic patient records for bench marking in rheumatological care</td>
<td>PsA: an integrated perspective</td>
<td>Autoinflammatory diseases in children and adults</td>
<td>Immunogenicity of biologics; myth or reality?</td>
<td>Which target/outcome is more relevant in the management of SLE?</td>
<td>Joint EULAR-EFIS session: Tilt the balance: from disease to tolerance induction</td>
</tr>
<tr>
<td></td>
<td>WIN: Do published guidelines and recommendations improve the quality of care in rheumatology?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30-19:00</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Macrophage M2 polarization: implications in fibrotizing diseases</td>
<td></td>
</tr>
</tbody>
</table>

**In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

**See detailed satellite symposia programme on pages 217 to 226**
In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** See detailed satellite symposia programme on pages 217 to 226
## Congress at a Glance

### FRIDAY, 16 JUNE 2017

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:45</td>
<td></td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session</td>
<td></td>
</tr>
<tr>
<td>09:45-10:15</td>
<td></td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>Scleroderma treatment</td>
<td>PuA: the options grow!</td>
<td>From classics to new: synthetic DMARDs in RA</td>
<td>New treatments in SLE, Sjögren's and APS</td>
<td>Axial spondyloarthritis from risk factor to clinical outcomes</td>
<td>Rheumatoid arthritis - causes and courses</td>
</tr>
<tr>
<td>11:45-13:30</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50-13:30</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Osteoarthritis</td>
<td>Comorbidities in rheumatoid arthritis</td>
<td>Life-threatening presentation of rheumatic diseases</td>
<td>AxSpA: from bug to gut and to disease phenotype</td>
<td>Pregnancy meets rheumatic patients</td>
<td>Neuronal and hormonal alterations in arthritis</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis</td>
<td>What is behind vasculitis?</td>
<td>Comorbidities in connective tissue diseases</td>
<td>Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs</td>
<td>Personalised care for back pain</td>
<td>Regulatory molecules in connective tissue</td>
</tr>
<tr>
<td>17:30-19:00</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
</tr>
</tbody>
</table>

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
*** See detailed satellite symposia programme on pages 217 to 226
**In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

**In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

***See detailed satellite symposia programme on pages 217 to 226***
# Congress at a Glance

## SATURDAY, 17 JUNE 2017

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
<th>N101/N102</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td><strong>What is New (WIN) WIN/How to Treat (HOT)</strong>&lt;br&gt;WIN: Rheumatoid arthritis treatment&lt;br&gt;WIN: Juvenile idiopathic arthritis</td>
<td>Clinical Science session&lt;br&gt;Reverse translation - learning from clinical trials in SLE, Sjögren’s and APS</td>
<td>Challenges in Clinical Practice session&lt;br&gt;Myositis</td>
<td>From Bench to Bedside&lt;br&gt;Genomic imprinting and posttranslational modifications</td>
<td>Clinical Science session&lt;br&gt;Optimising treatment for osteoarthritis. Take the phenotype in account: “one size does not fit all”</td>
<td>Basic and Translational Science session&lt;br&gt;Targeting adipose tissue inflammation</td>
<td>HPR session&lt;br&gt;Trials and tribulations of medication adherence</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td><strong>POSTER VIEWING AND COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05-12:00</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-13:30</td>
<td><strong>What is New (WIN) WIN/How to Treat (HOT)</strong>&lt;br&gt;WIN: Rheumatoid arthritis treatment&lt;br&gt;WIN: Juvenile idiopathic arthritis</td>
<td>Clinical Science session&lt;br&gt;Systemic sclerosis</td>
<td>Challenges in Clinical Practice session&lt;br&gt;The challenges of MRI in axSpA</td>
<td>From Bench to Bedside&lt;br&gt;How diet influences musculoskeletal diseases</td>
<td>Clinical Science session&lt;br&gt;Can targeting disease activity in hand osteoarthritis improve our treatment in the 21st century?</td>
<td>Basic and Translational Science session&lt;br&gt;Why we do develop autoimmunity</td>
<td>HPR session&lt;br&gt;Closing the gap between objective measures and self-report in fibromyalgia</td>
</tr>
<tr>
<td>13:45-14:45</td>
<td><strong>Clinical and Basic/Translational Highlight session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td><strong>Paediatric Rheumatology session</strong>&lt;br&gt;Outcome in juvenile idiopathic arthritis</td>
<td>Educational session&lt;br&gt;Getting financial support to research in RMDs, through Horizon 2020: opportunities, good practices, and successful experiences</td>
<td>EULAR Projects in Education and Training&lt;br&gt;Challenging projects in education and training</td>
<td>Practical skills session*&lt;br&gt;MRI II</td>
<td>Practical skills session*&lt;br&gt;Capillaroscopy II</td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td><strong>PARE session</strong>&lt;br&gt;Workshop: Strengthening your organisation - how to manage volunteers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-12:00</td>
<td><strong>POSTER VIEWING AND COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05-12:00</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-13:30</td>
<td><strong>The Young Rheumatologist</strong>&lt;br&gt;Interactive cases from the HOT and WIN sessions</td>
<td>PARE/HPR Joint session&lt;br&gt;Suffering in silence. Optimising the management of psychological wellbeing for people with RMDs</td>
<td>EULAR Projects in Health Professionals&lt;br&gt;Showcasing the EULAR Online Course for Health Professionals</td>
<td>Practical skills session*&lt;br&gt;Ultrasound, clinical, diagnostic and therapeutic skills II</td>
<td>Practical skills session*&lt;br&gt;Laboratory course - from the clinic to the lab and back II</td>
<td></td>
</tr>
<tr>
<td>13:45-14:45</td>
<td><strong>PARE Highlight session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Scientific Programme

08:00 - 20:00 Registration area (Hall 2)

Registration

13:00 - 14:30 South Auditorium

Basic and Translational Science session
Joint EULAR-APLAR session: Novel animal models - where no researcher has gone before...

Learning objectives:
To understand, how novel animal models work

Chairperson(s):
Gerd R. Burmester (Germany)
Kazuhiko Yamamoto (Japan)

Thomas Pap (Germany) 13:05
Abstract N° SP0001
Relevance of animal models in osteoarthritis

Xinhua Yu (Germany) 13:25
Abstract N° SP0002
Novel animal models in SSC

Yoichiro Iwakura (Japan) 13:45
Abstract N° SP0003
Novel animal model in arthritis

Kazuhiko Yamamoto (Japan) 14:05
Abstract N° SP0004
From the animal model to the patient. Similarities and differences

13:30 - 14:30 N101/N102

Health Professionals session
Health Professionals Welcome session

Learning objectives:
To gain a historic perspective on the development of the role of health professionals in rheumatology and an understanding of future possibilities and challenges

Chairperson(s):
Christina H. Opava (Sweden)
Milena Gobbo Montoya (Spain)

Thea Vliet Vlieland (Netherlands) 13:35
Abstract N° SP0005
Looking back at 70 years of EULAR and 30 years of HP involvement: a rehabilitation perspective

Jackie Hill (United Kingdom) 13:50
Abstract N° SP0006
Looking back at 70 years of EULAR and 30 years of HP involvement: a nursing perspective

Johannes W. J. Bijlsma (Netherlands) 14:05
Abstract N° SP0007
70 years past and a view of the future

Annette de Thurah (Denmark) 14:15
Abstract N° SP0008
The future for HPs in rheumatology

14:30 - 15:00 Exhibition (Hall 10)

Break

15:00 - 16:30 Hall 6

What is New (WIN) & How to Treat (HOT) session

WIN session

Chairperson(s):
Eduardo Collantes Esteves (Spain)
Elsa Sousa (Portugal)

Pedro Machado (United Kingdom) 15:05
WIN: Axial and peripheral spondyloarthritis

Rik Lories (Belgium) 15:45
WIN: Psoriatic arthritis
Clinical Science session
Moving towards new criteria in SLE, Sjögren’s and APS

Learning objectives:
To get insights into new initiatives evaluating classification systems of SLE, Sjögren’s and APS

Chairperson(s):
Ricardo Cervera (Spain)
Hendrika Bootsma (Netherlands)

Martin Aringer (Germany)  15:05
Abstract N° SP0010
Classification of SLE - challenges and potential solutions

Simon Bowman (United Kingdom)  15:25
Abstract N° SP0011
Sjögren’s criteria revisited!

Pier Luigi Meroni (Italy)  15:45
Abstract N° SP0012
Advanced APS criteria 2016/2017

Antonella Arighi (Italy)  16:05
Abstract N° SP0013
The lupus low disease activity state (LLDAS) definition discriminates responders in a systemic lupus erythematosus (SLE) trial: post-hoc analysis of the phase IIB muse trial of anifrolumab

E. Morand (Australia)  16:15
A. Berglind, T. Sheytanova, R. Tummala, G. Illei
Abstract N° OP0001
The lupus low disease activity state (LLDAS) definition discriminates responders in a systemic lupus erythematosus (SLE) trial: post-hoc analysis of the phase IIB muse trial of anifrolumab

S. Johnson (Canada)  16:15
Abstract N° OP0002
Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus

15:00 - 16:30  Hall 7A
Challenges in Clinical Practice session
The differential diagnosis of diffuse skin sclerosis and of Raynaud’s phenomenon and a practical approach to assessment

Learning objectives:
• To learn assessment strategies in SSc
• To learn the identification of parameters for risk stratification

Chairperson(s):
Ariane L. Herrick (United Kingdom)
Armando Gabrielli (Italy)

Annabel Suarez (United Kingdom)  15:05
Abstract N° SP0013
Case 1 presentation: Widespread cutaneous thickening - could this be early diffuse cutaneous systemic sclerosis?

John Pauling (United Kingdom)  15:15
Abstract N° SP0014
Case 1 discussion: The differential diagnosis of diffuse sclerosing skin disease and a practical approach to assessment

Michael Hughes (United Kingdom)  15:45
Abstract N° SP0015
Case 2 presentation: New onset Raynaud’s phenomenon - could this be early limited cutaneous systemic sclerosis?

Ariane L. Herrick (United Kingdom)  15:55
Abstract N° SP0016
Case 2 discussion: The differential diagnosis of Raynaud’s phenomenon and practical approach to assessment with a focus on imaging

15:00 - 16:30  Hall 7B
From Bench to Bedside
Controlling the balance between cancer and autoimmunity

Learning objectives:
To understand the link between cancer and its treatment with autoimmunity

Chairperson(s):
Leonard Calabrese (United States)
Xavier Mariette (France)

Anthony Rosen (United States)  15:05
Abstract N° SP0017
The same mechanism at the origin of cancer and autoimmunity

Aurélien Marabelle (France)  15:25
Abstract N° SP0018
Check points inhibitors - from discovery to clinical applications

Thierry Schaeverbeke (France)  15:45
Rheumatic immune related adverse events with cancer immunotherapy

C. Calabrese (United States)  16:05
E. Kirchner, A. Kontzias, V. Velcheti, C. Calabrese
Abstract N° OP0003
Rheumatic immune related adverse events of checkpoint therapy for cancer: case series of an emerging nosologic entity

R. Belkhir (France)  16:15
Abstract N° OP0004
Rheumatoid arthritis occurring after immune checkpoint inhibitors
15:00 - 16:30  N103/N104

**Clinical Science session**

**Fibromyalgia: a disease of the peripheral or central nervous system?**

**Chairperson(s):**
Stephen McMahon (United Kingdom)
Fabiola Atzeni (Italy)
Rolf-Detlef Treede (Germany)
Claus Jensen (Denmark)

**15:05**
**Abstract N° SP0019**
Signs, symptoms and comorbidities of fibromyalgia
Claudia Sommer (Germany)

**15:25**
**Abstract N° SP0020**
Peripheral pathologies in fibromyalgia
Eva Kosek (Sweden)

**15:45**
**Abstract N° SP0021**
Central pathologies in fibromyalgia
S. A. Provan (Norway)

**16:05**
**Abstract N° OP0005**
Fibromyalgia in patients with rheumatoid arthritis in a 10-year perspective
F. Atzeni (Italy)

**16:15**
**Abstract N° OP0006**
Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients
M. Rizzi, D. Radovanovic, P. Santus, A. Airoldi, F. Frassanito, S. Vanni, A. Cristiano, R. Casale, R. Furlan, P. Sarzi-Puttini

15:00 - 16:30  N101/N102

**Health Professionals session**

**Wearable technologies in 21st century healthcare**

**Learning objectives:**
To understand the current state-of-the-art in wearables and the applications and implications of wearables in clinical practice and research

**Chairperson(s):**
Thijs Swinnen (Belgium)
Jette Primdahl (Denmark)

**15:05**
**Abstract N° SP0023**
Review of wearable technologies - the state of the art
Alex Clarke-Cornwell (United Kingdom)

**15:23**
**Abstract N° SP0024**
Wearable technologies in research and clinical trials
Alma Leora Culén (Norway)

**15:59**
**Abstract N° OP0009-HPR**
The effect of an 8-week water exercise program on anaerobic exercise capacity in children with juvenile idiopathic arthritis
D. Bayraktar (Turkey)

15:00 - 16:30  N105/N106

**Clinical Science session**

**Assessment and management of osteoporosis**

**Learning objectives:**
- To understand how bone biomarkers can aid in the diagnosis and monitoring of osteoporosis
- To be familiar with the state-of-the-art technique in assessing osteoporotic fracture risk
- To be aware of the emerging therapy for osteoporosis

**Chairperson(s):**
P. López de Figueroa (Spain)

**16:15**
**Abstract N° OP0008**
Deficient autophagy induces chondrocyte dysfunction through lamin A/C accumulation in aging and osteoarthritis
P. López de Figueroa (Spain)
The clinical use of biomarkers for osteoporosis
Kristina Åkesson (Sweden) 15:05
Abstract N° SP0025
The clinical use of biomarkers for osteoporosis

Roland D. Chapurlat (France) 15:30
Abstract N° SP0026
Novel imaging techniques for assessing osteoporotic fracture risk

Piet Geusens (Netherlands) 15:55
Abstract N° SP0027
Emerging therapies for osteoporosis

W. Lems (Netherlands) 16:20
Abstract N° OP0010
Effect of denosumab compared with risedronate in glucocorticoid-treated individuals: results from the 12-month primary analysis of a randomized, double-blind, active-controlled study

The Young Rheumatologist

Systematic literature review: the link from science to clinical practice
Learning objectives:
- To guide young clinicians through the process of a systematic literature review
- To illustrate the use of evidence from systematic literature reviews in the formulation of recommendations
- To show practical examples of application of a systematic literature review into daily clinical practice

Chairperson(s):
Felicie Rivellese (Italy)
Laure Gossec (France)
Sofia Ramiro (Netherlands) 15:05
Abstract N° SP0028
Systematic literature review: where to start?

Robert B. M. Landewé (Netherlands) 15:30
Abstract N° SP0029
Linking science to clinical practice: from the systematic literature review to the formulation of recommendations

Karen Visser (Netherlands) 15:55
Abstract N° SP0030
Beyond the recommendations: examples of systematic literature review in daily clinical practice

S. Hilliquin (France) 16:20
B. Hugues, S. Mitrovic, L. Gossec, B. Fautrel
Abstract N° OP0011
Does a very early therapeutic intervention in very early arthritis/pre-rheumatoid arthritis patients prevent the onset of rheumatoid arthritis: a systematic review and metanalysis

Joint session Clinical/HPR/PARE

EULAR Campaign: Don’t Delay, Connect Today
Learning objectives:
- To experience how access to early diagnosis is enabled
- To learn how tight control optimises therapies targeting remission
- To understand what markers signify illness progression
- To comprehend how lifestyle factors (smoking, obesity, alcohol, inactivity) influence the progression of rheumatic diseases

Chairperson(s):
Gerd R. Burmester (Germany)
Ailsa Bosworth (United Kingdom)

Andreas Schwarting (Germany) 15:05
Ways to improve early diagnosis despite limited rheumatologists’ resources

Christian D. Mallen (United Kingdom) 15:23
How could GPs enhance the early diagnosis of rheumatic diseases?

Paul Kirwan (Ireland) 15:41
The contribution of physiotherapists to early detection of inflammatory arthritis

John Church (Ireland) 15:59
The EULAR Campaign and how organisations can get involved

L. A. Bennett (United Kingdom) 16:17
J. S. Nijjar, G. Fragoulis, S. Siebert, I. B. McInnes
Rheumatosphere: reach new heights in diagnosis and treatment of arthritis by engaging, empowering and inspiring

EULAR Projects in Paediatric Rheumatology

Standing Committee session on Paediatric Rheumatology
Learning objectives:
- To present the European recommendations on management of paediatric rheumatic diseases

Chairperson(s):
Tadej Avcin (Slovenia)
Carine Wouters (Belgium)

Michael Beresford (United Kingdom) 15:05
SHARE recommendations on systemic vasculitides
Francesco Zulian (Italy) 15:25
Abstract N° SP0035
SHARE recommendations on juvenile scleroderma

Annet van Royen (Netherlands) 15:45
Abstract N° SP0036
SHARE recommendations on juvenile dermatomyositis

S. O. Hetlevik (Norway) 16:05
T. M. Aalekken, M. B. Lund, B. Flate, E. B. Noreand, M. Rygg, V. Lilleby
Abstract N° OP0013
Pulmonary manifestations in juvenile onset mixed connective tissue disease after long-term disease duration - a Norwegian case-control study

P. Marteau (France) 16:15
Abstract N° OP0014
Conventional radiography in juvenile idiopathic arthritis: joined recommendations from the French societies for rheumatology, radiology and paediatric rheumatology

15:00 - 16:30  N107/N108
Practical skills session*

Crystals I

Learning objectives:
To learn how to use a microscope to detect and interpret crystals in synovial fluid from scratch

Chairperson(s):
Eliseo Pascual (Spain)
Anne K. Tausche (Germany)

Tutors:
Eleonora Norkuviene (Lithuania)
Francisca Sivera (Spain)
José Pimentao (Portugal)
Francesca Oliviero (Italy)

15:00 - 16:30  N109/N110
Practical skills session*

Ultrasound basic I

Chairperson(s):
George A. W. Bruyn (Netherlands)
Marion Kortekaas (Netherlands)

Georgios Filippou (Italy) 15:05
Abstract N° SP0037
How to assess US elementary lessons in CPPD + demo

Peter Mandl (Austria) 15:25
Abstract N° SP0038
How to assess cartilage in RA and pitfalls + demo

Annamaria Iagnocco (Italy) 15:45
Abstract N° SP0039
How to evaluate the subtal joint + demo

Ingrid Möller (Spain) 16:05
Abstract N° SP0040
How to scan the hip - new approaches + demo

Tutor:
Lykke Midtboell Oernbjerg (Denmark)

16:30 - 17:00 Exhibition (Hall 10)
Coffee break

17:00 - 18:30 Hall 8

Abstract session
Still breaking news on TNF inhibitors in rheumatoid arthritis

Chairperson(s):
Bernard Combe (France)
Jackie Nam (United Kingdom)

R. Caporali (Italy) 17:05
Abstract N° OP0015
Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or without short-term high-dose glucocorticoids: results of a phase IV multicenter, randomized, double blind study (cmanagement.gov: NCT00480272)

C. Turesson (Sweden) 17:15
T. Frisell, M. Dehlin, D. Di Giuseppe, N. Feltelius, A. Kastbom, J. Askling on behalf of ARTIS study group
Abstract N° OP0016
Comparative effectiveness at 1 year of different anti-TNF drugs as first biologic DMARD in patients with rheumatoid arthritis - results from the nationwide Swedish register

X. Mariette (France) 17:25
Abstract N° OP0017
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
T. Pham (France) 17:35
C. Barral, D. Hajage, B. Fautrel, P. Laforgue, F. Tubach
Abstract N° OP0018
Tool and threshold predicting a successful biological DMARDs tapering in patients with RA remission determination

J. Pope (Canada) 17:45
E. Rampakakis, E. Grant, L. Bessette, J. Lazovskis, B. Harouei, J. S. Sampalis
Abstract N° OP0019
DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs: interim results from a Canadian observational randomized study

T. Shimizu (United States) 17:55
Abstract N° OP0020
Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using HR-PQCT

R. Alten (Germany) 18:05
J. Glover, N. Matsunaga, D. Chisholm, M. Genovese
Abstract N° OP0021
Efficacy and safety results of a phase III study comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product, in patients with active rheumatoid arthritis

G. W. Reed (United States) 18:15
R. A. Gerber, Y. Shan, L. Takiya, K. J. Dandreo, D. Gruben, J. M. Kremer, G. V. Wallenstein
Abstract N° OP0022
TNF-α and tofacitinib monotherapy and comparative effectiveness in clinical practice: results from Corrona registry

K. K. Eklund (Finland) 17:15
Abstract N° OP0024
Drug trough levels and antidrug antibodies in nonselected ankylosing spondylitis patients using self-injected anti-TNF drugs

J. Ruwaard (Netherlands) 17:25
A. F. Marsman, M. T. Nurmohamed, H. te Velthuis, K. Bloem, T. Rispen, G. J. Wolbink
Abstract N° OP0025
Antidrug antibodies detection is strongly influenced by the type of assay used

P. Carron (Belgium) 17:35
G. Varkas, H. Cypers, L. Van Praet, D. Elewaut, F. van den Bosch
Abstract N° OP0026
High drug-free remission in early peripheral spondyloarthritis after induction therapy with golimumab

D. Xu (China) 17:55
J. Fan, Q. Chen, K. Qin, X. Li, C. Gao
Abstract N° OP0028
Low dose IL-2 therapy can recovery Th17/Treg cell balance in patients with ankylosing spondylitis

A. M. Devauchelle (France) 17:45
O. Vittecoq, T. Lequerre, P. Michelin, F. Vincent
Abstract N° OP0029
Evaluation of the efficiency of sacroiliac joints corticoid injections under scan control and its relationship with the presence or absence of sacroilitis lesions seen on MRI of patients with spondyloarthritis

E. Nikiphorou (United Kingdom) 17:55
D. van der Heijde, S. Horton, R. Landewé, A. Moltó, M. Dougados, F. van den Bosch, S. Ramiro
Abstract N° OP0030
Inequity in biologic DMARD prescription for SpA across the globe. Results from the ASAS COMOSpA study

D. van der Heijde (Netherlands) 17:05
X. Baraliakos, K. G. Hermann, R. Landewé, P. M. Machado, W. Maksymowycz, O. Davies, N. de Peyrecave, B. Hoepken, L. Bauer, T. Nurminen, J. Braun
Abstract N° OP0023
Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

E. Nikiphorou (United Kingdom) 17:00 - 18:30
D. van der Heijde, S. Norton, R. Landewé, A. Moltó, M. Dougados, F. van den Bosch, S. Ramiro
Abstract N° OP0030
Inequity in biologic DMARD prescription for SpA across the globe. Results from the ASAS COMOSpA study

17:00 - 18:30 Hall 7A

Abstract session
Progress in management of SpA
Chairperson(s):
Xenophon Baraliakos (Germany)
Manouk de Hooge (Belgium)
D. van der Heijde (Netherlands) 17:05
X. Baraliakos, K. G. Hermann, R. Landewé, P. M. Machado, W. Maksymowycz, O. Davies, N. de Peyrecave, B. Hoepken, L. Bauer, T. Nurminen, J. Braun
Abstract N° OP0023
Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

P. Carron (Belgium) 17:35
G. Varkas, H. Cypers, L. Van Praet, D. Elewaut, F. van den Bosch
Abstract N° OP0026
High drug-free remission in early peripheral spondyloarthritis after induction therapy with golimumab

M. Mozicafreddo, M. Cuccioli, A. Grieco, C. Paolini, C. Tonnini, S. Salvucci, E. Avvedimento, A. Funaro, A. Gabrielli
Abstract N° OP0031
Development of a novel epitope-based diagnostic assay for systemic sclerosis

17:00 - 18:30 Hall 7B

Abstract session
Early diagnosis of systemic sclerosis and myositis: biomarkers and diagnostic tool
Chairperson(s):
Christopher Denton (United Kingdom)
Vanessa Smith (Belgium)
G. Moroncini (Italy) 17:05
M. Mozicafreddo, M. Cuccioli, A. Grieco, C. Paolini, C. Tonnini, S. Salvucci, E. Avvedimento, A. Funaro, A. Gabrielli
Abstract N° OP0031
Development of a novel epitope-based diagnostic assay for systemic sclerosis
17:00 - 18:30  N103/N104

Abstract session
SLE, Sjögren’s, APS - clinical aspects

Chairperson(s):
Elisabet Svenungsson (Sweden)
Georges Bertsias (Greece)

I. E. Bultink (Netherlands) 17:05
A. Lalmohamed, F. de Vries
Abstract N° OP0039
A population-based study on mortality and the influence of medication use in 4356 patients with systemic lupus erythematosus and 21845 matched controls from the United Kingdom

V. Devauchelle-Pensec (France) 17:15
Abstract N° OP0040
Integration of salivary-gland ultrasonography in classification criteria for primary Sjögren’s syndrome: an international vignette-based study

B. Moghaddam (Canada) 17:25
J. A. Avina-Zubieta, E. C. Sayre
Abstract N° OP0041
All-cause, cardiovascular and malignancy related mortality in systemic lupus erythematosus (SLE): a population-based study

I. Rua-Figueroa (Spain) 17:35
J. López-Longo, M. Galindo-Izquierdo, V. Del Campo, J. De la Torre Cisneros, E. Uriarte, P. Vela, E. Tomero, J. Pego-Reigosa
Abstract N° OP0042
Bacteremia in systemic lupus erythematosus patients from RELESSER registry: risk factors, clinical and microbiological characteristics and outcomes

X. Liu (China) 17:45
X. Jing, X. Wu, J. Wang, Z. Liang, M. Hao, J. Chen, C. Gao, X. Li
Abstract N° OP0043
The number of circulating regulatory T cells is reduced and low-dose IL-2 selectively stimulates its proliferation in patients with systemic lupus erythematosus

A. Alunno (Italy) 17:55
O. Bistoni, F. Carubbi, G. Cafaro, E. Valentini, R. Giacomelli, R. Gerli
Abstract N° OP0044
Antibodies anti-saccharomyces cerevisiae in primary Sjögren’s syndrome: prevalence, clinical associations and possible cross-reactivity with disease specific autoantigens
Abstract session
Osteoporosis treatment gap, new options and new strategies

Chairperson(s):
Roland D. Chapurlat (France)
Willem F. Lerns (Netherlands)

M. Sehgal (United States) 17:05
A. Mithal, A. Mithal, G. Singh
Abstract N° OP0047
Osteoporotic hip fracture prevention: are we in a crisis?

P. Geusens (Netherlands) 17:15
M. Oates, A. Miyauchi, J. Adachi,
M. Lazaretti-Castro, P. R. Ebeling, C. A. Perez Nino,
C. J. Milmont, A. Grauer, C. Libanati
Abstract N° OP0048
Romosozumab rapidly reduces clinical vertebral fracture incidence: results from the FRAME study

A. Makhzoum (Canada) 17:25
L. Petriw, M. Sattin, T. Towheed
Abstract N° OP0049
Systematic review of randomized controlled trials evaluating bisphosphonates for the prevention and treatment of glucocorticoid-induced osteoporosis

A. Spångéus (Sweden) 17:35
K. Åkesson, Ö. Ljunggren, J. Banefelt, L. Karlsson,
G. Ortsäter, C. Libanati, E. Toth, O. Ström
Abstract N° OP0050
The treatment gap after fracture in osteoporosis patients in Sweden

M. I. Danila (United States) 17:45
F. Anderson, S. Greenspan, A. LaCroix, J. Nieves,
S. Silverman, N. Watts, J. Curtis, K. Saag
Abstract N° OP0051
The activating patients at risk for osteoporosis study: a randomized trial within the global longitudinal study of osteoporosis in women cohort

Health Professionals session
Rehabilitation and modern drug treatment - needs and challenges

Learning objectives:
• To identify current rehabilitation needs in patients with RMDs
• To describe challenges and experiences with rehabilitation complementing modern pharmacological treatment
• To gain insight into how and why physical activity and work rehabilitation are important cornerstones of rehabilitation

Chairperson(s):
Norelee Kennedy (Ireland)
Hana Smucrova (Czech Republic)
Mathilda Björk (Sweden) 17:05
Abstract N° SP0041
Current needs for rehabilitation

Florin Catrina (Romania) 17:23
Abstract N° SP0042
The art of juggling - a patient’s perspective

Nina Brodin (Sweden) 17:41
Physical activity: subjective and objective outcome

Yeliz Prior (United Kingdom) 17:59
Abstract N° SP0043
Work retention rehabilitation in practice

B. A. Esbensen (Denmark) 18:17
Abstract N° OP0055–HPR
Preferences for self-management and support services in patients with inflammatory arthritis: a Danish nationwide cross-sectional study
Abstract session

Basic and clinical science in paediatric rheumatology

Chairperson(s):
Michael Beresford (United Kingdom)
Isabelle Koné-Paut (France)

C. Fisher (United Kingdom) 17:05
D. Eleftheriou, D. Sen, Y. Ioannou
Abstract N° OP0056
IL-23P19 is up-regulated in monocyte-derived macrophages from HLA B27 positive patients with enthesitis related arthritis

G. Horneff (Germany) 17:15
Abstract N° OP0057
Fluorescence optical imaging in juvenile idiopathic polyarticular disease before and during antirheumatic treatment

N. Ruperto (Italy) 17:25
Abstract N° OP0058
Improvement in patient-reported outcomes in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs treated with SC abatacept

L. Domínguez Casas (Spain) 17:35
Abstract N° OP0059
Golimumab versus tocilizumab for severe and refractory juvenile idiopathic arthritis-uveitis. Multicenter study of 33 patients

M. Listing (Germany) 17:45
Abstract N° OP0060
Health behavior in adolescents with juvenile idiopathic arthritis - results of the inception cohort of newly diagnosed patients (ICON)

Abstract session

Impact of rheumatic diseases

Chairperson(s):
Annelies Boonen (Netherlands)
Karen Visser (Netherlands)

O. Fogel (France) 18:05
Abstract N° OP0060
Assessment of biotherapies’ efficacy in blau syndrome: data from an international retrospective cohort of 23 cases

F. De Benedetti (Italy) 18:15
Abstract N° OP0063
Canakinumab treatment in patients with Colchicine-resistant FMF (CrFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40
C. A. Guillen-Astete (Spain) 17:25
A. Braña-Cardeñosa, M. Zamorano-Serrano, P. Gallego-Rodriguez, C. De la Casa-Resino
Abstract N° OP0066
The problem based learning applied to teaching rheumatological topics among non-rheumatology residents

B. T. van Dijk (Netherlands) 17:35
R. M. ten Brinck, H. W. van Steenbergen, A. H. van der Helm-van Mil
Abstract N° OP0067
Development and validation of a model to facilitate recognition of arthritis by general practitioners

J. Yazdany (United States) 17:45
R. Myslinski, T. Johansson, S. Kazi
Abstract N° OP0068
Practices participating in the ACR's rheumatology informatics system for effectiveness (RISE) national registry show improvements in quality of care

J. S. Lee (Republic of Korea) 17:55
Abstract N° OP0069
The burden of ankylosing spondylitis: a population based study

S. Rodrigues Manica (Portugal) 18:05
A. Sepriano, S. Ramiro, F. M. Pimentel-Santos, P. Putrik, E. Nikipherou, A. Moltó, M. Dougados, D. van der Heijde, R. Landewé, F. van den Bosch, A. Boonen
Abstract N° OP0070
The role of individual and country-level socio-economic factors in work participation in patients with spondyloarthritis across 22 countries worldwide: results from the COMOSpA study

E. S. Norli (Norway) 18:15
G. Hetland Brinkmann, T. K. Kvien, S. Lillegrenav, O. Bjørneboe, A. Julsrud Haugen, H. Nygaard, C. Thunem, E. Lie, M. D. Mjaavatten
Abstract N° OP0071
Sick leave after six months in 664 patients with recent-onset inflammatory arthritis

PARE session
Comorbidities: having one RMD is enough - we don't need anything else

Learning objectives:
- To experience how to prevent comorbidities
- To provide information to patients who are at risk
- How to monitor patients for comorbidities

Chairperson(s):
Jeanette Andersen (United Kingdom)
Kristijonas Mazuras (Lithuania)

Cindy Rusthoven (Netherlands) 17:05
The patient experience on comorbidities

Laure Gossec (France) 17:23
Abstract N° SP0044
Screening for comorbidities in daily practice: who and how?

Alisa Bosworth (United Kingdom) 17:41
Abstract N° SP0045
Do patient organisations have a role to play in preventing comorbidities?

Silvia Garcia-Diaz (Spain) 17:59
Abstract N° SP0046
Prevention and the protective role of exercise and lifestyle interventions on comorbidities

L. Proulx (Canada) 18:17
N. Robertson, D. P. Richards, L. Wilhelm, J. Gunderson, C. Reece, A. Sirois, A. McKinnon
Abstract N° OP0072-PARE
Pregnancy and parenting with arthritis - developing an educational resource for patient by patients

17:00 - 18:30  N115/N116

Risk factors for developing diseases or comorbidities

Chairperson(s):
Deborah Symmons (United Kingdom)
Delphine Courvoisier (Switzerland)

A. H. van der Helm-van Mil (Netherlands) 17:05
L. E. Burgers, F. Slijehult, R. M. ten Brinck, H. W. van Steenbergen, R. B. Landewé, S. Rantapää-Dahlqvist,
Abstract N° OP0073
Performance of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis - a longitudinal study

H.-H. Chen (Taiwan, Province of China) 17:15
Abstract N° OP0074
Association between a history of mycobacterial infection and the risk of Sjögren’s syndrome: a nationwide, population-based case-control study

H. Lu (United States) 17:25
Abstract N° OP0075
Osteoporotic fracture risk assessment using FRAX following hematopoietic stem cell transplantation
D. Aletaha (Austria) 17:35
R. Panaccione, M. Davis, S. Johnson, M. Skup, V. Garg
Abstract N° OP0076
Risk of developing additional immune mediated manifestations for patients with systemic arthritides

J. W. Park (Republic of Korea) 17:45
Abstract N° OP0077
Primary prophylaxis for pneumocystis pneumonia in patients with rheumatic disease and treated with prolonged, high-dose steroid: a retrospective cohort study with 12-year observation

S. Tiosano (Israel) 17:55
O. Gendelman, A. Watad, D. Comaneshter, A. Cohen, H. Amital
Abstract N° OP0078
The long-term prognostic significance of pulmonary hypertension in sarcoidosis - a big data analysis

A. Linauskas (Denmark) 18:05
A. L. de Thurah, K. Overvad, M. B. Johansen, K. Stengaard-Pedersen
Abstract N° OP0079
Body fat percentage and waist circumference were associated with the development of rheumatoid arthritis - a Danish follow-up study

C.-F. Kuo (Taiwan, Province of China) 18:15
P.-H. Tsai, L.-H. Huang, S.-F. Luo
Abstract N° OP0080
Risk of autism spectrum disorder in children born to mothers with systemic lupus erythematosus and rheumatoid arthritis in Taiwan

17:00 - 18:30 N107/N108
Abstract session
Scleroderma, myositis and related syndromes, etiology, pathogenesis
Chairperson(s):
Ulf Müller-Ladner (Germany)
Elise Siegert (Germany)

J. Schniering (Switzerland) 17:25
M. Benešová, M. Brunner, C. Feghali-Bostwick, R. Schibli, O. Distler, C. Müller, B. Maurer
Abstract N° OP0083
Molecular targeted imaging biomarkers for personalized medicine strategies in systemic sclerosis-related interstitial lung disease

M. Stellato (Switzerland) 17:35
M. Rudnik, F. Renoux, E. Pachera, D. Kayalar, K. Sotlar, K. Klingel, J. Henes, P. Blysztczuk, O. Distler, G. Kania
Abstract N° OP0084
Rescue from the failing heart in systemic sclerosis, a novel insight: targeting TGF-β/Fra2-dependent autophagy

E. R. Volkmann (United States) 17:45
A.-M. Hoffmann-Vold, Y.-L. Chang, J. Jacobs, K. Tillisch, E. Mayer, P. J. Clements, J. Hov, M. Kummer, Ø. Midtvedt, V. Lagishetty, Ø. Molberg, J. Braun
Abstract N° OP0085
Longitudinal analysis of the gastrointestinal microbiota in systemic sclerosis

E. Pachera (Switzerland) 17:55
Abstract N° OP0086
Long noncoding RNA H19X as a new therapeutic target for fibrosis

M. Hirabayashi (Japan) 18:05
Abstract N° OP0087
Platelet-specific FLI1-knockout mice show accelerated wound closure associated with increased myofibroblast formation in the inflammatory phase

M. Rudnik (Switzerland) 18:15
M. Stellato, V. Milleret, P. Blysztczuk, B. Maurer, K. Klingel, J. Henes, K. Sotlar, M. Ehrbar, O. Distler, G. Kania
Abstract N° OP0088
The role and function of monocyte-derived fibroblast-like cells in multi-organ fibrosis in systemic sclerosis

Abstract session
Scleroderma, myositis and related syndromes, etiology, pathogenesis
Chairperson(s):
Ulf Müller-Ladner (Germany)
Elise Siegert (Germany)

J. Avouac (France) 17:05
Abstract N° OP0081
Pan-PPAR agonist IVA337 is effective in the prevention of experimental lung fibrosis and pulmonary hypertension

C. Corallo (Italy) 17:15
M. Cutolo, S. Soldano, N. Volpi, D. Franci, A. Montella, C. Chirico, R. Nuti, N. Giordano
Abstract N° OP0082
Fibrosis and microangiopathy are the main histopathological hallmarks of scleroderma-related myopathy
**Abstract session**

**Novel insights in inflammatory mediators**

**Chairperson(s):**
Iain B. McInnes (United Kingdom)  
Javier Rodriguez-Carrio (Spain)

**S. Kim (United States)**
17:05  
Abstract N° OP0089  
Combination therapy of selective MMP9 and TNF inhibitors are efficacious in the mouse CIA model of rheumatoid arthritis

**C. Marchetti (United States)**
17:15  
B. Swartzwelter, M. I. Koenders, C. A. Dinarello, L. A. Joosten
Abstract N° OP0090  
The human safe NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of experimental arthritis

**D. Popp (Germany)**
17:25  
F. Rühle, W. de Jager, T. Vogl, J. Roth
Abstract N° OP0091  
S100A8 triggers a novel immune-regulatory mechanism in developing dendritic cells

**G. Cavalli (Italy)**
17:35  
Abstract N° OP0092  
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance

**B. Le Goff (France)**
17:45  
Abstract N° OP0093  
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro

**B. Mulhearn (United Kingdom)**
17:55  
S. Viatte, T. Hussell, A. Barton
Abstract N° OP0094  
Development of a 37-channel mass cytometry (CyTOF) panel to predict treatment response in rheumatoid arthritis

**M. Y. Md Yusof (United Kingdom)**
18:05  
Abstract N° OP0095  
Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression score
Scientific Programme

07:45 - 19:15 Registration area (Hall 2)

08:15 - 09:45 South Auditorium

Basic and Translational Science session

Cytokines and chemokines

Learning objectives:
• To learn about the interaction of pro and anti-inflammatory as well as angiogenic mediators
• To learn about the role of inflammatory and angiogenic mediators in initiation and resolution of inflammation
• What new treatment options are emerging?

Chairperson(s):
Patrizia Rovere-Querini (Italy)
Rainer H. Straub (Germany)

Lars Rönnblom (Sweden) 08:20
Abstract N° SP0047
Type I interferon system in autoimmunity

Sander W. Tas (Netherlands) 08:45
Abstract N° SP0048
Targeting of angiogenic molecules

David S. Pisetsky (United States) 09:10
Abstract N° SP0049
DNA aggregates as alarmins

I. Bodewes (Netherlands) 09:35
Abstract N° OP0097
Systemic IFN type I and type II signatures in primary Sjögren’s syndrome reveal differences in disease severity

10:15 - 11:45 Hall 6

What is New (WIN) & How to Treat (HOT) session

WIN session

Chairperson(s):
Jaime C. Branco (Portugal)
Paul Studenic (Austria)

Carlo Martinoli (Italy) 10:20
WIN: What is the use of imaging for regional pain syndromes?

Afton Hasset (United States) 11:00
WIN: Fibromyalgia

10:15 - 11:45 Hall 8

Abstract session

Progress in biological treatment of RA

Chairperson(s):
Roy Fleischmann (United States)
Paul Emery (United Kingdom)

T. Dörner (Germany) 10:20
Abstract N° OP0098
Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate

M. Galeazzi (Italy) 10:30
G. Sebastiani, R. Voll, J. Wollenhaupt, O. Viapiana, J. Dudler, E. Selvi, C. Baldi, M. Bardelli, B. Bannert, S. Finzel, C. Specker, P. Sarzi Puttini, F. Bootz, D. Neri on behalf of the DEKAVIL study group
Abstract N° OP0099
Safety, tolerability and initial signs of efficacy of the fully human immunocytokine dekavil (F8IL10): a novel therapeutic approach for rheumatoid arthritis

H. Wadström (Sweden) 10:40
T. Frisell, J. Askling on behalf of The ARTIS study group
Abstract N° OP0100
Overall cancer risk in patients with rheumatoid arthritis treated with TNF inhibitors, tocilizumab, abatacept, or rituximab

T. Simon (United States) 10:50
Abstract N° OP0101
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: analysis of all available clinical trial data

09:45 - 10:15 Exhibition (Hall 10)

Coffee break
V. Strand (United States) 11:00
L. Gossec, C. Proudfoot, C. Chen, M. Reaney,
S. Guillonneau, T. Kimura, J. van Adelsberg, Y. Lin,
E. Mangan, H. van Hoogstraten, G. R. Burmester
Abstract N° OP0102
Patient reported benefits of sarilumab monotherapy versus adalimumab monotherapy in adult patients with active rheumatoid arthritis

B. Dasgupta (United States) 11:10
K. Campbell, A.-C. Bay-Jensen, M. Karsdal,
K. Sweet, M. Sims, M. J. Loza
Abstract N° OP0103
The effect of sirukumab plus methotrexate on circulating biomarkers of joint destruction in moderate to severe rheumatoid arthritis patients from the SIRROUND-D phase 3 study

Y. Urata (Japan) 11:20
S. Abe, B. Devers, Y. Nakamura, H. Takemoto,
K.-I. Furukawa
Abstract N° OP0104
Tocilizumab: dose reduction or interval spacing - which proves a better tapering strategy for rheumatoid arthritis in clinical remission?

S. Mohan (United States) 11:30
M. Michalska, J. Yourish, J. Pei, S. Gale,
C. Birchwood, E. Berber
Abstract N° OP0105
Long-term safety of tocilizumab from large clinical trial and postmarketing populations

10:15 - 11:45 Hall 7A

Abstract session

PsA: a fascinating disease

Chairperson(s):
Stefan Siebert (United Kingdom)
Francesco Carubbi (Italy)

L. E. Kristensen (Denmark) 10:20
C. Ballegaard, P. Højgaard, L. Dreyer, R. Cordtz,
T. S. Jørgensen, M. Skougaard, S. Tarp
Abstract N° OP0106
The impact of comorbidities on effect and discontinuation of tumour necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study

P. G. Conaghan (United Kingdom) 10:30
V. Strand, R. Alten, E. Sullivan, S. Blackburn,
L. Huneault, H. Tian, K. Gandhi, S. Jugl
Abstract N° OP0107
Pain still remains a high unmet need among psoriatic arthritis patients receiving existing biologic treatment: results from a multi-national real-world survey

R. Landewé (Netherlands) 10:40
C. T. Ritchlin, L. C. Coates, D. Aletaha, B. Guérette,
Y. Zhang, F. Ganz, M. Hojnik
Abstract N° OP0108
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity

B. Michelsen (Norway) 10:50
E. Lie, K. M. Fagerli, E. K. Kristianslund,
H. B. Hammer, G. Haugeberg, T. K. Kvien
Abstract N° OP0109
Is mental health comparable in rheumatoid and psoriatic arthritis patients? A comparative analysis of real life longitudinal data from the NOR-DMARD study

M. Jani (United Kingdom) 11:00
H. Chinoy, A. Barton on behalf of Outcomes of psoriatic arthritis Study Syndicate (OUTPASS)
Abstract N° OP0110
Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from OUTPASS

L. Eder (Canada) 11:10
A. Polachek, R. Cook, V. Chandran, D. Gladman
Abstract N° OP0111
The association between sonographic enthesitis and radiographic joint damage in psoriatic arthritis

T. S. Jørgensen (Denmark) 11:20
M. Skougaard, S. Roftring-Madsen, L. Coates,
A. Egberg, K. Amris, L. Dreyer, P. Højgaard,
J. Guldberg-Møller, J. F. Merola, P. Frederiksen,
H. Gudbergsen, L. E. Kristensen
Abstract N° OP0112
In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational DANBIO registry study

A. Ortolan (Italy) 11:30
M. Lorenzin, G. Tadiotto, F. Oliviero, A. Hoxha,
S. Piaserico, L. Punzi, R. Ramonda
Abstract N° OP0113
Metabolic syndrome and liver stiffness in psoriatic arthritis and psoriasis patients: a case-control study

10:15 - 11:45 Hall 7B

Abstract session

More or less imaging in axial SpA?

Chairperson(s):
Percival D. Sampaio-Barros (Brazil)
Helena Marzo-Ortega (United Kingdom)
Abstract N° OP0114
Low dose computed tomography detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort
M. Dougados (France) 10:30
A. Sepriano, A. Molto, S. Ramiro, M. De Hooge, R. van den Berg, V. Navarro Compan, C. De Mattei, R. Landewé, D. van der Heijde
Abstract N° OP0115
Evaluation of the changes in structural damage in axial spondyloarthritis on plain pelvic radiographs: the 5 years data of the DESIR cohort
M. Dougados (France) 10:40
A. Sepriano, A. Molto, S. Ramiro, M. De Hooge, R. van den Berg, V. Navarro Compan, C. De Mattei, R. Landewé, D. van der Heijde
Abstract N° OP0117
Bone marrow oedema in sacroiliac joints of young athletes shows most frequently in the posterior inferior ilium
M. Protopopov (Germany) 11:00
J. Sieper, H. Hainbel, J. Listing, M. Rudwaleit, D. Poddubny
Abstract N° OP0118
Impact of radiographic damage in the sacroiliac joints on function and mobility in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort
B. Meghnathi (France) 11:10
A. Etcheto, A. Saraux, M. Dougados, A. Moltó
Abstract N° OP0119
Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort
S. Akar (Turkey) 11:20
Y. C. Kaplan, S. Ecemis, E. K. Arslan, O. Gercik, D. Solmaz
Abstract N° OP0120
The role of smoking in the development and progression of structural damage in patients with ankylosing spondylitis: the preliminary results of a systematic review and meta-analysis
W. P. Maksymowych (Canada) 11:30
Abstract N° OP0121
Validation of MRI structural lesions using computed tomography in patients with axial spondyloarthritis

10:15 - 11:45 N103/N104
Abstract session
Clinical and therapeutical news in systemic sclerosis

Chairperson(s):
Armando Gabrielli (Italy)
Timothy R. Radstake (Netherlands)
S. R. Johnson (Canada) 10:20
N. Hakami, Z. Ahmad, D. N. Wijeyusundera
Abstract N° OP0122
Venous thromboembolism in systemic sclerosis: prevalence, risk factors and impact on survival
A. Herrick (United Kingdom) 10:30
Abstract N° OP0123
Prediction of progressive skin thickening in early diffuse systemic sclerosis using three-monthly skin scores from the European sclerodema observational study (ESOS)
E. R. Volkmann (United States) 10:40
M. Sim, D. P. Tashkin, D. Khanna, P. J. Clements, M. Roth, D. Forst, A. Pickney, E. Goldmuntz, L. Keyes-Estein, R. Elashoff, K. Sullivan on behalf of SLS I working group
Abstract N° OP0124
Treatment with cyclophosphamide for systemic sclerosis-related interstitial lung disease does not improve survival after 12 years of follow up
X. Yang (China) 10:50
Abstract N° OP0125
Mortality in patients with dermatomyositis/polymyositis in a Chinese medical centre
R. Spiera (United States) 11:00
L. Hummers, L. Chung, T. Frech, R. Domsic, D. Forst, J. Gordon, M. Mayes, R. Simms, S. Constantine, B. White
Abstract N° OP0126
A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis
N. Hashimoto (Japan) 11:10
M. Kitano, T. Nakazawa, T. Iwasaki, T. Hashimoto
Abstract N° OP0127
Ten years follow-up of gastrointestinal involvement by the small intestinal clearance in patients with systemic sclerosis
V. Poindron (France) 11:20
E. Chatelus, M. Canuet, P. Germain, S. El Ghannudi, T. Martin
Abstract N° OP0128
Detection of sub-clinical diffuse myocardial fibrosis by native T1 mapping magnetic resonance imaging in a prospective systemic sclerosis cohort
Mycophenolate mofetil versus cyclophosphamide in scleroderma-related interstitial lung disease in a real-life scenario

Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase III randomised, placebo-controlled trial

Optimal dose of tocilizumab for the treatment of giant cell arteritis: efficacy, safety, and exposure-efficacy analysis from GiACTA Investigators

MicroRNA-223-3P expression in affected skin of adult IGA vasculitis correlates with the severity of skin involvement

Do patients’ treatment beliefs affect treatment choices in knee and hip osteoarthritis?

Reducing arthritis fatigue - clinical teams (RAFT) using cognitive-behavioural approaches: an RCT
**Abstract session**

**RA: really a systemic disease?**

**Chairperson(s):**
Michael Nurmohamed (Netherlands)
Fabiola Atzeni (Italy)

---

**10:15 - 11:45 N105/N106**

---

**N. Nealon Lennox (Ireland)** 10:40
**S. O’Neill, A. Hannigan**

Abstract N° OP0140-HPR

Acceptance and commitment therapy: a retrospective study of outcomes from a hospital-based, group, pain rehabilitation programme in rheumatology services in the South East of Ireland

---

**W. Peter (Netherlands) 10:50**

Abstract N° OP0141-HPR

An innovative measurement instrument to assess activity limitations in hip and knee osteoarthritis: the computerized animated activity questionnaire (AAQ) and its psychometric properties

---

**R. Geenen (Netherlands) 11:00**
**N. Cameron, M. B. Kool, F. Estévez-López, I. López-Chicheri**

Abstract N° OP0142-HPR

The potential buffering role of self-efficacy and pain acceptance against invalidation in rheumatic diseases

---

**M. Björk (Sweden) 11:10**
**I. Thyberg, E. Valtersson, G. Östlund, B. Stenström, A. Sverker**

Abstract N° OP0143-HPR

Disability in the feet related to participation in daily life in patients with early RA - an interview study in the Swedish TIRA project

---

**M. Henriques (Portugal) 11:20**
**C. Duarte, M. Ndosi, A. Marques, J. A. P. da Silva, R. J. O. Ferreira**

Abstract N° OP0144-HPR

“It can’t be zero”: a qualitative study of patients’ perspective on patient global assessment in rheumatoid arthritis

---

**E. Filhol (France) 10:20**
**C. Gaujoux- Viala, B. Combe, J. Morel, C. Hua, A. Nutz, C. Lukas, F. Fiaisler**

Abstract N° OP0146

Decrease in cardiovascular event excess risk in rheumatoid arthritis since 2000*: a meta- analysis of controlled studies

---

**M. Skieita (Sweden) 10:30**
**L. Söderström, S. Rantapää Dahlqvist, S. Wällberg Jonsson, T. Moore**

Abstract N° OP0147

Trends in mortality, comorbidity and treatment after acute myocardial infarction in patients with rheumatoid arthritis 1998-2013

---

**J. A. Sparks (United States) 10:40**
**T. Lesperance, N. A. Accortt, D. H. Solomon**

Abstract N° OP0148

Impact of a cardiovascular event on DMARD treatment among patients with rheumatoid arthritis, psoriatic arthritis, or psoriasis

---

**M. Holmqvist (Sweden) 10:50**
**L. Ljung, J. Askling**

Abstract N° OP0149

Mortality in new-onset rheumatoid arthritis - has modern rheumatology had an impact?

---

**A. V. de Jonge (Netherlands) 11:00**

Abstract N° OP0150

Paradoxical effect of biological DMARDs in rheumatoid arthritis patients with overweight and obesity: less often clinical remission, but also less radiological damage

---

**T. Neumann (Germany) 11:10**
**C. Dawczynski, M. Dittrich, K. Goetze, A. Welzel, P. Oelzner, S. Voelker, A. M. Schaible, F. Troisi, L. Thomas, S. Pace, A. Koeberle, O. Werz, P. Schlattmann, S. Lorkowski, G. Jahrreis**

Abstract N° OP0151

Docosahexaenoic acid treatment of rheumatoid arthritis: a randomized, double-blind, placebo-controlled, cross-over study

---

**A. Onishi (Japan) 11:20**

Abstract N° OP0152

Docosahexaenoic acid treatment of rheumatoid arthritis: a randomized, double-blind, placebo-controlled, cross-over study

---

**S. Subesinghe (United Kingdom) 11:30**
**A. I. Rutherford, R. Byng-Maddick, J. B. Galloway**

Abstract N° OP0153

Recurrent infections in rheumatoid arthritis patients, results from the BSRBR
Abstract session

Advances in RA and SpA pathophysiology

Chairperson(s):
Francesco Ciccia (Italy)
Rebecca Hasseli (Germany)

C. Ospelt (Switzerland) 10:20
E. Karouzakis, J. Hähnlein, J. F. Semmelink,
R. E. Gay, P. P. Tak, D. M. Gerlag, S. Gay,
L. G. van Baarsen
Abstract N° OP0154
Altered lymph node stromal cells during the earliest phases of rheumatoid arthritis

M. Shi (China) 10:30
H. Xu, G. Chen
Abstract N° OP0155
MDM2-mediated sumoylation of P53 contributes to the migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis

B. Bergström (Sweden) 10:40
H. Carlsten, A.-K. H. Ekwall
Abstract N° OP0156
Methotrexate increases expression of the cell cycle regulators LBH and P21 and reduces fibroblast-like synoviocyte proliferation after mitogen stimulation

A. Pajak (Switzerland) 10:50
Y. Horai, E. Pachera, M. Brock, S. Gay, M. Neidhart,
O. Distler, A. Jungel
Abstract N° OP0157
Apoptosis resistance of synovial fibroblasts of patients with rheumatoid arthritis is regulated by the long non-coding RNA FAS-AS1

A. Arellano-Martinez (Mexico) 11:00
V. Gonzalez-Diaz, G. E. Martinez-Bonilla,
S. Cerpa-Cruz, S. R. Gutierrez-Ureña,
J. Reyes-Rueda, K. M. Garcia-Osuna,
E. Gonzalez-Diaz
Abstract N° OP0158
Prevalence of immunization of patients with autoimmune disease in Mexico

M. Van Tok (Netherlands) 11:10
S. Na, J. Taurog, D. Baeten, L. van Duivenvoorde
Abstract N° OP0159
The initiation, but not the persistence, of experimental spondyloarthritis in HLA-B27/HU82M transgenic rats is crucially dependent on the IL-23 axis

P. Jacques (Belgium) 11:20
K. Debusschere, H. Cypers, F. van den Bosch,
D. Souza, M. Brown, G. Nabozny, D. Dove,
A. Klimowicz, D. Elewaut
Abstract N° OP0160
Gut-derived TNF as risk factor for the development of sacroiliac inflammation

C. Robin-Jagerschmidt (France) 11:30
S. Lavazais, F. Marsais, A. Monjardet, A. Cauvin,
C. Saccomani, I. Parent, D. Merciris, E. Chanudet,
M. Borgonovi, L. Lepescheux, M. Auberval,
S. Dupont, P. Clement-Lacroix, R. Galien
Abstract N° OP0161
The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis

PARE session

Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design

Learning objectives:
To address the most urgent challenges of bringing participatory research to a higher level:

- representativeness education
- support and recognition of patients as collaborative partners
- avoiding unintended forms of tokenism

Chairperson(s):
Jennifer Horonjeff (United States)
Jürgen Clausen (Germany)
Ana-Maria Orbai (United States)

Elsa Mateus (Portugal) 10:40
Abstract N° SP0051
Becoming a patient research partner in the field of rheumatology. My expectations and the challenges of being educated and taken seriously

Heidi Lempp (United Kingdom) 11:00
Abstract N° SP0052
Building patient partnerships in health care service design and delivery

S. R. Stones (United Kingdom) 11:20
Abstract N° OP0162-PARE
An exploration of lived experiences amongst adults with rheumatoid arthritis using an online research community platform: a pilot study

J. Clausen (Germany) 11:30
Abstract N° OP0163-PARE
Invigorating the principle of participatory research in Germany - setup of a training course for patient representatives
Abstract session
Osteoarthritis: new horizons for treatment

Chairperson:
Weiya Zhang (United Kingdom) 10:20
M. A. Bowes (United Kingdom) 10:20
G. Guillard, A. Brett, G. R. Vincent, P. G. Conaghan
Abstract N° OP0164
Optimizing recruitment criteria for an osteoarthritis structure modification trial: data from the OAI

A. C. Bay-Jensen (Denmark) 10:30
A. Bihlet, I. Byrjalsen, J. R. Andersen, Y. He, A. S. Siebuhr, C. S. Thudium, B. J. Riis, C. H. Christiansen, M. A. Karsdal
Abstract N° OP0165
A neoepitope fragment of C-reactive protein is prognostic of radiographic knee OA

Y. Yazici (United States) 10:40
T. E. McAlindon, A. Gibofsky, N. E. Lane, N. Skrepnik, E. Armas, C. J. Swearingen, Y. Yazici (United States)
Abstract N° OP0166
Radiographic outcomes from a randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, injectable, WNT pathway inhibitor (SM04690) in the treatment of osteoarthritis of the knee: week 26 interim analysis

R. Stevens (United States) 10:50
Abstract N° OP0167
Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study

M. Kloppenburg (Netherlands) 11:00
Abstract N° OP0168
A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1alpha and -1beta dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA)

Z. Zhu (Australia) 11:10
L. L. Laslett, W. Han, B. Antony, F. Cicuttini, G. Jones, C. Ding
Abstract N° OP0169
Early osteophytes detected by MRI are associated with changes in knee pain and structures in older adults: a population-based cohort study

A. Veenbrink (Netherlands) 11:20
F. Kroon, R. de Mutsert, W. Visser, S. le Cessie, F. Rosendaal, M. Kloppenburg
Abstract N° OP0170
Leptin and adiponectin mediate the association between body mass index and hand and knee osteoarthritis

K. Wang (China) 11:30
C. Ding, M. J. Hannon, Z. Chen, C. Kwoh, D. J. Hunter
Abstract N° OP0171
Signal intensity alteration within infrapatellar fat pad predicts total knee arthroplasty within four years: data from the osteoarthritis initiative

Abstract session
Cellular drivers of inflammation in rheumatic disease

Chairperson(s):
Dirk Elewaut (Belgium)
João E. Fonseca (Portugal)
G. Balzaretti (Netherlands) 10:20
P. Klarenbeek, M. de Hair, M. Doorenpleet, B. van Schaik, M. van de Sande, D. Gerlag, A. van Kampen, F. Baas, P. P. Tak, N. de Vries
Abstract N° OP0172
Expanded T cell clones present in synovium at onset of rheumatoid arthritis are already present in the synovium in the seropositive “at risk” stage

P. Klarenbeek (Netherlands) 10:30
P.-P. Tak, M. E. Doorenpleet, M. de Hair, M. van Beers-Tas, A. van Kampen, D. van Schaardenburg, D. Gerlag, F. Baas, N. de Vries
Abstract N° OP0173
Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis

K. Skriner (Germany) 10:40
Z. Konthur, M. Wiemkes, T. Häupl, G. R. Burmester
Abstract N° OP0174
New protein array technology identifies rituximab treated non responder rheumatoid arthritis patients are generating a new autoantibody repertoire

E. Corsiero (United Kingdom) 10:50
L. Jagemann, E. Prediletto, C. Pitzalis, M. Bombardieri
Abstract N° OP0175
Characterization of novel stromal-derived autoantigens recognized by RA synovial monoclonal antibodies

D. Elewaut (Belgium) 11:00
E. Gilis, J. Staai, R. Beyaert
Abstract N° OP0176
The paracaspase MALT1 plays a central role in the pathogenesis of rheumatoid arthritis
H. U. Scherer (Netherlands) 11:10
Abstract N° OP0177
N-glycosylation sites in the variable domain of B cell receptors specific for citrullinated antigens

T. Crowley (United Kingdom) 11:20
Abstract N° OP0178
Fibroblast priming is common to many sites, and psoriatic skin fibroblasts may acquire inflammatory memory

R. Biavasco (Italy) 11:30
M. Norelli, B. Camisa, D. Cesana, P. Gallina, B. Gentner, M. Ponsoni, L. Dagna, A. Bondanza, E. Montini
Abstract N° OP0179
BRAFV600E promotes myeloid skewing in multisystemic langerhans cell histiocytosis humanized mouse model

10:15 - 11:45  N109/N110
Abstract session
Joint health & joint damage: a tale of three tissues

Chairperson(s):
Frank Beier (Canada)
Andreea Ioan-Facsinay (Netherlands)
D. Amantini (France) 10:20
Abstract N° OP0180
Pharmacological characterization of the ADAMTS-5 inhibitor GLPG1972: an oral anti-catabolic agent for the treatment of osteoarthritis

H. Fahmi (Canada) 10:30
Y. Ouhaddi, L. Habouri, J. -P. Pelletier, J. Martel-Pelletier, M. Benderdour
Abstract N° OP0181
Deletion of the prostaglandin D2 receptor DP1 exacerbates aging-associated and instability-induced osteoarthritis

D. McGonagle (United Kingdom) 10:40
T. Baboolal, S. Al Hinai, E. Jones, J. Reckless, M. Foster, R. Doyle, K. af Forselles, S. Westbrook
Abstract N° OP0182
Convergence of joint repair and pain pathways via nerve growth factor and P75 expressing mesenchymal stem cells - a novel explanation for osteoarthritis progression with anti-NGF in osteoarthritis

S. Ashraf (United Kingdom) 10:50
J. Burston, V. Chapman, C. de Moor
Abstract N° OP0183
Cordycepin, a novel compound, reduces knee joint pathology and pain in the monosodium iodoacetate (MIA) rat model of osteoarthritis

A. Najm (France) 11:00
B. Le Goff, F. Blanchard, J. Amiaud, C. Charrier, V. Krenn
Abstract N° OP0184
Imsyc immunologic synovitis score: a new histological score for discriminating inflammatory and non-inflammatory arthritis

A. Cuervo Aguilera (Spain) 11:10
R. Celis, J. Ramírez, M. V. Hernández, V. Ruiz-Esquide, J. Inciarte-Mundo, R. Sanmarti, J. D. Cañete
Abstract N° OP0185
Immunohistologic study of synovitis from patients with undifferentiated arthritis who evolved to rheumatoid arthritis or psoriatic arthritis after follow-up

A. Mediero (Spain) 11:20
Abstract N° OP0186
Tenofovir, a nucleoside analog reverse transcriptase inhibitor for treatment of HIV, promotes osteoclast differentiation and bone lost in vivo in a mechanism depending on ATP release and adenosine, and dipyridamole may be a useful treatment to revert the effects

E. Wiebe (Germany) 11:30
Abstract N° OP0187
Transgenic disruption of glucocorticoid-signalling in mature osteoblasts and osteocytes attenuates structural bone damage in a long-term murine K/BXN serum-induced arthritis model

11:45 - 13:30 Exhibition (Hall 10)
Poster viewing & lunch

11:50 - 13:30 Poster area (Hall 10)
Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tours on Thursday please refer to pages 48 to 56.
Poster tour
T1: Genetic basis, epigenetics and genomics in disease
Chairperson(s): Elena Neumann (Germany), Hyun-Dong Chang (Germany)
Abstracts N° THU0001 - THU0010

Poster tour
T2: Inflammatory mediators in rheumatic disease
Chairperson(s): Martin Herrmann (Germany), Marije Koenders (Netherlands)
Abstracts N° THU0025 - THU0034

Poster tour
T3: RA disease course and prognosis
Chairperson(s): Ingemar Petersson (Sweden), Lars E. Kristensen (Denmark)
Abstracts N° THU0068 - THU0077

Poster tour
T4: MTX, GCs and JAK inhibitors in RA
Chairperson(s): Tsutomu Takeuchi (Japan), Diederik De Cock (United Kingdom)
Abstracts N° THU0168 - THU0176

Poster tour
T5: Pathomechanism in SLE, SS, APS
Chairperson(s): Thomas Dörner (Germany), Martin Aringer (Germany)
Abstracts N° THU0216 - THU0225

Poster tour
T6: Novelty in the clinical approach to SLE, Sjögren’s and APS I
Chairperson(s): Angela Tincani (Italy), Maria G. Lazzaroni (Italy)
Abstracts N° THU0246 - THU0257

Poster tour
T7: Vasculities clinical aspects I
Chairperson(s): Leonard Calabrese (United States), José Hernandez-Rodriguez (Spain)
Abstracts N° THU0294 - THU0303

Poster tour
T8: Progress in management of spondyloarthritis
Chairperson(s): Dirk Elewaut (Belgium), Anabela Barcelos (Portugal)
Abstracts N° THU0345 - THU0354

Poster tour
T9: A stroll among the crystals
Chairperson(s): Alexander So (Switzerland), Mariano Andrés (Spain)
Abstracts N° THU0401 - THU0410

Poster tour
T10: Paediatric rheumatology
Chairperson(s): Tadej Avcin (Slovenia), Alessandro Consolaro (Italy)
Abstracts N° THU0486 - THU0495

Poster tour
T11: Clinical features and treatment of orphan diseases
Chairperson(s): Ruxandra Ionescu (Romania), Andra Balanescu (Romania)
Abstracts N° THU0538 - THU0547

Poster tour
T12: Rheumatology training and disease burden
Chairperson(s): Annamaria Iagnocco (Italy), Rucsandra Dobrota (Switzerland)
Abstracts N° THU0596 - THU0605

Poster tour
T13: Economical impact of biosimilars and discussing risks with patients
Chairperson(s): Désirée van der Heijde (Netherlands), Polina Putrik (Netherlands)
Abstracts N° THU0648 - THU0657

Poster tour
T14: Outcomes across all rheumatology
Chairperson(s): Robert B. M. Landewé (Netherlands), Elien Mahler (Netherlands)
Abstracts N° THU0695 - THU0704

Poster tour HPR
T15: From top to toe; health professional practice
Chairperson(s): Rikke H. Moe (Norway), Branka Rimac (Croatia)
Abstracts N° THU0750-HPR - THU0759-HPR

12:00 - 13:30 Poster area (Hall 10)

Poster tour PARE
T16: PARE - Poster tour I
Chairperson(s): Maarten de Wit (Netherlands), Kristijonas Mazuras (Lithuania)
Abstracts N° PARE0001 - PARE0011
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session/Topic</th>
<th>Chairperson(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>Hall 6</td>
<td><strong>What is New (WIN) &amp; How to Treat/Manage (HOT) session</strong></td>
<td><strong>WIN &amp; HOT session</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chairperson(s):</strong></td>
<td><strong>Miguel Angel Gonzalez-Gay (Spain)</strong>, <strong>Cristina Ponte (Portugal)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>WIN: Antiphospholipid syndrome</td>
<td><strong>Raashid Luqmani (United Kingdom)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HOT: Vasculitis treatment</td>
<td><strong>Abstract N° SP0053</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chairperson(s):</strong></td>
<td><strong>Munther Khamashta (United Kingdom)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:35</strong></td>
<td><strong>Abstract N° SP0053</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>14:15</strong></td>
<td><strong>HOT: Vasculitis treatment</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:30 - 15:00 Hall 8</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Clinical Science session</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Treat-to-target in axSpA: reality or utopy?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Learning objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• To learn about the possibilities and challenges of treating to target in axSpA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• To gain insight into whether treating to target in axSpA is possible in daily clinical practice, and how</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chairperson(s):</strong></td>
<td><strong>Annelies Boonen (Netherlands)</strong>, <strong>Lianne Gensler (United States)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Jürgen Braun (Germany)</strong></td>
<td><strong>Abstract N° SP0054</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>The concept of treat-to-target</strong></td>
<td><strong>13:35</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maxime Dougados (France)</strong></td>
<td><strong>Abstract N° SP0055</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>What are the challenges for applying T2T in axSpA?</strong></td>
<td><strong>13:55</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Désirée van der Heijde (Netherlands)</strong></td>
<td><strong>Abstract N° SP0056</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Treat-to-target recommendations in axSpA - update of the recommendations T2T in axSpA</strong></td>
<td><strong>14:15</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A. Moltó (France)</strong></td>
<td><strong>Abstract N° OP1088</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>L. Gossec, R. Landewé, D. van der Heijde, M. Dougados</strong></td>
<td><strong>Defining clinically important worsening based on ASDAS-CRP for axial spondyloarthritis: a data-based consensus by the assessment in spondyloarthritis international society (ASAS)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Abstract N° OP0188</strong></td>
<td><strong>A. Ciurea (Switzerland)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Abstract N° OP0190</strong></td>
<td><strong>Tumor necrosis factor inhibitor treatment reduces spinal radiographic progression in ankylosing spondylitis by decreasing disease activity: a longitudinal analysis in a large prospective cohort</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:30 - 15:00 Hall 7A</strong></td>
<td><strong>Challenges in Clinical Practice session</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>What choice after failure of the first anti-TNF</strong></td>
<td><strong>Learning objectives:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>To learn the help for choosing a second biologic</strong></td>
<td><strong>Chairperson(s):</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Josef S. Smolen (Austria)</strong></td>
<td><strong>Ena Sharma (United States)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Cem Gabay (Switzerland)</strong></td>
<td><strong>Case 1 presentation: Primary anti-TNF failure</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:35</strong></td>
<td><strong>Roy Fleischmann (United States)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:45</strong></td>
<td><strong>Case 1 discussion: A second anti-TNF or another mode of action is the same</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>14:15</strong></td>
<td><strong>Felten Renaud (United States)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Case 2 presentation: Secondary anti-TNF failure</strong></td>
<td><strong>14:15</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Jacques-Eric Gottenberg (France)</strong></td>
<td><strong>Case 2 discussion: Another mode of action is better than a second anti-TNF</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>14:25</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>13:30 - 15:00 Hall 7B</strong></td>
<td><strong>From Bench to Bedside</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Calcium crystal deposition in rheumatic diseases</strong></td>
<td><strong>Learning objectives:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Recognise the extent and mechanisms of calcium crystal deposition in rheumatic diseases</strong></td>
<td><strong>Chairperson(s):</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Recognise the imaging modalities that contribute to clinical management</strong></td>
<td><strong>Frederic Lioté (France)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Recognise the association between calcium crystal formation and osteoarthritis</strong></td>
<td><strong>Alexander So (Switzerland)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Mechanisms of CPP and HA crystal deposition in man</strong></td>
<td><strong>Hang-Korng Ea (France)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Abstract N° SP0057</strong></td>
<td><strong>Mechanisms of CPP and HA crystal deposition in man</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Calcium crystals and their link to osteoarthritis</strong></td>
<td><strong>Jessica Bertrand (Germany)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Review of the different imaging modalities to detect calcium deposition diseases</strong></td>
<td><strong>13:35</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A. Najm, T. Garraud, P. Layrolle, F. Blanchard, B. Le Goff</strong></td>
<td><strong>Patrick Omoumi (Switzerland)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Abstract N° OP0190</strong></td>
<td><strong>14:15</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Histological characterization of rotator cuff calcific tendinopathy</strong></td>
<td><strong>C. Darriuertot-Laffite (France)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A. Ciurea (Switzerland)</strong></td>
<td><strong>14:35</strong></td>
</tr>
</tbody>
</table>
A. Combier (France) 14:45
M. Forien, A. Gardette, E. Palazzo, P. Dieudé, S. Ottaviani
Abstract N° OP0191
Comparison of ultrasonography and radiography of the wrist for diagnosis of calcium pyrophosphate deposition

13:30 - 15:00  N103/N104

Clinical Science session
Fifty shades of remission in RA

Learning objectives:
• To be able to understand the broad spectrum of remission, clinical, biochemical as well as image-wise
• To appreciate the pro’s and con’s of involving imaging aspects in the concept of remission
• To appreciate the pro’s and con’s of involving biochemical aspects in the concept of remission

Chairperson(s):
Jonathan Kay (United States)
Sander W. Tas (Netherlands)

Maarten Boers (Netherlands) 13:35
Abstract N° SP0059
Remission: more than clinical

Maria-Antonietta d’Agostino (France) 13:55
Abstract N° SP0061
Imaging is required for remission: PRO

Espen A. Haavardsholm (Norway) 14:07
Abstract N° SP0062
Imaging is required for remission: CON

Daniel Aletaha (Austria) 14:19
Abstract N° SP0063
Biomarkers are required for remission: CON

Ronald van Vollenhoven (Netherlands) 14:31
Abstract N° SP0064
Biomarkers are required for remission: PRO

A. Sepriano (Netherlands) 14:43
Abstract N° OP0192
Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission: results from the BIODAM cohort

13:30 - 15:00  South Auditorium

Basic and Translational Science session
Innate immunity

Learning objectives:
• What are the underlying mechanisms orchestrating the initiation and resolution of inflammation?
• What is the clinical relevance of the newly described features of innate immune cells and complement?
• What new treatment options are emerging?

Chairperson(s):
Reinhard E. Voll (Germany)
Yi Zhao (China)

Andrés Hidalgo (Spain) 13:35
Abstract N° SP0061
Neutrophils patrol healthy tissues

Gerhard Krönke (Germany) 13:55
Abstract N° SP0062
Differential scavenging of apoptotic cells and bacteria

Patrizia Rovere-Querini (Italy) 14:15
Abstract N° SP0063
The role of muscle in innate immune responses

F. Ciccia (Italy) 14:35
A. Rizzo, R. Alessandro, S. Raimondo, G. Guggino, A. Cavazza, C. Salvareni, G. Triolo
Abstract N° OP0193
Inflammation of adventitial nerves occurs in giant cell arteritis patients and it is characterized by inflammasomes, UPR and autophagy activation

G. Steiner (Austria) 14:45
A. Fischer, B. Meyer, B. Niederreiter
Abstract N° OP0194
Involvement of toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis and during osteoclastogenesis

13:30 - 15:00  N101/N102

Joint session HPR/PARE/Paediatric Rheumatology
To be and to become: transition from pediatric to adult care

Learning objectives:
• To understand the patient perspective
• To learn about the scientific evidence and comprehend the clinical implementation of the transition process

Chairperson(s):
Tadej Avcin (Slovenia)
Erik Taal (Netherlands)

Wendy Olsder (Netherlands) 13:35
Abstract N° SP0064
To be and to become: reflections on my transition
### Paediatric Rheumatology session

#### Heterogeneity in JIA

**Learning objectives:**
To discuss biologic basis, cytokine profiling and clinical phenotypic variability in JIA

**Chairperson(s):**
Sebastian Vastert (Netherlands)
Fabrizio de Benedetti (Italy)

*Biologic basis of heterogeneity in JIA*

Rae Yeung (Canada) 13:35

*JIA cytokine profiling*

Wilco de Jager (Netherlands) 13:55

*Clinical insights into JIA heterogeneity*

Alessandro Consolaro (Italy) 14:15

*K. Minden, I. Foeldvari, G. Ganser, J. P. Haas, J. Brunner, I. Becker on behalf of BIKER collaborative group*

G. Horneff (Germany) 14:35

*Changing patterns of juvenile idiopathic arthritis patients treated with etanercept from 2000 to 2016 in the German BIKER registry population*

N. L. Mallalieu (United States) 14:45

*Evaluation of a dosing regimen for tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis*

### 13:30 - 15:00  N105/N106

#### Clinical Science session

**EULAR - EMA session**

**Learning objectives:**
- To address important issues in regulatory affairs of both EMA and FDA regarding the value of registries
- To address the increasing bureaucracy in carrying out clinical trials and how to consider new imaging tools

**Chairperson(s):**
Ferdinand C. Breedveld (Netherlands)
Vibeke Strand (United States)

*Registries in musculoskeletal diseases and their regulatory use*

Frank Behrens (Germany) 13:35

*News from OMERACT - imaging and more*

Badrul A. Chowdhury, (United States) 14:29

**The FDA’s view**

Faculty 14:47

#### PARE session

**Barrier-free employment for young people with RMDs**

**Learning objectives:**
- To explore barriers to employment that young people with RMDs face
- To look at possible solutions to employ and keep young people with RMDs in the workplace

**Chairperson(s):**
Andri Phoka (Cyprus)
Alessia Alunno (Italy)

*Young patients: ready, brilliant and able to work!*

Jeanette Andersen (United Kingdom) 13:55

*Challenges and potential solutions about staying in work as a young person with an RMD*

Maureen McAllister (United Kingdom) 14:15

*Practical employability support for young people with RMDs*

G. O’Leary (Ireland) 14:35

*Fit for work online: supporting employees with RMDs, employers and healthcare professionals*
13:30 - 15:00 N117/N118

**EULAR Projects in Epidemiology and Health Services**

**Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal**

**Learning objectives:**
- To review and discuss the impact of epidemiological research in rheumatic and musculoskeletal diseases
- To review the overall impact of epidemiological research in RMDs
- To learn about strategies for successful development of epidemiological and public health research from other medical areas

**Chairperson(s):**
- Loreto Carmona (Spain)
- Pedro Machado (United Kingdom)
- Deborah Symmons (United Kingdom)

**Ingemar Petersson (Sweden) 13:35**
The impact of epidemiological research in rheumatic and musculoskeletal diseases over the past decade

**Laure Gossec (France) 14:11**
The future of epidemiological research in rheumatic and musculoskeletal disorders

**William G. Dixon (United Kingdom) 14:29**
The future of public health and health services research in rheumatic and musculoskeletal disorders

**T. Frisell (Sweden) 14:47**
E. Baecklund, K. Bengtsson, D. Di Giuseppe, H. Forsblad-d’Elia, J. Asking on behalf of the ARTIS study group

Abstract N° OP0200
Confounding by indication will make non-TNFI BDMARDs appear more harmful than TNFI BDMARDs - a nationwide study of channeling in Sweden 2010-2014

---

**13:30 - 15:00 N109/N110**

**Practical skills session* Ultrasound advanced I**

**Chairperson(s):**
- Georgios Filippou (Italy)
- Esperanza Naredo (Spain)

**Sarah Ohrndorf (Germany) 13:35**
How to score synovitis quantitatively - validity and feasibility + demo

**Mads Ammitzboll (Denmark) 13:55**
How to use image fusion + demo

**David Bong (Spain) 14:15**
How and when to assess cervical facet joints + demo

**Jelena Vojinovic (Serbia) 14:35**
How to evaluate joints in JIA + patient cases

**Tutor:**
Lykke Midtboell Oernbjerg (Denmark)

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
15:30 - 17:00  Hall 6

What is New (WIN) & How to Treat (HOT) session

WIN session

Chairperson(s):
Loreto Carmona (Spain)
Elena Nikiphorou (United Kingdom)
William G. Dixon (United Kingdom) 15:35
WIN: Disease registers and electronic patient records for benchmarking in rheumatological care

Tore K. Kvien (Norway) 16:15
WIN: Do published guidelines and recommendations improve the quality of care in rheumatology?

15:30 - 17:00  Hall 7A

Challenges in Clinical Practice session

Autoinflammatory diseases in children and adults

Learning objectives:
To understand challenges in approaching autoinflammatory diseases in children and adults

Chairperson(s):
Jelena Vojinovic (Serbia)
Ruxandra Ionescu (Romania)

Stefan Blazina (Slovenia) 15:35
Case 1 presentation: Chronic nonbacterial osteomyelitis - a child with bone pain

Hermann Girschick (Germany) 15:45
Case 1 discussion: Diagnosis and management of chronic nonbacterial osteomyelitis

Claudia Deaconu (Romania) 16:15
Abstract N° SP0080
Case 2 presentation: Recurrent episodes of fever and arthritis in adult patient

Luca Cantarini (Italy) 16:25
Case 2 discussion: Diagnosis and management of autoinflammatory diseases in adults

15:30 - 17:00  Hall 8

Clinical Science session

PsA: an integrated perspective

Learning objectives:
• To understand the utility of various imaging modalities in predicting the development of psoriatic disease
• To appreciate the diversity in inflammatory pathways in skin and synovial tissue in patients with psoriatic disease
• To formulate strategies to reach optimal outcomes in PsA with the available treatment choices

Chairperson(s):
Lai-Shan Tam (China)
Laura Coates (United Kingdom)
Mikkel Østergaard (Denmark) 15:35
Abstract N° SP0078
Can imaging be a predictor of psoriatic disease?

Rik Lories (Belgium) 15:55
Abstract N° SP0079
Pathologies across the tissues in PsA

Filip van den Bosch (Belgium) 16:15
New and old agents: how to use our new toys?

P. Nash (Australia) 16:35
B. Kirkham, M. Okada, P. Rahman, B. Combe,
D. H. Adams, L. N. Kerr, C. H. Lee, C. L. Shuler,
M. C. Genovese
Abstract N° OP0201
A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)

D. D. Gladman (Canada) 16:45
W. F. C. Rigby, V. F. Azevedo, F. Behrens, R. Blanco,
A. Kaszuba, E. Kudlac, C. Wang, S. Menon,
T. Hendrikx, K. S. Kanik
Abstract N° OP0202
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

15:30 - 17:00  Hall 7B

From Bench to Bedside

Immunogenicity of biologics; myth or reality?

Learning objectives:
• To understand the origin of anti-drug antibodies
• To focus on the experience of drug monitoring in gastroenterology and thus drawing conclusions in our clinical practice

Chairperson(s):
Gert-Jan Wolbink (Netherlands)
Claudia Mauri (United Kingdom)

Bernard Maille (France) 15:35
Abstract N° SP0081
The T cell response against biologics

Ann Gils (Belgium) 15:55
Abstract N° SP0082
Immunogenicity of biologics in inflammatory bowel diseases

Johannes W. J. Bijlsma (Netherlands) 16:15
Abstract N° SP0083
As a rheumatologist, does it have any consequence in my daily practice?
Clinical Science session

Which target/outcome is more relevant in the management of SLE?

Learning objectives:
• To define the clinical manifestations to be targeted for remission
• To discuss novel biomarkers for the definition of disease activity and/or patients’ subsets
• To highlight the importance of collecting the patients’ feelings by means of PROs

Chairperson(s):
Angela Tincani (Italy)
Georges Bertsias (Greece)

Andrea Doria (Italy) 15:35
Clinical targets

Carlo Chizzolini (Switzerland) 15:55
Abstract N° SP0084
Biological targets

Matthias Schneider (Germany) 16:15
Abstract N° SP0085
Patient reported outcomes

S. Nakayamada (Japan) 16:35
Abstract N° OP0205
Association between T follicular helper cell and plasmablast correlates with disease activity in patients with systemic lupus erythematosus

D. Jesus (Portugal) 16:45
M. Rodrigues, A. Matos, C. Henriques, J. Da Silva, L. Inês
Abstract N° OP0206
Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients
Martin Neovius (Sweden) 15:53
Costs of comorbidity

Hanne Dagfinrud (Norway) 16:11
Abstract N° SP0089
How to prevent and treat cardiovascular comorbidity with exercise?

Mariette de Rooij (Netherlands) 16:29
Abstract N° SP0090
Comorbidity-adapted exercise for patients with knee osteoarthritis

M. A. Martin Martinez (Spain) 16:47
Abstract N° OP0209-HPR
Incidence of first cardiovascular event in Spanish patients with chronic inflammatory rheumatic diseases: prospective data from the CARMA project

Kanta Kumar (United Kingdom) 15:55
Abstract N° SP0093
The challenges and solutions for engaging patients from ethnic backgrounds in rheumatology care

Tidiane Diao (Sweden) 16:15
Abstract N° SP0094
The Swedish experience - how a patient organisation could reach out to immigrants and develop through integration

S. R. Stones (United Kingdom) 16:35
S. M. Cruickshank, S. M. M. Verstappen on behalf of MyJIA Expert Advisory group
Abstract N° OP0210-PARE
The development and evaluation of an interactive health communication application to educate and empower young people living with juvenile idiopathic arthritis: a pilot study

A. Bosworth (United Kingdom) 16:45
C. O’Neill, K. R. Martin
Abstract N° OP0211-PARE
Who cares? An investigation of the health and perceived social care needs of people with rheumatoid arthritis living in Scotland

15:30 - 17:00  N111/N112

Practical skills session*
Data visualisation: tables and graphs for publication and presentation I

Chairperson(s):
Maarten Boers (Netherlands) 15:35
Abstract N° SP0091
Data visualisation: tables and graphs for publication and presentation

15:30 - 17:00  N115/N116

PARE session
Difficult to reach patient groups

Learning objectives:
• To understand how socio-economic factors influence access to treatment and quality of healthcare
• To realise what barriers exist for people with a migration background and how these barriers can be overcome
• To learn how patient organisations can support disadvantaged people

Chairperson(s):
Boryana Boteva (Bulgaria)
Neil Betteridge (United Kingdom)
Michael Zänker (Germany) 15:35
Abstract N° SP0092
The vicious circle of educational level of rheumatoid arthritis and risk of poverty - results of a cross-sectional multicentre study in Germany

15:30 - 17:00  N117/N118

EULAR Projects in Musculoskeletal Imaging

Chairperson(s):
Esperanza Naredo (Spain)
Xenophon Baraliakos (Germany)
Christian Dejaco (Austria) 15:35
Abstract N° SP0095
EULAR Recommendations for the use of imaging in the diagnosis and management of large vessel vasculitis in clinical practice

Maria-Antonietta d’Agostino (France) 15:50
Development of EULAR Recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology

Paz Collado (Spain) 16:05
Abstract N° SP0096
EULAR-PReS Standardised procedures for ultrasound imaging in paediatric rheumatology

Frédérique Gandjbakhch (France) 16:20
Definition of rheumatoid arthritis bone erosion

Maria-Antonietta d’Agostino (France) 16:35
EULAR recommendation/criteria for the appropriate use of MSK US in rheumatology clinical practice

Ingrid Möller (Spain) 16:50
Abstract N° SP0097
EULAR standardised procedures for rheumatology ultrasound imaging

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
**15:30 - 17:00  N107/N108**

**Practical skills session*\**

**Capillaroscopy I**

**Chairperson(s):**
Francesca Ingegnoli (Italy)
Alberto Sulli (Italy)

**Vanessa Smith (Belgium) 15:35**
Abstract N° SP0098
The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease

**Alberto Sulli (Italy) 15:45**
Scoring the capillaroscopic images: manual versus (semi)automatic systems

**Ariane L. Herrick (United Kingdom) 15:55**
How to distinguish the major capillaroscopic patterns in connective tissue diseases

**Maurizio Cutolo (Italy) 16:05**
Abstract N° SP0099
Why capillaroscopy can predict disease severity and prognosis

**Walter Hermann (Germany) 16:15**
Abstract N° SP0100
How to select the most appropriate capillaroscopic device: pro’s and con’s

**Faculty 16:25**
Live practical session with patients and case discussion

---

**15:30 - 17:00  N109/N110**

**Practical skills session*\**

**Ultrasound, clinical, diagnostic and therapeutic skills I**

**Learning objectives:**
- To learn how to perform US guided procedures
- To learn the basic principles and practical aspects of the physical examination
- To learn how to read and interpret pathological findings of imaging modalities
- To show and discuss interactively the relevance of competency skills in US

**Chairperson(s):**
Nemanja Damjanov (Serbia)
Dario Roccatello (Italy)

**Peter Mandl (Austria) 15:35**
Abstract N° SP0101
Diagnostic and therapeutic ultrasound-guided procedures

**Michael Doherty (United Kingdom) 15:53**
Abstract N° SP0102
How to perform a quick and efficient physical examination

**Roberto Caporali (Italy) 16:11**
How to read and interpret imaging tools: X-Ray

---

**17:30 - 19:00  South Auditorium**

**Basic and Translational Science session**

**Macrophage M2 polarization: implications in fibrotizing diseases**

**Learning objectives:**
To be updated regarding the mechanisms and role played by macrophage polarization (M1->M2) during the fibrotic process and related diseases

**Chairperson(s):**
Oliver Distler (Switzerland)
Ulf Müller-Ladner (Germany)

**Antonio Sica (Italy) 17:35**
Abstract N° SP0104
Molecular and epigenetic basis of macrophage polarized activation

**Niels Camara (Brazil) 17:55**
Abstract N° SP0105
Macrophages during the fibrotic process: friend or foe

**Robert Lafyatis (United States) 18:15**
Alternative activation of monocyte/macrophages in pathophysiology of fibrotizing diseases

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Guided Poster Tours

Thursday, 15 June 2017 11:50 - 13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis on the day of the poster tour.

Poster Tour T1: Genetic basis, epigenetics and genomics in disease

Chairperson(s): Elena Neumann (Germany), Hyun-Dong Chang (Germany)


THU0007 DEEP SEQUENCING TRANSCRIPTOME ANALYSIS OF THE EFFECT OF TRAUMEEL VERSUS DICLOFENAC THERAPEUTIC ACTION IN WOUND HEALING / G. St. Laurent, III - B. Sellheim - M. Tackett - J. Zhou - D. Shtokalo - Y. Vyatkin - P. Kapranov - I. Toma - T. Mccaffrey*


THU0010 ALTERED MIRNAS PROFILES IN PLASMA-DERIVED EXOSOME OF PATIENTS WITH ANKYLOSING SPONDYLITIS BY SMALL RNA-SEQ ANALYSIS / Y. Huang* - T. Li - Z. Huang - W. Deng - S. Zheng - X. Guo - Z. Huang

* Presenting author
**Poster Tour T2: Inflammatory mediators in rheumatic disease**

**Chairperson(s):** Martin Herrmann (Germany), Marije Koenders (Netherlands)

**THU0025**

**THU0026**
- OSM IS MORE EFFECTIVE THAN IL-6 AT INDUCING ENDOMYT DEGRADATION IN HUMAN DERMAL MICROVASCULAR CELLS / K. Nevin* - L. Stavski - M. Feeney - N. Wisniacki - M. Trojanowska

**THU0027**

**THU0029**

**THU0030**

**THU0031**

**THU0032**
- THE ROLE OF S100A9 IN PAIN RESPONSE DURING EXPERIMENTALLY INDUCED ACUTE SYNOVITIS / E. J. W. Geven* - N. Ishii - T. Yamauchi - N. Yasuda - T. Imai

**THU0033**
- LOCAL INJECTION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN EXPERIMENTAL INFLAMMATORY OA RESULTS IN INTERLEUKIN-1B-MEDIATED ATTRACTION OF PMNS AND REDUCED S100A8/A9 RELEASE / S. van Dalen* - A. Sloetjes - M. Helsen - B. Walgreen - E. Geven - P. van Lent

**THU0034**

**THU0035**

**THU0036**

**THU0037**

**THU0038**

**THU0039**
- BODY MASS INDEX IN EARLY RHEUMATOID ARTHRITIS IN UNDERWEIGHT PATIENTS IS ASSOCIATED WITH MORE PROGRESSION OF EROSIONS OVER 15 YEARS AND IN OBESE PATIENTS WITH LESS PROGRESSION OF JOINT SPACE NARROWING / S. Ajeganova* - K. Forslind - B. Svensson - I. Hafström

**THU0040**

**THU0041**

**THU0042**
- ANTI-COLLAGEN TYPE II ANTIBodies ARE ASSOCIATED WITH AN ACUTE ONSET RHEUMATOID ARTHRITIS PHENOTYPE AND PROGNOSTICATE LOWER DEGREE OF INFLAMMATION / V. A. Manivel* - M. Mullazehi - L. Padyukov - H. Westerlind - L. Klareskog - L. Alfredsson - S. Saevarsdottir - J. Rönnelid

---

* Presenting author
**Poster Tour T4: MTX, GCs and JAK inhibitors in RA**

**Chairperson(s):** Tsutomu Takeuchi (Japan), Diederik De Cock (United Kingdom)

**THU0168**


**THU0169**

 One-Third of Patients with Rheumatoid Arthritis Eligible for a First Biologic Are Not Adherent to Methotrexate: Results of a Cross-Sectional Survey of 244 Patients / C. Beauvais* - V. Hautin-Monteil - M.-C. Ducrot - R.-M. Filpo

**THU0170**


**THU0171**


**THU0172**

 Improvement of Disease Activity in a 5-Year Cohort of Rheumatoid Arthritis Patients Treated Under Treatment to Target Recommendations and a Multispeciality Care Model Receiving Conventional DMARD Therapy / P. Santos-Moreno* - D. Gomez - E. Castillo - R. Giraldo - G. Ballesteros - P. H. Harrison - A. van der Aa

**THU0173**


**THU0174**


**THU0175**

 Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response as Early as One Month Predicts 12-Month Radiographic Progression; Data from a Study Using Tofacitinib and Methotrexate in Patients with Early RA / P. G. Conaghan* - M. A. Bowes - M. Østergaard - G. Guillard - D. Chapman - A. Stein - J. Andrews - Z. Xie - A. Koenig - K. Soma - B. Wilkinson

**THU0176**

 Efficiency and Safety of Rapamycin Combined with Low-dose IL-2 Treatment Compared with Methotrexate in Patients with Rheumatoid Arthritis / Z. Li* - H. Niu - M. Chen - H. Yao - J. Luo - C. Gao - X. Li - C. Wang

---

**Poster Tour T5: Pathomechanism in SLE, SS, APS**

**Chairperson(s):** Thomas Dörner (Germany), Martin Aringer (Germany)

**THU0216**


**THU0217**


**THU0218**


**THU0219**

 Autoantibody Profile of Children with Juvenile Dermatomyositis from a Tertiary Care Centre in North India / S. Guleria* - A. Sharma - A. Gupta - A. Rawat - D. Suri - S. Singh

**THU0220**


**THU0221**


**THU0222**

 Prophylactic and Therapeutic Administration of an Anti-CD40 Antagonist Antibody Blocks and Reverses Proteinuria and Nephritis in NZB/W-F1 Mice / S. Perper - S. Westmoreland - Y. Liu - M. Duval - J. Seagal - B. McRae - S. Clarke*

**THU0223**


**THU0224**


**THU0225**

Poster Tour T6: Novelty in the clinical approach to SLE, Sjögren's and APS I

**Chairperson(s):** Angela Tincani (Italy), Maria G. Lazzaroni (Italy)

**THU0246**

**THU0247**
THE PRESENCE OF ANTI-RO AND ANTI-LA ANTIBODIES IS ASSOCIATED WITH TUBULOINTERSTITIAL DAMAGE IN LUPUS NEPHRITIS / A. Londono Jimenez* - W. B. Movrey - A. Broder

**THU0248**

**THU0249**
SUBCLINICAL HAND ARTHROPATHY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. A. Guillen-Astete* - M. Revenga-Martinez - A. Zea-Mendoza

**THU0250**
EFFECT OF FETAL UMBILICAL ARTERY DOPPLER ON PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS / Z. Zhan* - D. Chen - Q. Oiu - Y. Yang

**THU0251**

**THU0252**

**THU0253**
TRIPLE POSITIVITY TO ANTIPHOSPHOLIPID ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: INCREASED RISK OF ARTERIAL THROMBOSSES AND ABDORTIONS / F. Signorelli - G. Balbi - R. A. Levy*

**THU0254**

**THU0255**
COMPARISON OF REMISSION AND LUPUS LOW ACTIVITY STATE AS PREDICTORS OF ORGAN DAMAGE / M. Petri* - L. S. Magder

**THU0256**

**THU0257**
ENHANCED ACTIVATION OF NLRP3 INFLAMMASOMES IN PATIENTS WITH SJÖGREN’S SYNDROME / J. N. Kim - S.-K. Kim - J.-Y. Choe*

Poster Tour T7: Vasculities clinical aspects I

**Chairperson(s):** Leonard Calabrese (United States), José Hernandez-Rodriguez (Spain)

**THU0294**

**THU0295**
CLINICAL FEATURES OF TAKAYASU’S ARTERITIS FROM AN INCEPTION COHORT: EARLY DISEASE IS CHARACTERIZED BY “SYSTEMIC INFLAMMATION” / F. Alibaz-Oner*

**THU0296**
THE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS (GCA) IN ROUTINE CLINICAL PRACTICE / S. Monti* - A. Floris - C. Ponte - S. Vaggers - W. A. Schmidt - A. P. Diamantopoulos - C. Pereira - R. Luigmari

**THU0297**

**THU0298**

**THU0299**

**THU0300**

**THU0301**

**THU0302**

**THU0303**

* Presenting author
**Poster Tour T8: Progress in management of spondyloarthritis**

**Chairperson(s):** Dirk Eieuwat (Belgium), Anaabela Barcelos (Portugal)

**THU0345**

**THU0346**

**THU0347**

**THU0348**
SAFETY AND EFFICACY OF INTRAVENOUS GOLIMUMAB IN ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS THROUGH WEEK 28 / A. Deodhar* - J. D. Revelle - D. D. Harrison - L. Kim - K. H. Lo - E. Hsiia

**THU0349**

**THU0350**
EFFECT OF NSAID CONSUMPTION ON CARDIOVASCULAR EVENTS IN Spondyloarthritis / E. Riével* - A. Etcheto - F. van den Bosch - D. van der Heijde - R. Landewé - M. Dougados - A. Molto on behalf of ASAS-COMOSPA taskforce

**THU0351**

**THU0352**

**THU0353**

**THU0354**

**Chairperson(s):** Alexander So (Switzerland), Mariano Andrés (Spain)

**THU0401**

**THU0402**

**THU0403**
URATE-LOWERING TREATMENT AND RISK OF INCIDENT UROLITHIASIS IN PEOPLE WITH GOUT: A NESTED CASE-CONTROL STUDY / C.-F. Kuo* - J.-S. Chen

**THU0404**

**THU0405**
SELF-REPORTED SEVERITY OF GOUT IN A PRIMARY CARE SETTING AND ASSOCIATED FACTORS: RESULTS FROM A GOUT SURVEY IN PRIMARY CARE / C.-F. Kuo* - J.-S. Chen

**THU0406**
EFFECT OF NSAID CONSUMPTION ON CARDIOVASCULAR EVENTS IN Spondyloarthritis / E. Riével* - A. Etcheto - F. van den Bosch - D. van der Heijde - R. Landewé - M. Dougados - A. Molto on behalf of ASAS-COMOSPA taskforce

**THU0407**

**THU0408**
GOUT IS AN IMPORTANT PREDICTOR OF WORK DISABILITY IN BOTH MEN AND WOMEN / V. Sigurdardottir* - P. Drivelegka - A. Svärd - L. T. Jacobsson - M. Dehlin

**THU0409**

* Presenting author
**Poster Tour T10: Paediatric rheumatology**

**Chairperson(s): Tadej Avcin (Slovenia), Alessandro Consolaro (Italy)**

**THU0486**
ANGIOPOETIN-2 AS A NEW VALUABLE MARKER OF DISEASE ACTIVITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / J. Świderska-Jaros* - E. Smolewska

**THU0487**
REAL-LIFE TREATMENT WITH CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - FIRST EXPERIENCE FROM THE BIKER REGISTRY / G. Horneff* - F. Dressler - A. Thon - K. Minden on behalf of BIKER collaborative group

**THU0488**
The impact of oligoarticular and polyarticular juvenile idiopathic arthritis over the first five years following diagnosis / S. J. W. Shoop-Worrall* - S. M. Verstappen - J. E. McDonagh - W. Thomson - K. L. Hyrich on behalf of CAPS

**THU0489**

**THU0490**

**THU0491**

**THU0492**
MACROPHAGE ACTIVATION SYNDROME AS THE INITIAL MANIFESTATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS / S. Sato* - E. Della Torre - M. Hofer - J. Kuemmerle-Deschner - C. Shi* - J. Li - D. Qi - L. Qiao

**THU0493**
Effectiveness of vaccines in CAPS patients treated with Canakinumab: results from an open-label phase 3 extension study / P. Brogan* - M. Hofer - J. Kuemmerle-Deschner - B. Lauwers - A. Speziale - X. Wei - R. Laxer

**Poster Tour T11: Clinical features and treatment of orphan diseases**

**Chairperson(s): Ruxandra Ionescu (Romania), Andra Balanescu (Romania)**

**THU0538**

**THU0539**

**THU0540**

**THU0541**
ROLE OF IL-1 INHIBITION IN ADULT ONSET STILL’S DISEASE (AOSD): A RETROSPECTIVE, OBSERVATIONAL MULTICENTRIC STUDY FROM THE ITALIAN SOCIETY OF RHEUMATOLOGY STUDY GROUP ON AUTOINFLAMMATORY DISEASES / S. Colafrancesco* - R. Priori - P. Sfriso - G. Valesini - L. Punzi - M. Galeazzi - L. Cantarini on behalf of the study group on Autoinflammatory diseases (Italian Society of Rheumatology)

**THU0542**
ANti-INTERLEUKIN 1 THERAPY IN FMF AMYLOIDOSIS: A SINGLE CENTER EXPERIENCE (CASE SERIES) / S. Ugurlu* - B. Ergezen - A. Hacioglu - H. Ozdogan

**THU0543**

**THU0544**
THE IMPORTANCE OF R202Q POLYMORPHISM IN CLINICAL EXPRESSION OF FMF: A SINGLE CENTER CROSS-SECTIONAL STUDY / S. Yilmaz - E. Tekgoz - F. I. Cinar - M. Cinar*

**THU0545**
COMPARISON OF THE CLINICAL AND LABORATORY FEATURES AT ONSET BETWEEN MULTICENTRIC CASTLEMAN’S DISEASE AND ADULT-ONSET STILL’S DISEASE / A. González García* - W. A. Sifuentes Giraldo - J. L. Morell Hita - J. L. Patier de la Peña

**THU0546**
REAL-LIFE TREATMENT WITH CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - FIRST EXPERIENCE FROM THE BIKER REGISTRY / G. Horneff* - F. Dressler - A. Thon - K. Minden on behalf of BIKER collaborative group

* Presenting author
**Poster Tour T12: Rheumatology training and disease burden**

**Chairperson(s):** Annamaria Iagnocco (Italy), Rucsandra Dobrota (Switzerland)

**THU0596**
RHEUMATOLOGY SPECIALTY TRAINING IN EUROPEAN UNION COUNTRIES / N. Cikes* - J. Dudler - F. Listé - D. E. Bax - N. D. S. Bax on behalf of UEMS Rheumatology Section and Board Union Européenne des Médecins Spécialistes, Avenue de la Couronne 20, Bruxelles 1050

**THU0597**

**THU0598**

**THU0599**
BENEFIT RISK RATIO FOR BIOLOGICAL AGENTS IN JUVENILE IDIOPATHIC ARTHRITIS, A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS / N. Cabrera* - P. Janiaud - A. Belot - B. Kassai - J.-C. Lega

**THU0600**

**THU0601**

**THU0602**

**THU0603**

**THU0604**

**THU0605**
IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS / M. Belhassen* - F. Tubach - C. Hudry - M.-C. Woronoff - L. Levy-Bachelot - L. Mamezec - E. Van Ganse - B. Fautrel

**Poster Tour T13: Economical impact of biosimilars and discussing risks with patients**

**Chairperson(s):** Désirée van der Heijde (Netherlands), Polina Putrik (Netherlands)

**THU0648**
USE OF OUTPATIENT RHEUMATOLOGIC HEALTH CARE SERVICES BEFORE AND AFTER SWITCH FROM ORIGINATOR TO BIOSIMILAR INFILIXIMAB / B. Glintborg* - J. Sorensen - M. L. Hetland

**THU0649**

**THU0650**
THE EFFECT OF ANTI-TNF THERAPY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING Spondylitis and Psoriatic Arthritis OVER ONE YEAR - REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA / J. Zavada* - L. Szczukova - K. Pavelka - P. Fekete - J. Vencovsky on behalf of collaborators of the ATTRA registry

**THU0651**

**THU0652**

**THU0653**

**THU0654**
IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS / M. Belhassen* - F. Tubach - C. Hudry - M.-C. Woronoff - L. Levy-Bachelot - L. Mamezec - E. Van Ganse - B. Fautrel

**THU0655**

**THU0656**

**THU0657**

* Presenting author
**Poster Tour T15: HPR: From top to toe; health professional practice**

**Chairperson(s): Rikke H. Moe (Norway), Branka Rimac (Croatia)**

- **THU0750-HPR**

- **THU0751-HPR**
  - EFFECTIVENESS OF FOOT ORTHOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS RELATED TO QUALITY OF LIFE AND PAIN. A SYSTEMATIC REVIEW AND META-ANALYSIS / G. Gijon-Nogueron* - L. Ramos-Petersen - S. Garcia-Mayor - J. M. Morales-Asecono

- **THU0752-HPR**

- **THU0753-HPR**

- **THU0754-HPR**
  - WORK STATUS IN WOMEN WITH FIBROMYALGIA – A 12-YEAR FOLLOW UP STUDY / S. Johannesson* - L. Nordeman - M. Joelsson - K. Mannerkorpi - A. Bergenheim

- **THU0755-HPR**

- **THU0756-HPR**

- **THU0757-HPR**

- **THU0758-HPR**
  - APPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND / K. Niedermann* - C. Madelaine-Bonjour - M. Roiffier - A. Kocher on behalf of Health Professionals in Rheumatology Switzerland

- **THU0759-HPR**
  - DOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS? / M. Karapinar* - T. Firat - N. Kirdi

* Presenting author
**Poster Tour T16: PARE poster tour I**

Chairperson(s): Maarten de Wit (Netherlands), Kristijonas Mazuras (Lithuania)

**PARE0001**

**PARE0002**

**PARE0003**

**PARE0004**
PATIENT REPORTED LONG-TERM EFFECTS OF SIX WEEK PROGRESSIVE RESISTANCE TRAINING PROGRAMME FOR RHEUMATOID ARTHRITIS / R. Tekkatte* - A. Suarez - B. Berntzen - D. Collins - E. Price - L. Williamson

**PARE0005**
EDUCATIONAL PROGRAM FOR OLDER ADULTS WITH KNEE OSTEOARTHRITIS / M. R. Espanha* - P. P. Marconcin - P. L. Campos - F. G. Yázigi

**PARE0006**
PATIENT INVOLVEMENT IN BASIC RESEARCH: A PILOT STUDY / Y. Neijland* - C. van den Ende - F. van den Hoogen - P. van der Kraan - F. van de Loo - M. Lieon

**PARE0007**

**PARE0008**
TRANSITION: PARTICULARLY DIFFICULT TIME FOR YOUNG PEOPLE WITH AR / U. G. Viora* - E. Fusaro - S. Martino - D. Montin

**PARE0009**

**PARE0010**
SIGNIFICANCE OF FOOT PROBLEMS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A PATIENT-LED QUALITATIVE STUDY / S. de Souza* - H. Lempp

**PARE0011**
ASK THE USERS - ESTABLISHING A DIGITAL USER PANEL / C. R. Ziegler*

* Presenting author
Thursday, 15 June 2017

11:45 - 13:30

Genomics, genetic basis of disease and HLA/T cell recognition


THU0007  DEEP SEQUENCING TRANSCRIPTOME ANALYSIS OF THE EFFECT OF TRAUMEEL VERSUS DICLOFENAC THERAPEUTIC ACTION IN WOUND HEALING / G. St. Laurent, III - B. Seilheimer - M. Tackett - J. Zhou - D. Shtokalo - Y. Vyatkin - P. Kapranov - I. Toma - T. Mccaffrey*


THU0010  ALTERED MIRNAS PROFILES IN PLASMA-DERIVED EXOSOME OF PATIENTS WITH ANKYLOSING SPONDYLITIS BY SMALL RNA-SEQ ANALYSIS / Y. Huang* - T. Li - Z. Huang - W. Deng - S. Zheng - X. Guo - Z. Huang


THU0012  HLA-DBR1 ALLELES PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RELATION TO DISEASE SUSCEPTIBILITY AND SEVERITY / A. Paradowska-Gorycka - B. Stypinska* - E. Haladyj - K. Romanowska-Prochnicka - A. Pawlik - M. Olesinska


* Presenting author
Cytokines and inflammatory mediators


THU0026  OSM IS MORE EFFECTIVE THAN IL-6 AT INDUCING ENDOMET OF HUMAN DERMAL MICROVASCULAR CELLS / K. Nevins* - L. Stawski - M. Feeney - N. Wisniacki - M. Trojanowska


THU0029  BACTERIAL/PERMEABILITY-INCREASING PROTEIN DOWNREGULATES THE INFLAMMATORY RESPONSE TO PATHOGENIC CRYSTALS IN VITRO AND IN VIVO / A. Scano* - R. Luisetto - F. Oliviero - P. Galozzi - R. Ramondi - L. Punzi


THU0035  CYTOKINE PROFILING OF AQUEOUS HUMOR IN BEHÇET’S DISEASE PATIENTS WITH ACTIVE OCULAR INVOLVEMENT / A. Soriano* - S. Croci - L. Cimino - M. Bonacini - E. Calò - A. Zerbini - M. Parmeggiani - T. Pérez Sandoval


THU0038  BIMEKIZUMAB DUAL INHIBITION OF IL-17A AND IL-17F PROVIDES EVIDENCE OF IL-17F CONTRIBUTION TO CHRONIC INFLAMMATION IN DISEASE-RELEVANT CELLS / A. Arco* - R. Okoye - T. Smallie - D. Baeten - M. Archer - C. Simpson - M. Griffiths - S. Shaw


THU0040  NOVEL AKT ACTIVATOR SC-79 IS A POTENTIAL TREATMENT FOR ALCOHOL-INDUCED OSTEONECROSIS OF THE FEMORAL HEAD / C. Xiyuan*
THU0041  PROGRANULIN AND DERIVATIVES CAN BE EMPLOYED AS LATENT DUAL-FUNCTION CHONDROGENIC AND ANTI-INFLAMMATORY THERAPEUTICS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS / C. M. A. Schultz* - Y. Chemajovsky

THU0042  LONGITUDINAL IP-10 SERUM LEVELS ASSOCIATE WITH THE COURSE OF DISEASE ACTIVITY AND ACHIEVING DMARD-FREE SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS / A. van Hooij - D. Boeters* - E. Tjon Kon Fat - S. van den Eeden - P. Corstjens - A. van der Helm-van Mil - A. Geluk

THU0043  TARGETED MEDICINE: THERAPEUTIC USE OF FUNCTIONAL CYTOKINE ASSAYS IN COMPLEX INFLAMMATORY ARTHRITIS / E. E. P. Htut* - L. Ceron-Gutierrez - R. Doffinger - J. Rees

THU0044  CHONDROTIN SULPHATE INHIBITS MONOCYTE CHEMOATTRACTANT PROTEIN-1 RELEASE FROM 3T3L1 ADIPOCYTES: A NEW TREATMENT OPPORTUNITY FOR OBESITY-RELATED METABOLIC SYNDROMES? / E. Montell* - T. V. Stabler - V. B. Kraus


THU0048  SOLUBLE URIC ACID INCREASED THE EXPRESSION OF ABCG2 AND PODZ1 IN HUMAN INTESTINAL CELL LINES THROUGH THE TLRA4/TLRPR3/CASPASE-1 AND PI3K/akt SIGNALING PATHWAYS / M. Chen - X. Lu - H. Wu*


THU0051  ASSOCIATION BETWEEN PROACTIVE TNF AND EULAR RESPONSE TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS / J. Poudroux* - H. Marotte - J.-E. Gottenberg - S. Paul


THU0061  REGULATION OF OSTEOCLAST RECRUITMENT AND ACTIVATION BY RESOLVIN D1 / H. A. Benabdoune - P. Rondon - O. Shi - J. C. Fernandes - H. Fahmi - M. Benderdour*


THU0063  IL-1 FAMILY CYTOKINES AND RECEPTORS IN IGG4-RELATED DISEASE / R. Capecci - P. Italiani - I. Puxeddu - F. Pratesi - A. Tavoni - D. Boraschi - P. Migliorini*


THU0065  CYTOKINES AND LIPOCALIN-2 IN PREGNANT WOMEN WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS / T. T. Pedersen* - S. M. Molnesen - M. Wallenius - T. H. Flo - M. Haug

THU0066  OSTEOCLAST DIFFERENTIATION GENE EXPRESSION PROFILE REVEALS CCL4 MEDIATES RANKL-INDUCED OSTEOCLAST MIGRATION / W. Xuan - X. Feng - Y. Shi - F. Wang - M. Zhang - W. Tan*

THU0067  NLRP3 INFLAMMASOME ACTIVITY IN MONOCYTES IS REGULATED BY 15-LIPOTYGENASE / Y. Kusche* - K. Barczyk-Kahlert - J. Roth

* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome


THU0069  HOW MANY RHEUMATOID ARTHRITIS PATIENTS IN REMISSION EXPERIENCE PAIN? WHAT TYPES AND WITH WHAT FREQUENCY WERE PAINKILLERS RECEIVED? IS REACHING REMISSION A REALISTIC GOAL? / E. Torkiak* - M. Suzuki - Y. Matsumaya


THU0074  BODY MASS INDEX IN EARLY RHEUMATOID ARTHRITIS IN UNDERWEIGHT PATIENTS IS ASSOCIATED WITH MORE PROGRESSION OF EROSIONS OVER 15 YEARS AND IN OBESE PATIENTS WITH LESS PROGRESSION OF JOINT SPACE NARROWING / S. Aeijanova* - K. Forslind - B. Svensson - I. Hafström


THU0077  ANTI-COLLAGEN TYPE II AUTOANTIBODIES ARE ASSOCIATED WITH AN ACUTE ONSET RHEUMATOID ARTHRITIS PHENOTYPE AND PROGNOSTICATE LOWER DEGREE OF INFLAMMATION / V. A. Manivel* - M. Mullazehi - L. Padyukov - H. Westerlind - L. Klæreskog - L. Alfredsson - S. Saevarsdottir - J. Rönnelid

THU0078  CONCOMITANT USE OF CONVENTIONAL SYNTHETIC DMARDS AND RESPONSE TO BARICITINIB / A. Kavanagh* - C. Helt - D. Muram - J. Alam - V. Arora - A. L. Pinto Correia - I. de la Torre - R. van Vollenhoven

THU0079  EVALUATION OF SYNOVITIS IN THE FOOT AND THE ANKLE NOT INCLUDED IN THE 28-JOINT DISEASE ACTIVITY SCORE USING ULTRASONOGRAPHY AND HISTOLOGICAL FINDINGS IN THE PATIENTS WITH RHEUMATOID ARTHRITIS / A. Abe* - H. Ishikawa


THU0083  THE RELEVANCE OF ELEVATED CRP AS AN INCLUSION CRITERION IN CLINICAL TRIALS IN PATIENTS WITH RHEUMATOID ARTHRITIS / C. Scoville* - J. Subotnicki - S. Zhong - E. Keystone


THU0089  M-DA52, DA52 (CRP) AND RAPID3 SCORES AT BASELINE ARE GOOD PREDICTORS OF RADIOGRAPHIC DISEASE PROGRESSION AT 1 AND 2 YEARS: DATA FROM THE AMBLE TRIAL / E. Keystone* - H. Ahmad - Y. Yazici - E. Muratti - J. Ye - M. Bergman

THU0090  INFLUENCE OF AGE AT DISEASE ONSET ON CLINICAL, FUNCTIONAL, AND ULTRASONOGRAPHIC OUTCOMES IN A MONOCENTRIC EARLY RHEUMATOID ARTHRITIS COHORT / E. Galuppi* - I. Farina - C. De Giorgio - C. A. Sciré - M. Govoni

* Presenting author

THU0092 CHRONIC PAIN INCREASES INDEPENDENT OF THE DISEASE ACTIVITY AND DEPRESSION IN FEMALES WITH RHEUMATOID ARTHRITIS / F. G. Yurdakul* - A. Kilçarslan - H. Bodur

THU0093 PERSISTENCE OF POWER DOPPLER ULTRASOUND-DETECTED RESIDUAL SYNOVITIS IN CONSECUTIVE ULTRASOUND EXAMINATIONS IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION PREDICTS UNFAVORABLE OUTCOME OVER ONE YEAR / G. Mouterde* - C. Lukas - N. Filippi - G. Marin - N. Molinari - J. Morel - B. Combe

THU0094 FACTORS ASSOCIATED WITH RADIOGRAPHIC REMISSION (RR) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHILE NON-BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) USING / O. Iaremenko - G. Mykytenko*

THU0095 IMPACT OF ULTRASOUND-DETECTED TENOSYNOVITIS AND SYNOVITIS ON DISEASE FLARE, DISABILITY AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RA IN CLINICAL REMISSION: RESULTS OF THE STARTER STUDY / G. Sakellaridou* - G. Filippou - E. Bells - C. A. Scirè - G. Carrara - A. Iagnocco on behalf of STARTER study group and US study group of the Italian Society for Rheumatology

THU0096 MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) IS ASSOCIATED WITH THE PROGRESSION OF STRUCTURAL BONE DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION / G. Schett* - S. Finzel - M. Hagen - M. Englbrecht - J. Haschka - C. Figuereido - J. Fogagnolo Cobra - J. Rech

THU0097 CHANGE IN SELF-REPORTED PAIN REFLECTS PSYCHOLOGICAL AND FUNCTIONAL STATE RATHER THAN INFLAMMATORY BURDEN IN UNITED STATES LATINOS WITH ESTABLISHED RHEUMATOID ARTHRITIS / G. Karpouzas* - E. Hernandez - C. Cost - S. Ormseth


THU1002 CLINICAL DISEASE ACTIVITY MEASURES ARE IMPORTANT DRIVERS OF MAJOR CHANGE IN MEDICAL TREATMENT IN US VETERANS ENROLLED IN THE VETERANS AFFAIRS RHEUMATOID ARTHRITIS (VARA) REGISTRY / G. W. Cannon* - C.-C. Teng - N. A. Accortt - D. Collier - S. Mehrnoba - B. C. Sauer

THU1003 ANTI-RA33 AUTOANTIBODIES ARE ASSOCIATED WITH THERAPEUTIC RESPONSES TO M ETHOTREXATE AND ANTI-TNF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. Steiner* - D. Sieghart - P. Studenic - T. Horn - D. Aletaha - J. Smolen


THU1007 ASSOCIATION OF GLOBAL DNA METHYLATION WITH MTX RESPONSE AND ADVERSE EVENTS IN EARLY RHEUMATOID ARTHRITIS / H. Gosselt* - M. D. Rotte - M. Chisholm - M. Hazes - R. D. Jonge - S. Heil

THU1008 SUBCLINICAL CENTRAL NERVOUS SYSTEM DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS: DISEASE ACTIVITY AND CYTOKINES / I. Tekeoğlu* - S. Sağ - A. Kamanlı - M. S. Sağ - K. Nas

THU1009 UPDATED ESTIMATION OF THE EQSD QUALITY OF LIFE QUESTIONNAIRE UTILITY VALUES THROUGH HAQ-DI MAPPING FOR SPAIN / I. Gorostiza* - L. Ansola - E. Galindez


THU1104 EFFECTS OF SMOKING ON BARICITINIB EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED ANALYSIS FROM TWO PHASE 3 CLINICAL TRIALS / J. Curtis* - P. Emery - G. Burmester - V. Arora - J. Alam - D. Muram - L. Klareskog

* Presenting author
THU0115  DISABILITY (HAQ) AND QUALITY OF LIFE (SF-12) AS RELATED TO RELATIVE AND HEALTH LITERACY IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. G. Kuipers* - M. Koller - F. Zeman - K. Mueller - J. U. Rueffer

Rheumatoid arthritis - comorbidity and clinical aspects


THU0118  WHAT IS THE ROLE OF STEROIDS IN INDUCING DIABETES MELLITUS IN PATIENTS WITH RHEUMATOID ARTHRITIS? AN OBSERVATIONAL COHORT STUDY / A. Emamifar* - R. Hvidt Larsen - R. Assmussen Andreasen - I. M. Jensen Hansen


THU0120  PREVALENCE OF CHRONIC KIDNEY DIASEASE IN RHEUMATOID ARTHRITIS PATIENTS AND ITS ASSOCIATION WITH MULTIMORBIDITY / A. Y. Zakhavorova* - E. Galushko - Y. Uskova - A. Gordiev


THU0124  OCCUPATIONAL EXPOSURE TO ASBESTOS AND RISK OF RHEUMATOID ARTHRITIS / A. Ilar* - P. Gustavsson - P. Wiebert - C. Bengtsson - L. Klareskog - L. Alfredsson


THU0128  FEATURES OF ULTRASOUND DOPPLEROGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL HYPOTHYROID DYSFUNCTION / A. Knyazeva* - O. Rebrova - N. Bludova - T. Meshcheryakova


THU0133  THE COURSE OF LOWER EXTREMITY FUNCTION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OVER THE FIRST FIVE YEARS / M. Mellibom Bengtsson - C. Book - S. Hagem - L. T. Jacobsson - C. Turesson

THU0134  INTERSTITIAL LUNG DISEASE AND RHEUMATOID ARTHRITIS. MULTICENTER STUDY WITH TOCILIZUMAB / C. Ferri on behalf of InsPiRAtE study group


THU0136  FEATURES OF ULTRASOUND DOPPLEROGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL HYPOTHYROID DYSFUNCTION / A. Knyazeva* - O. Rebrova - N. Bludova - T. Meshcheryakova


THU0138  DAS 28 CORRELATED POORLY WITH THE OBJECTIVE EVIDENCE OF INFLAMMATION AS DETECTED BY ULTRASOUND (US) EXAMINATION OF HANDS AND FEET IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS (RA) / C. Ciurtin* - G. Brown - A. Cotton - J. Guinto - A. Jones - V. Morris

* Presenting author


THU0142  MATRIX METALLOPROTEINASE-3 AND ANTIBODIES (IgG) AGAINST OXIDIZED LOW-DENSITY LIPOPROTEIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Gerasimova* - T. Popkova - M. Cherkasova - E. Alexandrova - A. Novokov


THU0145  IMPACT OF DIFFERENT FORMULATIONS OF "PATIENT GLOBAL ASSESSMENT" ON REMISSION CLASSIFICATION BY DISEASE ACTIVITY INDICES IN RHEUMATOID ARTHRITIS / G. Eugénio* - R. Ferreira - C. Silva - C. Medeiros - J. A. P. Silva - C. Duarte

THU0146  QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS - DEMOGRAPHIC AND SOCIO-ECONOMIC ASSOCIATIONS / H. Baharuddin* - N. Zainudin - H. Mohd Yusof - I. S. Lau

THU0147  THORAX CT FINDINGS IN A LARGE COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS:HUR-BIO REAL LIFE RESULTS / A. San - B. Arman - A. Erden - L. Kilic - A. Akdogan - S. Apras Bilgen - I. Ertenli*


THU0150  OPTIMIZING COMORBIDITY RISK MANAGEMENT IN RA BY TRANSLATING A NURSE-LED INTERVIEW INTO AN EASILY INTERPRETABLE TRAFFIC LIGHT SYSTEM / K. Krüger* - R. Eder - C. Müller - R. Hecker


THU0153  ASSOCIATION BETWEEN PLASMA LIPIDS, DISEASE ACTIVITY AND PCSK9 LEVELS IN RA PATIENTS / M. Reslinga* - G. Lambert - A. Thedrez - J. Kastelien - M. Nurmoehamed

THU0154  IMPACT OF BASELINE MODIFIED RHEUMATOID DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL AND EFFECTIVENESS OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED WITH RHEUMATOID ARTHRITIS (RA), SPONDYLOARTHITIS (SPA), AND PSORIATIC ARTHRITIS (PSA) IN REAL-WORLD SETTINGS / M. Fornaro* - M. Di Carlo - S. Gentilescchi - M. G. Giannotta - L. Cantarini - F. Salaffi - G. Lapadula - F. Iannone


THU0156  RELATIONSHIP OF MATRIX METALLOPROTEASE 3 TITER AND SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CHIKARA STUDY / M. Tada* - Y. Yamada - K. Mandai - N. Hidaka


THU0158  RHEUMATOID ARTHRITIS MAY NOT INFLUENCE EATING BEHAVIOURS CHARACTERISTICS / N. Bulut - M. E. Tezcan*

Rheumatoid arthritis - non biologic treatment


THU0169 ONE-THIRD OF PATIENTS WITH RHEUMATOID ARTHRITIS ELIGIBLE FOR A FIRST BIOLOGIC ARE NOT ADHERENT TO METHOTREXATE: RESULTS OF A CROSS-SECTIONAL SURVEY OF 244 PATIENTS / C. Beauvais*, V. Hautin-Monteil, M.-C. Ducrot, R.-M. Filpo


THU0176 EFFICIENCY AND SAFETY OF RAPAMYCIN COMBINED WITH LOW-DOSE IL-2 TREATMENT COMPARED WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS / Z. Li*, H. Niu, M. Chen, H. Yao, J. Luo, C. Gao, X. Li, C. Wang


THU0178 LONG-TERM SAFETY PROFILE OF METHOTREXATE IN PATIENTS WITH RA IN ROUTINE CARE / A. B. Nalawade*, S. M. Akerkar, B. D. Pandey

THU0179 INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / Z. Li*, H. Niu, M. Chen, H. Yao, J. Luo, C. Gao, X. Li, C. Wang

THU0180 SYSTEMS BASED INVESTIGATION OF THE ANTI-IMMUNOGENIC POTENTIAL OF DMARDS FOR RHEUMATOID ARTHRITIS USING HUMAN PRIMARY CELL-BASED BIOMAP® PHENOTYPIC PROFILING / A. O’Mahony*, E. Choy


THU0182 MONOTHERAPY WITH THE JAK1-SELECTIVE INHIBITOR FILGOTINIB DISPLAYS AN ANTI-INFLAMMATORY BIOMARKER PROFILE IN RHEUMATOID ARTHRITIS PATIENTS / A. Kavanaugh*, A. van der Aa, W. Li, L. Goyal, Y. Pan, P. Harrison, C. Tasset, J. Tarrant, R. Galien

THU0183 IMPROVED ADHERENCE TO NEWLY PRESCRIBED DMARDS WITH CO-PRESCRIPTION WITH LOW DOSE STEROIDS IN RHEUMATOID ARTHRITIS PATIENTS ATTENDING CLINIC AT A DISTRICT GENERAL HOSPITAL IN THE UK / A. N. Naguliyadda, K. Culfear, A. Nandagudi, A. Bharadwaj*
THU0184  ADHERENCE PROFILES TO METHOTREXATE OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) ELIGIBLE FOR BIOLOGICS: TYPOLOGIES FROM FORGET. A CROSS-SECTIONAL SURVEY OF 244 PATIENTS / C. Beauvais* - V. Hautin-Montel - M.-C. Ducrot - R.-M. Filip

THU0185  COMPARISON OF TOFACITINIB SAFETY AND EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS, OR TO ONE OR MORE BIOLOGICAL DMARDS / C. Charles-Schoeman* - J. Kremer - S. Krishnaswami - K. Soma - J. Geier - R. Zhang - S. Strengholt - G. Burmester


THU0187  DO WE TODAY ALTERNATIVE THERAPIES RHEUMATOID ARTHRITIS TWO OR MORE DISEASE-MODIFYING DRUGS? THE STORY OF HOW A SIMPLE DRUG PENTOXIFYLLINE MAY ENHANCE THE ACTION OF METHOTREXATE IN RHEUMATOID ARTHRITIS / D. S. Bublikov* - D. A. Anchugina - I. E. Babushkin


THU0189  SAFETY OF FOUR TREATMENT REGIMENS IN EARLY RHEUMATOID ARTHRITIS / E. Fedorenko* - G. Lukina - Y. Sigidin - D. Karateev

THU0190  DERMATOLOGICAL GUIDELINES FOR MONITORING METHOTREXATE TREATMENT REDUCE DRUG-SURVIVAL COMPARED TO RHEUMATOLOGICAL GUIDELINES / H. Bernelot Moens* - F. Busger op Vollenbroek - R. Janssens - C. Doggen


THU0195  CONSISTENT EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO NON-MTX CSDMARDS / J. Tesser* - A. Gül - E. Olech - K. Oelke - T. Lukic - C. W. Murray - C. Zhang - L. Takiya


THU0199  TOFACITINIB IMPROVES LEFT VENTRICAL MASS AND CARDIAC OUTPUT IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. Kume* - K. Amano - S. Yamada - T. Kanazawa - K. Hatta

THU0200  RISK FOR DEVELOPING ADVERSE EFFECTS CAUSED BY SALAZOSULFAPYRIDINE IN RHEUMATIC DISEASES / K. Nakanishi* - M. Kinjo

THU0201  OLDER AGE, HYPOALBUMINAEMIA AND RENAL FAILURE MIGHT BE POOR PROGNOSIS FACTORS FOR LOW DOSE METHOTREXATE-INDUCED MYELOSUPPRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS / X.-N. Wei - D.-H. Zheng - Y.-Q. Mo - J.-D. Ma - Y.-L. Chen - L. Dai*

THU0202  UNAFFORDABLE CONVENTIONAL AND ABSENT BIOLOGIC DMARDS: INCREASING THE BURDEN OF RHEUMATOID ARTHRITIS IN FYROM / O. Gjergjeva - N. Memeti - L. Damjanovska-Krstikj*

THU0203  CHANGES IN C-REACTIVE PROTEIN AND LIPID LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABT-494, A SELECTIVE JAK-1 INHIBITOR / M. Nurmohamed* - Y. Zhang - J. Lin - H. Camp


THU0205  EFFECTS OF THE JAK1-SELECTIVE INHIBITOR FILGOTINIB ON MULTIBIOMARKER DISEASE ACTIVITY SCORES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE / M. C. Genovese* - W. Li - L. Goyal - Y. Pan - A. van der Aa - C. Jamoul - P. Harrison - C. Tasset - R. Galien - J. Tarrant


SLE, Sjögren's and APS - etiology, pathogenesis and animal models

THU0208

THU0209

THU0210
CHANGES IN HEMOGLOBIN LEVELS UPON TREATMENT WITH ABT-494, A SELECTIVE JAK-1 INHIBITOR, AND RELATION TO BASELINE LEVELS OF C-REACTIVE PROTEIN / V. Strand* - M. Genovese - J. Kremer - M. Schiff - Y. Li - J. Sokolove

THU0211
META-ANALYSIS OF SERIOUS INFECTIONS WITH BARICITINIB, TOFACITINIB AND BIOLOGIC DMARDS IN RHEUMATOID ARTHRITIS / V. Strand* - S. Adahieh - R. DeMasi - S. Krishnaswami - J. Geier - S. Menon - J. J. Gomez-Reino

THU0212

THU0213
COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB 2 MG AND 4 MG IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS / Y. H. Lee* - Y. H. Seo - G. G. Song

THU0214
LONG-TERM OUTCOME OF IGURATIMOD, CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG DEVELOPED IN JAPAN, IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD CLINICAL SETTING / Y. Hirano* - M. Isono - Y. Okada - Y. Oishi

THU0215
EFFECTS OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DMARDs / Z. Li* - Y. An - G. Li - L. Wang - K. Kwok - Q. Wu on behalf of China ORAL group

THU0216

THU0217

THU0218

THU0219
AUTOANTIBODY PROFILE OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A TERTIARY CARE CENTRE IN NORTH INDIA / S. Guleria* - A. Sharma - A. Gupta - A. Rawat - D. Suri - S. Singh

THU0220

THU0221
DOWNREGULATED EXPRESSION OF MIR200B-5P IN MINOR SALIVARY GLANDS (MSG) OF PATIENTS WITH SJÖGREN’S SYNDROME (SS) ASSOCIATED LYMPHOMA / E. Kapsogeorgou* - A. Papageorgiou - M. Voulgarelis - A. G. Tzioufas

THU0222
PROPYLHACETIC AND THERAPEUTIC ADMINISTRATION OF AN ANTI-CD40 ANTAGONIST ANTIBODY BLOCKS AND REVERSES PROTEINURIA AND NEPHRITIS IN NZB/W-F1 MICE / S. Perper - S. Westmoreland - Z. Liu - M. Duval - J. Seagal - B. McRae - S. Clarke*

THU0223

THU0224
ASSOCIATION OF IRAK-M WITH NEUROPSYCHIATRIC SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / S. Sacre* - R. Thwaites - K. Davies

THU0225

THU0226
DIFFERENTIAL SUSCEPTIBILITY OF TH17 AND T REGULATORY CELLS TO APOPTOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS - THE MODULATORY EFFECTS OF STATIN / J. Sun - J. Frostegard - A. Liu*

THU0227

THU0228
INTRA-RENAL ACTIVATION OF ADAPTIVE IMMUNE EFFECTORS IS ASSOCIATED WITH HIGHER DISEASE SEVERITY IN LUPUS NEPHRITIS / C. Pamfil* - N. Demoulin - M. Jadoul - S. Aydin - F. A. Houssiau - B. Lauwerys

THU0229

* Presenting author
THU0230  

THU0231  

THU0232  

THU0233  
EPIDEMIC CELL COUNTING: A NOVEL TOOL TO QUANTIFY IMMUNE CELLS IN SALIVARY GLANDS DETECTS ROBUST CORRELATIONS OF TFH CELLS WITH IMMUNOPATHOLOGY / J. A. van Roon* - F. M. Moret - S. L. Blokland - A. A. Kruize - G. Bertsias

THU0234  
EXOSOME-DELIVERED MIR-146A REGULATES SENESCENCE OF BONE MARROW- MESENCHYMAL STEM CELLS FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS THROUGH TARGETING IRAK1 AND TRAF6 / J. Ji* - Y. Wu - X. Kong - Z. Zhang - Z. Gu

THU0235  

THU0236  
WHOLE TRANSCRIPTOME ANALYSIS OF APL TREATED HUVECS MAPS PROINFLAMMATORY AND PROCOAGULANT PATHWAYS / M. D. Patsouras* - S. Foutadakis - E. Alexopoulou - M. Agelopoulos - D. Thanos - J. A. van Roon - F. M. Moret

THU0237  
REGRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS THROUGH TARGETING IRAK1 AND TRAF6 / J. Ji* - Y. Wu - X. Kong - Z. Zhang - Z. Gu

SLE, Sjögren's and APS - clinical aspects (other than treatment)

THU0238  
P-GLYCOPROTEIN MONOCLONAL ANTIBODY IMPROVES LUPUS-LIKE SYNDROME IN MRL/LPR MICE / S. L. Blokland - A. A. Kruize - G. Bertsias

THU0239  

THU0240  
DIFFERENTIATION OF THF CELLS WITH IMMUNOPATHOLOGY / J. A. van Roon* - F. M. Moret - S. L. Blokland - A. A. Kruize - G. Bertsias

THU0241  

THU0242  
PATHOLOGICAL ANALYSIS IN PRIMARY SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMA / S. Al-Ali* - A. Skelton - S. Cockell - J. Tam - K. James - J. S. Bowman - B. Griffiths - D. Young - U. Registry - W. P. Ng

THU0243  

THU0244  
THE ROLE OF STEM CELL-LIKE MEMORY T CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS / Y. J. Lee* - H. Kwon - E. B. Lee

THU0245  

SLE, Sjögren's and APS - clinical aspects (other than treatment)

THU0246  

THU0247  

THU0248  

THU0249  
SUBCLINICAL HAND ARTHROPATHY IN PATIENTS WITH SYSTEMIC LUPUS ERITEMATOSUS / C. A. Guillen-Astete* - M. Revenga-Martinez - A. Zea-Mendoza

THU0250  
EFFECT OF FETAL UMBILICAL ARTERY DOPPLER ON PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERITEMATOSUS / Z. Zhan* - D. Chen - Q. Qiu - Y. Yang

THU0251  

THU0252  

THU0253  
TRIPLE POSITIVITY TO ANTIPHOSPHOLIPID ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: INCREASED RISK OF ARTERIAL THROMBOSES AND ABORTIONS / F. Signorelli - G. Balbi - R. A. Levy*

THU0254  

THU0255  
COMPARISON OF REMISSION AND LUPUS LOW ACTIVITY STATE AS PREDICTORS OF ORGAN DAMAGE / M. Petri* - L. S. Magder

THU0256  
DEVELOPMENT AND VALIDATION OF A SCORE TO PREDICT THE RISK OF SEVERE INFECTION IN SLE / I. Gergianaki* - A. Fanouriakis - C. Adamichou - G. Spyrou - P. Sidiropoulos - D. Boumpas - G. Bertsias

THU0257  
ENHANCED ACTIVATION OF NLRP3 INFLAMMASOMES IN PATIENTS WITH SJÖGREN'S SYNDROME / J. N. Kim - J. -Y. Choe*

* Presenting author
THU0258  

THU0259  

THU0260  
**LOW PLASMA CONCENTRATIONS OF APOLIPOPROTEIN M CORRELATE TO DISEASE ACTIVITY AND ENDOTHelial DYSFUNCTION IN SLE / A. Bengtssson* - H. Tydén - C. Lood - B. Gullstrand - B. Dahlbäck - A. Jönsen**

THU0261  
**PREGNANCY COURSE AND OUTCOME IN SLE PATIENTS COMPARED TO PATIENTS WITH OTHER CONNECTIVE TISSUE AND INFLAMMATORY RHEUMATIC DISEASES - DATA FROM A PROspective COHORT STUDY / A. Strangfeld - C. Bungartz - A. Weiß - M. Schneider - J. Richter - A. Zink - R. Fischer-Betz**

THU0262  
**CHANGES IN SONOElastOGRAPHIC CHARACTERISTICS IN SJÖGREN’S SYNDROME - A FIVE-YEAR FOLLOW UP / B. Hofauer* - M. Bas - N. Mansour - A. Knopf**

THU0263  
**PREVALENCE OF REMISSION AND ITS EFFECTS ON ORGAN DAMAGE AND QUALITY OF LIFE IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. C. Mok* - L. Y. Ho - S. M. Tse - K. Chan**

THU0264  
**RESPONSIVENESS OF LUPUSPRO v1.8 AMONG CHINESE PATIENTS WITH LUPUS / C. C. Mok* - L. Y. Ho - S. M. Tse - K. Chan - J. Block - M. Jolly**

THU0265  

THU0266  

THU0267  

THU0268  
**PREVALENCE AND FEATURES OF CELIAC DISEASE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES: RESULTS OF A LARGE MULTICENTER STUDY / E. Bartoloni* - A. Alunno - O. Bistoni - L. Cavagna - L. Nalotto**

THU0269  
**RELAPSE AND NON-ST ABNORMALITIES ARE ASSOCIATED WITH HIGHER MODIFIED FRAMINGHAM RISK SCORE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITHOUT CLINICAL CARDIOVASCULAR DISEASE / E. George - T. Perez-Recio - L. Geraldino-Pardilla**

THU0270  
**HOMOCYSTEINE, ANTIPHOSPHOLIPID ANTIBODIES AND RISK OF VASCULAR EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / G. Stojan* - W. Fu - M. Petri**

THU0271  
**THE PERFORMANCE OF DIFFERENT CLASSIFICATION CRITERIA IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: AN INTERPRETATION OF THEIR CONTRIBUTION FOR DEFINITIVE DIAGNOSIS, WHEN EITHER CRITERIA USED ALONE OR IN COMBINATION / Z. Kosuva Ozturk - G. Can - F. Onen - M. Birlik**

THU0272  

THU0273  

THU0274  
**FOOTPRINTS OF NEUTROPHIL EXTRACELLULAR TRAPS ARE ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I. Jeremic* - O. Djuric - B. Bonacci Nikoloi**

THU0275  

THU0276  
**INTERFERON-RELATED CHEMOKINE IP-10 IS A POTENTIAL BIOMARKER IN INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS / W. Lambers - K. De Leeuw* - M. Onen - M. Bojinca - D. Opris-Belinski - A. Balanescu**

THU0277  
**REASONS FOR DEFICIENCY OF PHYSICAL INACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L. Lipovsky* - C. Baerwald - O. Seifert**

THU0278  

THU0279  
**ARE THE PULMONARY INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED WITH A HIGHER PREVALENCE OF COMORBIDITIES? / M. Cebanu* - V. Salaru - V. Sadovici - M. Pasali - N. Loghin-Oprea**

THU0280  

THU0281  

THU0282  
**COMPARISON OF CLASSIFICATION CRITERIA FROM 2002 AND 2016 IN AN INCIDENT COHORT DIAGNOSED 2007 TO 2011 FROM STOCKHOLM COUNTY SWEDEN / M. Kvarnström* - L. Lipovsky* - C. Baerwald - O. Seifert**

THU0283  

* Presenting author

THU0285  USE OF CONTRACEPTIVE METHODS IN A SINGLE CENTER COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS FROM ARGENTINA / R. A. Gomez* - F. M. Paniego - M. Garcia Carrasco - D. Dubinsky - G. Nasswetter

THU0286  RECURRENCE OF ARTERIAL AND VENOUS THROMBOSSES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME / G. Balbi - F. Signorelli - R. A. Levy*


THU0292  DIAGNOSTIC ACCURACY OF ULTRASOUND AND ULTRASONOGRAPHIC FEATURES OF SALIVARY GLANDS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME / V. Milic* - G. Radunovic - N. Damjanov


Vasculitis


THU0295  CLINICAL FEATURES OF TAKAYASU’S ARTERITIS FROM AN INCEPTION COHORT: EARLY DISEASE IS CHARACTERIZED BY “SYSTEMIC INFLAMMATION” / F. Alibaz-Oner*

THU0296  THE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS (GCA) IN ROUTINE CLINICAL PRACTICE / S. Monti* - A. Floris - C. Ponte - S. Vaggers - W. A. Schmidt - A. P. Diamantopoulos - C. Pereira - R. Luqmami


THU0305  EPIDEMIOLOGY OF ANCA-ASSOCIATED VASCULITIS IN NORTHERN NORWAY / A. T. Nilsen* - R. A. Watts - W. Koldingsnes


* Presenting author


THU0309  TREATMENT WITH METHOTREXATE AND RISK OF RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS IN CLINICAL PRACTICE / D. Freitès Núñez** - J. Font - C. León - I. Morado - L. Rodríguez-Rodríguez - L. León - Z. Rosales - D. Fernández - J. Jover - L. Abadó


THU0312  PERFORMANCE CHARACTERISTICS AND PREDICTORS OF TEMPORAL ARTERY ULTRASOUND AND BIOPSY FOR THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A REAL WORLD POPULATION; A PROSPECTIVE COHORT STUDY / R. Conway - S. Di Bello - L. O'Neill - G. M. McCarthy - C. C. Murphy - D. J. Veale - U. Fearon - R. P. Killeen - E. J. Heffernan - E. S. Molloy*

THU0313  INFERIOR AND SUPERIOR VENA CAVA THROMBOSIS IN BEHÇET'S DISEASE. MOROCCAN EXPERIENCE / F. Z. Alaaoui* - M. Moudarit

THU0314  RADIOLOGIC ACTIVITY IS THE MAJOR DETERMINANT FOR PHYSICIAN'S DECIDING ACTIVE DISEASE IN TAKAYASU ARTERITIS / G. Kenar - P. Cetin - H. Yarkan - B. Zengin - G. Can - M. Birlik - F. Onen*


THU0319  MR ANGIOGRAPHY FOR EVALUATION OF VASCULAR INFLAMMATION IN ELDER PATIENTS WITH LARGE VESSEL VASCULITIS / L. Smitienko* - P. Novikov - E. Atyasova

THU0320  DIFFERENT PATTERNS OF VASCULAR INVOLVEMENT IN PET/CT ACCORDING TO CRANIAL SYMPTOMS IN BIOPSY PROVEN GIANT CELL ARTERITIS, A PRELIMINARY STUDY / J. Mestre Torres* - I. Navales - F. Martínez - J. Loureiro - S. Bujan - C. Pérez - M. Simó - R. Solans

THU0321  ALTERATIONS IN THE PERIPHERAL B CELL COMPARTMENT IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROME) / M. Rizzi - M. Engesser - R. E. Voll - A. Troilo - I. Janowska - N. Venhoff - J. Thiébaut


THU0326  SHORT AND LONG-TERM FOLLOW-UP WITH ADALIMUMAB IN REFRACTORY UVEITIS ASSOCIATED TO BEHÇET'S DISEASE. MULTICENTER STUDY OF 74 PATIENTS / L. Domínguez-Casas* - V. Calvo-Río - E. Beltrán - J. S-Bursón - P. Navari* - J. Loureiro - S. Bujan - C. Pérez - M. Simó - R. Solans

THU0327  ASSESSMENT BETWEEN THE TC/HDL RATIO AND DISEASE ACTIVITY IN PATIENTS WITH TAKAYASU ARTERITIS / L. Pan* - J. Du - H. Liao


THU0330  MYCOBACTERIAL CORD FACTOR ANALOG INDUCES HIGH IL-6 SECRETION AND MICLE RECEPTOR EXPRESSION IN PATIENTS WITH TAKAYASU ARTERITIS / N. Gupta** - J. Kabeer Doss - H. Mohan - R. Goel - D. Danda


THU0332  CARDIAC INVOLVEMENT IN POLYARTERITIS NODOSA: A RETROSPECTIVAL PATHOLOGICAL STUDY OF 37 AUTOPSY CASES / O. Zimba* - M. Bagriy

* Presenting author
Spondyloarthritis - treatment


THU0353  CHANGE IN MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINT AFTER TWO YEARS OF ETANERCEPT THERAPY IN COMPARISON TO A CONTEMPORARY CONTROL COHORT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS / D. van der Heijde - X. Baraliakos - A. Deodhar - M. Brown - S. P. Sherlock - D. Li - D. Fleishaker - T. Hendrikx - T. K. Kvien on behalf of the NOR-SWITCH study group


THU0355  INFLUENCE OF ADALIMUMAB AND SULFASALAZINE ON STRUCTURE OF HYALINE CARTILAGE OF HIP JOINTS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY / A. Petrov* - H. Zayeva - A. Petrov


THU0357  EXPLORE THE ASSOCIATION BETWEEN GIANT CELL ARTERITIS AND CARDIO-ANKLE VASCULAR INDEX (CAVI) MEASUREMENT OF ARTERIAL STIFFNESS / P. Sessa* - E. M. Bartels


THU0359  CLINICAL PRESENTATION AND OUTCOMES OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS: ANCA-NEGATIVE VERSUS ANCA-POSITIVE / Zagovozdkina - P. Novikov - S. Moiseev* - T. K. Kvien on behalf of the NOR-SWITCH study group


THU0363  A RHEUMATOLOGY LED PATHWAY FOR THE INITIAL MANAGEMENT OF GCA IMPROVES DIAGNOSTIC OUTCOMES COMPARED TO THE GENERALIST / Z. Farah* - M. Gulati - M. Matheou - H. Alam - S. Hamdulay


THU0358 ROSUVASTATIN IMPROVES NITRIC OXIDE AND ENDOTHELIAL FUNCTION AND SUPPRESSES INFLAMMATORY DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS / A. Syngle* - N. Garg - P. Krishan

THU0359 SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 TRIALS / A. Deodhar* - X. Baraliakos - H. Marzo-Ortega - J. Sieper - M. Andersson - B. Porter - T. Fox


THU0362 EFFECT OF BIOTECHNOLOGICAL DRUGS ON EXTRA-ARTICULAR MANIFESTATIONS OF ANKYLOSING SPONDYLITIS: SYSTEMATIC REVIEW / A. R. Pinto - C. V. Pessa - L. S. Inês

THU0363 IMPACT OF ADALUMABUM ON CLINICAL OUTCOMES, HEALTHCARE RESOURCE UTILIZATION AND SICK LEAVES IN ANKYLOSING SPONDYLITIS PATIENTS IN CENTRAL AND EASTERN EUROPE / D. Opris-Belinski* - S. Erdes - A. Cantagrel - A. Ruyssen-Witrand - A. Constantin


THU0367 THE INFLUENCES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON SERUM VEGF AND BMP-2 LEVELS IN PATIENTS WITH AXIAL SPONDYLARTHROPSIS / G. Gao* - L. Lu - Z. Li - Y. Li

THU0368 CLINICAL AND IMAGING CHARACTERISTICS OF PATIENTS WITH AXIAL SPONDYLARTHROPATHY REPORTING FLARE SYMPTOMS IMMEDIATELY PRIOR TO NEXT DOSE IN ROUTINE TNFi THERAPY / R. Ansell - H. Mathiessen - M. Merashli - N. Busquets-Pérez - D. McGonagle - H. Marzo-Ortega


THU0370 INCREASED INTERLEUKIN-17A CONCENTRATION REMAINS HIGH IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TUMOR NECROSIS A INHIBITORS WITHIN THE YEAR / I. Z. Gayduková* - A. Rebrov

THU0371 THERAPY MODIFICATIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH A BIOLOGIC IN THE UNITED STATES - DESCRIPTIVE ANALYSES FROM AN ADMINISTRATIVE CLAIMS DATABASE / J. A. Walsh* - O. Adejoro - B. Chastek - G. Chun - Y. Park


THU0373 LONG-TERM EFFECTS OF TNF-ALPHA INHIBITORS ON BONE MINERAL DENSITY AND THE INCIDENCE OF VERTEBRAL FRACTURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Beek* - M. van der Weijden - W. W. Dijkers - G. Lapadula - M. Nurmohamed - J. van der Horst-Bruinsma

THU0374 CHARACTERISTICS ASSOCIATED WITH IMPROVEMENTS IN SPARCC SIJ AND ASDAS SCORES IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLARTHROPATHY TREATED WITH ETANERCEPT / K. de Vlam* - A. Burden - M. A. Dilleen - C. Boone


THU0376 IMPACT OF THE ADALUMABUM PATIENT SUPPORT PROGRAM ON CLINICAL OUTCOMES IN ANKYLOSING SPONDYLITIS: RESULTS FROM THE COMPANION STUDY / L. Beas* - C. Thorne - B. Millson - K. Charland - M. A. Dilleen - C. Boone

THU0377 LOW DOSE IL-2 THERAPY CAN RECOVERY TH17/TREG CELL BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS / A. Oelke* - G. Chun - M. A. Dilleen - C. Boone


THU0379 IMPACT OF TIME SINCE DIAGNOSIS, AGE, AND NUMBER OF PRIOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON 52-WEEK CLINICAL RESPONSE TO ADALUMABUM IN PATIENTS WITH ANKYLOSING SPONDYLITIS / J. Sieper - A. Deodhar - M. Hoinik - Y. Zhang - M. Dougdados


* Presenting author
Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis


**THU0383** INCIDENTALITY OF UVEITIS IN NON-STERoidal ANTI-INFLAMMATORY DRUGS VERSUS TUMOR NECROSIS FACTOR INHIBITORS AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS: A RETROSPECTIVE COHORT STUDY / M. J. Kim* - E. E. Lee - E. Y. Lee - Y. W. Song - E. B. Lee

---


**THU0389** THE EFFECT AND SAFETY OF YISAIPU (YISAIPU) IN THE TREATMENT OF PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN CHINA / M. Zhao* - G. Shi - Y. Tao - X. Wang - S. Cao - Z. Lin - Z. Liao - Q. Kong - J. Gu

**THU0390** Effect of rehabilitation on the chest expansion in patients with ankylosing spondylitis / S. D. Jancic

**THU0391** FEMALE GENDER IS ASSOCIATED WITH A POORER RESPONSE TO TNF INHIBITORS IN ANKYLOSING SPONDYLITIS / T. Rusman* - M. T. Nurmohamed - J. C. van Denderen - I. Visman - I. E. van der Horst-Bruinsma


**THU0395** HIGH NUMBER OF PREVIOUS BIOLOGIC USE AND COMORBIDITIES IN FIRST REAL WORLD SECUKINUMAB STUDY IN PSA AND AS: NON-INTERVENTIONAL, AQUILA STUDY IN GERMANY / U. Kiltz* - C. Legeler - M. Maier-Peuschel - J. A. Veit - C. Mann - H.-P. Tony

**THU0396** EFFICACY OF SWITCHING BMARDS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW / V. Navarro-Compañ - E. de Miguel - A. Balsa - P. Diaz del Campo - J. Gratacos

**THU0397** SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 3 EXTENSION TRIAL (MEASURE 1) / X. Baraliakos* - A. J. Kivitz - A. Deodhar - J. Braun - J. C. Wei - E. M. Delicha - Z. Talloccy - B. Porter on behalf of the MEASURE 1 study group

**THU0398** SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, MEASURE 2 / X. Baraliakos* - M. Schiff - K. Pavelka - A. Widmer - B. Porter - C. Gailliez on behalf of the MEASURE 2 study group

**THU0399** TAPERING THERAPY OF TNF-INHIBITOR FOR MRI CHANGES IN SPONDYLOARTHRITIS / Y. Song - Y. Cui* - Y. Zhang - H. Zeng - Y. Zeng

**THU0400** RISK FACTORS OF SAGITTAL TRANSLATION AFTER PEDICLE SUBTRACTION OSTEOTOMY ON ANKYLOSING SPONDYLITIS / Y.-S. Park* - J. Kim - J.-S. Park

* Presenting author


THU0406  SERUM URIC ACID LOWERING TREATMENT APPEARS UNNECESSARY DURING HEMODIALYSIS / M. Andrés - R. Soriano - E. Oliveira - C. Trigo - M. D. Arenas - E. Pascual*


THU0408  GOUT IS AN IMPORTANT PREDICTOR OF WORK DISABILITY IN BOTH MEN AND WOMEN / V. Sigurdardottir* - P. Drivelegka - A. Svärd - L. T. Jacobsson - M. Dehlin


THU0415  A STRUCTURED MONITORING PROGRAM FOR DRUG ALLERGY IN PATIENTS NEWLY INITIATED ON ALLUPURINOL / B. Y. Thong* - K.-Y. Gan - B.-H. Ang

THU0416  RAPID TOPHUS RESOLUTION IN CHRONIC REFRACTORY GOUT PATIENTS TREATED WITH PEGLOTICASE / B. Mandeli* - A. Yeo - P. Lipsky


THU0419  RISK OF TOTAL HIP AND KNEE REPLACEMENT IN GOUT PATIENTS PRIOR TO AND FOLLOWING DIAGNOSIS: A NATIONAL POPULATION STUDY IN TAIWAN / C. F. Kuo* - J. S. Chen - K. H. Yu - S. F. Luo


THU0421  PRIMARY FEMALE GOUT HAD ITS UNIQUE ULTRASOUND FEATURES / D. F. Lin* - X. Guo - J. Cao - Y. Wu - J. Gu


THU0423  THE RELATIONSHIP BETWEEN CLINICAL DISEASE ACTIVITY, SYMPTOM DURATION AND ULTRASONOGRAPHIC CHANGES IN GOUT / E. Norkuviene* - M. Petraitis - I. Apanaviciene - D. Virviciute - A. Baranauskaite


THU0426  THE FIRST METATARSOPHALANGEAL JOINT (MTP1) IS NOT THE MAIN LOCALIZATION OF GOUT AT DIAGNOSIS IN SUB-SAHARAN AFRICA / F. Kema Lekpa* - M. S. Doualla - H. Namme Luma

THU0427  LONG-TERM ADHERENCE TO URATE-LOWERING THERAPY IN GOUT: DO NOT BLAME ON THE PATIENTS / F. Perez-Ruiz* - I. Unnoagüena - S. P. Chinchilla


THU0430  PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF CONCOMITANT MULTIPLE DOSE ADMINISTRATION OF VERINURAD (RDEA3170) AND FEBUXOSTAT IN HEALTHY ADULT MALE SUBJECTS / J. T. VanderLugt* - M. Gillen - X. Yang - S. Liu - S. Walker - V. Clauson - M. Kankam

THU0431  COMPARATIVE EFFECTIVENESS OF ALLOPURINOL VERSUS FEBUXOSTAT FOR PREVENTING INCIDENT RENAL DISEASE IN OLDER ADULTS: AN ANALYSIS OF MEDICARE CLAIMS DATA / J. Singh* - J. Cleveland

THU0432  PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF CONCOMITANT MULTIPLE DOSE ADMINISTRATION OF VERINURAD (RDEA3170) AND ALLOPURINOL IN ADULT MALE SUBJECTS WITH GOUT / J. Hall* - M. Gillen - X. Yang - S. Liu - S. Walker - V. Clauson - M. Kankam

THU0433  RAPID TOPHUS RESOLUTION IN CHRONIC REFRACTORY GOUT PATIENTS TREATED WITH PEGLOTICASE / B. Y. Thong* - K.-Y. Gan - B.-H. Ang

* Presenting author
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACODYNAMIC EFFECTS AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH FEBUXOSTAT VERSUS FEBUXOSTAT ALONE IN ADULTS WITH GOUT: A PHASE 2A, OPEN-LABEL STUDY / R. Fleischmann P. Winkle - J. J. Hall* - S. Valdez - S. Liu - X. Yan - L. Hicks - M. Hernandez-Illas</td>
<td></td>
</tr>
<tr>
<td>PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH FEBUXOSTAT VERSUS FEBUXOSTAT ALONE AND VERINURAD ALONE IN JAPANESE ADULTS WITH GOUT OR ASYMPTOMATIC HYPERURICEMIA: A PHASE 2A, OPEN-LABEL STUDY / M. Shiramoto - S. Liu - Z. Shen - J. Hall*</td>
<td></td>
</tr>
<tr>
<td>CLINICAL SIGNIFICANCE OF DELTA NEUTROPHIL INDEX IN THE DIFFERENTIAL DIAGNOSIS BETWEEN SEPTIC ARTHRITIS AND ACUTE GOUT ATTACK WITHIN 24 HOURS AFTER HOSPITALISATION / J. Y. Pyo* - S. M. Jung - J. J. Song - Y.-B. Park - S.-W. Lee</td>
<td></td>
</tr>
<tr>
<td>IMPACT OF DIURETICS ON THE URATE LOWERING THERAPY IN PATIENTS WITH GOUT: ANALYSIS OF AN INCEPTION COHORT / L. Raineri* - C. Contrero - M. Andrés</td>
<td></td>
</tr>
<tr>
<td>LACK OF PREDICTIVE VALUE OF THE NAID/FAAN CRITERIA TO IDENTIFY SUBJECTS WITH EVIDENCE OF IMMUNE ACTIVATION AFTER RECEIVING PEGLOTICASE FOR CHRONIC FRUSTRATORY GOUT / L. Calabrese* - A. Kavanagh - A. Yeo - P. Lipsky</td>
<td></td>
</tr>
<tr>
<td>SYNOVIAL FLUID LEUKOCYTE COUNT AND ITS ASSOCIATION WITH CRYSTAL DEPOSITION IN ASYMPTOMATIC HYPERURICEMIA: A PRELIMINARY REPORT / M. Andrés* - J. A. Bernal - M. D. Arenas - E. Pascual</td>
<td></td>
</tr>
<tr>
<td>GOUTY ARTHRITIS: DECISION MAKING FOLLOWING DUAL ENERGY CT SCAN IN CLINICAL PRACTICE, A RETROSPECTIVE ANALYSIS / M. Gamala* - S. Linn-Rasker - M. Nix - B. Heggelman - J. van Laar - P. Pasker-de Jong - J. Jacobs - R. Klaassen</td>
<td></td>
</tr>
<tr>
<td>CO-MORBID GOUT IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES, BUT NOT CARDIOVASCULAR EVENTS OR MORTALITY / M. Mian* - S. K. Patel - B. Wai - P. M. Srivastava - R. R. C. Buchanan - L. M. Burrel</td>
<td></td>
</tr>
<tr>
<td>CHARACTERIZATION OF PATIENTS WITH CHRONIC FRUSTRATORY GOUT WHO DO AND DO NOT HAVE CLINICALLY APPARENT TPHI: RESPONSE TO PEGLOTICASE / N. L. Edwards* - J. Singh - O. Troum - A. Yeo - P. Lipsky</td>
<td></td>
</tr>
<tr>
<td>EVIDENCE BASED DEVELOPMENT OF CRITERIA FOR COMPLETE RESPONSE IN PATIENTS WITH CHRONIC REFRACTORY GOUT / N. Schlesinger* - P. Khanna - A. Yeo - P. Lipsky</td>
<td></td>
</tr>
<tr>
<td>HOSPITAL READMISSIONS FOR GOUT IN THE UNITED STATES: A NATIONAL DATABASE STUDY / N. Annapureddy* - A. Saha - P. Poojary - K. Chauhan - G. Nadkarni</td>
<td></td>
</tr>
<tr>
<td>A METHOD FOR COUNTING CALCIUM PYROPHOSPHATE CRYSTALS IN THE SYNOVIAL FLUID / P. Montagna* - R. Brizzolari - S. Soldano - M. Cutoio - M. A. Cimmino</td>
<td></td>
</tr>
<tr>
<td>IMMEDIATE AND LONG-TERM EFFICACY OF ANAKINRA IN ACUTE FLARES DUE TO HYDROXYAPATITE CALCIFICATIONS: A REAL-LIFE EXPERIENCE OF 13 CASES / P. Zufferey* - R. Valcov - A. So</td>
<td></td>
</tr>
<tr>
<td>HEART AND CAROTID CALCIFICATIONS: A REAL-LIFE EXPERIENCE OF 13 CASES / P. Zufferey* - R. Valcov - A. So</td>
<td></td>
</tr>
<tr>
<td>ROLE OF PHYSICAL EXERCISE IN PATIENTS WITH HIP ARTHROPLASTY FOR ASEPTIC NECROSIS OF THE FEMORAL HEAD / R. I. Marcu* - S. Patru - A. C. Bighea - D. Matei</td>
<td></td>
</tr>
<tr>
<td>IMPLICATIONS OF NLK3 INSERTIONS IN GOUTY PATIENTS - A STUDY OF 45 PATIENTS / J. J. Song - Y.-B. Park - S.-W. Lee</td>
<td></td>
</tr>
<tr>
<td>READY OR NOT? CHANGES IN THE CLINICAL PROFILE OF GOUT PATIENTS OVER THE LAST 25 YEARS / D. C. Taylor - S. Baumgartner</td>
<td></td>
</tr>
<tr>
<td>UNCONTROLLED GOUT / R. Morlock* - P. Chevalier - A. B. Klein</td>
<td></td>
</tr>
<tr>
<td>RATE OF HOSPITALIZATION FOR HEART FAILURE IS LOWER IN PATIENTS WITH CONTROLLED GOUT VERSUS UNCONTROLLED GOUT / R. Morlock* - P. Chevalier - A. B. Klein</td>
<td></td>
</tr>
<tr>
<td>LESS THAN HALF OF PATIENTS TREATED WITH HIGH-DOSE ALLOPURINOL REACH SUA TARGET / R. Morlock* - D. C. Taylor - S. Baumgartner</td>
<td></td>
</tr>
<tr>
<td>EXPLORING DUAL MODULATION OF GLUT9 AND OAT3, AN APICAL AND BASOLATERAL TRANSPORTERS IN PROXIMAL TUBULES AND EXPERIMENTAL MICE / S. H. Lee* - S. B. Kim - D.-S. Oh</td>
<td></td>
</tr>
<tr>
<td>MORTALITY IN PATIENTS WITH GOUT: A SYSTEMATIC REVIEW / S. Mitchell - H. Liedgens - E. Johannes*</td>
<td></td>
</tr>
<tr>
<td>EPIDEMOLOGY OF GOUT AND HYPERURICEMIA IN NEW CALEDONIA / T. Bardin* - E. Magnat - P. Clesner - P. Richette - B. Rouchon</td>
<td></td>
</tr>
</tbody>
</table>

* Presenting author
Fibromyalgia

THU0468  DIAGNOSTIC EXPERIENCE OF PATIENTS WITH FIBROMYALGIA - A SYSTEMATIC SYNTHESIS OF QUALITATIVE STUDIES / A. M. Mengshoel* - J. Sim - B. Ahlsen - S. Madden


THU0470  WORK AND PROFESSIONAL RECOGNITION IN FIBROMYALGIA PATIENTS - A NATIONAL FRENCH WEB BASED SURVEY ON SICK LEAVE IN 1870 FIBROMYALGIA FEMALE PATIENTS / F. Laroche* - D. Azoulay - J. Guérin - J. Coste - S. Perrot

THU0471  THE EFFECTS OF TAPPING THERAPY ON PAIN, SYMPTOM SEVERITY, DYSFUNCTIONS IN DAILY LIFE, DEPRESSION, AND QUALITY OF LIFE IN PATIENTS WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL / H. J. Suhr* - S. T. Choi - J. S. Song - S. H. Shin

THU0472  FAST3 (FIBROMYALGIA ASSESSMENT SCREENING TEST): A COMPOSITE INDEX BASED ON MDHAQ PROVIDES CLUES TO THE PRESENCE OF SECONDARY FIBROMYALGIA IN PATIENTS WITH A PRIMARY DIAGNOSIS OF RHEUMATOID ARTHRITIS AT HIGHER LEVELS THAN IDENTIFIED IN THE MEDICAL RECORD: A CROSS SECTIONAL STUDY FROM ROUTINE CARE / I. Castrejon* - K. Gibson - J. A. Block - T. Pincus


Basic science in paediatric rheumatology

THU0484  RO56 EXPRESSION DECREASES WITH AGE IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF CHILDREN AND ADOLESCENTS AND CORRELATES WITH TLR7 STIMULATION IN PDCS OF PREPUBERTAL CHILDREN / A. Radziszewska* - K. Webb - H. Peckham - Y. Ioannou

Paediatric rheumatology

THU0486 ANGIOPETIN-2 AS A NEW VALUABLE MARKER OF DISEASE ACTIVITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / J. Świdrowska-Jaros* - E. Smolewska

THU0487 REAL-LIFE TREATMENT WITH CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - FIRST EXPERIENCE FROM THE BIKER REGISTRY / G. Horneff* - F. Dressler - A. Thon - K. Minden on behalf of BIKER collaborative group


THU0492 MACROPHAGE ACTIVATION SYNDROME AS THE INITIAL MANIFESTATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS / S. Sato* - Y. Ueijma - E. Suganuma - T. Takano - S. Fujinaga - Y. Kawano

THU0493 STUDY OF LONG-TERM OUTCOME OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A SINGLE-CENTRE IN NORTH INDIA / A. Sharma* - A. Gupta - A. Rawat - D. Suri - S. Singh

THU0494 CLINICAL FEATURES OF CHILDREN WITH KAWASAKI DISEASE IN DIFFERENT AGE GROUPS IN SOUTHWEST CHINA / L. Shi* - J. Li - D. Qie - L. Qin

THU0495 EFFECTIVENESS OF CHILDHOOD VACCINATIONS IN CAPS PATIENTS TREATED WITH CANAKINUMAB: RESULTS FROM AN OPEN-LABEL PHASE 3 EXTENSION STUDY / P. Brogan* - M. Hofer - J. Kuemmerle-Deschner - B. Lauwers - A. Speziale - X. Wei - R. Laxer

THU0496 PULMONARY SYMPTOMS AS THE FIRST PRESENTATION OF KAWASAKI DISEASE IN CHILDREN / A. Gupta* - A. Kumar - D. Suri - S. Singh

THU0497 RHEUMATOLOGICAL MANIFESTATIONS OF X-LINKED AGAMMAGLOBULINEMIA: PROFILE OF 17 CASES FROM A TERTIARY CARE CENTER IN NORTH INDIA / A. Gupta* - D. Suri - A. Gupta - A. Rawat - S. Singh


THU0500 PHOTOBIOSIMULATION OF CHRONIC CERVICAL PAIN IN JUVENILE POLYARTHRITIS / C. Ilioaie* - L. M. Ilioaie


THU0505 LOW LITERACY BUT NOT PARENTAL SMOKING OR BREAST FEEDING WORSENS OUTCOME IN JUVENILE IDIOPATHIC ARTHRITIS IN A LOW INCOME POPULATION / F. A. C. Rocha* - J. I. Vasques - L. N. Rocha - W. A. Sifuentes Giraldo - A. L. Boteanu - M. L. Gámir Gámir - A. Zea Mendoza

THU0506 ASSOCIATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO, PLATELET-TO-LYMPHOCYTE RATIO, PLATELET INDICES AND SERUM AMYLOID A LEVELS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / M. Petri - K. E. Sullivan

THU0507 ASSOCIATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO, PLATELET-TO-LYMPHOCYTE RATIO, PLATELET INDICES AND SERUM AMYLOID A LEVELS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / M. Petri - K. E. Sullivan

THU0508 THE IMPACT OF OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS OVER THE FIRST FIVE YEARS FOLLOWING DIAGNOSIS / S. J. W. Shoop-Worrall* - S. M. Verstappen - J. E. McDonagh - W. Thomson - K. L. Hyrich on behalf of CAPS


* Presenting author


THU0514 PREDICTIVE VALUE OF SUBCLINICAL SYNOVITIS DETECTED BY DOPPLER ULTRASOUND IN RELATION TO FLARE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH BIOLOGIC THERAPY AFTER TAPERING BIOLOGIC THERAPY / J. C. Nieto-González* - A. Boteanu - J. C. López-Robledillo - P. Collado - A. Rodríguez - D. Clemente - M. L. Gámir - I. Monteagudo - E. Naredo


THU0516 LONGER TERM OUTCOMES OF CRMO IN A TERTIARY ADULT HOSPITAL AND YOUNG ADULT RHEUMATOLOGY CENTRE IN THE UK / K. E. N. Clark* - F. Josephs - N. Daly - Y. Ioannou - C. L. Murphy - D. Sen


THU0521 ENTHESIS-RELATED ARTHRITIS: NON-PERIPHERAL PATTERN IS ASSOCIATED WITH TH17 CELLS / M. Katsicas* - C. Carrara - A. Bernasconi - J. Rossi - R. Russo

THU0522 CORRELATION BETWEEN SERUM CALPROTECTIN (MRP8/14), CLINICAL AND ULTRASOUND ASSESSMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / M. Romano* - V. Gerloni - M. Gattinara - O. De Lucia - P. L. Meroni

THU0523 MORTALITY AND CAUSES OF DEATH AMONG JUVENILE IDIOPATHIC ARTHRITIS PATIENTS IN FINLAND / M. Kylönen* - H. Kautiainen - K. Puolakka - P. Vahasalo


THU0531 USE OF RITUXIMAB IN PAEDIATRIC RHEUMATOLOGY - EXPERIENCES FROM A SINGLE TERTIARY CENTRE / S. Deepak* - R. Obrien - K. Warrier - E. Mcdermott - S. Rangaraj

THU0532 PAEDIATRIC UEVIETIS IN FRENCH REFERRAL OPHTHALMOLOGIC CENTERS: A DESCRIPTIVE ANALYSIS OF 74 CHILDREN / L. Moal - A. Rousseau - G. Titah - M. Labetoulle - B. Bodaghi - S. Guillaume Cizmon

THU0533 DO JIA CORE OUTCOME VARIABLES AT BASELINE PREDICT CLINICALLY INACTIVE DISEASE STATES AT ONE YEAR? / S. J. W. Shoop-Worrall* - S. M. Verstappen - J. E. McDonagh - W. Thomson - K. L. Hyrich on behalf of CAPS

THU0534 BASELINE CHARACTERISTICS AND DESCRIPTIVE SAFETY DATA OF INTRAVERSEOUS ABATACTE-TREATED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN A US HEALTHCARE CLAIMS DATABASE / T. Simon* - S. Singhal - N. Ray - Z. Guo


THU0536 CHILDHOOD ONSET OF BEÇET DISEASE (BD) SYMPTOMS IN AN ADULT COHORT OF BD PATIENTS / V. Paisal* - E. Al-Abadi - S. Protheroe - D. Carruthers - D. Situnayake - S. Powell - D. Mitton - T. Southwood

THU0537 FAMILY AND PATIENT’S PERCEPTION OF DIETARY INTERVENTION IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) / E. M. Little - S. Grevich - J. L. Huber - D. L. Suskind - M. C. Bradford - A. M. Stevens - Y. Zhao

* Presenting author
Other orphan diseases


THU0541 ROLE OF IL-1 INHIBITION IN ADULT ONSET STILL’S DISEASE (AOSD): A RETROSPECTIVE, OBSERVATIONAL MULTICENTER STUDY FROM THE ITALIAN SOCIETY OF RHEUMATOLOGY STUDY GROUP ON AUTOINFLAMMATORY DISEASES / S. Colafrancesco* - R. Priori - P. Sfriso - G. Valesini - L. Punzi - M. Galeazzi - L. Cantarini on behalf of the study group on autoinflammatory diseases (Italian society of rheumatology)


THU0544 THE IMPORTANCE OF R202Q POLYMORPHISM IN CLINICAL EXPRESSION OF FMF: A SINGLE CENTER CROSS-SECTIONAL STUDY / S. Yilmaz - E. Tekgoz - F. I. Cinar - M. Cinar*

THU0545 COMPARISON OF THE CLINICAL AND LABORATORY FEATURES AT ONSET BETWEEN MULTICENTRIC CASTLEMAN’S DISEASE AND ADULT-ONSET STILL’S DISEASE / A. González García* - W. A. Sifuentes Giraldo - J. L. Morell Hitz - J. L. Patier de la Peña


THU0552 COMPLIANCE TO COLCHICINE TREATMENT IN FAMILIAL MEDITERRANEAN FEVER RELATED AMYLOIDOSIS / B. Yurttas* - S. Ugurlu - H. Ozdogan


THU0554 IMMUNOGLOBULIN G4-RELATED DISEASE IN HONG KONG - CLINICAL FEATURES, TREATMENT PRACTICES AND ASSOCIATIONS / P. H. Li* - C. Ho - C.-S. Lau


THU0556 SALVARY GLAND ENLARGEMENT IN IG4-RELATED DISEASE IS ASSOCIATED WITH MULTIORGAN INVOLVEMENT AND HIGHER BASAL DISEASE ACTIVITY / E. Martin-Nares* - A. Angeles-Angeles - G. Hernandez-Molina

THU0557 VENOUS VESSEL WALL THICKNESS IN LOWER EXTREMITY IS INCREASED IN MALE BEHÇET’S DISEASE PATIENTS WITHOUT VASCULAR INVOLVEMENT / F. Aliaz-Öner* - A. Mutis - R. Ergelen - Z. Erturk - T. Ergun - H. Direskeneli

THU0558 THERAPEUTIC RESPONSE TO PRENISONAE ACCORDING TO THE AGE IN POLYMYALGIA RHEUMATICA: A CONTROLLED STUDY / A. Tsereteli - F. Verhoeven* - M. Sondag - X. Guillot - C. Prati - D. Wendling

THU0559 PERSISTENT PRURITIC SKIN LESIONS WITH DYSKERATOTIC CELLS IN UPPER LAYER OF EPIDERMIS ARE SPECIFIC AND ASSOCIATED WITH HIGH LEVELS OF SERUM IL-18 IN ADULT-ONSET STILL’S DISEASE / H. Nishikawa* - Y. Taniguchi - N. Aoyama - Y. Terada

THU0560 DEVELOPMENT OF SYMPTOMS IN VERY EARLY PHASE IN PATIENT WITH ADULT ONSET STILL DISEASE / H. Tamai* - Y. Kaneko - N. Nishina - J. Kikuchi - T. Takeuchi

* Presenting author

THU0562 INFLAMMATORY JOINT DISEASE TRIGGERED BY IMMUNE CHECKPOINT INHIBITORS / L. Tucker* - S. Sacks - H. Al-Mosawi

THU0563 THE IMMUNOMODULATION EFFECT OF BM-MSCS ON THE INFLAMMATORY CHEMOKINES OF RATS WITH COLLAGEN TYPE II INDUCED ARTHRITIS / J. Fan - L. Zhang* - D. Ma - G. Zhang - K. Xu - J. Gao

THU0564 IGG4-RELATED DISEASE IN THE MALTESE POPULATION / S. Chetcuti Zammit - M. Rogers* - P. Ellul

THU0565 MACROPHAGE ACTIVATION SYNDROME IN ADULTS WITH INFAMMATORY RHEUMATIC DISEASES / M. Olejáróva* - K. Jarůšová

THU0566 CLINICAL AND GENETIC PHENOTYPES OF CHINESE PATIENTS WITH ADULT AUTOIMMUNE DISEASES: REPORT FROM AN ADULT REFERENCE CENTER / M. Shen* - D. Wu - X. Zeng

THU0567 PREVALENCE AND AUTOIMMUNE RHEUMATIC DISEASE IN PATIENTS WITH AUTOIMMUNE/INFAMMATORY SYNDROME INDUCED BY ADJUVANTS ASSOCIATED TO SILICONE BREAST IMPLANT / O. Vera Lastra* - N. E. Torres - Olivera - G. Medrano-Rodríguez - M. D. P. Cruz-Dominguez - J. Sepulveda.Delgado - L. J. Jara - G. Medina

THU0569 TREATMENTS OF UVEITIS IN A REFERRAL MULTIDISCIPLINARY UNIT IN NORTHERN SPAIN / P. Fanlo* - H. Heras - O. Terry - G. Espinosa - A. Adan

THU0570 ANAKINRA AS A SUCCESSFUL TREATMENT OF IDIOPATHIC RECURRENT PERICARDITIS: TAPER OR NOT TO TAPER? CASE SERIES AT THE UNIVERSITY OF SOUTHERN CALIFORNIA / P. S. Chihibar* - G. Ehresmann


THU0573 CONCOMITANT AUTOIMMUNE DISEASES IN PATIENTS WITH SARCOIDOSIS / S. Kobak* - F. Sever - H. Semiz - M. Orman


THU0576 THERAPEUTIC OPTIONS FOR PATIENTS WITH RARE RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS / T. T. A. Bender* - M. Mücke - J. Leyens - C. Stieber - D. Kravchenko - M. F. Seidel


Education


THU0581 WHAT WE SEE, WHAT WE LEARN, AND THE PREVALENCE OF RHEUMATIC DISEASES IN OUR POPULATION; THE PATIENT’S UNIVERSITY - AN INNOVATIVE CONCEPT IN THE EDUCATION OF PATIENTS WITH RHEUMATOID ARTHRITIS / L. Carton - D. Lafarge - G. Montagu - T. Pham - F. Tubach - J. Sellam on behalf of therapeutic education section of the French Society of Rheumatology and Club Rhumatismes Inflammation

THU0582 2-YEAR ADHERENCE TO THE TREATMENT OF OSTEOPOROSIS FOLLOWING A THERAPEUTIC PATIENT EDUCATION PROGRAM / D. Poivret* - C. Wilcke - V. Noirez - C. Goetz

THU0583 EFFECT OF AN ONLINE EDUCATIONAL INTERVENTION IN THE KNOWLEDGE OF PATIENT REGISTRIES AND THERAPEUTIC OPTIONS FOR PATIENTS WITH RARE RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS / T. T. A. Bender* - M. Mücke - J. Leyens - C. Stieber - D. Kravchenko - M. F. Seidel

THU0584 FIVE YEARS OF EXPERIENCE WITH THE LUPUS ACADEMY: AN EFFECTIVE MODEL FOR BUILDING A ROBUST COMMUNITY OF PRACTICE FOR GEOGRAPHICALLY DIVERSE LEARNERS / R. Cervera - E. Jackson* - E. McDardell - J. R. Curtis

THU0585 THE PATIENT’S UNIVERSITY - AN INNOVATIVE CONCEPT IN THE EDUCATION OF PATIENTS WITH RHEUMATOID ARTHRITIS / F. Rodriguez* - L. Villarreal - P. Santos-Moreno - M. Cabrera - D. Builtrago-Garcia - C. Caicedo

THU0586 SAFETY OF BIOLOGICS AND CONVENTIONAL DMARDS: AN ETHNOGRAPHIC STUDY INVESTIGATING PATIENTS’ DECISIONS AND PRACTICES TO DEVELOP AN EDUCATIONAL SMARTPHONE APP / G. Montagu* - C. Beaunais - F. Madrisotti - T. Pham - S. Tropé - F. Tubach - J. Sellam on behalf of therapeutic education section of the French Society of Rheumatology and Club Rhumatismes Inflammation

* Presenting author
Public health, health services research and health economics

**THU0599**

**BENEFIT RISK RATIO FOR BIOLOGICAL THERAPIES IN JUVENILE IDIOPATHIC ARTHRITIS, A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS** / N. Cabrera* - P. Janiaud - A. Belot - B. Kassai - J.-C. Lega

**THU0600**


**THU0601**

**CARDIOVASCULAR SCREENING AMONG PATIENTS WITH INFLAMMATORY ARTHRITIS: TO WHAT EXTENT DO PATIENTS FOLLOW RECOMMENDATIONS?** / A. H. Kjeldgaard* - K. Hørslev-Petersen - R. D. Christensen - J. Søndergaard - J. Primdahl

**THU0602**


**THU0603**

**DISEASE BURDEN OF KNEE OSTEOARTHRITIS PATIENTS UNDERGOING JOINT REPLACEMENT COMPARED TO MATCHED CONTROLS: A POPULATION-BASED ANALYSIS OF A DUTCH MEDICAL CLAIMS DATABASE OVER 12 MONTHS** / S. Mahmood* - P. van Riel - S. S. Youssef

**THU0604**


**THU0605**

**IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS / M. Belhassen* - F. Tubach - C. Hudry - M.-C. Woronoff - L. Levy-Bachelot - L. Lamezec - E. Van Ganse - B. Fautrel

**THU0606**

**COGNITIVE DYSFUNCTION IN CONNECTIVE TISSUE DISEASES** / A. Dima* - L. Groseanu - A. Balanescu - E. Van Ganse - B. Fautrel

**THU0607**


**THU0608**

**THE USE OF A PORTFOLIO AMONG YOUNG RHEUMATOLOGISTS: RESULTS OF AN EMEUNET SURVEY** / M. Van Onna* - F. Sivera - V. Navarro-Cómpán - E. Nikiforou - A. Mollo - S. Ramiro on behalf of the EMEUNET working group

**THU0609**


**THU0610**

**DO JUNIOR DOCTORS PRESCRIBE DISEASE MODIFYING ANTI RHEUMATIC DRUGS SAFELY?** / M. K. Nisar* - H. Weller

**THU0611**

**QUALITATIVE ASSESSMENT OF US-GUIDED INJECTIONS VIDEOS PUBLISHED ON VIDEO SHARING PLATFORMS** / S. H. Bourdais* - C. Darrieutort-Laffite - Y. Maugars - B. Le Goff

**THU0612**


**THU0613**

**THE VIEWS AND PERCEPTIONS OF NON-SPECIALIST, HOSPITAL JUNIOR DOCTORS ON JOINT ASPIRATION OF THE ACUTE HOT-SWOLLEN-JOINT, AND THEIR TRAINING IN THIS CLINICAL SKILL** / Z. Farah*

**THU0614**

**ASSOCIATION BETWEEN ALLOPURINOL DOSE-TITRATION AND SERUM URIC ACID LEVELS IN GOUT PATIENTS: V. Stoica - C. Mihai

**THU0615**

**THE VIEWS AND PERCEPTIONS OF NON-SPECIALIST, HOSPITAL JUNIOR DOCTORS ON JOINT ASPIRATION OF THE ACUTE HOT-SWOLLEN-JOINT, AND THEIR TRAINING IN THIS CLINICAL SKILL** / Z. Farah*

**THU0616**

**THE VIEW OF A PORTFOLIO AMONG YOUNG RHEUMATOLOGISTS: RESULTS OF AN EMEUNET SURVEY** / M. Van Onna* - F. Sivera - V. Navarro-Cómpán - E. Nikiforou - A. Mollo - S. Ramiro on behalf of the EMEUNET working group

**THU0617**

**ASSOCIATION BETWEEN ALLOPURINOL DOSE-TITRATION AND SERUM URIC ACID LEVELS IN GOUT PATIENTS** / V. Stoica - C. Mihai

**THU0618**


**THU0619**

**THE USE OF A PORTFOLIO AMONG YOUNG RHEUMATOLOGISTS: RESULTS OF AN EMEUNET SURVEY** / M. Van Onna* - F. Sivera - V. Navarro-Cómpán - E. Nikiforou - A. Mollo - S. Ramiro on behalf of the EMEUNET working group

**THU0620**


**THU0621**

**CAN YOU HEAR THE JOINTS CRYING? MUSCULOSKELETAL EXAMINATION IN JUNIOR DOCTORS’ MEDICAL ADMISSION CLERKINGS** / F. Y. H. Kwok* - L. H. Lee - A. Gupta

* Presenting author
THU0611

THU0612

THU0613

THU0614
FIDELITY OF AN INTERVENTION TO INCREASE PHYSICAL ACTIVITY IN OLDER ADULTS WITH CHRONIC PAIN: ANALYSIS OF AUDIO-RECORDED CONSULTATIONS FROM THE IPP07 PILOT TRIAL / C. Jinks* - J. Proctor - E. L. Healey - J. McBeth - C. A. G. Chew Graham on behalf of the IPP0 team

THU0615
PARTICIPANTS’ EXPERIENCE OF THE MAKING IT WORK PROGRAM, AN ONLINE PROGRAM TO HELP PEOPLE WITH INFLAMMATORY ARTHRITIS REMAIN EMPLOYED / A. Li - C. Backman - B. van As - P. Rogers - M. Gignac - L. Li - J. Esdaile - D. Lacaillé

THU0616
PATIENTS’ PERCEPTION ON DISEASE PROGRESSION AND ADHERENCE TO BIOLOGIC THERAPY / E. Cefai* - D. Balzan - C. Mercieca - A. A. Borg

THU0617
INFORMATION ON DISEASE AND TREATMENTS OF PATIENTS WITH RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS BIOLOGICALS: SOURCES AND SATISFACTION. RHEU-LIFE SURVEY / F. de Toro* - E. Battle - C. González - M. Calvo - M. Arteaga - L. Cea-Calvo

THU0618

THU0619

THU0620
PERSISTENCE WITH BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS - A RETROSPECTIVE DATABASE STUDY IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS / J. Mahlich - H. Kameda* - R. Sruamsiri

THU0621
DECREASE IN THE TEMPORARY WORK INCAPACITY DUE TO MUSCULOSKELETAL DISEASES: UTILITY OF DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA / J. Zavada* - L. Szczukova - J. Vencovsky - P. Horák

THU0622

THU0623

THU0624

THU0625

THU0626

THU0627

THU0628
PATTERNS OF ETANERCEPT DOSE ADJUSTMENTS IN A REAL-WORLD SETTING: A CANADIAN RETROSPECTIVE COHORT STUDY / M. Khraishi* - Y. Zhang - J. Ivanovic - B. Millson - E. Singh - J. Woolcott - H. Jones

THU0629
COORDINATION OF CARE FOR RHEUMATOID ARTHRITIS PATIENTS WITH CARDIOVASCULAR COMORBIDITIES - DESIGN OF AN INFORMATION AND COMMUNICATIONS TECHNOLOGY PLATFORM TO SUPPORT RHEUMATOLOGY OUTPATIENTS / J. V. Cordeiro* - A. Fernandes - C. D. Lopes - G. Victorino - P. Lobato Faria - M. J. Cercas - J. C. Branco - F. M. Pimentel-Santos

THU0630
PATIENTS’ PERCEPTION ON DISEASE PROGRESSION AND ADHERENCE TO BIOLOGIC THERAPY / E. Cefai* - G. Chehab - M. Schneider on behalf of the PICASO consortium (www.picaso-project.eu)

THU0631

THU0632
PARTICIPANTS’ EXPERIENCE OF THE MAKING IT WORK PROGRAM, AN ONLINE PROGRAM TO HELP PEOPLE WITH INFLAMMATORY ARTHRITIS REMAIN EMPLOYED / A. Li - C. Backman - B. van As - P. Rogers - M. Gignac - L. Li - J. Esdaile - D. Lacaillé

* Presenting author
OCTOBER 2017 / 83
15 June 2017


THU0635 PRECISE AND SIMPLE ALGORITHM TO IDENTIFY RA CASES IN ELECTRONIC MEDICAL RECORDS / R. Knevél* - S. Raychaudhuri - K. Liao - T. W. Huizinga


THU0639 RHEUMATOLOGICAL MEDICATION USE IN PREGNANCY, PLANNING PREGNANCY, AND BREASTFEEDING AT MOTHERSAFE DURING THE YEARS 2010 TO 2015 / S.-N. Luong* - D. Kennedy - J. V. Bertouch

THU0640 SECOND LINE TREATMENT PERSISTENCE AND COSTS AMONG PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS / J. Dalén - A. Svendsen - C. M. Black - A. Svedbom - C. M. Black - A. Rosman - J. V. Bertouch


THU0643 PATIENT DECISIONS RELATED TO HIP AND KNEE ARTHROPLASTY AND THE FACTORS INFLUENCING THEM / W. B. Nowell* - S. Venkatachalam - E. Harden - T. Concannon


THU0645 INTERCHANGEABILITY FROM INFLIXIMAB ORIGINATOR TO INFLIXIMAB BIOSIMILAR: EFFICACY AND SAFETY IN A PROSPECTIVE OBSERVATIONAL STUDY ON 89 PATIENTS / Y. Presberg* - V. Foltz - C. L. Amour - P. Tilleul - D. Zerkak - C. Bard - B. Fautrel

THU0646 INTERACTIONS BETWEEN STEPS PER DAY AND RISK FACTORS FOR OSTEOARTHRITIS ON MRI-DETECTED OSTEOPHYES IN A POPULATION BASED COHORT STUDY / Z. Zhu* - W. Han - S. Zheng - K. Wang - T. Winzenberg - F. Ciucuttini - C. Ding - G. Jones on behalf of Musculoskeletal Unit, Menzies Institute for Medical Research

THU0647 USE OF OUTPATIENT RHEUMATOLOGICAL HEALTH CARE SERVICES BEFORE AND AFTER SWITCH FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB / B. Glintborg* - J. Sorensen - M. L. Hetland


THU0649 THE EFFECT OF ANTI-TNF THERAPY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER ONE YEAR - REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA / J. Zavada* - L. Szczukova - K. Pavelka - P. Horák - J. Vencovsky on behalf of collaborators of the ATTRA registry


THU0654 THE INFLUENCE OF RISK PRESENTATION FORMAT ON WILLINGNESS TO START A MEDICATION / R. Cozmuta* - L. Fraenkel - E. Wilhelms - V. Reyna - J. Nolte

THU0655 DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% AND A 0.2% RISK? / R. Cozmuta* - L. Fraenkel - E. Wilhelms - V. Reyna - J. Nolte
THU0656 ETANERCEPT BIOSIMILAR USAGE AND ASSOCIATED COST SAVINGS IN GERMANY / K. Thakur* - A. Handrich - E. Psachoulia


Validation of outcome measures and biomarkers


THU0659 SKIN MICROVASCULAR FLOW ASSESSED BY DYNAMIC OPTICAL COHERENCE TOMOGRAPHY: FIRST NON-INVASIVE QUANTITATIVE OUTCOME MEASURE OF MICROVASCULAR DAMAGE IN SYSTEMIC SCLEROSIS / A. Daniel* - G. Abignano - S. Eng - L. Green - P. Emery - F. Del Galdo


THU0665 CAN ONE GIVE UP BASDAI IN FAVOR OF ASDAS IN MONITORING SPONDYLOARTHRITIS PATIENTS ON BIOLOGICS? / C. Göbelinsch* - D. Obris-Belinski - R. Ionescu

THU0666 PATIENT GLOBAL ASSESSMENT IS MORE SENSITIVE TO CHANGE THAN HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN EARLY AXIAL SPONDYLOARTHRITIS OVER 3 YEARS: DATA FROM THE DESIR COHORT / D. Puymaigord-Zemmour* - C. Desthiels - A. Ruyssen-Witrand - F. Bautrel - L. Gosses


THU0668 RELIABILITY OF PATIENT GLOBAL ASSESSMENT IN RHEUMATOID ARTHRITIS PATIENTS / G. Kageyama* - A. Onishi - Y. Ueda - J. Saegusa - A. Monnoubo

THU0669 THE ASSOCIATION BETWEEN HARRIS HIP SCORE AND DISEASE ACTIVITY OR HIP MRI FEATURES IN ANKYLOSING SPONDYLITIS / Z. Wu - L. He - M. Yang - Y. Liu - D. He - Y. Zhang - C. Wang - H. Xu*

THU0670 DETECTION OF SERUM ANTI-DNASE I ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS USING IMPROVED IMMUNOSORBENT ASSAY / I. P. Gontar* - I. A. Zborovskaya - L. N. Shilova - E. G. Korenskaya

THU0671 CAN AN INNER DISPOSABLE GLOVE BE USED UNDER AN ELECTROGONIOMETRIC GLOVE FOR MEASURING IMMUNOSORBENT ASSAY / A. S. Trofimenko - I. P. Gontar* - I. A. Zborovskaya - L. N. Shilova - E. G. Korenskaya

THU0672 REAL WORLD EVIDENCE COMPARING THE PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM TO THE CDAI IN RHEUMATOID ARTHRITIS PATIENTS / J. R. Curtis* - S. Kafka - D. Parenti - S. Black - S. Xu - Y. Wang - C. O. Bingham III


THU0675 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A TOOL TO ASSESS THE FEARS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / L. Gossec* - P. Chauvin - C. Hudry - C. Corvalán - Á. Briceño - R. Ionescu - R. G. Turchetti - M. Mosca


THU0680 VALIDATION OF EQ-SD, RAPID-3 AND HADS QUESTIONNAIRES FOR THE ASSESSMENT OF THERAPY EFFICACY IN PANNICULITIS PATIENTS / N. Savushkina* - V. Amirdjanova - O. Egorova - B. Belov

* Presenting author


THU0689  MODERATE TO GOOD CONSTRUCT VALIDITY OF GLOBAL PRESENTEEISM MEASURES WITH MULTI-ITEM PRESENTEEISM MEASURE AND PATIENT REPORTED HEALTH OUTCOMES: EULAR-PRO WORKER PRODUCTIVITY STUDY / S. Leggett - A. Boonen - D. Lacaille - S. Talli - M. Bojinka - J. Karlson - D. Beaton - B. Fautrel - J. Canas da Silva - C. Hoffstetter - S. Verstappen* on behalf of EULAR-PRO at-work productivity co-investigators.


THU0692  MODERATE TO GOOD CONSTRUCT VALIDITY OF GLOBAL PRESENTEEISM MEASURES WITH MULTI-ITEM PRESENTEEISM MEASURE AND PATIENT REPORTED HEALTH OUTCOMES: EULAR-PRO WORKER PRODUCTIVITY STUDY / S. Leggett - A. Boonen - D. Lacaille - S. Talli - M. Bojinka - J. Karlson - D. Beaton - B. Fautrel - J. Canas da Silva - C. Hoffstetter - S. Verstappen* on behalf of EULAR-PRO at-work productivity co-investigators.


THU0698  FEASIBILITY AND RELIABILITY OF DISEASE-SPECIFIC, PATIENT REPORTED OUTCOME MEASURE IN RHEUMATOID ARTHRITIS: TR AIMS2- SF / T. Duruoz* - C. Unal Ertek - C. Sanal Top.


THU0701  THE EFFECTS OF STRUCTURAL DAMAGE ON FUNCTIONAL DISABILITY IN PSORIATIC ARTHRITIS / M. P. M. Pimentel-Santos - T. M. Bombardieri - F. M. Pimentel-Santos.


* Presenting author.
Rehabilitation

THU0705  EXPERIMENTAL USE OF 3D PRINTING TECHNOLOGY FOR THE CONSTRUCTION OF DEVICES AS INTEGRATION OF OCCUPATIONAL THERAPY INTERVENTION WITH RHEUMATOID ARTHRITIS PATIENTS (RA) / G. Sandri - A. Bottini* - F. Franchi - M. T. Mascia

THU0706  LOW DISEASE ACTIVITY AFTER A SHORT COURSE OF DRUG THERAPY AND REHABILITATION IS ASSOCIATED TO A GREATER IMPROVEMENT IN FUNCTIONAL CAPACITY IN RHEUMATOID ARTHRITIS / B. Cunha* - B. Ferreira - L. Moreira - C. Barros - A. Gushiken - J. Kauer - T. Ferreira on behalf of SARAR 2 cohort

THU0707  RACE & REHABILITATION DESTINATION AFTER TOTAL HIP REPLACEMENT / E. R. Vina* - M. Kallan - A. Collier - S. Taravati - B. Isleten

THU0708  LONG-TERM OUTCOME AND RISK FOR TOTAL ARTHROPLASTY OF KNEE OSTEOARTHRITIS AFTER COMPREHENSIVE REHABILITATION / F. Angst* - T. Benz - A. Aeschlimann - S. Lehmann - B. Winteler - M. L. Verra


THU0711  IMPACT OF SPORTS PRACTICE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED STUDIES / L. Bouleau* - C. Palazzo - M. Kerzoncuf - T. Pham


THU0719  LONG-TERM COURSE OF HEALTH AND WORKING CAPACITY AFTER A REHABILITATION PROGRAM FOR WHIPLASH INJURY / T. Benz* - P. Haiduk - S. Lehmann - F. Gysi-Klaus - B. A. Michel - A. Aeschlimann - F. Angst

HPR: Interventions (educational, physical, social and psychological)

THU0720-HPR  PHYSICAL ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES / A. Lopez Esteban* - I. Janta - J. C. Nieto Gonzalez - F. Garcia - C. Garaballu - T. del Rio - C. Barbero - C. Gonzalez - J. Lopez Longo - I. Monteagudo


THU0722-HPR  THE EFFECTS OF KINESIO TAPING ON PAIN, JOINT RANGE OF MOTION, MUSCLE STRENGTH AND DISABILITY IN IMPINGEMENT SYNDROME / A. Yildiz* - Y. Buyuktepe

THU0723-HPR  A PHYSIOTHERAPY-LED IN-PATIENT INTENSIVE REHABILITATION PROGRAMME FOR ANKYLOSING SPONDYLITIS: FOLLOW-UP OUTCOMES / C. Clarke* - P. Taggart - J. Monaghan - J. McKnight - A. Cairns

THU0724-HPR  SELF-MANAGEMENT EXERCISE PROGRAM ASSOCIATED TO SPA THERAPY INCREASED THE PHYSICAL ACTIVITY LEVEL OF PEOPLE WITH SYMPTOMATIC KNEE OSTEOARTHRITIS: A QUASI-RANDOMIZED CONTROLLED TRIAL / C. Gay* - C. Auclair - N. Boisseau - L. Gerbaud - E. Coudeyre

THU0725-HPR  ESTIMATION OF THE EFFECT OF FOOT ORTHOTICS ON HIP JOINT LOADING FOR RHEUMATOID ARTHRITIS patients using MRI-based musculoskeletal models: A pilot study / M. Sarti - R. Expositor-Rodríguez - C. Terwee


THU0729-HPR  PATIENTS AND CAREGIVERS PREFERENCES RELATED WITH THE USE OF INFORMATIC TECHNOLOGY TOOLS FOR EDUCATION IN RHEUMATOID ARTHRITIS / S. Henao - F. Rodriguez* - L. Villarreal - P. Santos-Moreno - M. Cabrera - D. Buitrago-Garcia - C. Caicedo

* Presenting author
**HPR: Measuring health (development and measurement properties of PROs, tests, devices)**

**THU0738-HPR**

**PRESENTING AUTHOR**

**THU0739-HPR**

**THU0740-HPR**

**THU0741-HPR**

**THU0742-HPR**

**THU0743-HPR**

**THU0744-HPR**

**THU0745-HPR**

**THU0746-HPR**

**THU0747-HPR**

**THU0748-HPR**

**THU0749-HPR**

**THU0750-HPR**

**THU0751-HPR**

**HPR: Epidemiology and public health (including prevention)**

**THU0752-HPR**

**THU0753-HPR**

**THU0754-HPR**

**THU0755-HPR**

* Presenting author
HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)


HPR: Professional education, training and competencies

THU0758-HPR APPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT RECOMMENDATIONS FOR PATIENT PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND / K. Niedermann* - C. Madelaine-Bonjour - M. Roffler - A. Kocher on behalf of Health Professionals in Rheumatology Switzerland

HPR: Interventions (educational, physical, social and psychological)

THU0759-HPR DOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS? / M. Karapinar* - T. Firat - N. Kirdi

HPR: Service developments, innovation and economics in healthcare

THU0760-HPR PATIENT ADVICE LINE - THE POTENTIAL CLINICAL AND FINANCIAL BENEFITS TO A RHEUMATOLOGY DEPARTMENT / A. Mason* - C. Beevor - J. Ledingham


THU0763-HPR ADDRESSING THE ELEPHANT IN THE ROOM: A POSSIBLE NEW AND EFFECTIVE WAY TO INCREASE PATIENT ADHERENCE TO MEDICAL ADVICE / G. Grenhaug* - S. Arnesen


THU0767-HPR ADVANCED PRACTICE MUSCULOSKELETAL PHYSIOTHERAPY SERVICES: A NATIONAL EVALUATION / O. Fennelly* - C. Blake - O. Fitzgerald - R. Breen - A. Brennan - J. Ashton - C. Cunningham on behalf of the National Clinical Programmes for Rheumatology and Orthopaedics

THU0768-HPR PHONE FOLLOW-UP PROGRAM ENHANCES TREATMENT SAFETY AND DRUG CONCORDANCE ON DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) THERAPY FOR RHEUMATOLOGY PATIENTS / P. F. Lee* - Y. S. Cheung - C. K. Lam - M. C. Leung - C. M. Chan - W. L. Ng


THU0770-HPR COST SAVINGS BY FAVOURING INFlixIMAB BIOSIMILARS IN THE EASTERN REGION OF AUSTRIA / B. Reichardt - G. Reiter - T. Stamm* - V. Nell-Duxneuner

THU0771-HPR INCORPORATING SENIOR PHARMACIST INPUT IN TERIPARATIDE PATHWAY ENSURES ADHERENCE TO PRESCRIBING GUIDANCE - AUDIT/QUALITY IMPROVEMENT RESULTS FROM A DISTRICT RHEUMATOLOGY UNIT / W. Gan* - L. Bromilow - S. Vasireddy

THU0772-HPR VARIATION IN RHEUMATOLOGY NURSING CARE IN THE NETHERLANDS: A SURVEY AMONG NURSES / Y. Van Eijk-Hustings* on behalf of working group Rheumatology Nursing Research

* Presenting author
07:45 - 19:15 Registration area (Hall 2)

Registration

08:15 - 09:45 South Auditorium

Basic and Translational Science session

Mucosal B cells: gatekeepers of immune function

Learning objectives:
• To provide overview of B cells in gut homeostasis
• To discuss how mucosal B cells can promote immune regulation in arthritic disease

Chairperson(s):
Veerle Somers (Belgium)
Peggy Jacques (Belgium)
Claudia Mauri (United Kingdom)

Claudia Mauri (United Kingdom) 08:20
How microbiota shape regulatory B cells

Anca Catrina (Sweden) 08:50
Abstract N° SP0106
The lung in RA as driver of ACPA: cause or consequence

A. Chiba (Japan) 09:20
G. Murayama, N. Tamura, K. Yamaji, Y. Takasaki, S. Miyake
Abstract N° OP0214
Activation status of mucosal-associated invariant T cells reflects pathology of systemic lupus erythematosus

S. Hirose (Japan) 09:30
L. Qingshun, M. Ohtsuji, H. Nishimura, H. Amano, S. J. Verbeek
Abstract N° OP0215
Role of inhibitory IgG Fc receptor IIB on B cells and monocytes in YAA-related murine lupus

10:15 - 11:45 Hall 6

What is New (WIN) & How to Treat/Manage (HOT) session

WIN & HOT session

Chairperson(s):
Jaime Calvo Alén (Spain)
David S. Pisetsky (United States)
Christopher Denton (United Kingdom)

Christopher Denton (United Kingdom) 10:20
Abstract N° SP0107
HOT: Scleroderma treatment

Jacques-Eric Gottenberg (France) 11:00
WIN: Sjögren’s syndrome

10:15 - 11:45 Hall 8

Abstract session

PsA: the options grow!

Chairperson(s):
Lai-Shan Tam (China)
Axel Hueber (Germany)
P. J. Mease (United States)

P. J. Mease (United States) 10:20
Abstract N° OP0216
Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs): a randomised, placebo-controlled, phase 3 trial

E. G. Araujo (Germany) 10:30
M. Englbrecht, S. Hoepken, S. Finzel, A. Hueber, J. Rech, G. Schett
Abstract N° OP0217
Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PsA patients with active enthesitis - results from the enthesial clearance in psoriatic arthritis (ECLIPsA) study

A. Deodhar (United States) 10:40
A. Gottlieb, W.-H. Boehncke, B. Dong, Y. Wang, W. Barchuk, X. L. Xu, E. Hsia
Abstract N° OP0218
Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study
P. Nash (Australia) 10:50
Abstract N° OP0219
Early onset of efficacy with apremilast monotherapy in biologic-naïve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial

J. O’Dell (United States) 11:00
A. Kivitz, K. Papp, C. Leonardi, K. Jensen, H. Tang, B. Finck on behalf of the PsOsim study group
Abstract N° OP0220
Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritis

D. van der Heijde (Netherlands) 11:10
Abstract N° OP0221
Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks

I. B. McInnes (United Kingdom) 11:20
P. J. Mease, C. Ritchlin, P. Rahman, A. Gottlieb, B. Kirkham, R. Kajekar, E. M. Delicha, L. Pricep, S. Mpofu on behalf of the FUTURE 2 study group
Abstract N° OP0222
Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2

P. Mease (United States) 11:30
A. Gottlieb, D. van der Heijde, O. FitzGerald, A. Johnsen, M. Nys, S. Banerjee, S. Gladman
Abstract N° OP0223
Abatacept in the treatment of active psoriatic arthritis: 1-year results from a phase III study

10:15 - 11:45 Hall 7A

Abstract session
From classics to new: synthetic DMARDs in RA

Chairperson(s):
Peter C. Taylor (United Kingdom)
Ana Filipa Mourão (Portugal)

S. A. Bergstra (Netherlands) 10:20
C. F. Allaart, R. van den Berg, A. Chopra, N. Govind, T. W. Huizinga, R. B. Landé on behalf of METEOR working group
Abstract N° OP0224
Similar short term clinical response to initial treatment with high versus low dose methotrexate in mono- and combination therapy in early rheumatoid arthritis patients

R. Davies (United Kingdom) 10:30
M. Lunt, A. Barton, K. L. Hyrich, S. M. M. Verstappen on behalf of RAMS co-investigators
Abstract N° OP0225
The effect of a low versus high first prescribed dose of methotrexate on EULAR response at six months using data from the RAMS study

V. Stouten (Belgium) 10:40
J. Joly, D. De Cock, S. Pazmino, K. van der Eist, R. Westhoven, P. Verschueren on behalf of CareRA study group
Abstract N° OP0226
Sustained effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA slim) for early rheumatoid arthritis in a treat-to-target setting: 2 year results of the CareRA trial

T. Brunekeef (Netherlands) 10:50
H. Bernelot Moens
Abstract N° OP0227
Remission induction with methotrexate step-up therapy versus combination of hydroxychloroquine, methotrexate and triamcinolone: 3 year results

R. Westhoven (Belgium) 11:00
A. Kavanaugh, C. Jamoul, C. Tasset, P. Harrison, A. van der Aa
Abstract N° OP0229
Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies

R. Fleischmann (United States) 11:10
Abstract N° LB0003
Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial

K. L. Winthrop (United States) 11:20
Abstract N° OP0230
The effectiveness of zoster vaccine in RA patients subsequently treated with tofacitinib
Abstract session

New treatments in SLE, Sjögren's and APS

Chairperson(s):
Falk Hiepe (Germany)
Alessia Alunno (Italy)
I. Rodríguez-Pintó (Spain)

G. Espinosa, D. Erkan, Y. Shoenfeld, R. Cervera on behalf of CAPS registry project group (European Forum on Antiphospholipid Antibodies)

Abstract N° OP0231
The effect of “triple therapy” with anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins on the mortality of catastrophic antiphospholipid syndrome (CAPS) patients

D. J. Wallace (United States)


Abstract N° OP0232
Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE

S. Fasano (Italy)

D. Margiotta, L. Navarini, L. Pierro, A. Riccardi, I. Pantano, A. Afeltra, G. Valentini

Abstract N° OP0233
Primary prophylaxis of cardiovascular events in systemic lupus erythematosus: a retrospective analysis of 291 patients from two Italian centers

L. E. Cheng (United States)


Abstract N° OP0234
Clinical and biologic effects of ICOSL blockade by AMG 557 in subjects with lupus arthritis

Y. M. El-Sherbiny (United Kingdom)


Abstract N° OP0235
A novel B cell specific IFN-I biomarker is associated with plasmablast numbers following B cell depletion therapy in SLE

C. M. Yelnik (France)


Abstract N° OP0236
Benefit and safety of antithrombotic treatment in 264 pregnancies in patients with antiphospholipid syndrome

V. Dobronravov (Russian Federation)

M. A. Dooley, S. A. Haq, I. Adzerikho, O. Bugrova, D. Isenberg, F. Houssiau, N. Solomons, R. Huizinga on behalf of AURA-LV study group

Abstract N° LB0002
48 week complete remission of active lupus nephritis with voclosporin

A. Shojaei (United States)

J. L. Garrido-Castro (Spain)


Abstract N° OP0238
Measurement of spinal mobility in axial spondyloarthritis using inertial sensors: reliability and validation preliminary results

S. Alivernini (Italy)


Abstract N° OP0239
Histological features of joint and colonic inflammation in inflammatory bowel disease patients treated with anti-TNF

K. Bengtsson (Sweden)


Abstract N° OP0240
ERAP1 is a susceptibility factor for early axial spondyloarthritis meeting the ASAS classification criteria: results from the DESIR and SPACE cohorts

A. de Koning (Netherlands)

M. Hameetman, C. Micelli, M. Dougados, D. van der Heijde, F. Kurreeman, F. A. van Gaalen

Abstract N° OP0241
ERAP1 is a susceptibility factor for early axial spondyloarthritis meeting the ASAS classification criteria: results from the DESIR and SPACE cohorts

A. Shoenfeld, O. Bugrova, D. Isenberg, F. Houssiau, N. Solomons, R. Huizinga on behalf of AURA-LV study group

Abstract N° LB0002
48 week complete remission of active lupus nephritis with voclosporin

A. Shojaei (United States)

J. L. Garrido-Castro (Spain)


Abstract N° OP0238
Measurement of spinal mobility in axial spondyloarthritis using inertial sensors: reliability and validation preliminary results

S. Alivernini (Italy)


Abstract N° OP0239
Histological features of joint and colonic inflammation in inflammatory bowel disease patients treated with anti-TNF

K. Bengtsson (Sweden)


Abstract N° OP0240
ERAP1 is a susceptibility factor for early axial spondyloarthritis meeting the ASAS classification criteria: results from the DESIR and SPACE cohorts

A. de Koning (Netherlands)

M. Hameetman, C. Micelli, M. Dougados, D. van der Heijde, F. Kurreeman, F. A. van Gaalen

Abstract N° OP0241
ERAP1 is a susceptibility factor for early axial spondyloarthritis meeting the ASAS classification criteria: results from the DESIR and SPACE cohorts
D. Puyraimond-Zemmour (France) 11:00
C. Desthieux, A. Ruysse-Witrand, B. Fautrel, L. Gossec
Abstract N° OP0242
Health-related quality of life improved only slightly although disease activity decreased over 3 years in early axial spondyloarthritis: 442 patients from the DESIR cohort

J. Sieper (Germany) 11:10
Abstract N° OP0243
Predictors of remission at week 12 in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab treatment in the ability-3 study

F. van Gaalen (Netherlands) 11:20
Abstract N° OP0244
Family matters: value of family history of spondyloarthritis in the diagnostic work-up of patients with chronic back pain: results from the SPACE and DESIR cohorts

J. Freeston (United Kingdom) 11:00
Abstract N° OP0250
Can RANKL serum levels predict future progression to rheumatoid arthritis in ACPA-negative patients?

L. Dreyer (Denmark) 11:10
R. Cordtz, S. Hawley, D. Prieto-Alhambra, L. E. Kristensen, S. Overgaard, A. Odgaard
Abstract N° OP0251
Incidence of knee and hip replacements in rheumatoid arthritis patients following introduction of biological DMARDs: an interrupted time series analysis using nationwide health care registers

J. Wallman (Sweden) 10:20
J. K. Söderling, A. Gülfe, L.-E. Kristensen, M. Neovius, T. Olofsson
Abstract N° OP0246
Impact of disease activity measures on sick leave in biologics-treated patients with rheumatoid arthritis: observational data from Southern Sweden

A. Vanier (France) 10:30
J. S. Smolen, C. Allaart, R. Van Vollenhoven, P. Verschueren, N. Vastesaeger, S. Saevarsdottir, K. Visser, D. Aletaha, B. Combe, B. Fautrel
Abstract N° OP0247
An improved matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases

K. L. Winthrop (United States) 10:40
M. C. Genovese, M. Harigai, L. Chen, C. L. Dickson, D. L. Hyslop, A. Nishikawa, J. D. Bradley, M. Dougados
Abstract N° OP0248
Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib

M. Hagen (Germany) 10:50
Abstract N° OP0249
Multi-biomarker disease activity and autoantibody status lead to cost effective tapering algorithms in rheumatoid arthritis patients in sustained remission

S. A. Bergstra (Netherlands) 11:20
R. B. Landewé, T. W. Huizinga, C. F. Allaart
Abstract N° OP0252
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy

R. Seror (France) 11:30
G. Gusto, M. C. Boutron-Ruault, X. Mariette
Abstract N° OP0253
Passive smoking in childhood and history of chronic diarrhea increases the risk of developing rheumatoid arthritis (RA)
HPR Abstract session
Move to improve

Chairperson(s):
Peter Oesch (Switzerland)
Francoise Alliot (France)

K. Elleegaard (Denmark) 10:20
C. von Bülow, A. Repke, C. Bartholdy, I. S. Hansen,
S. Rifbjerg, R. Christensen, M. Henriksen,
E. Waehrens
Abstract N° OP0254-HPR
Hand exercise for women with rheumatoid arthritis
and decreased ADL ability: an exploratory randomised
controlled trial

G. Berdal (Norway) 10:30
K. Hagen, H. Dagfinrud, P. Mowinckel, I. Be,
T. N. Dager, A. Dingsør, S. Eppeland, J. Hagfors,
B. Hamnes, M. Nielsen, A.-L. Sand-Svartrud,
B. Slungaard, S. Wigers, I. Kjeken
Abstract N° OP0255-HPR
An add-on programme improved the short-term, but
not the long-term effect of rehabilitation in patients with
rheumatic diseases: results from a pragmatic multi-centre
stepped-wedge cluster randomized controlled trial

C. Boström (Sweden) 10:40
F. Russ, F. Eriksson, S. Pettersson, I. Gunnarsson,
E. Svenungsson
Abstract N° OP0256-HPR
Physical activity and inactivity in patients with systemic
lupus erythematosus

L. Villarreal (Colombia) 10:50
S. Henao, D. Buitrago-Garcia, P. Santos-Moreno
Abstract N° OP0257-HPR
Relationship between sleep disorders and disease activity
in patients with rheumatoid arthritis

E. Lange (Sweden) 11:00
D. Kucharski, K. Svensson, S. Svedlund,
I. Gjertsson, K. Mannerkorpi
Abstract N° OP0258-HPR
Intensive physical exercise for elderly persons with
rheumatoid arthritis improves physical capacity

S. T. Miyamoto (Brazil) 11:10
V. Valim, L. Carletti, W.-F. Ng, R. Altoé, A. J. Perez,
L. H. Dias, É. V. Serrano, A. M. Subtil, V. B. Cândido,
M. Trenceli, D. Lendrem, J. Natour
Abstract N° OP0259-HPR
Supervised walking improves aerobic capacity, exercise
tolerance, fatigue and perceived improvement in women with
primary Sjögren’s syndrome: a randomized controlled trial

K. Mannerkorpi (Sweden) 11:20
A. Larsson, A. Palstam, M. Ernberg, B. Gerdle,
E. Kosek
Abstract N° OP0260-HPR
Higher satisfaction with activity-related symptoms after
15-week resistance exercise in women with fibromyalgia

Gout session
Gout: advances in diagnosis and management

Chairperson(s):
Eliseo Pascual (Spain)
Nicola Dalbeth (New Zealand)

M. I. Dehlin (Sweden) 11:00
A. Gaffo (United States) 11:20
K. Risum (Norway) 11:30
A. M. Selvaag, Ø. Molberg, H. Dagfinrud, H. Sanner
Abstract N° OP0261-HPR
Physical activity level measured by accelerometer is
comparable between juvenile idiopathic arthritis patients
and controls, but patients spend less time in vigorous
physical activity

T. R. Merriman (New Zealand) 11:10
N. Dalbeth (New Zealand) 11:30
M. Cadzow, R. Topless, D. Mount, H. Choi,
Y. Okada, J. Boocock, E. Stahl
Abstract N° OP0263
Trends and costs for gout hospitalization in Sweden

N. Dalbeth (New Zealand) 11:00
S. Nicolaou, S. Baumgartner, J. Hu, M. Fung,
H. K. Choi
Abstract N° OP0264
Can moderate alcohol intake lower the risk of myocardial
infarction and mortality even among gout patients?

A. Gaffo (United States) 10:50
N. Dalbeth, J. Singh, K. Saag, W. Taylor
Abstract N° OP0265
Validation of a definition for attack (flare) in patients with
established gout

N. Dalbeth (New Zealand) 11:00
S. Nicolaou, S. Baumgartner, J. Hu, M. Fung,
H. K. Choi
Abstract N° OP0266
Presence of monosodium urate crystals by dual-energy
computed tomography in gout patients treated with
allopurinol

L. Stamp (New Zealand) 11:10
M. Morillon, W. Taylor, N. Dalbeth, J. Singh,
R. Christensen
Abstract N° OP0267
Serum urate as a surrogate endpoint for gout flares:
results of a systematic review and meta-regression
analysis of randomized trials
M. Doherty (United Kingdom) 11:20
Abstract N° OP0268
Nurse-led care versus general practitioner care of people with gout: a UK community-based randomised controlled trial

M. Bredemeier (Brazil) 11:30
L. M. Lopes, M. A. Eisenreich, G. K. Bongiorno, S. Hickmann
Abstract N° OP0269
Effect of xanthine oxidase inhibitors on the incidence of cardiovascular events: a systematic review and meta-analysis of randomised controlled trials

10:15 - 11:45  N111/N112
Abstract session
Low back pain and fibromyalgia

Chairperson(s):
Samantha Hider (United Kingdom)
James Prior (United Kingdom)

C. Nguyen (France) 10:20
Abstract N° LB0001
Intradiscal glucocorticoid injection for patients with chronic low back pain associated with active discopathy: a randomized trial

L. Hansen (Denmark) 10:30
U. Fredberg, T. P. Krogh, T. Ellingsen, L. B. Hansen
Abstract N° OP0270
Long-term prognosis in chronic plantar fasciitis based on disease duration and ultrasonic changes

M. J. Nissen (Switzerland) 10:40
L. Brulhart, A. Faundez, A. Finckh, D. Courvoisier, S. Genevey
Abstract N° OP0271
Corticosteroid injections for greater trochanteric pain syndrome: a randomized double-blind placebo-controlled trial

G. Singh (United States) 10:50
L. Alekseeva, D. Gorlachev, A. Barinov, E. Nasonov, A. Mithal
Abstract N° OP0272
Chronic low back pain and anxiety: significant decrease with glucosamine-chondroitin sulfate treatment in a large, community-based, pilot, open prospective interventional study

D. Weitzman (Israel) 11:00
D. Ben-Ami Shor, S. Dahan, Y. Bar-On, V. Shalev, G. Chodick, H. Amital
Abstract N° OP0273
A retrospective database study of one-year adherence and persistence with pharmacological therapy among fibromyalgia patients in Israel

F. Laroche (France) 11:10
J. Quérin, D. Azoulay, J. Coste, S. Perrot
Abstract N° OP0274
Fibromyalgia in real life. A national French web-based survey in 4516 patients

10:15 - 11:45  N115/N116
Abstract session
PARE

Chairperson(s):
Gráinne O’Leary (Ireland)
Karl Cattelaens (Germany)
Stefanie Hulst (Netherlands) 10:20
Edgar Sterne Prize 2017: Diagnosis from the perspective of a child

E. F. Mateus (Portugal) 10:30
S. Crisostomo, M. Santos, M. Serapioni, A. R. Matos on behalf of MAIS PARTICIPAÇÃO, melhor saúde
Abstract N° OP0276-PARE
More participation, better health - promoting public involvement in health

M. Ekroth (Finland) 10:40
T. Pakkala
Abstract N° OP0277-PARE
Initial information package for children diagnosed with JIA

L. Grange (France) 10:50
Abstract N° OP0278-PARE
The French patient’s association (AFLAR: French league against rheumatism) has generated the French national alliance against osteoarthritis and the first general convention of osteoarthritis in France: a campaign to create a national lobbying tool to improve the management of osteoarthritis

C. B. Jacklin (United Kingdom) 11:00
S. Arora
Abstract N° OP0279-PARE
NRAS know your DAS app self-assessment tool empowering patients
J. Andersen (United Kingdom) 11:10
S. Badreh, A. Charlet, K. Lerstrom, K. H. Wheeler
Abstract N° OP0280-PARE
Patient panels on access and adherence to treatment for SLE patients

A. Phoka Charalambous (Cyprus) 11:20
I. Cederlund, M. Neylander
Abstract N° OP0281-PARE
Educating patient experts/patient partners - a new way

K. Nordlund (Sweden) 11:30
M. Beermann
Abstract N° OP0282-PARE
#Doesntshowdoesntexist/#synsintefinnsinte - a photo campaign by unga reumatiker

H. Ahmad (United States) 10:30
J. Ye, S. Banerjee, P. Conaghan
Abstract N° OP0284
Evaluation of the impact of baseline levels of MRI-detected inflammation on treatment response in early, seropositive, MTX-naive RA: data from the AVERT trial

B. D. Nielsen (Denmark) 10:40
L. C. Gormsen, I. T. Hansen, K. K. Keller, P. Therkildsen, E.-M. Hauge
Abstract N° OP0285
Attenuation of fluorine-18-fluorodeoxyglucose uptake in large vessel giant cell arteritis after short-term high-dose steroid treatment - a diagnostic window of opportunity

M. Ammitzbøll-Danielsen (Denmark) 10:50
M. Østergaard, N. Esperanza, A. Iagnocco, I. Möller, M.-A. D’Agostino, F. Gandjbakhch, L. Terslev
Abstract N° OP0286
The utility of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

S. Seven (Denmark) 11:00
S. J. Pedersen, M. Østergaard, I. J. Sorensen, U. M. Dehn, S. Krabbe, L. Terslev
Abstract N° OP0287
Ultrasonography-detected peripheral enthesitis in patients with axial spondyloarthritis - anatomical distribution, morphology and response to anti-TNF therapy

P. Mandl (Austria) 11:10
Abstract N° OP0288
Reliability of a EULAR-OMERACT semi-quantitative scoring system for the assessment of cartilage in rheumatoid arthritis

N. P. Sundisater (Norway) 11:20
Abstract N° OP0289
Treat-to-target in early rheumatoid arthritis: association between sustained remission and joint damage

E. Pimenta (Brazil) 11:30
Abstract N° OP0290
Correlation of CXCL13 and ultrasonographic findings of Jaccoud arthropathy in systemic lupus erythematosus

Abstract session
Imaging and treatment response in rheumatology

Chairperson(s):
Philip Conaghan (United Kingdom)
James Dale (United Kingdom)

M. S. Stoenoiu (Belgium) 10:20
A. Pesonen, N. Bello, R. Christensen, M. Østergaard, E. Naredo, L. Terslev
Abstract N° OP0283
Ultrasonographic evaluation in rheumatoid arthritis using the global OMERACT/EULAR ultrasound synovitis score (GLOESS)

S. Seven (Denmark) 11:00
S. J. Pedersen, M. Østergaard, I. J. Sorensen, U. M. Dehn, S. Krabbe, L. Terslev
Abstract N° OP0287
Ultrasonography-detected peripheral enthesitis in patients with axial spondyloarthritis - anatomical distribution, morphology and response to anti-TNF therapy

Abstract session
From genetics through epigenetics to proteomics: understanding disease mechanisms

Chairperson(s):
Anne Barton (United Kingdom)
Caroline Osprey (Switzerland)

S. L. Smith (United Kingdom) 10:20
J. Bowes, J. Cobb, A. Hinks, S. Sampath, A. Warwood, L. Wedderburn, K. Hyrich, W. Thomson on behalf of Childhood Arthritis Prospective Study (CAPS), United Kingdom Juvenile Idiopathic Arthritis Genetics Consortium (UKJIGC), Childhood Arthritis Response to Medication Study (CHARMS), Biologics for Children with Rheumatic Diseases (BCRD) and BSPAR-Etanercept
Abstract N° OP0291
Identification of novel susceptibility loci in a large UK cohort of juvenile idiopathic arthritis (JIA) cases
A. Aterido (Spain) 10:30

Abstract N° OP0292
Genetic variation associated with cardiovascular risk in autoimmune diseases

X. M. Teitsma (Netherlands) 10:40
J. W. Jacobs, M. Mokry, A. Pethö-Schramm, M. E. Borm, J. M. van Laar, J. W. Bijlsma, F. P. Lafeber

Abstract N° OP0293
Weighted gene co-expression network analysis of DMARD-naïve early RA patients achieving sustained drug-free remission after initiating tocilizumab therapy

S. Ferrari (Switzerland) 10:50
R. Rizzoli, R. Chapurlat, M. L. Brandi, H. Martínez, M. Herrero, J. Vergés, M. Artieda, D. Tejedor, A. Martínez, J. Blanch, S. Palacios

Abstract N° OP0294
Fracture prediction using a genetic markers algorithm compared to FRAX in three European cohorts

V. Anaparti (Canada) 11:00
I. Smolik, X. Meng, N. Mookherjee, H. El-Gabalawy

Abstract N° OP0295
Unique whole blood microRNA biosignature for rheumatoid arthritis

H. Purvis (United Kingdom) 11:10

Abstract N° OP0296
Autoimmune associated gene PTPN22 negatively regulates dectin-1 signalling in dendritic cells

B. Stiburkova (Czech Republic) 11:20
K. Pavelcova, L. Petru, P. Cepek, J. Zavada, K. Pavelka

Abstract N° OP0297
Functional polymorphisms of the ABCG2 gene in primary gout

P. Martin (United Kingdom) 11:30
K. Duffus, A. McGovern, A. Yarwood, A. Barton, J. Worthington, S. Eyre, G. Orozco

Abstract N° OP0298
Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases

Abstract session
Innovative insights into mechanism of SLE, Sjögren’s and APS

Chairperson(s):
David Isenberg (United Kingdom)
Isabelle Peene (Belgium)

S. Truglia (Italy) 10:20
C. Alessandri, F. Ciccia, A. Rizzo, T. Colasanti, F. Miranda, F. R. Spinelli, F. Ceccarelli, G. Triolo, A. Capozzi, M. Sorice, G. Valesini, F. Conti

Abstract N° OP0299
Serum and glomerular expression of IL32 in lupus nephritis

E. Pontarini (United Kingdom) 10:30
W. Murray-Brown, C. Croia, E. Astorri, D. Lucchesi, N. Lepse, N. Sutcliffe, A. Tappuni, C. Pitzalis, M. Bombardieri

Abstract N° OP0300
Enrichment of T follicular-helper cells (TFH) and exclusion of T follicular-regulatory cells (TFR) from ectopic germinal centers in salivary glands of Sjögren’s syndrome patients

H. Liu (United States) 10:40
B. Higgs, W. Rees, C. Morehouse, K. Streicher, P. Brohawn, G. Illei, K. Ranade

Abstract N° OP0301
Type I IFN gene signature test-high and -low patients with moderate to severe SLE disease activity have distinct gene expression signatures of immunologic pathways and cell types

T. Kraaij (Netherlands) 10:50
S. W. Kamerling, J. A. Bakker, T. W. Huizinga, T. J. Rabelink, C. van Kooten, Y. K. Teng

Abstract N° OP0302
Significant reductions of pathogenic autoantibodies by synergistic rituximab and belimumab treatment effectively inhibits neutrophil extracellular traps in severe, refractory SLE - the synbiose study

S. L. Blokland (Netherlands) 11:00

Abstract N° OP0303
The salivary gland secretome as a potential new tool to identify biomarkers of dryness and immunopathology in primary Sjögren’s syndrome and non-autoimmune Sicca patients

J. Rangel-Moreno (United States) 11:10
S. Cochran, S. Tamir, M. Lee, S. Shacham, J. Anolik

Abstract N° OP0304
Selective inhibitors of nuclear export prevent lupus progression by targeting germinal center formation and autoreactive antibody secreting cells
M. Wahren (Sweden)  11:20
Abstract N° OP0305
Type I IFN system activation in newborns exposed to anti-Ro/SSA autoantibodies in utero

L. L. van den Hoogen (Netherlands)  11:30
Abstract N° OP0306
Downregulation of microRNAs in plasmacytoid dendritic cells is associated with a type I interferon signature in systemic lupus erythematosus and antiphospholipid syndrome

11:45 - 13:30 Exhibition (Hall 10)
Poster viewing & lunch

11:50 - 13:30  Poster area (Hall 10)

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tours on Friday please refer to pages 106 to 113.

Poster tour
F1: RA stromal cells - reloaded
Chairperson(s): Ulf Müller-Ladner (Germany), Christophe Richez (France)
Abstracts N° FRI0022 - FRI0031

Poster tour
F2: RA all over the body
Chairperson(s): Zoltán Szekanecz (Hungary), Agnes Szentpetery (Sweden)
Abstracts N° FRI0129 - FRI0138

Poster tour
F3: TNF inhibitors in RA = always and again
Chairperson(s): Xavier Mariette (France), Diane van der Woude (Netherlands)
Abstracts N° FRI0179 - FRI0190

Poster tour
F4: Trends in non-TNF alpha biologicals for RA I
Chairperson(s): Johannes W. J. Bijlsma (Netherlands), Xavier M. Teitsma (Netherlands)
Abstracts N° FRI0212 - FRI0222 & FRI0178

Poster tour
F5: Novelty in the clinical approach to SLE, SJögren’s and APS II
Chairperson(s): Angela Tincani (Italy), Mariele Gatto (Italy)
Abstracts N° FRI0255 - FRI0265

Poster tour
F6: Vasculitides clinical aspects II
Chairperson(s): Eamonn S. Molloy (Ireland), Alessandra Soriano (Italy)
Abstracts N° FRI0303 - FRI0312

Poster tour
F7: Scleroderma and myositis: etiology
Chairperson(s): Gabriela Riemekasten (Germany), Otavio Marques (Germany)
Abstracts N° FRI0353 - FRI0362

Poster tour
F8: Indexes and predictors in systemic sclerosis and myositis
Chairperson(s): Maurizio Cuttono (Italy), Vanessa Smith (Belgium)
Abstracts N° FRI0363 - FRI0372

Poster tour
F9: New drivers in RA and SPA pathophysiology
Chairperson(s): Maxime Breban (France), Elena Neumann (Germany)
Abstracts N° FRI0420 - FRI0423 & FRI0080 - FRI0084

Poster tour
F10: Outcome in AxSpA: does it matter?
Chairperson(s): Sofia Ramiro (Netherlands), Alexandre Sepriano (Portugal)
Abstracts N° FRI0472 - FRI0481

Poster tour
F11: Osteoporosis risk assessment and treatment: new tools and new strategies
Chairperson(s): Lai-Shan Tam (China), Priscilla Wong (China)
Abstracts N° FRI0524 - FRI0533
### Poster tour

**F12: What’s new in orphan diseases?**
Chairperson(s): Ruxandra Ionescu (Romania), Predrag Ostojic (Serbia)
Abstracts N° FRI0582 - FRI0591

**F13: Imaging advances in arthritis - what is new?**
Chairperson(s): Lene Terslev (Denmark), Signe Moeller-Bisgaard (Denmark)
Abstracts N° FRI0623 - FRI0632

**F14: Risk factors for RMDs or comorbid conditions**
Chairperson(s): Axel Finckh (Switzerland), Elena Nikiphorou (United Kingdom)
Abstracts N° FRI0683 - FRI0692

### Poster area (Hall 10)

**F15: PARE Poster tour II**
Chairperson(s): Dieter Wiek (Germany), Nele Caeyers (Belgium)
Abstracts N° PARE0012 - PARE0022

### Hall 6

**What is New (WIN) & How to Treat/Manage (HOT) session**

**WIN & HOT session**
Chairperson(s): Francisco J. Blanco (Spain), Francisca Sivera (Spain)
Margreet Kloppenburg (Netherlands) 13:35
WIN: Osteoarthritis
Alexander So (Switzerland) 14:15
HOT: Gout and other crystal induced arthritis treatment

### Hall 7A

**Challenges in Clinical Practice session**

**Life-threatening presentation of rheumatic diseases**

Learning objectives:
To be aware of acute and life-threatening presentation of rheumatic diseases both in adults and children

Chairperson(s):
Gabriela Riemekasten (Germany), Jordi Anton (Spain)

Caroline Birolo (Italy) 13:35
Abstract N° SP0109
Case 1 presentation: Paediatric difficult case presentation

Carine Wouters (Belgium) 13:45
Case 1 discussion: Life-threatening presentation of paediatric rheumatic diseases: an overview

Elise Siegert (Germany) 14:15
Case 2 presentation: Adult difficult case presentation

Maria C. Cid (Spain) 14:25
Abstract N° SP0110
Case 2 discussion: Life-threatening presentation of adult rheumatic diseases: an overview

### Hall 7B

**Clinical Science session**

**Comorbidities in rheumatoid arthritis**

Learning objectives:
To get an update on 3 out of the main comorbidities in RA; zoster, lymphomas and lung disease

Chairperson(s):
Maxime Dougdados (France), Anja Strangfeld (Germany)
Leonard Calabrese (United States) 13:35
Abstract N° SP0108
Herpes zoster: how to prevent, to diagnose and to treat

**Herpes zoster: how to prevent, to diagnose and to treat**
Athol Wells (United Kingdom) 13:55
Interstitial lung disease in RA and its treatment: where are we?

**L. B. Novette (France)** 14:15
Lymphomas in RA and its treatment: where are we?

G. Nocturne (France) 14:35
Abstract N° OP0307
Treatment of BAFF transgenic mice with anti-TNF: monoclonal anti-TNF are associated with a higher risk of lymphoma than etanercept

P. Raaschou (Sweden) 14:45
J. Söderling, J. Askling on behalf of the ARTIS study group
Abstract N° OP0308
TNF inhibitor treatment and risk of cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study from Sweden

**Herpes zoster: how to prevent, to diagnose and to treat**

**From Bench to Bedside**

**AxSpA: from bug to gut and to disease phenotype**

Learning objectives:
- To gain insight into pathophysiological and clinical data supporting - or not - possible interventions in order to inhibit radiographic progression in axSpA
• To stimulate a debate between both parties: pro and against a possible inhibition of radiographic progression in axSpA
• To learn about the role of mechanical stress in new bone formation and how to possibly intervene in order to inhibit it

Chairperson(s):
Lars Vereecke (Belgium)
Uta Kiltz (Germany)
Jose U. Scher (United States)

13:35
How microbiota shape the inflammatory response
Dirk Elewaut (Belgium)

13:53
The gut and SpA: implication for disease phenotype

Georg Schett (Germany)

14:11
What drives new bone formation in axSpA?
Progress from basic research

Robert B. M. Landewé (Netherlands)
Abstract N° SP0111
Inhibiting bone formation in axSpA in the clinic: are we there yet?

F. Ciccia (Italy)

14:47
G. Guggino, A. Rizzo, S. Milling, M. Luchetti,
D. Baeten, R. Alessandro, G. Triolo
Abstract N° OP0309
Intestinal sclerostin-serotonin axis is modulated by dysbiosis and regulates ILC3 expansion in as patients

Clinical Science session

Pregnancy meets rheumatic patients

Learning objectives:
• The use of new anti-rheumatic drugs in pregnancy
• To gain information on the main maternal and fetal complications in lupus pregnancy
• To address the long-term outcome of children born to women with rheumatic diseases

Chairperson(s):
Dimitrios Boumpas (Greece)
Guido Valesini (Italy)
Monika Østensen (Norway)

13:35
Abstract N° SP0112
Which drugs in pregnant patients?

Rebecca Fischer-Betz (Germany)

13:55
Abstract N° SP0113
Pregnancy in SLE: still challenging fetal and maternal issues

Laura Andreoli (Italy)

14:15
Abstract N° SP0114
Children of patients with rheumatic diseases: disease and treatment related problems

B. Blomjous (Netherlands)

14:35
C. Abheiden, S. Kroese, J. van Laar, R. Derksen,
I. Buitink, A. Voskuyl, A. Lely, M. de Boer,
J. de Vries, R. Fritsch-Stork
Abstract N° OP0310
Pregnancy outcome in women with systemic lupus erythematosus, a multicenter cohort-study

A. R. Lisney (Germany)

14:45
F. Szelinski, K. Reiter, G. R. Burmester,
C. Scholz, T. Rose, T. Dörner
Abstract N° OP0311
High maternal expression of SIGLEC1 on CD14+ monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block

Basic and Translational Science session

Neuronal and hormonal alterations in arthritis

Learning objectives:
• To understand the role of the (peripheral) neuronal system in arthritis
• To understand hormonal influence on pathophysiological processes in arthritis
• To understand potential intervention mechanisms to benefit arthritis patients via targeting the neuronal and hormone system

Chairperson(s):
Elena Neumann (Germany)
Silvia Capellino (Germany)
Rainer H. Straub (Germany)

13:35
Abstract N° SP0115
Neurotransmitters and innervation in synovium

Maurizio Cutolo (Italy)

14:15
Neurotransmitters and hormones as modulators in bone

R. Omdal (Norway)

14:35
E. Larssen, C. Brede, A. Hjelle, A. B. Tjensvoll,
K. B. Norheim, K. Bårdssen, K. Jonsdottir, P. Ruoff,
M. M. Nilsen
Abstract N° OP0312
A proteomic signature of fatigue in primary Sjögren’s syndrome

S. Welle (Germany)

14:45
A. M. Wolf, M. F. Seidel
Abstract N° OP0313
P75 low affinity receptor of nerve growth factor on peripheral leukocytes and CD11C-positive dendritic cells are upregulated in patients with systemic lupus erythematosus
13:30 - 15:00  N101/N102

Health Professionals session

Fighting osteoporosis fragilities

Learning objectives:
To get an overview of:
• osteoporosis and osteoporotic fracture socio-economic impact
• non-pharmacological prevention strategies
• future perspectives

Chairperson(s):
Ricardo Ferreira (Portugal)
Jo Adams (United Kingdom)

John Kanis (United Kingdom) 13:35
Abstract N° SP0117
Osteoporotic fractures in Europe: are we doing enough?

Sonya M. Stephenson (United Kingdom) 13:53
Abstract N° SP0118
Establishing and implementing fracture liaison services

Andrea Marques (Portugal) 14:11
Abstract N° SP0119
Predicting fracture risk: accuracy and feasibility of tools

Debra J. Rose (United States) 14:29
Abstract N° SP0120
Predicting the risk of falls and promoting balance in older adults

K. Niedermann (Switzerland) 14:47
B. Zindel, A. Meichtry, V. Krafft
Abstract N° OP0314-HPR
A home-based fall prevention programme reduces fear of falling in seniors

13:30 - 15:00  N105/N106

Paediatric Rheumatology session

Biological agents in juvenile idiopathic arthritis: open issues

Learning objectives:
To gain information on possible side effects related to the use of biological agents in paediatric patients with juvenile idiopathic arthritis and how to discontinue the treatment

Chairperson(s):
Marion van Rossum (Netherlands)
Dirk Foell (Germany)

Joost F. Swart (Netherlands) 13:35
Abstract N° SP0121
Long-term side effects of biological agents in JIA

Pierre Quartier (France) 13:55
Abstract N° SP0122
Autoimmune phenomena associated with biological agents

Gerd Horneff (Germany) 14:15
When and how to discontinue biological agents in JIA

A. F. Mourão (Portugal) 14:35
Abstract N° OP0315

E. Alexeeva (Russian Federation) 14:45
Abstract N° OP0316
Duration of clinical remission and flare rates in patients with juvenile idiopathic arthritis after withdrawal of biological treatment (preliminary data)

13:30 - 15:00  N111/N112

Practical skills session*

Data visualisation: tables and graphs for publication and presentation II

Maarten Boers (Netherlands) 13:35
Abstract N° SP0091
Data visualisation: tables and graphs for publication and presentation

13:30 - 15:00  N115/N116

PARE session

Health equity and economy - a vital relationship

Learning objectives:
• To define health equity
• To explore the concepts and principles of equity in health
• To explore the link between health equity and health economics

Chairperson(s):
Polina Pchelnikova (Russian Federation)
Elsa Mateus (Portugal)

Neil Betteridge (United Kingdom) 13:35
Mind the gap! EULAR: campaigning for equity in Europe

Polina Putrik (Netherlands) 13:55
Abstract N° SP0123
Uncovering the equity gap in rheumatic and musculoskeletal diseases

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Bruno Fautrel (France) 14:15
Abstract N° SP0124
Health economics and health equity: two complementary disciplines

A. Bosworth (United Kingdom) 14:35
C. Jacklin, T. Burke, A. Rose, I. Jacob, S. Verstappen
Abstract N° OP0317-PARE
An independent review of people with rheumatoid arthritis (RA) and their caregiver’s lost work time

F. J. Carreira Roca (Spain) 14:45
A. I. Vázquez Lojo, V. Romero Pazos on behalf of LIRE-LRG
Abstract N° OP0318-PARE
Consulting services to employers of people with RMDs

**EULAR Projects in Clinical Affairs**

**Biomarkers in cardiovascular rheumatology - state-of-the-art 2017**

**Learning objectives:**
- To illustrate the relation between inflammation and cardiovascular disease
- To show the background and use of vascular markers in clinical rheumatology

**Chairperson(s):**
Ulf Müller-Ladner (Germany)
Mariola Kurowska-Stolarska (United Kingdom)
Ernest Choy (United Kingdom) 13:35
Abstract N° SP0125
Inflammation and cardiovascular disease - relevant metabolic biomarkers

Uta Ceglarek (Germany) 13:53
Myths and facts about the lipidome and lipids in inflammatory rheumatic diseases

Zoltán Szekanecz (Hungary) 14:11
Abstract N° SP0126
The vessel wall in IMIDs - new emerging vascular markers

Michael Nurmohamed (Netherlands) 14:29
Abstract N° SP0127
Tapering biologics induces a pro-thrombotic state in rheumatoid arthritis

K. Sacre (France) 14:47
G. Divard, R. Abbas, C. Chenevier-Gobeaux, B. Escoubet, M.-P. Chauveheid, A. Dossier, M. Dehoux, T. Papo
Abstract N° OP0319
High sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematosus patients: a cross-sectional controlled study

**Practical skills session**

**MRI I**

**Learning objectives:**
To learn how to use MRI for assessment of inflammation and damage in spondyloarthritis and rheumatoid arthritis in clinical practice

**Chairperson(s):**
Mikkel Østergaard (Denmark)
Kay-Geert Hermann (Germany)

Iriss Eshed (Israel) 13:35
Abstract N° SP0128
MRI of enthesitis - by conventional and wholebody MRI - including patient cases

Daniel Glinatsis (Denmark) 13:55
Are MRI findings important to the rheumatoid arthritis patient? - relation to patient reported outcomes - including patient cases

Mikkel Østergaard (Denmark) 14:15
Abstract N° SP0129
Classification, diagnosis and differential diagnosis of axial spondyloarthritism by MRI - including patient cases

Kay-Geert Hermann (Germany) 14:35
MRI of the sacroiliac joint - lessons learnt from comparisons with CT - including patient cases

**Practical skills session**

**Ultrasound basic II**

**Chairperson(s):**
Marion Kortekaas (Netherlands)
George A. W. Bruyn (Netherlands)

Georgios Filippou (Italy) 13:35
Abstract N° SP0037
How to assess US elementary lessons in CPPD + demo

Peter Mandl (Austria) 13:55
Abstract N° SP0038
How to assess cartilage in RA and pitfalls + demo

Annamaria Iagnocco (Italy) 14:15
Abstract N° SP0039
How to evaluate the subtalar joint + demo

Ingrid Möller (Spain) 14:35
How to scan the hip - new approaches + demo

**Tutor:**
Lykke Midtboell Oernbjerg (Denmark)

**15:00 - 15:30**
**Exhibition (Hall 10)**
**Coffee break**

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
15:30 - 17:00  Hall 6

What is New (WIN) & How to Treat/Manage (HOT) session

WIN session

Chairperson(s):
Nuria Guanabens (Spain)
Sandrine Bours (Netherlands)

Piet Geusens (Netherlands) 15:35
Abstract N° SP0130
WIN: Osteoporosis

Christian Jorgensen (France) 16:15
WIN: Regenerative medicine

15:30 - 17:00  Hall 8

Clinical Science session

What is behind vasculitis?

Learning objectives:
• To understand the impact of the immune system on the development of atherosclerosis
• To understand the role of viruses and viral infection on the development of vasculitis

Chairperson(s):
Rebecca Fischer-Betz (Germany)
Maxime Dougados (France)

Zoltán Szekanecz (Hungary) 15:35
Abstract N° SP0131
Autoimmune atherosclerosis

Leonard Calabrese (United States) 15:55
Abstract N° SP0132
Viruses driving vasculitis

Raashid Luqmani (United Kingdom) 16:15
Abstract N° SP0133
ANCA and their environment

D. Cornec (France) 16:35
B. Kabat, J. Mills, M. Cheu, A. Hummel,
D. Schroeder, M. Cascino, P. Brunetta, D. Murray,
M. Snyder, F. Fervenza, G. Hoffman, C. Kallenberg,
C. Langford, P. Merkei, P. Monach, P. Seo, R. Spiera,
W. St. Clair, S. Ytterberg, J. Stone, D. Barnidge,
U. Specks
Abstract N° OP0320
Determinants of rituximab pharmacokinetics and clinical outcomes in patients with ANCA-associated vasculitis

G. Pugnet (France) 16:45
M. Mouguert, D. Chauveau, A. Huart, D. Ribes,
S. Faguer, L. Sailler
Abstract N° OP0321
Risk of coronary artery disease and ischemic stroke in patients with ANCA-associated vasculitis. A French population-based study

15:30 - 17:00  Hall 7A

Challenges in Clinical Practice session

Comorbidities in connective tissue diseases

Learning objectives:
• How to treat/prevent the infections occurring more frequently in immunosuppressed patients
• To understand and treat the different causes of depression and mood disorders in patients with connective tissue diseases

Chairperson(s):
Maria Tektonidou (Greece)
Maria Galindo Izquierdo (Spain)

Micaela Fredi (Italy) 15:35
Case 1 presentation: Infections in immunosuppressed patient

Nathalie Costedoat (France) 15:45
Case 1 discussion: The challenge to prevent and manage simultaneously infections and autoimmunity

Francesca Spinelli (Italy) 16:15
Case 2 presentation: Depression and mood disorders

Marta Mosca (Italy) 16:25
Case 2 discussion: Improving the quality of life: how to recognize and manage the different presentations of mood disorders

15:30 - 17:00  Hall 7B

From Bench to Bedside

Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs

Learning objectives:
• Basics of systems biology including the involvement of cytokines in immunology and rheumatology systems
• The peculiar nature of cytokines and their differential role in various immune-mediated inflammatory diseases (IMID)
• The fact that not all cytokines and not all IMIDs are the same, various cytokine signatures may be involved in the pathogenesis of different IMIDs
• Anti-cytokine targeting strategies may follow this cytokine taxonomy

Chairperson(s):
Ronald van Vollenhoven (Netherlands)
Agnes Szentpetery (Sweden)

Mary K. Crow (United States) 15:35
What are the implication of our understanding of cytokine networks for the management of diseases such as RA and SLE?

Iain B. McInnes (United Kingdom) 15:53
The exciting cytokine network: differences between RA, SpA and other IMIDs
Georg Schett (Germany) 16:11
Reflection of the cytokine network in differential efficacy of various biologics in IMIDs

Jens Humrich (Germany) 16:29
Abstract N° SP0134
Interleukin-2 therapy in SLE

K. Sato (Japan) 16:47
Y. Aizaki, Y. Araki, T. Mimura
Abstract N° OP0322
A novel hierarchical relationship between interleukin-17A and interferon-alpha is indicated by analysis of multiple cytokines in the serum of Adult-Onset Still’s disease and Behçet’s disease

15:30 - 17:00  South Auditorium

Basic and Translational Science session

Regulatory molecules in connective tissue

Learning objectives:
• To understand how immunoregulatory molecules can act on pathophysiology
• To illustrate the mechanisms of matrix-related molecules on systemic inflammatory diseases

Chairperson(s):
Steffen Gay (Switzerland)
Ladislav Senolt (Czech Republic)

Thomas Pap (Germany) 15:35
Abstract N° SP0135
Myostatin, sclerostin, syndecan and more...

Christopher Denton (United Kingdom) 15:55
Abstract N° SP0136
Multifactorial tissue growth factors

Martin Herrmann (Germany) 16:15
Abstract N° SP0137
From glycosylation to inflammation

T. W. Kragstrup (United States) 16:35
Abstract N° OP0326
Epigenetically-driven distal expression of the IncRNA HOTTIP shapes inflammatory, adhesive and proliferative characteristics of hand synovial fibroblasts in arthritis

15:30 - 17:00  N103/N104

Clinical Science session

Personalised care for back pain

Learning objectives:
• To understand the principles of stratification for patients with low back pain
• To appreciate the role of novel treatment options for low back pain
• To understand the role of spinal stimulation in treating back pain patients

Chairperson(s):
Stefan Bergman (Sweden)
Alexandre Sepriano (Portugal)

Nadine E. Foster (United Kingdom) 15:35
Beyond stratification: what’s next for back pain?

Hanne Albert (Denmark) 15:55
New therapeutic options for back pain

Adnan Al-Kaisy (United Kingdom) 16:15
Spinal cord stimulation for the treatment of back pain

S. Ahmed Yahia (France) 16:35
Abstract N° OP0323
Discopathy associated with modic changes is not related to any infectious process: a prospective monocentric study

A. Karateev (Russian Federation) 16:45
A. Tsurgan, N. Gontarenko
Abstract N° OP0324
Management of musculoskeletal pain using an algorithm for selection of analgesics

15:30 - 17:00  N101/N102

Health Professionals session

Patient engagement in research: best practices, benefits, and challenges

Learning objectives:
• To describe best practices for engaging patients in research at different levels during research and how the engagement plans match expectations of the funding agencies
• To demonstrate the benefits and challenges for researchers and patient research partners

Chairperson(s):
Elizabeth A. Schlenk (United States)
Thea Vliet Vlieland (Netherlands)
Maarten de Wit (Netherlands) 15:35  
Abstract N° SP0138  
The challenges of patient involvement in scientific research

Anthony Redmond (United Kingdom) 16:00  
Abstract N° SP0139  
Meaningful patient and public involvement in planning research

Janet L. Poole (United States) 16:25  
Abstract N° SP0140  
Patient engagement in research: a PCORI exemplar

K. Cresswell (United Kingdom) 16:50  
S. Parsons, S. Stones, J. E. McDonagh, W. Thomson, L. Lunt  
Abstract N° OP0327-PARE  
Your Rheum - giving young people a voice in rheumatology research

15:30 - 17:00 N111/N112

The Young Rheumatologist

RA treatment in patients wanting to become pregnant - interactive session

Learning objectives:
• To learn the different strategies of induction treatment of rheumatoid arthritis
• To learn the different treatments in RA patients planning/during pregnancy
• To learn the factors affecting conception and pregnancy in RA patients

Chairperson(s):
Karen Schreiber (United Kingdom)  
Alessia Alunno (Italy)

Annemiek Willemze (Netherlands) 15:35  
Abstract N° SP0141  
Case 1 presentation: New RA, but what about a new baby?

Radboud Dolhain (Netherlands) 15:45  
Case 1: Interactive discussion

Patrícia Nero (Portugal) 16:15  
Abstract N° SP0142  
Case 2 presentation: Foreplay and finale: factors affecting fertility, birth and lactation in RA patients

Monika Østensen (Norway) 16:25  
Case 2: Interactive discussion

15:30 - 17:00 N115/N116

PARE session

Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs

Learning objectives:
• To present latest advances in the management and treatment of psoriatic arthritis
• To explore the potential advantages and safety issues of the use of biosimilars with special attention to the fears and concerns of patients regarding adverse events

Chairperson(s):
Dieter Wiek (Germany)  
Simon Stones (United Kingdom)

Laura Coates (United Kingdom) 15:35  
Abstract N° SP0143  
A new day for people with psoriatic arthritis: a heterogeneous disease that can be treated well?

Faculty: Q&A 16:00

L. M. Thomsen (Denmark) 16:10  
Abstract N° OP0328-PARE  
Patient safety in relation to biosimilars - how can we act as a patient organization?

Alfons den Broeder (Netherlands) 16:20  
Abstract N° SP0144  
Biosimilars in rheumatic diseases: society chances versus patient concerns

Faculty: Q&A 16:45

15:30 - 17:00 N117/N118

EULAR Projects in Investigative Rheumatology

From pre-RA to established RA

Chairperson(s):
Xavier Mariette (France)  
Axel Finckh (Switzerland)

Rene Toes (Netherlands) 15:35  
Abstract N° SP0145  
Pathophysiologic processes leading to the development of autoimmunity

Diane van der Woude (Netherlands) 15:55  
Abstract N° SP0146  
Can we predict who is going to develop rheumatoid arthritis?

Faculty: Q&A 16:20

Kevin Deane (United States) 16:15  
Abstract N° SP0147  
Can we prevent the onset of rheumatoid arthritis in high risk individuals?

Bernard Lauwerys (Belgium) 16:35  
Abstract N° SP0148  
Pathophysiology of established RA synovitis
**15:30 - 17:00  ** N107/N108  

**Practical skills session*  
**Laboratory course - from the clinic to the lab and back I**

**Chairperson(s):**  
Gerd R. Burmester (Germany)  
Thomas Dörner (Germany)

**Thomas Dörner (Germany)  15:35**  
ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder

**Pierre Miossec (France)  16:00**  
Vasculitis, systemic autoimmunity

**Eugen Feist (Germany)  16:25**  
Abstract N° SP0149  
New trends in biomarkers in inflammatory joint diseases

15:30 - 17:00  N109/N110

**Practical skills session*  
**Ultrasound advanced II**

**Chairperson(s):**  
Esperanza Naredo (Spain)  
Georgios Filippou (Italy)

**Sarah Ohrndorf (Germany)  15:35**  
How to score synovitis quantitatively - validity and feasibility + demo

**Mads Ammitzboll (Denmark)  15:55**  
How to use image fusion + demo

**David Bong (Spain)  16:15**  
Abstract N° SP0076  
How and when to assess cervical facet joints + demo

**Jelena Vojinovic (Serbia)  16:35**  
Abstract N° SP0077  
How to evaluate joints in JIA + patient cases

**Tutor:**  
Lykke Midtboell Oernbjerg (Denmark)

**17:30 - 19:00  ** South Auditorium  

**Basic and Translational Science session**  
**Switching T on and off:**  
how T cells drive and regulate chronic inflammation

**Learning objectives:**  
Provide a scientific understanding of the mechanisms via which T cells promote and regulate inflammation

**Chairperson(s):**  
Vivianne Malmström (Sweden)  
Leonie Taams (United Kingdom)

**Vijay Kuchroo (United States)  17:35**  
How T cells drive and regulate chronic inflammation: a story of mice and men

**David C. Wraith (United Kingdom)  17:55**  
Learning from other fields: developing peptide immunotherapy for human autoimmune disease

**Lars Klareskog (Sweden)  18:15**  
Becoming more tolerant: can we induce T cell tolerance in RA?

**S. Abdollahi-Roodsaz (United States)  18:35**  
H. Evans-Marin, R. Rogier, J. Scher, D. Roeleveld, M. Koenders  
Abstract N° OP0329  
Involvement of T helper 17 cells in inflammatory arthritis depends on the host intestinal microbiota

**F. Renoux (Switzerland)  18:45**  
M. Stellato, D. Impellizzeri, A. Vogtseder, R. Huang, A. Subramaniam, C. Dees, J. H. W. Distler, G. Kania, O. Boyman, O. Distler  
Abstract N° OP0330  
FRA2 overexpression leads to systemic autoimmunity by decreasing IL-2 responsiveness and thymic treg development

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Guided Poster Tours

Friday, 16 June 2017

11:50 - 13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis on the day of the poster tour.

Poster Tour F1: RA stromal cells - reloaded

Chairperson(s): Ulf Müller-Ladner (Germany), Christophe Richez (France)


FRI0023 ARTESUNATE CAN INHIBIT MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES VIA SUPPRESSION OF MATRIX METALLOPROTEINASE 9 IN RHEUMATOID ARTHRITIS PATIENTS / J. Jing - T. Yan - J.-D. Ma - Y.-Q. Mo - L. Dai*


FRI0026 IDENTIFICATION OF MICRONAS CANDIDATES SPECIFICALLY EXPRESSED IN MONOCYTES OF UNDIFFERENTIATED ARTHRITIS PATIENTS WHO PROGRESSED TO RHEUMATOID ARTHRITIS / E. Kuca-Warnawin - A. Radzikowska - M. Ciechomska - U. Skalska - M. Jakubaszek - B. Kwiatkowska - W. Maslinski


* Presenting author
**Poster Tour F2: RA all over the body**

**Chairperson(s): Zoltán Szekanecz (Hungary), Agnes Szentpetery (Sweden)**

**FRIO129**
COMPARATIVE SAFETY OF BIOLOGIC DMARD INITIATION IN RA: A POPULATION-BASED OBSERVATIONAL STUDY OF MALIGNANCY RISK / S. Suisa* - S. Dell'Arielli - T. Simon

**FRIO130**

**FRIO131**
The 2010 ACR/EULAR CRITERIA ARE INSUFFICIENTLY ACCURATE IN THE EARLY IDENTIFICATION OF AUTOANTIBODY-NEGATIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE LEIDEN-EAC AND ESPOIR COHORTS / D. Boeters* - C. Gaujoux-Viala - A. Constantin - A. van der Helm-van Mil

**FRIO132**
HIGH DISEASE ACTIVITY IS A PREDICTOR OF DEPRESSION AND PERSISTENT DEPRESSION IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / R. Joshi - M. Movahedi - E. Rampakakis - A. Cesta - X. Li - S. Couto - J. Sampalis - C. Bombardier - B. Kuriya* on behalf of OBRI investigators

**FRIO133**
IS THERE INCREMENTAL MENTAL HEALTH BURDEN ASSOCIATED WITH RHEUMATOID ARTHRITIS? / V. Strand - on behalf of OBRI investigators

**FRIO134**
CLUSTER ANALYSIS OF PULMONARY LESIONS IN RHEUMATOID ARTHRITIS(RA); AIRWAY DISEASE IS SHARED AND CRITICAL PULMONARY ABNORMALITY IN RA / A. Tanaka* - Y. Namiki - R. Yamazaki - H. Okada - S. Arai - T. Owada - R. Maezawa - M. Arima - K. Kurasaawa

**FRIO135**
TREATMENT OF JAPANESE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH LOW-DOSE PREDNISOLONE FOR MAXIMUM 1 YEAR LEADS TO EARLIER IMPROVEMENT OF DISEASE ACTIVITY AND DOES NOT WORSEN BONE METABOLISM STATUS AND RATES OF NEW COMPLICATIONS / E. Torikai* - M. Suzuki - Y. Matsuymura

**FRIO136**
OVARIAN RESERVE, AS ASSESSED BY MEASURING SERUM ANTI-MÜLLERIAN HORMONE LEVELS, DECLINES MORE RAPIDLY OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS COMPARED TO CONTROLS / J. Brouwer* - G. Casten - M. H. Visser - N. S. Erler - R. J. Dolijn

**FRIO137**

**FRIO138**
LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS - A PORTUGUESE REALITY / A. C. Duarte* - S. Sousa - R. Asmussen Andeasen - I. M. J. Jensen Hansen

---

**Poster Tour F3: TNF inhibitors in RA = always and again**

**Chairperson(s): Xavier Mariette (France), Diane van der Woude (Netherlands)**

**FRIO179**
MINIMAL TO NO TRANSFER OF CERTOLIZUMAB PEGOL INTO BREAST MILK: RESULTS FROM CRADLE, A PROSPECTIVE, POSTMARKETING, MULTICENTER, PHARMACOKINETIC STUDY / M. E. B. Clowse* - F. Förger - M. Kosinski - R. Rendas-Baum - D. Brooks - R. Ganguly

**FRIO180**
MULTIPLE SCLEROSIS RISK-ALLELE STUDY IN PATIENTS WITH DEMYELINATING SIDE EFFECTS ON ANTI-TNF ALPHA THERAPY / S. Bitoun* - C. Verstuyft - C. Miceli-Richard - J.-M. Berthelot - C. Richez - C. Cauquil - A. Cordeiro - M. J. Santos - J. Canas da Silva

**FRIO181**
TAPERING OR CESSATION OF ANTIVIRAL AGENT IN HEPATITIS B VIRUS-INFECTED PATIENTS CONCOMITANTLY TREATED WITH BIOLOGIC AGENTS / B. Ghang* - D.-H. Lim - W. J. Seo - Y.-G. Kim - B. Yoo

**FRIO182**

**FRIO183**
ASSESSING ADHERENCE OF RA PATIENTS TREATED WITH ETANERCEPT USING ETANERCEPT SERUM TROUGH CONCENTRATIONS AND PATIENT SELF-REPORT / E. Vogelzang* - R. Hebing - M. Nurmoehamed - M. I'Ami - C. Krieckhaer - G. Wolbink

**FRIO184**

**FRIO185**
ASSESSING ADHERENCE OF RA PATIENTS TREATED WITH ETA-NERCEPT USING ETA-NERCEPT SERUM TROUGH CONCENTRATIONS AND PATIENT SELF-REPORT / E. Vogelzang* - R. Hebing - M. Nurmoehamed - M. I'Ami - C. Krieckhaer - G. Wolbink

**FRIO186**

**FRIO187**
A SYSTEMATIC REVIEW AND BIVARIATE META-ANALYSIS OF STUDIES THAT MEASURED ADALIMUMAB DRUG LEVELS BY ELISA TO DETECT TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS / S. Gavan* - K. Payne - A. Barton

**FRIO188**

**FRIO189**
RADIOGRAPHIC PROGRESSION BY DISEASE ACTIVITY STATES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB2 OR REFERENCE INFLIXIMAB / J. S. Smolen* - J.-Y. Choe - E. Keystone - Y. H. Rho - Y. Lee - S. Lee

**FRIO190**

* Presenting author
**Poster Tour F4: Trends in non-TNF alpha biologicals for RA I**

**Chairperson(s):** Johannes W. J. Bijlsma (Netherlands), Xavier M. Teitsma (Netherlands)

**FRIO212** COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC MONOTHERAPY IN RHEUMATOID ARTHRITIS / E. Silvagni* - A. Bortoluzzi - G. Carrara - M. Govoni - C. Scirià

**FRIO213** COMPARATIVE EFFECTIVENESS OF ABATACEPT, RITUXIMAB, TOCILIZUMAB AND ANTI-TNF BIOLOGICAL DMARDS IN RA: RESULTS FROM THE NATIONWIDE SWEDISH REGISTER / T. Frisell* - M. Delin - D. Di Giuseppe - N. Feltelius - A. Kastbom - C. Turesson - J. Asling on behalf of the ARTIS study group


**FRIO218** SHARED EPITOME POSITIVITY IS RELATED TO EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS / K. Oryoji* - K. Yoshida - S.-I. Mizuki


**FRIO220** ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (MPCS): A NOVEL APPROACH TO TREATING BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS / S. Kafaja* - K. R. Segal - D. Skerrett - S. Itescu - D. E. Furst


**Poster Tour F5: Novelty in the clinical approach to SLE, Sjögren’s and APS II**

**Chairperson(s):** Angela Tincani (Italy), Marielle Gatto (Italy)

**FRIO255** PATTERNS OF DISEASE ACTIVITY IMPACT ON ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS / A. Bortoluzzi* - M. Padovan - E. Silvagni - C. A. Scirià - M. Govoni


**FRIO257** ULTRASOUND CONSENSUS DEFINITIONS ON NORMAL AND ABNORMAL FINDINGS IN SALIVARY GLANDS IN SJÖGREN’S SYNDROME: RESULTS OF AN OMERACT DELPHI PROCESS / S. Jousse-Joulin* - F. Gandjbakhch - C. Scirè - N. S. Krogh - M. L. Hetland


**FRIO259** UNRABY ANGIOSTATIN, CXL4 AND VCAM-1 AS BIOMARKERS FOR LUPUS NEPHRITIS / C. Scirè - N. S. Krogh - M. L. Hetland


* Presenting author


FRIO263  SYSTEMIC DISEASE ACTIVITY PROGRESSION IN A LARGE COHORT OF PRIMARY SJÖGREN'S SYNDROME: A LONG-TERM FOLLOW-UP DATA BASED ON THE ESSDAI SCORE / L. Quattrocchio* - S. Zandonella Callegher - S. Gandolfo - C. Fabro - S. De Vita


FRIO265  CYTOKINES AND CORRELATIONS WITH PATIENT REPORTED OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND POPULATION CONTROLS / S. Pettersson* - H. Idborg - S. Eketjäll - I. Gunnarsson - E. Svennungsson

Poster Tour F6: Vasculitides clinical aspects II

Chairperson(s): Eamonn S. Molloy (Ireland), Alessandra Soriano (Italy)


FRIO304  THE UTILITY OF 18F FDG-PET/CT IN DISTINGUISHING BENIGN FROM MALIGNANT RETROPERITONEAL FIBROSIS / Y. Wang* - Z. Guan - D. Gao - J. Zhu - J. Zhang - F. Huang

FRIO305  RELATIVE FDG ACCUMULATION OF THE AORTIC WALL LESIONS TO AORTIC BLOOD POOL IN 18F-FDG-PET AND PET/CT COULD BE AN USEFUL TOOL FOR THE PREDICTION OF DISEASE RELAPSE AFTER SUCCESSFUL TREATMENT IN TAKAYASU ARTERITIS / A. Ihata* - Y. Kunishita - K. Minegishi - R. Yoshimi - Y. Kirino - H. Nakajima


Poster Tour F7: Scleroderma and myositis: etiology

Chairperson(s): Gabriela Riemekasten (Germany), Otavio Marques (Germany)


FRIO356  ANTISENSE LONG NONCODING RNAS ARE DEREGULATED IN SKIN TISSUE OF SSC PATIENTS / T. Messemaker - F. Franceschini


* Presenting author
**Poster Tour F8: Indexes and predictors in systemic sclerosis and myositis**

**Chairperson(s): Maurizio Cutolo (Italy), Vanessa Smith (Belgium)**


**FRI0361** INTERLEUKIN-4 INDUCES CLASS-SWITCHING TO IGG4 AND SYNERGISTICALLY CONTRIBUTES TO PLASMA STEM CELLS DIFFERENTIATION WITH INTERLEUKIN-21 THROUGH CD40 DEPENDENT MANNER IN IGG4-RELATED DISEASE / M. Akiyama* - Y. Yasuoka - K. Yoshimoto - T. Takeuchi


**Poster Tour F9: New drivers in RA and SPA pathophysiology**

**Chairperson(s): Maxime Breban (France), Elena Neumann (Germany)**

**FRI0402** ASSOCIATION OF SUPRESSOR OF CYTOKINE SIGNALING -3 (SOCS-3) EXPRESSION WITH INTERLEUKIN-23 RECEPTOR (IL-23R) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN ANKYLOSING SPONDYLITIS (AS) / M. A. Sánchez* - R. Villares - J. Polo y La Bordá - J. Campos - J. M. Rodríguez-Frame - J. Sanz - B. J. Robles Flores - A. Royuela - P. Lucas - M. Mellado - J. Muñoz

**FRI0421** DYSREGULATED MIR-125 PROMOTES JOINT ANGIOGENESIS IN PSORIASIS THROUGH ALTERED BIOENERGETICS / A. Royuela - P. Lucas - M. Mellado - J. Muñero


* Presenting author
Poster Tour F10: Outcome in AxSpA: does it matter?

Chairperson(s): Sofia Ramiro (Netherlands), Alexandre Sepriano (Portugal)


FRI0472 PATIENT-PHYSICIAN DISCORDANCE IN GLOBAL ASSESSMENT IN 401 EARLY AXIAL SPONDYLOARTHRITIS (ASXPA) PATIENTS FROM THE DESIR COHORT: WHAT IS THE EFFECT ON OUTCOMES AT 3 YEARS? / C. Desthieux* - A. Moito - A. Saraux - B. Fautrel - L. Gossec

FRI0473 DOES AXIAL SPONDYLOARTHRITIS PHOTOPHORE CORRELATE WITH IMAGING MORPHOTYPE? / X. Baraliakos* - A. Szumski - H. E. Jones - L. Gensler


FRI0480 SCORING SYNDROMES/PHTHYES ON CT SPINE IMAGES OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIS) COHORT / F. de Bruin - R. van den Berg - X. Baraliakos - J. Braun - F. van Gaalen - M. Reijnierse - D. van der Heijde

FRI0481 INTERPLAY BETWEEN PATIENT GLOBAL ASSESSMENT, PAIN AND FATIGUE AND INFLUENCE OF OTHER CLINICAL DISEASE ACTIVITY MEASURES IN PATIENTS WITH ACTIVE SPONDYLOARTHRITIS / O. R. Madsen* - E. L. Egsmose

Poster Tour F11: Osteoporosis risk assessment and treatment: new tools and new strategies

Chairperson(s): Lai-Shan Tam (China), Priscilla Wong (China)


FRI0526 ANTI-OSTEOPOROTIC THERAPY DECREASE CANCER RISK IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES / Y.-C. Chen* - C.-H. K.

FRI0527 LACUNARITY OF TRABECULAR BONE MICROARCHITECTURE, TBL


FRI0530 EFFECTIVENESS OF AN ORTHOPEDIC FRACTURE LIAISON SERVICE COMPARED WITH STANDARD CARE / A. Naranjo* - S. Fernández Conde - S. Ojeda - S. Rodríguez - L. Torres Hernández - I. Bernad oscos - I. Rodríguez - V. Kraev - C. Hernández Carballo - P. Laynez

FRI0531 DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN ELDERLY MEN WITH PROSTATE CANCER INITIATING ANDROGEN DEPRIVATION THERAPY REDUCES SUBSEQUENT FRACTURE RISK / M. E. Suarez-Almazor* - G. M. Cabanillas Salazar - H. Zhao - B. Shi - J. Kim - L. Elting


* Presenting author
Poster Tour F12: What's new in orphan diseases

Chairperson(s): Ruxandra Ionescu (Romania), Predrag Ostojc (Serbia)


FRI0583 IGG4-RELATED DISEASE AMONG PATIENTS PREVIOUSLY DIAGNOSED WITH IDIOPATHIC RETROPERITONEAL FIBROSIS. A NATIONWIDE DANISH STUDY / N. Lomborg* - M. Jakobsen - C. S. Bode - P. Junker


FRI0590 CANCER IS FREQUENT IN PATIENTS WITH ANTICENTROMERE PATTERN / C. Vázquez-Triñanes* - V. Alende - L. Vannozzi - S. Guerriero - S. Gentileschi - D. Bacherini - R. Franceschini - B. Sopeña on behalf of Círculo de estudio de las enfermedades autoinmunes de Galicia (CEAG)


Poster Tour F13: Imaging advances in arthritis - what is new?

Chairperson(s): Lene Terslev (Denmark), Signe Moeller-Bisgaard (Denmark)


FRI0627 ULTRASOUND HAND EXAMINATION IS MORE SENSITIVE IN DIAGNOSING HAND OSTEARTHRITIS THAN CONVENTIONAL RADIOGRAPHY: COMPARISON BETWEEN DIFFERENT ULTRASONOGRAPHIC SCORES / S. Hussain* - P. Sivakumar - C. Ciurtin

FRI0628 ULTRASOUND SHOWS SIGNS OF INFECTION IN MOST PATIENTS WITH RHEUMATOID ARTHRITIS IN LONGSTANDING CLINICAL REMISSION, IRRESPECTIVE OF CONVENTIONAL SYNTHEITIC OR BIOLOGIC DMARD THERAPY / U. Moller Dehn* - C. H. Brahe - M. L. Hetland - V. Fana - S. Krabbe - M. Ammitzbøll-Danielsen - M. Østergaard - L. Terslev

FRI0629 MAGNETIC RESONANCE IMAGING (MRI) INFLAMMATION OF THE FEET DEMONSTRATES SUBCLINICAL INFLAMMATORY DISEASE IN CUTANEOUS PSORIASIS PATIENTS WITHOUT CLINICAL ARTHRITIS / A. J. Mathew* - P. Bird - A. Gupta - R. E. George - D. Danda


Poster Tour F14: Risk factors for RMDs or comorbid conditions

**Chairperson(s):** Axel Finckh (Switzerland), Elena Nikipherou (United Kingdom)

**FRI0683**

**FRI0684**
EARLY TREATMENT WITH METHOTREXATE IMPROVES ALL-CAUSE AND CARDIOVASCULAR SURVIVAL AMONG AN INCEPTION COHORT OF SENIORS WITH RHEUMATOID ARTHRITIS / J. Widdifield* - J. M. Paterson - A. Huang - S. Bernatsky

**FRI0685**

**FRI0686**

**FRI0687**

**FRI0688**

**FRI0689**
LIPID PEROXIDATION AS RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION IN ANTIPHOSPHOLIPID SYNDROME (APS) PATIENTS / L. Stoianovich* - N. Stanisavljevic - A. Dijokovic - M. Zdravkovic

**FRI0690**

**FRI0691**

**FRI0692**
KEEP CALM AND TELL ME YOUR STORY!: A NARRATIVE MEDICINE PILOT PROJECT FOR ITALIAN YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES / U. G. Viora* - R. Giannelli - M. G. Pisu - G. Voltan on behalf of ANMAR Italia - ANMAR Young

**FRI0693**
WE DO THE IMPOSSIBLE, BECAUSE THE POSSIBLE EVERYONE CAN DO WAD AWARENESS CAMPAIGN / H. Bankova* - B. Ivkov - S. Bozhinova - B. Boteva

**FRI0694**

---

Poster Tour F15: PARE Poster tour II 12:00-13:30

**Chairperson(s):** Dieter Wiek (Germany), Nele Caeyers (Belgium)

**PARE0012**
EDUCATING YOUNG CHILDREN, PARENTS AND DOCTORS THROUGH THE MEDIUM OF AN ILLUSTRATED CHILDREN’S BOOK / T. Egert* - Y. Egert - R. Vitman - W. Costello

**PARE0013**
BEHIND THE SMILE - RA AWARENESS VIDEOS - RAISING AWARENESS OF THE HIDDEN IMPACT OF RHEUMATOID ARTHRITIS / C. B. Jacklin* - D. Saunders

**PARE0014**
EXPLORING THE ADDDED VALUE OF A BOOSTER SESSION AFTER COMPLETING THE DUTCH SELF-MANAGEMENT TRAINING “CHALLENGING ARTHRITIS” / M. Vos* - R. van den Brink - S. de Jong - J. Ammerlaan

**PARE0015**

**PARE0016**
KEEP CALM AND TELL ME YOUR STORY!: A NARRATIVE MEDICINE PILOT PROJECT FOR ITALIAN YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES / U. G. Viora* - S. Ostuzzi on behalf of ANMAR Italia - ANMAR Young

**PARE0017**
EMPOWERING PATIENTS WITH OSTEOARTHRITIS WITH NON-PHARMACOLOGICAL MEASURES / J. Vergés* - J. Monfort - M. Bibas - M. T. Vergés

**PARE0018**
WE DO THE IMPOSSIBLE, BECAUSE THE POSSIBLE EVERYONE CAN DO WAD AWARENESS CAMPAIGN / H. Bankova* - B. Ivkov - S. Bozhinova - B. Boteva

**PARE0019**
ADHERENCE TO THERAPY: A COMPARISON BETWEEN THREE PATIENTS POPULATIONS WITH AUTOIMMUNE INFLAMMATORY DISEASES / U. G. Viora* - R. Giannelli - M. G. Pisu - G. Voltan on behalf of ANMAR Italia

**PARE0020**

**PARE0021**

---

* Presenting author
Scientific Poster Session 2

Friday, 16 June 2017 11:45 - 13:30

Cartilage, synovium and osteoimmunology

FRI0001 ALL STAGES OF SYNOVIAL MESENCHYMAL STEM CELL ACTIVITY INCLUDING ADHESION, PROLIFERATION, MIGRATION AND CHONDROGENIC DIFFERENTIATION ARE SUPPORTED BY HUMAN PLATELET LYSATE-IMPLICATIONS FOR NOVEL ONE STAGE JOINT REGENERATIVE PROCEDURES / A. Altaie* - T. G. Baboolal - E. Jones - O. Wall - D. McGonagle

FRI0002 DEVELOPMENT OF AN IN VITRO MULTI-COMPONENT 3D JOINT MODEL TO SIMULATE THE PATHOGENESIS OF ARTHRITIS / A. Damerau* - A. Lang - M. Pfeiffenberger - F. Buttgereit - T. Gaber


FRI0004 14-3-3ETA AS A NOVEL INVADOSOME REGULATORY MOLECULE IN RHEUMATOID ARTHRITIS / C. Lalanne - R. R. Lavoie - M. Charbonneau - J. Savill - A. Marotta* - C. Dubois


* Presenting author
Rheumatoid arthritis - etiology, pathogenesis and animal models

**FRI0022**

**FRI0023**
ARTESUNATE CAN INHIBIT MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES VIA SUPPRESSION OF MATRIX METALLOPROTEINASE 9 IN RHEUMATOID ARTHRITIS PATIENTS / J. Jing - T. Yan - J.-D. Ma - Y.-Q. Mo - L. Dai*

**FRI0024**

**FRI0025**

**FRI0026**
IDENTIFICATION OF MICRORNAS CANDIDATES SPECIFICALLY EXPRESSED IN MONOCYTES OF UNDIFFERENTIATED ARTHRITIS PATIENTS WHO PROGRESSED TO RHEUMATOID ARTHRITIS / W. Jing - T. Yan - J.-D. Ma - Y.-Q. Mo - L. Dai*

**FRI0027**

**FRI0028**

**FRI0029**

**FRI0030**

**FRI0031**
DNA OXIDASE ENZYME TET3 EXACERBATES SYNOVIAL INFLAMMATION AND BONE DESTRUCTION / A. Kawabe* - A. de Paulis - G. Marone - C. Pitzalis

**FRI0032**

**FRI0033**

**FRI0034**

**FRI0035**

**FRI0036**

**FRI0037**

**FRI0038**
RELEASE OF PEPTIDYLARGININE DEIMINASE 2 FROM ACTIVATED NEUTROPHILS / M. A. Steffensen - D. Damgaard - M. Bassi - C. H. Nielsen*

CHARACTERIZATION OF ANTI-CARBAMYLATED SYNOVIAL PROTEIN ANTIBODIES (ANTI-CARPS) IN RHEUMATOID ARTHRITIS PATIENTS / C. Regueiro* - A. Montes - M. D. Boveda - S. Amhaz-Escanlar - E. Perez-Pampin - A. Mera-Varela - A. Gonzalez


BIAF-F EXPRESSION IN NAÏVE CD5+IgM+ B CELLS IN RHEUMATOID ARTHRITIS PATIENTS REPOPULATING AFTER RITUXIMAB / E. Becerra* - I. de la Torre - M. J. Leandro - G. Cambridge

PEPTIDES HIGHLY SPECIFIC TO THE VARIABLE REGION OF TNF-ALPHA-SPECIFIC REFERENCES LICENSED (RL) MONOCLONAL ANTIBODIES (MAB), AS POTENTIAL TOOL TO EFFECTIVELY ASSESS SIMILARITY BETWEEN BIOSIMILARS AND THE CORRESPONDING RL MAB / E. Favoino* - C. Ionescu - F. Perosa

NON-STERoidal ANTI-INFLAMMATORY DRUGS ARE MORE BENEFICIAL THAN ANTI-TNFa DRUGS ON THE RADIOGRAPHIC DAMAGE IN ARTHRITIS: A STUDY IN ADJUVANT INDUCED ARTHRITIS / F. Verhoeven* - C. Prati - P. Totoson - R. Bordy - D. Wendling - C. Demougeot


FC GAMMA RECEPTOR IV ENHANCES BONE EROSION IN EXPERIMENTAL ARTHRITIS BY PROMOTING INFUX OF PMNS / I. Di Ceglie* - G. Ascone - M. van den Bosch - J. S. Verbeek - P. van der Kraan - M. van Lent

TYPE II COLLAGEN SECRETED FROM ARTICULAR CHONDROCYTES IS MAINLY DESTROYED BY CATHEPSIN S BIOSIMILARS AND THE CORRESPONDING RL MAB / E. Favoino* - C. Ionescu - F. Perosa

BIOFILM PORPHYROMONAS GINGIVALIS AMOUNT AND DISEASE ACTIVITY IN ADJUVANT INDUCED ARTHRITIS MODEL / R. Bordy-Patoson - F. Verhoeven - C. Prati - A. M. Lammertstma - G. Jansen - C. F. M. Molthoff


ELEVATED 14-3-3ETA LEVELS PREDICT WORSE RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RECENT-ONSET INFLAMMATORY ARTHRITIS: WHICH EFFECT OF METHOTREXATE? A STUDY IN ADJUVANT INDUCED ARTHRITIS / F. Verhoeven* - C. Prati - P. Totoson - R. Bordy - D. Wendling - C. Demougeot


IDENTIFICATION OF CITRULLINATION SITES SPECIFIC FOR PEPTIDYLARGININE DEIMINASE 2 (PAD2) AND PAD4 IN FIBRINOGEN FROM SYNOVIAL FLUID OF PATIENTS WITH RHEUMATOID ARTHRITIS / M. Sharma* - K. Yamaoka - T. Takeuchi - K. Hirahara - C. Scheinecker - G. Steiner - W. Ellimeier


SYNOVIOCYTES OF PATIENTS WITH RHEUMATOID ARTHRITIS / L. Yan* - Y. Wen


* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome


FR10065 HELMINTHES BASED NOVEL COMPOUND, TUFTSN-PHOSPHORYLCHOLINE (TPC) AMELIORATES ESTABLISHED MURINE ARTHRITIS / T. Bashir - J. Lachnich - M. Fridkin - Y. Shoenfeld - M. Blank*


FR10068 REDUCTION OF PROLIFERATION, MIGRATION AND INVASION OF RHEUMATOID SYNOVIOTICCYTES BY ALL-TRANS RETINOIC ACID / N. Mosquera - A. Rodríguez-Trillo - S. B. Bravo - A. Mera - C. Conde


FR10073 RAGE ACTIVITY INFLUENCES CO-DEVELOPMENT OF JOINT AND VASCULAR DISEASE IN RA / S. Yu* - L.-S. Tam


FR10076 LACTATE/SLC5A12-INDUCED METABOLIC SIGNALING NETWORK: A NEW TARGET IN RHEUMATOID ARTHRITIS / V. Pucino* - J. Smith - D. Cucchi - K. Blighe - M. Bombardieri - C. Pitzalis - C. Mauro

FR10077 GUT COMMENSALS MODULATE INFLAMMATION VIA T REGULATORY CELLS / V. Taneja*

FR10078 ADENOSINMONOFOSFAT-AKTIVATING PROTEIN KINASE (AMFK) - THE BIOPOWER REGULATOR OF AN AUTOPHAGY IN RHEUMATOID ARTHRITIS (PA) / V. I. Shihkin* - G. V. Kudriavtseva - V. V. Shishkin - A. Malenko


FR10084 THE TONSIL MICROBIOME IS INVOLVED IN RHEUMATOID ARTHRITIS / J. Li* - J. He - K. Deng - J. Qin - Y. Jin - J. Chen - Z. Li

* Presenting author


ANALYSIS OF NEUTROPHILS, LYMPHOCYTES, AND PLATELETS IN POOLED PHASE 2 AND PHASE 3 STUDIES OF EFFECT OF STARTING DOSE OF BARICITINIB IN ACHIEVING SUSTAINED LOW DISEASE ACTIVITY / J. R. Curtis* - P. Taylor - I. B. McInnes - C. Pitzalis

PATIENT-PROVIDER Discordance May be Associated with Increased Risk of Subsequent Flares in Patients with Rheumatoid Arthritis / E. Myasoedova - C. S. Crowson - K. McCarthy-Fruin - E. L. Matteson


Time to and Factors Associated with Initiation of Biological Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis in Colombia / J. E. Machado-Alba* - L. F. Calvo-Torres - A. M. Bañol-Giraldo - S. Garcia-Betancourt on behalf of Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia. Universidad Tecnológica de Pereira- Audifarma S.A


Pain Reduction is Associated with Improved Work Productivity in Patients with Rheumatoid Arthritis / J. M. Davis, III*


RA in Male Carpenters: Occupational Wood Dust Exposure Increases AcPA and RF Seropositivity and Significantly RAES RF TITERES / K. Bellis* - M. Whallet - D. Murphy - D. Hutchinson


* Presenting author
Rheumatoid arthritis - comorbidity and clinical aspects

**FR10129** COMPARATIVE SAFETY OF BIOLOGIC DMARD INITIATION IN RA: A POPULATION-BASED OBSERVATIONAL STUDY OF MALIGNANCY RISK / S. Suisse* - S. Dell’Aniello - T. Simon


* Presenting author
FRI0132 HIGH DISEASE ACTIVITY IS A PREDICTOR OF DEPRESSION AND PERSISTENT DEPRESSION IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / R. Joshi - M. Movahedi - E. Rampakakis - A. Cesta - X. Li - S. Couto - J. Sampalis - C. Bombardier - B. Kuriya* on behalf of OBRI investigators

FRI0133 IS THERE INCREMENTAL MENTAL HEALTH BURDEN ASSOCIATED WITH RHEUMATOID ARTHRITIS? / V. Strand - M. Kosinski - R. Rendas-Baum - D. Brooks - R. Ganguly*

FRI0134 CLUSTER ANALYSIS OF PULMONARY LESIONS IN RHEUMATOID ARTHRITIS(RA); AIRWAY DISEASE IS SHARED AND CRITICAL PULMONARY ABNORMALITY IN RA / A. Tanaka* - Y. Namiki - R. Yamazaki - H. Okada - S. Arai - T. Owada - R. Maezawa - M. Arima - K. Kurasawa

FRI0135 TREATMENT OF JAPANESE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH LOW-DOSE PREDNISOLONE FOR MAXIMUM 1 YEAR LEADS TO EARLIER IMPROVEMENT OF XIMUL 1 ACTIVITY AND DOES NOT WORSEN BONE METABOLISM STATUS AND RATES OF NEW COMPLICATIONS / E. Torikai* - M. Suzuki - Y. Takahashi - M. Matsuura

FRI0136 OVARIAN RESERVE, AS ASSESSED BY MEASURING SERUM ANTI-MULLERIAN HORMONE LEVELS, DECREASES MORE RAPIDLY OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS COMPARED TO CONTROLS / J. Brouwer* - J. S. Laven - J. M. Hazes - N. S. Erler - J. A. Visser - R. J. Dohlain


FRI0139 PREVALENCE OF HYPERPARATHYROIDISM IS HIGHER AMONG RHEUMATOID ARTHRITIS PATIENTS COMPARED TO THE GENERAL POPULATION: AN OBSERVATIONAL, COHORT STUDY / A. Emamifar* - L. Stilgren - R. Hviid Larsen - P. A. Poulsen Andersen - I. M. Jensen Hansen


FRI0142 NEUTROPENIA IN RHEUMATOID ARTHRITIS, INCIDENCE, PROGNOSTIC FACTORS, NATURAL HISTORY AND OUTCOME / G. E. Fraguoli* - I. B. Mclnnes - D. Porter - S. Sie* on behalf of SERA collaborators


FRI0144 EVALUATION OF FACTORS AFFECTING FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. Klinic Kamic* - S. Unsal Delialioglu - S. Ozel - F. Yurdakul - H. Bodur

FRI0145 DOES PAIN HAVE INFLUENCE ON HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) ON HAQ-DI IN REAL CLINICAL PRACTICE / I. Yoshii* - T. Chijiwa


FRI0147 ANTI-MULLERIAN HORMONE LEVELS IN FEMALE RHEUMATOID ARTHRITIS PATIENTS TRYING TO CONCEIVE - THE ROLE OF OVARIAN FUNCTION IN TIME TO PREGNANCY IN A NATIONWIDE COHORT STUDY / J. Brouwer* - J. S. Laven - J. M. Hazes - J. A. Visser - R. J. Dohlain

FRI0148 THE EFFECT OF TNF INHIBITORS, METHOTREXATE (MTX), AND THE OTHER DMARDS THERAPY ON DIABETIC CONTROL IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA); TREATMENT WITH MTX ALONE IMPROVED DIABETES CONTROL MORE THAN TNF INHIBITORS PLUS MTX / K. Fujiko* - M. Takanu - M. Fuwa - I. Mori - T. Ishizuka

FRI0149 DOES THYROXIN SUBSTITUTION PREDICT NON-RESPONSE TO METHOTREXATE IN EARLY RA? / K. Waldenlind* - S. Sævedstøl - C. Bengtsson - J. Asling

FRI0150 EPIDEMIOLOGICAL DESCRIPTION OF PSYCHOLOGICAL, SEXUAL AND SLEEP DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CORRELATION BETWEEN THEM AND DISEASE ACTIVITY / L. Villarruel* - S. Henao - D. Buitrago-García - P. Santos-Moreno


FRI0153 COMPARISON OF CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS Versus METHOTREXATE: RESULTS AT 24-MONTHS OF FOLLOW-UP / M. Krhaisi* - M. Stutz - A. Lewis - C. Molla - E. Rampakakis


FRI0155 PREVALENCE OF HBV INFECTION AND RISK OF REACTIVATION ON BIOLOGIC TREATMENT: A POPULATION-BASED OBSERVATIONAL STUDY OF RHEUMATOID ARTHRITIS SUBJECTS IN A NORTHERN ITALY AREA / M. Moneri* - L. Sangiovanni - E. Lupi - S. Fagiulli - M. Limonta

FRI0156 PREVALENCE OF HYPERPARATHYROIDISM IS HIGHER AMONG RHEUMATOID ARTHRITIS PATIENTS COMPARED TO THE GENERAL POPULATION: AN OBSERVATIONAL, COHORT STUDY / A. Emamifar* - R. Hviid Larsen - R. Asmussen Andersen - I. M. Jensen Hansen

* Presenting author
**Rheumatoid arthritis - anti-TNF therapy**


**FRI0181** TAPERING OR CESSION OF ANTIVIRAL AGENT IN HEPATITIS B VIRUS-INFECTED PATIENTS CONCOMITANTLY TREATED WITH BIOLOGIC AGENTS / B. Ghang* - D.-H. Lim - W. J. Seo - Y.-G. Kim - B. Yoo


* Presenting author
FRIO183 ASSESSING ADHERENCE OF RA PATIENTS TREATED WITH ETANERCEPT USING ETANERCEPT SERUM TROUGH CONCENTRATIONS AND PATIENT SELF-REPORT / E. Vogelzang* - R. Hebing - M. Nurmohamed - M. I.Aimi - C. Kriekaat - G. Wolbink


FRIO185 A SYSTEMATIC REVIEW AND BIVARIATE META-ANALYSIS OF STUDIES THAT MEASURED ADALIMUMAB DRUG LEVELS BY ELISA TO DETECT TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS / S. Gavan* - K. Payne - A. Barton


FRIO187 RADIOGRAPHIC PROGRESSION BY DISEASE ACTIVITY STATES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB2 OR REFERENCE INFliximab / J. S. Smolen* - J.-Y. Cho - E. Keystone - Y. H. Rho - Y. Lee - S. Lee


FRIO191 INCIDENCE OF DISEASE WORSENING IN INFLAMMATORY ARTHRITIS PATIENTS ON LONG-TERM INNOVATOR INFliximab THERAPY / A. M. Marrache* - E. Psaradellis - J. Vaillancourt - E. Rappakakis - F. Nantel

FRIO192 CLINICAL PRACTICE GUIDE FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA). SYSTEMATIC REVIEW: IN PATIENTS WITH RA, WHICH IS THE SAFEST THERAPY FOR PATIENTS WITH PREVIOUS CANCER? / M. B. Nishishinya - C. A. Pereda - P. Diaz del Campo - A. Balsa* on behalf of Evidence based Rheumatology Working Group (SER) and GUIPCAR working group

FRIO193 EFFECT OF VALENCY OF ANTI-TNFs ON ELIMINATION MEDIATED BY ANTI-DRUG ANTIBODIES / J. Silva - Working Group (SER) and GUIPCAR working group


FRIO196 BIOMILARIS IN THE UK: EARLY REAL WORLD DATA FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BILOGICS REGISTERS FOR RHEUMATOID ARTHRITIS / D. De Cock* - K. Watson - K. L. Hyrich on behalf of BSRBR-RA Control Centre Consortium


FRIO198 USABILITY AND SAFETY OF SB5 (AN ADALIMUMAB BIOSIMILAR) PRE-FILLED SYRINGE AND PRE-FILLED PEN IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Ghil* - J. Niebrzydowski - A. Zielińska - Y. Lee

FRIO199 SYSTEMATIC REVIEW AND META-ANALYSIS ON CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS IN ADULTS / J. A. Bernal* - P. Vela - V. Ruiz Garcia - A. Burls - J. B. Cabello - S. Bort-Marti


FRIO202 THE DIFFERENT EFFECT OF TNFA BLOCKERS AND SDMARDS ON LIPOPROTEIN SUBCLASSES IN RA PATIENTS. A PERSPECTIVE CONTROLLED LONGITUDINAL STUDY / M. Zakalka* - M. Karakota - G. Koliakos - L. Settas

FRIO203 GOLIMUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING Spondylitis (AS) - SUBANALYSIS FROM THE NON-INTEVENTIONAL EVALUATION GO-NICE / K. Krüger - G. R. Burmester - S. Wassenberg - M. Bohl-Bühler - M. H. Thomas*


FRIO205 CORRELATION OF PATIENT PREFERENCES TO TREATMENT OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ANTI-TNF AGENTS IN GREECE, THE PANORAMA STUDY / P. Sidiropoulos* - A. Bouns - P. Athanassiou - A. Andríanakos - E. Petrikou - A. Drosos - D. Vassilopoulos

* Presenting author
Rheumatoid arthritis - other biologic treatment

FRIO212 COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC MONOTHERAPY IN RHEUMATOID ARTHRITIS / E. Silvagni* - A. Bortoluzzi - G. Carrara - M. Govoni - C. Scirè

FRIO213 COMPARATIVE EFFECTIVENESS OF ABATACEPT, RITUXIMAB, TOCILIZUMAB AND ANTI-TNF BIOLOGICAL DMARDS IN RA: RESULTS FROM THE NATIONALWIDE SWEDISH REGISTER / T. Frissell* - M. Dehlin - D. Di Giuseppe - N. Feltelius - A. Kastborn - C. Turesson - J. Asling on behalf of the ARTIS study group


FRIO218 SHARED EPITOPE POSITIVITY IS RELATED TO EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS / K. Oryoji* - K. Yoshida - S.-I. Mizuki

FRIO219 ASSOCIATION BETWEEN CONVERSION TO ACPA/RF SERONEGATIVE STATUS AND CLINICAL OUTCOMES FOLLOWING TREATMENT WITH ABATACEPT IN COMBINATION WITH METHOTREXATE COMPARED WITH METHOTREXATE ALONE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND POOR PROGNOSTIC INDICATORS / D. Jansen - P. Emery - J. Smolen - R. Westhovens - M. Bar - S. Connolly - J. Ye - R. Toes - T. Huizinga*
FRI0227 SARILUMAB Significantly Suppresses Circulating Biomarkers of Bone Resorption and Cardiovascular Risk Compared with Adalimumab: Biomarker Analysis from the Phase 3 MONARCH Study / C. Gabay* - J. Mshid - C. Paccard - M. Zilberstein - N. M. Graham - A. Boyapati


FRI0232 TREATMENT EFFECTS OF ABATACEPT AND ANTI-TNF IN PATIENTS WITH RA WITH POOR PROGNOSTIC FACTORS: DATA FROM COMMUNITY RHEUMATOLOGY CLINICS / E. Alemao* - K. Knapp - V. Anupindi - S. Annamalai - G. Craig


FRI0235 CNONCUMITANT USE OF INTRAVENTRIOUS MALTYPREDNISOLONE TO OBTAIN HIGHER RETENTION RATE OF ABATACEPT IN RHEUMATOID ARTHRITIS / H. Sawada* - M. Suda - M. Kishimoto - M. Okada


FRI0238 EFFECT OF BASELINE ANTI-CYCLIC CITRULLINATED PEPTIDE 3 ANTIBODY TITRE ON CLINICAL RESPONSE TO INFILXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY / J. C. Sarmiento-Monroy* - N. Molano-González - M. Rodríguez-Jíménez - R. D. Martílla


FRI0242 ASSOCIATION BETWEEN CLINICAL AND RADIOGRAPHIC RESPONSES, AND PHYSICAL FUNCTION IN A PHASE 3 STUDY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS / M. C. Genovese* - H. van Hoogstraten - W. Kampman - S. Annamalai - G. Craig


FRI0246 IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH SIRUKUMAB ARE STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL, AND MEET OR EXCEED NORMATIVE VALUES IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: POST HOC ANALYSES OF A PHASE 3 TRIAL / V. Strand - K. McQuarrie - N. Li - R. Ganguly*

FRI0247 MEDIAN TIME TO LOW DISEASE ACTIVITY IS SHORTER IN TOCILIZUMAB COMBINATION THERAPY WITH CSMARDS AS COMPARED TO MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO CSMARDS AND/OR TNF INHIBITORS: SUBANALYSIS OF THE SWISS AND AUSTRIAN PATIENTS FROM THE ACT-SURE STUDY / R. Mueller* - W. Granger - P. Sidiropoulos - C. Goger - J. von Kompf

FRI0248 INCIDENCE OF MELANOMA IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB / S. Gale* - J. Wang - J. M. Nebesky - A. T. Linke - E. Berger

FRI0249 CIRCULATING FOLLICULAR HELPER-LIKE T CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT / S. Piantoni* - M. Scarsi - F. Regola - A. Tincani - P. Airò
SLE, Sjögren's and APS - clinical aspects (other than treatment)

FRI0255 PATTERNS OF DISEASE ACTIVITY IMPACT ON ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS / A. Bottoluzzi* - M. Padovan - E. Silvagni - C. A. Sciri - M. Govoni


FRI0257 UROLOGICAL ARIOSTATIN, CXL4 AND VCAM-1 AS BIOMARKERS FOR LUPUS NEPHRITIS / C. C. Mok* - S. Soliman - L. Y. Ho - F. Mohamed - F. I. Mohammed - C. Mohan

FRI0258 LONG-TERM PROGNOSIS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: CSTAR-PAH COHORT STUDY / J. Qian - M. Li - X. Zhang - Q. Wang* - J. Zhao - Z. Tian - X. Zeng on behalf of CSTAR group

FRI0259 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN PATIENTS WITH LUPUS NEPHRITIS (LN) / D. V. Monova - S. Monov* - M. Ivanova - E. Peneva


FRI0261 SKIN CANCER IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS / M. Taraborrelli* - C. Genitori - I. Cavazzana - M. Fredi - A. Tincani - P. Calzavara Pinton - F. Franceschini


FRI0263 SYSTEMIC DISEASE ACTIVITY PROGRESSION IN A LARGE COHORT OF PRIMARY SJÖGREN’S SYNDROME: A LONG-TERM FOLLOW-UP DATA BASED ON THE ESSDAI SCORE / L. Quattrocielo* - S. Zandonella Callegher - S. Gandolfo - C. Fabro - S. De Vito


FRI0265 CYTOKINES AND CORRELATIONS WITH PATIENT REPORTED OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND POPULATION CONTROLS / S. Pettersson* - H. Idborg - S. Eketjall - I. Gunnarsson - E. Svenungsson

FRI0266 COMPARISON OF CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH AND WITHOUT ASSOCIATED JACCOUD ARTHRATHOPHY / A. Alia Jiménez* - W. A. Sifuentes Giraldo - L. Villalobos Sánchez - M. J. García Villanueva - A. Zea Mendoza


FRI0269 “IF IT’S NOT MULTIPLE SCLEROSIS, LOOK FOR A CONNECTIVE TISSUE DISEASE”: ATYPICAL DEMYELINATING DISORDERS REFERRED TO A TERTIARY RHEUMATOLOGY CENTRE / A. Ferronari* - K. Voumvourakis - D. Tseronis - D. Kassara - A. Erden - P. Katsimbri - D. Boumpas

FRI0270 URINARY AND SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER IN INDIAN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RELATION TO RENAL INVOLVEMENT AND OVERALL DISEASE ACTIVITY / B. Abujum* - S. Singh

FRI0271 PREVALENCE AND ASSOCIATED FACTORS OF DEPRESSIVE DISORDERS IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / C. C. Mok* - L. Y. T. Lo - K. S. Poon - C. W. Cheng

FRI0272 EARLY DAMAGE ASSESSMENT AND PREDICTION OF DAMAGE ACCRUAL IN PRIMARY SJÖGREN’S SYNDROME USING SALIVARY GLAND ULTRASONOGRAPHY DURING 2 YEARS OF FOLLOW-UP / C. Baldini* - N. Luciano - C. Seghieri - F. Ferro - E. Elefante - M. Mosca

FRI0273 ROLE OF PROCALCITONIN AND C-REACTIVE PROTEIN IN SCREENING OF INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. H. Ho* - A. M. H. Leung

* Presenting author


PREVALENCE OF DEPRESSION BY BECK II AND IMPORTANCE OF FATIGUE BY FACIT IV QUESTIONNAIRES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS VS CONTROLS IN A SINGLE CENTER OF ARGENTINA / E. Avid* - A. Braillard-Poccard - M. Garcia Carrasco - N. Perez - G. Nasswetter - D. Dubinsky


PREVALENCE OF PRIMARY SJÖGREN’S SYNDROME IN A POPULATION-BASED COHORT IN THE UNITED STATES / G. Maciel* - C. Crowson - E. Matteson - D. Gomez


ASSOCIATION BETWEEN INSULIN RESISTANCE, SUBCLINICAL ATHEROSCLEROSIS AND ACTIVITY/DAMAGE STATUS IN SLE PATIENTS / H. Sánchez-Pérez* - B. Tejera Segura - M. A. Gonzalez-Gay - I. Ferraz-Amaro

UTILITY OF MORNING SAMPLE OF URINE PROTEIN/CREATININE RATIO FOR ASSESSMENT OF PROTEINURIA IN PATIENTS WITH LUPUS NEPHRITIS / H. Zhang* - J. Liang - B. Hua - L. Sun

CARDIOVASCULAR DAMAGE IN DECEASED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I. Padjen - M. Erceg - M. Gerec - M. Mayer - R. Stevanovic - B. Anić*

INCIDENCE OF LUPUS NEPHRITIS AND 18-MONTH FOLLOW UP IN COLOMBIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. A. Alzate* - D. Hernandez-Parra - J. C. Salazar-Urribe - P. Ortiz-Salazar - R. Pineda on behalf of Artemedica IPS, Medellin, Colombia

NAILFOLD CAPILLAROSCOPIC PICTURES IN A COHORT OF UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD) PATIENTS AND IN THOSE THAT MOVE TO SYSTEMIC LUPUS ERYTHEMATOSUS / M. Meroni* - C. Pizzorni - on behalf of Artmedica IPS, Medellin, Colombia


ULTRASOUND OF THE SALIVARY GLANDS HELPS TO DISTINGUISH BETWEEN PRIMARY AND SECONDARY SJÖGREN SYNDROME / R. Bergner* - H. Sattler - D. Wadsack - C. Löfler


UTILITY OF MORNING SAMPLE OF URINE PROTEIN/CREATININE RATIO FOR ASSESSMENT OF PROTEINURIA IN PATIENTS WITH LUPUS NEPHRITIS / H. Zhang* - J. Liang - B. Hua - L. Sun

CARDIOVASCULAR DAMAGE IN DECEASED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I. Padjen - M. Erceg - M. Gerec - M. Mayer - R. Stevanovic - B. Anić*

INCIDENCE OF LUPUS NEPHRITIS AND 18-MONTH FOLLOW UP IN COLOMBIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. A. Alzate* - D. Hernandez-Parra - J. C. Salazar-Urribe - P. Ortiz-Salazar - R. Pineda on behalf of Arthemedia IPS, Medellin, Colombia

NAILFOLD CAPILLAROSCOPIC PICTURES IN A COHORT OF UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD) PATIENTS AND IN THOSE THAT MOVE TO SYSTEMIC LUPUS ERYTHEMATOSUS / M. Meroni* - C. Pizzorni - on behalf of Artmedica IPS, Medellin, Colombia


ULTRASOUND OF THE SALIVARY GLANDS HELPS TO DISTINGUISH BETWEEN PRIMARY AND SECONDARY SJÖGREN SYNDROME / R. Bergner* - H. Sattler - D. Wadsack - C. Löfler


ROLE OF SERUM INTERLEUKIN-6 IN BLOOD BRAIN BARRIER DAMAGES IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / S. Hirohata* - Y. Matsueda - T. Yanagida - T. Yoshio

APPLICATION OF PROPENSITY SCORE-MATCHING METHODS TO COMPARE DATA FROM LONG-TERM EXTENSION TRIALS WITH DATA FROM AN EXISTING LUPUS REGISTRY / M. B. Urowitz - R. Wielage - K. A. Kelton - R. L. Ohsfeldt - Y. Asukai - S. Ramachandran*
**Vasculitis**

**FRI0303**

**FRI0304**
WITH POLYANGIITIS / A. Al-Soudi* - M. Doorenspleet - R. Esveldt - S. Tas - R. van Vollenhoven - P. Klarenbeek - N. de Vries

**FRI0305**

GASTROSCOPIC FEATURES AND CLINICAL CHARACTERISTICS IN 172 CASES OF CHILDREN WITH HENOCH-SCHONLEINPURPURA / H. Zeng*

THE DIAGNOSTIC VALUE OF ALPHA-1-ANTITRYPSIN PHENOTYPE IN SYSTEMIC VASCULITIS / I. Belyaeva* - S. SCHONLEINPURPURA / H. Zeng*

FATTAGE AND DEPRESSION IN PATIENTS WITH BEHÇET'S DISEASE / J. L. Silva* - D. Santos-Faria - J. Sousa-Neves - J. Rodrigues - J. Costa - C. Afonso - D. Peixoto


OCULAR INVOLVEMENT IN BEHÇET’S DISEASE ABOUT 221 CASES / K. Echchilali* - W. Bouissar - M. Moudatir - F.-Z. Alouai - H. Elkabli


B-CELL ACTIVATING FACTOR AS A BIOMARKER OF ACTIVITY OF SYSTEMIC NECROTIZING VASCULITIS (SNV) / L. Petelytska - O. laremenco* - K. laremenco

CLINICO-PATHOLOGICAL DISCREPANCIES AND CAUSES OF DEATH IN TAKAYASU ARTERITIS: A RETROSPECTIVE ANALYSIS OF 60 FATAL CASES / O. Zimb


RENAL INVOLVEMENT IN GRANULOMATOSIS WITH POLYANGITIS / N. Bulanov - E. Makarov - E. Kuznetsova - M. Bulanov - P. Novikov - S. Moiseev*

RHEUMATOID FACTOR IS CORRELATED WITH DISEASE ACTIVITY AND INFLAMMATOY MARKERS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS / S. Watanabe* - T. Gono - K. Nishina - N. Sugitani - E. Watanebe - H. Yabe - C. Terai


PAPULOPUSTULAR LESIONS ACCORDING TO AGE, SEX AND LOCALIZATION IN BEHÇET’S SYNDROME PATIENTS COMPARED HEALTHY AND DISEASED CONTROLS / Z. Kutlubay - Y. Ozguler* - G. Hatemi - K. Tascilar - C. Mat - H. Yazici


* Presenting author
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models


FR10361  INTERLEUKIN-4 INDUCES CLASS-SWITCHING TO IGG4 AND SYNERGISTICALLY CONTRIBUTES TO PLASMACLASTS DIFFERENTIATION WITH INTERLEUKIN-21 THROUGH CD40 DEPENDENT MANNER IN IGG4-RELATED DISEASE / M. Akiyama* - H. Yasuoka - K. Yoshimoto - T. Takeuchi


Scleroderma, myositis and related syndromes


FR10372  THE DUCAS: PROPOSAL FOR A DIGITAL ULCER ASSESSMENT SCORE IN SCLERODERMA / C. Bruni* - R. Colia - A. Mele - F. P. Cantatore

FR10373  SUBSTANCE P AND VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS DERIVING FROM PATIENTS WITH SYSTEMIC SCLEROSIS / A. Corrado* - E. Sanpaolo - R. Colia - A. Mele - F. P. Cantatore

* Presenting author

FRI0375  REAL-LIFE TREATMENT STRATEGIES FOR SYSTEMIC SCLEROSIS ACCORDING TO EXPERTS / A. Fernández-Codina* - K. M. Walker - J. E. Pope on behalf of the participating members of the Sclerodema Clinical Trials Consortium (SCTC) and Canadian Scleroderma Research Group (CSRG)


FRI0379  PREVALENCE OF FAM111 B GENE MUTATIONS IN SYSTEMIC SCLEROSIS / A. Gcetu* - G. Deshpande - A. A. Kalla - M. Tikly - B. Mayosi - B. Hodkinson


FRI0381  INCREASED RISK OF OSTEOPOROTIC FRACTURES IN ADULT PATIENTS WITH POLYMYSOTIS AND DERMATOMYSITIS: A NATIONWIDE POPULATION-BASED COHORT STUDY / C.-C. Lai* - W.-S. Chen - Y.-F. Tsao - Y.-S. Chu* - P. Hsieh

FRI0382  USE OF THE DETECT ALGORITHM FOR EARLY PULMONARY ARTERY HYPERTENSION DIAGNOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS IN EVERYDAY CLINICAL PRACTICE / C. Koutsianas* - S. Subasinghe - K. Douglas

FRI0383  DETECT SCREENING FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: DATA FROM AN EUSTAR COHORT / C. Ancuta* - C. Pomirleucu - R. Maxim - F. Mitu


FRI0388  LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS: UPDATE OF OUR CLINICAL EXPERIENCE / F. Lumetti* - M. Colaci - C. Esposito - E. Cochhiara - C. Vaccì - A. Spinella - G. Tiengo - D. Giuggioli - C. Ferri

FRI0389  FOOT INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SINGLE-CENTRE REPORT / G. Cuoka - D. Ruta - E. Frongillo - L. Pirro - A. Del Mastro - C. Romano


FRI0393  REAL-LIFE TREATMENT STRATEGIES FOR SYSTEMIC SCLEROSIS ACCORDING TO EXPERTS / A. Corrado* - A. Mele - A. Trotta - R. Colla - S. Di Bello - F. P. Cantatore


* Presenting author
Spondyloarthritis - etiology, pathogenesis and animal models

FR1040 ASSOCIATION OF SUPPRESSOR OF CYTOKINE SIGNALING -3 (SOCS-3) EXPRESSION WITH INTERLEUKIN-23 RECEPTOR (IL-23R) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN ANKYLOSING SPONDYLITIS (AS) / M. A. Sánchez* - R. Villares - J. Polo y La Borda - J. Campos - J. M. Rodríguez-Frade - J. Sanz - B. J. Robles Flores - A. Royuela - P. Lucas - M. Mellado - J. Mulero


* Presenting author
Spondyloarthritis - clinical aspects (other than treatment)


FR10432 CLINICAL WORSENING ACCORDING TO THE PATIENT IS INFREQUENT IN AXIAL SPONDYLOARTHRITIS: RESULTS OF THE ASAS-FLARE STUDY IN 1169 PATIENTS / A. Motto* - B. Meghnathi - L. Gosec - R. Landewé - D. van der Heijde - M. Dougados on behalf of ASAS-FLARE study group

FR10433 HIGH PREVALENCE OF HIODRANENITIS SUPPURATIVA IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / S. Arends - A. Rondags - F. Wink - B. Horváth - A. Spoorenberg*


FR10435 COMPARISON BETWEEN CENTRAL AND LOCAL ASSESSMENT OF RADIOGRAPHIC SACROILIITIS IN PATIENTS WITH RECENTLY DIAGNOSED AXIAL SPONDYLOARTHRITIS IN THE SPARTAKUS COHORT / E. E. Lee* - M. J. Kim - E. Y. Lee - Y. W. Song - E. B. Lee


FR10437 EFFECTS OF ANKYLOSING SPONDYLITIS ON PLANTAR PRESSURE DISTRIBUTION / E. Mesci* - N. Mesci - A. Işıgasoğlu

FR10438 RISK FACTORS FOR UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RETROSPECTIVE COHORT STUDY / E. E. Lee* - M. J. Kim - E. Y. Lee - Y. W. Song - E. B. Lee


FR10440 PRESENCE OF BONE MARROW EDEMA ON MAGNETIC RESONANCE IMAGING OF THE SACROILIAC JOINTS IN MILITARY RECRUITS BEFORE AND AFTER 6 WEEKS OF INTENSIVE PHYSICAL TRAINING / G. Varkas* - M. de Hooge - T. Renson - P. Carron - S. De Mits - G. Souverijns - D. Elewaut - F. van den Bosch

FR10441 NECK PAIN IN ANKYLOSING SPONDYLITIS: FOCUS ON ACTIVE INFLAMMATION AT THE CRANIOCERVICAL JUNCTION ON MRI / G. Slabodzin* - I. Rosner - A. Awinat - D. Rimar - A. Shipigelman - D. Militianu

FR10442 IDENTIFICATION OF ENTHESITIS AT THE ACHILLES TENDON INSERTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS USING DIGITAL RADIOGRAPHY / I. Sung* - S.-J. Kim

FR10443 THE EFFECT OF FIBROMYALGIA ON DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / I. Shapoval* - M. Stanislavchuk - K. Zaichko - L. Perebetuk

FR10444 INCIDENTE OF INFLAMMATORY BOWEL DISEASE EVENTS IN ADALIMUMAB CLINICAL TRIALS ACROSS INDICATIONS / J. R. Curtis - D. Elewaut - S. Chen - M. Hoijnik - N. Naveh - J. K. Anderson*


* Presenting author
FR10447 SEVERITY OF SACROILIITIS AND ERYTHROCYTE SEDIMENTATION RATE ARE ASSOCIATED WITH A LOW TRABECULAR BONE SCORE IN YOUNG MALE PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Y. Kang*


FR10449 ANALYSIS OF THE CANADIAN ADALIMUMAB POST-MARKETING OBSERVATIONAL EPIDEMIOLOGICAL STUDY ASSESSING EFFECTIVENESS IN ANKYLOSING SPONDYLITIS (COMPLETE-AS); ASSOCIATION BETWEEN BASELINE EXTRA ARTICULAR MANIFESTATIONS AND PATIENT-REPORTED OUTCOMES / L. Bessette* - B. Harauli - M. Khraisyi - W. Bensen - V. P. Remple


FR10453 CLINICAL AND THERAPEUTIC CHARACTERISATION OF A COLOMBIAN COHORT WITH SPONDYLOARTHRITIS/PATIENTS WITH TNF INHIBITORS / M. A. Alzate* - F. Ramirez - F. Vargas - D. Hernandez-Parrá - J. C. Salazar-Urribe - P. Ortiz-Salazar - R. Pinedo on behalf of Artmedica IPS, Medellin, Colombia


FR10455 RADIOGRAPHIC PROGRESSION OF HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF INHIBITORS / M. Konsta* - M. T. Nurmohamed - A. Iliopoulos - J. C. van Denderen - I. Visman - M. S. Khraishi - W. Bensen - V. P. Remple


FR10457 THE ROLE OF SERUM HMGB1 IN BONE REMODELING AND OSTEOPOROSIS IN A GROUP OF ANKYLOSING SPONDYLITIS PATIENTS / M. Calis* - I. Cueto - I. Gunturk - E. Cueto - C. Yazić


FR10459 DEVELOPMENT AND VALIDATION OF A SPANISH TOOL FOR SEMI-AUTOMATIC QUANTIFICATION OF SACROILIAC INFLAMMATION BY MAGNETIC RESONANCE IN SPONDYLOARTHRITIS (SCAISS) / P. Zarco* - R. Almodóvar - A. Bueno - L. M. Molinero


FR10461 MUSCLE WASTING IN MALE TNF-A BLOCKER NAİVE ANKYLOSING SPONDYLITIS PATIENTS: A COMPARISON OF GENDER DIFFERENCES IN BODY COMPOSITION WITH DUAL-ENERGY X-RAY ABSORPTIOMETRY / S. E. Ibáñez - H. C. Horn - I. M. Hansen


FR10463 OPTIMIZING THE ASSESSMENT OF Spondyloarthritis among ophtalmologists –A REGIONAL Survey / S. Goel* - P. Kumar - A. Moorthy

FR10464 ARTERIAL WALL INFLAMMATION IS NOT AFFECTED BY ANTI-IL17 TREATMENT IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS / L. J. Van Mens - S. L. Verweij* - A. W. R. van Kuijk* - E. S. G. Stroes* - D. L. Baeten

FR10465 ANGLES OF SACRUM INCLINATION EFFECT ON RADIOLOGIC IMAGING READING IN SPONDYLOARTHRITIS (THE ANTELOPE-DESIR STUDY) / M. A. Alzate* - F. Ramirez - F. Vargas - D. Hernandez-Parrá - J. C. Salazar-Urribe - P. Ortiz-Salazar - R. Pinedo on behalf of Artmedica IPS, Medellin, Colombia


FR10468 RADIOGRAPHIC HIP INVOLVEMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS. A STUDY OF ITS PREVALENCE AND DETERMINING FACTORS / X. Michelena - M. López de Recalde - H. C. Horn - I. M. Hansen

FR10469 DIFFERENCES BETWEEN ANKYLOSING SPONDYLITIS PATIENTS WITH AND WITHOUT RADIOGRAPHIC HIP INVOLVEMENT IN CHINA / X. Zhang* - G. Wei - J. Gu

FR10470 CIGARETTE SMOKING HAS A DOSE-DEPENDENT RELATIONSHIP WITH DISEASE ACTIVITY AND CORRELATES WITH MORE FUNCTIONAL LIMITATION AND WORSE HEALTH ASSESSMENT IN THE PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Jiang* - Z. Liao - Z. Lin - M. Yang - Y. Zhang - Q. Li - J. Gu


* Presenting author
Psoriatic arthritis


FR10474 DOES AXIAL SPONDYLOARTHRITIS PHENOTYPE CORRELATE WITH IMAGING MORPHOTYPE? / X. Baraliakos* - A. Szumski - H. E. Jones - L. Gensler


FR10480 SCORING SYNDROMEPHOTYES ON CT SPINE IMAGES OF PATIENTS WITH RADIOPHAGIC AXIAL SPONDYLOARTHRITIS FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIAS) COHORT / F. de Bruin - R. van den Berg - X. Baraliakos - J. Braun - F. van Gaalen - M. Reijnierse - D. van der Heijde


Psoriatic arthritis

FR10482 INSULIN RESISTANCE IN PATIENTS WITH PSORIATIC ARTHRITIS / A. Abogamal* - E. Mahmoud - S. Abdulhakim - S. Abdelatif - A. Abdelaziz


FR10487 APREMILAST IS ASSOCIATED WITH LONG-TERM (4-YEAR) DAS-28 (CRP) REMISSION AND IMPROVEMENTS IN SKIN DISEASE: RESULTS FROM A PHASE III STUDY IN DMARD/BIOLOGIC-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / C. J. Edwards* - F. J. Blanco - J. Crowley - M. McIlraith - M. Paris - N. Delev - L. Teng - C. A. Birbara


FR10489 CERTOLZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY / D. Gladman* - R. Fleischmann - K. Harris - L. Peterson - P. J. Mease

FR10490 REAL-LIFE EFFECTIVENESS OF TNF INHIBITORS IN PSORIATIC ARTHRITIS: ARE CHANGING NATIONAL POLICIES ON CHOICE OF TNF INHIBITOR REFLECTED IN RESPONSE TO TREATMENT? / E. K. Kristianslund* - K. M. Fagerli - K. Harris - L. Peterson - P. J. Mease


FR10492 OBESITY IS HIGHLY OVERREPRESENTED AMONG SWEDISH PATIENTS WITH PSORIATIC ARTHRITIS COMPARED WITH THE GENERAL POPULATION / E. Klingberg* - A. Bilberg - B. Eliasson - I. Larsson

FR10493 DISEASE ACTIVITY TOGETHER WITH DEPRESSION CONTRIBUTES TO WORK DISABILITY IN PSORIATIC ARTHRITIS / F. Farkas* - N. Ikumi - A. Szentpetery - B. Kirby - O. FitzGerald


FR10495 USE OF MELATONIN IN PATIENTS WITH PSORIATIC ARTHRITIS VIOLATIONS OF EMOTIONAL STATUS / I. Blaginina* - O. Rebrova - N. Bludova - O. Volman

* Presenting author
**FR10496**

**Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-world Data**


**FR10497**

**What Choices Do Rheumatologist Make in Escalating DMARD Therapy in Early PSA?**


**FR10498**

**Outcomes Associated with Achievement of Various Treatment Targets in Patients with Psoriatic Arthritis Receiving Adalimumab**

J. Smolen* - D. Aletaha - D. D. Gladman - Y. Zhang - F. Ganz

**FR10499**

**Real-world Study on the Patterns and Cost of Treatment Failure in Patients with Psoriatic Arthritis Using Us Claims Data**


**FR10500**

**Avoidance of Physical Activity Leads to Reduced Inflammatory Enthesis on Ultrasound**


**FR10501**

**Real-world Use of Secukinumab in Patients with Psoriatic Arthritis in the United States: Patient Profile and Dosing Regimen Use**

K. Oeleke* - G. Chun - Y. Li - X. Liu - J. B. Palmer

**FR10502**

**Ikekizumab Reduces Disease Activity in Active Psoriatic Arthritis Patients Who Had Previous Inadequate Response to Tumour Necrosis Factor-Inhibitors**


**FR10503**

**Validation of New Potential Targets for Remission in Patients with Psoriatic Arthritis Treated with Golimumab**


**FR10504**

**Apremilast Expands IL-10-Producing Regulatory B Cells, and Decreases TH1 and TH7 Cells in Psoriatic Arthritis and Psoriasis**


**FR10505**

**Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice**


**FR10506**

**Hla Profiles and Their Associations with Disease Phenotypes in a Canadian Psoriatic Arthritis (PsA) Cohort**

M. Khrashi* - C. Molta - Z. Khrashi - A. M. Lewis

**FR10507**

**The Relationship Between 10-Year Cardiovascular Risk Scores and Disease Activity in Patients with Psoriatic Arthritis**

N. Ikumi* - F. Farkas - A. Szentpetery - B. Kirby - O. FitzGerald

**FR10508**

**The Effect of Certolizumab Pegol on Extra-articular Manifestations of Psoriatic Arthritis over 4 Years of Treatment in Patients with and without Prior Anti-TNF Exposure**


**FR10509**

**Safety and Efficacy of Certolizumab, an Oral Janus Kinase Inhibitor, up to 24 Months in Patients with Active Psoriatic Arthritis: Interim Data from Opal Balance, a Randomized, Controlled Trial**


**FR10510**

**Correlation of the Routine Assessment of Patient Index Data (RAPID-3) with Other Psoriatic Arthritis Composite Disease Activity Measures in Patients Receiving Adalimumab**

P. Mease* - S. Chen - F. Ganz - W. Tillet

**FR10511**

**Secukinumab Demonstrates Consistent Safety over Long-term Exposure in Patients with Psoriatic Arthritis and Moderate-to-severe Plaque Psoriasis: Updated pooled safety analyses**


**FR10512**

**Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (156-week) Improvements in Basaii in Psoriatic Arthritis Patients: Pooled Results from 3 Phase III, Randomized, Controlled Trials**


**FR10513**

**Long-term (156 Weeks) Improvements in Physical Function of DMARD-naïve and DMARD/biologic/experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials**


**FR10514**

**Psoriatic Arthritis is Associated with Diagnostic Delay and Worse Outcome at Three Months When Compared to Rheumatoid Arthritis: Results from the UK National Audit for Inflammatory Arthritis**


**FR10515**

**Classic Cardiovascular Risk Factors and Minimal Disease Activity in Psoriatic Arthritis: Results from a Spanish Multicenter Study**


**FR10516**

**Assessment of Disease Remission by Power Doppler Ultrasonography in Patients with Psoriatic Arthritis**


**FR10517**

**Quality of life in Patients with Early Psoriatic Arthritis**

S. Monov* - A. Kopchev

**FR10518**

**Prescription Patterns of Tumour Necrosis Factor Inhibitor and Ustekinumab in Psoriatic Arthritis: A Nordic Population-based Cohort Study**


**FR10519**

**Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis**

T. Reygaerts* - S. Mitrovic - B. Fautrel - L. Gossec

**FR10520**

**Improved Patient-reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial**


* Presenting author
Osteoporosis


FRIO525  ASSOCIATION OF DYSMOBILITY SYNDROME WITH FRACTURE RISK IN THE MROS COHORT / B. Buehring* - B. L. Lewis - K. E. Hansen - S. R. Cummings - N. E. Lane - N. Binkley - K. E. Ensrud - P. M. Cawthon


FRIO530  EFFECTIVENESS OF AN ORTHOGERIATRIC FRACTURE LIAISON SERVICE COMPARED WITH STANDARD CARE / A. Naranjo* - S. Fernández Conde - S. Ojeda - S. Rodríguez - L. Torres Hernández - I. Bernardos - I. Rodríguez - V. Kraev - C. Hernández Carballo - P. Laynez

FRIO531  DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN ELDERLY MEN WITH PROSTATE CANCER INITIATING ANDROGEN DEPRIVATION THERAPY REDUCES SUBSEQUENT FRACTURE RISK / M. E. Suarez-Almazor* - G. M. Cabanillas Salazar - H. Zhao - B. Shi - J. Kim - L. Elting

FRIO532  DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN WOMEN WITH BREAST CANCER INITIATING THERAPY WITH AROMATASE INHIBITORS REDUCES SUBSEQUENT FRACTURE RISK / M. A. Ursani* - M. Suarez-Almazor - M. Yang - H.-F. Lu - H. Zhao - L. Elting


FRIO536  THE METHOD OF CALCULATING THE PROBABLE VALUE OF T-SCORE IN PATIENTS WITH MULTIFOCAL ATHEROCALCIFICATION / A. N. Kokov* - V. Masenko - S. Semenov - O. Barbarash

FRIO537  PREVENTION STRATEGY OF OSTEOPOROTIC FRACTURES IN PORTUGAL: AN ANALYSES ON A COHORT OF HIP FRACTURED PATIENTS / A. Daniel* - M. L. Marques - L. Brites - C. Torres - A. Marques - J. A. Pereira da Silva

FRIO538  EVALUATION OF FACTORS THAT INCREASE RISK FOR BREAST CANCER / A. Anand* - M. Ghafouri - M. Bukhari

FRIO539  IMPACT OF THE IMPLEMENTATION OF A FRACTURE LIAISON SERVICE IN PHARMACEUTICAL EXPENSES FOR OSTEOPOROSIS / A. Naranjo* - S. Ojeda - S. Rodríguez - I. Bernardos - A. Molina - F. de la Nuez - M. Negrín

FRIO540  EVALUATION OF BONE QUALITY USING THE NEW TRABECULAR BONE SCORE (TBS) TOOL IN RHEUMATOID ARTHRITIS PATIENTS / A. Casabella - A. Sulli - C. Seriolo - G. Botticella - L. Moffetta - M. Cutolo - S. Paolino - B. Russo*
FR10546 COMPARISON OF MINERAL BONE DENSITY AND RISK FRACTURE ASSESSED BY THE FRAX TOOL IN HIV-INFECTED PATIENTS FOLLOWED IN A SPANISH TERTIARY HOSPITAL WITH THOSE OF NON HIV-INFECTED SPANISH POPULATION / F. López Gutiérrez* - W. A. Sifuentes Giraldo - M. Vázquez Díaz - J. L. Casado Osorio


FR10549 IMPACT OF CHEMOTHERAPY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER IN TREATMENT WITH AROMATASE INHIBITORS / J. Loarce-Martos* - W. A. Sifuentes Giraldo - L. V. Maldonado Romero - M. Ahjón Lana - C. Velázquez Aroc - N. Martínez Jarzez - M. Vázquez Díaz


FR10551 USE OF GLUCOCORTICOID IS THE RISK FACTOR FOR INADEQUATE RESPONSE TO THE TREATMENT OF OSTEOPOROSIS BY DENOSUMAB / K. Orita* - T. Koike


FR10554 NEW BIOMARKER FOR DIAGNOSIS OF OSTEOPOROSIS IN RHEUMATOID ARTHRITIS PATIENTS / Y. Polyakova - L. Silvordenova* - Y. Akhn - V. Kratov - B. Zavadovsky


FR10556 LONG-TERM EFFECTS OF EXTEND STRENGTHENING EXERCISES ON QUALITY OF LIFE IN WOMEN WITH OSTEOPOROSIS / S. A. Raeissadat - A. Khalili - L. Sedighipour* - M. Heidari Almasi

FR10557 DOES WEIGHTED KYPHO-ORTHOSIS (WKO) REDUCE RISK OF FALL IN WOMEN WITH OSTEOPOROSIS? A PRELIMINARY STUDY / S. A. Raeissadat - S. M. Rayegani - L. Sedighipour* - M. Hashemi - M. H. Bahrami


FR10559 CORRELATION OF THE RISK ASSESSMENT TOOL (FRAX) AND ASYMMETRIC MORPHOMETRIC VERTEBRAL DEFORMITIES IN HIV-INFECTED PATIENTS / M. L. Marques* - C. Medina Quiñones - C. Macia Villa - W. A. Sifuentes Giraldo - M. Vázquez Díaz - J. L. Casado Osorio

FR10560 PREDICTORS OF FRACTURES IN FEMALE PATIENTS WITH ANOREXIA / M. Rahm - M. Bukhari*


FR10565 FRAGILITY FRACTURES IN PATIENTS ON DEPO-PROVERA ARE NOT ASSOCIATED WITH USUAL RISK FACTORS FOR FRACTURE / M. Dey* - M. Bukhari


FR10567 DIFFERENCES IN ADHERENCE TO OSTEOPOROSIS MEDICATIONS IN PATIENTS WITH RHEUMATIC DISEASES: A 3-YEAR RETROSPECTIVE COHORT STUDY / O. Nikifinetskaya* - N. Toropotsova


FR10572 IDENTIFYING WOMEN AND MEN AT HIGH FRACTURE RISK BY LEVERAGING THE ELECTRONIC MEDICAL RECORDS TO ESTIMATE FRAX TREATMENT THRESHOLDS / S. Amin* - E. Atkinson - S. Khosla


* Presenting author
138 / SCIENTIFIC POSTER SESSION 2 / FRIDAY 16 JUNE 2017

FRIO574 QUALITY OF LIFE ASSESSMENT IN POSTMENOPAUSAL OSTEOPOROSIS / S. Novkovic* - G. Stanoevich
FRIO575 SAFETY OF DENOSUMAB IN A MONOCENTRIC COHORT OF KIDNEY TRANSPLANT RECIPIENTS / S. Doddoli* - P. Laforgue - T. Pham
FRIO576 COMPARING TREATMENT INDICATION BY FRAX AND BMD ALONE IN RHEUMATIC PATIENTS ON LONG-TERM GLUCOCORTICOIDS IN HONG KONG / S. L. Lau* - M. L. Yip - L.-S. Tam - K. L. Lee on behalf of The Hong Kong GiOP study group
FRIO579 INFLUENCE OF ORAL PREDNISOLONE ON EFFECT OF DENOSUMAB ON OSTEOPOROSIS IN PATIENTS WITH JAPANESE RHEUMATOMATID ARTHRITIS, 24 MONTHS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - Y. Hirano - N. Takahashi - S. Asai - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group
FRIO580 PREDICT SARCOPENIA BY SONEOELASTOGRAPHY OF QUADRICEPS MUSCLE IN OSTEOPOROTIC PATIENTS / Y.-C. Chen* - C.-H. Ko
FRIO581 HEPATITIS B INCREASE MORTALITY IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES / Y.-C. Chen* - C.-H. Ko

Other orphan diseases

FRIO583 IG44-RELATED DISEASE AMONG PATIENTS PREVIOUSLY DIAGNOSED WITH IDIOPATHIC RETROPERITONEAL FIBROSIS. A NATIONWIDE DANISH STUDY / N. Lomborg* - M. Jakobsen - C. S. Bode - P. Junker
FRIO594 A CASE OF MOSAICISM IN TNF ASSOCIATED PERIODIC SYNDROME (TRAPS) / A. Kontzias* - C. Calabrese - D. Karali - F. Ulutatar
FRIO595 ANAKINRA TREATMENT IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: A SINGLE-CENTER EXPERIENCE (CASE SERIES) / B. Ergezen* - S. Ugurlu - H. Ozdogan
FRIO596 FATIGUE IN FAMILIAL MEDITERRANEAN FEVER (FMF) AND IT’S RELATIONS WITH OTHER CLINICAL PARAMETERS / C. Unal Ertekin* - T. Duruoz - D. Karali - F. Ulutatar

* Presenting author

Hyperferritinemic Syndrome in a General University Hospital / F. Pierini* - I. J. Gandino - J. M. Martinez Perez - S. Ruta - M. Scolnik - E. R. Soriano


Clinical Implications of Ultrasonography in Monitoring Disease Activity of Relapsing Polychondritis: The Assessment of Auricular Chondritis in 3 Cases / H. Nishikawa* - Y. Taniguchi - Y. Terada


Assessment of Panniculitis Clinical Outcomes: Risk Factors for Recurrence and Predictors of Slow Regression of Indurations / N. Savushkina* - O. Egorova - B. Belov


Eye Manifestations of Patients with Muckle-Wells Syndrome / S. Cekic - O. Yalcınbay - S. Kiliç*


A Retrospective Cohort Study About the Clinical Characteristics of Igg4-Related Diseases / X. Wu - C. Wang - Y. Miao - Y. Huang - L. Dong

* Presenting author
Diagnosisch and imaging procedures


FR0627 ULTRASOUND HAND EXAMINATION IS MORE SENSITIVE IN DIAGNOSING HAND OSTEOARTHRITIS THAN RADIOGRAPHY: COMPARISON BETWEEN DIFFERENT ULTRASONOGRAPHIC SCORES / S. Hussain* - P. Sivakumaran - C. Curtin.


FR0638 COMPARISON OF ULTRASOUND AND MRI IN THE DIAGNOSIS OF PROXIMAL AND DISTAL BICEPS TENDON PATHOLOGY / D. Huguet - C. Darrieutort-Laffite - B. Le Goff*.


FR0643 ENTHESITIS AND FOOT DISABILITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Hussain - P. Sivakumaran - C. Curtin.


* Presenting author.
FRI0647 COLOR DOPPLER AS A VALUABLE PROCEDURE FOR EARLY DIAGNOSIS OF OCULAR VASCULAR CHANGES IN BEHÇET'S DISEASE / H. H. Al Sherbeni* - S. Metawie - R. Abdel Salam - H. Azizi

FRI0648 CONCORDANCE BETWEEN THE TUBERCULIN SKIN TEST AND INTERFERON GAMMA RELEASE ASSAY FOR DIAGNOSIS LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS / I. Aktas* - F. Unlu Ozkan - T. Nazligul - H. Kuzu Okur

FRI0649 STANDARDIZED PROCEDURES FOR ULTRASOUND IMAGING IN PAEDIATRIC RHEUMATOLOGY: PROGRESS OF A EULAR TASK FORCE / I. Janta* - P. Collado Ramos - J. Vojinovic - E. Naredo - L. Carmona


FRI0652 MEDIAN NERVE ULTRASOUND FINDINGS AND CLINICAL CORRELATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A COMPARATIVE ANALYSIS WITH MATCHED CONTROL SUBJECTS / J. Sousa-Neves* - M. Cerqueira - D. Santos-Faria - J. Leite Silva - A. Raposo - C. Afonso - F. Teixeira

FRI0653 SALIVARY GLAND ULTRASOUND IS RELATED TO AUTOIMMUNITY IN PRIMARY SJÖGREN SYNDROME / J. C. Nieto-Gonzalez* - F. J. López-Longo - E. Estrada - E. Naredo


FRI0655 ULTRASOUND FINDINGS OF FEEDING VESSELS AND BONE SURFACE IRREGULARITY IN WRIST JOINTS OF HEALTHY CONTROLS / K. Misaki* - K. Ikeda - K. Inoue

FRI0656 SEMIAUTOMATIC ANALYSIS OF EROSION VOLUME BY HR-POCT IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. Chiba* - N. Iwamoto - M. Osaki - A. Kawakami

FRI0657 COMPARATIVE STUDY OF PAROTID ULTRASONOGRAPHY AND PAROTID GLAND ECT IN PREDICTING THE PATHOLOGICAL BIOPSY OF THE SALIVARY GLAND IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME / C. Xiaoemi - L. Cong* - W. Lijun - L. Caiyan - S. Yamei

FRI0658 LEG ELEVATION DOES NOT SUBSTANTIALLY AFFECT TBS RESULTS / D. Krueger - E. Siglinsky - D. Tran - L. Del Rio* - N. Binkley

FRI0659 INCLUSION OF THE ASSESSMENT OF CERVICAL FACET JOINTS IN THE M-SASSS SCORE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IMPROVING SENSITIVITY TO CHANGE / M. J. Moreno-Martínez* - M. J. Moreno-Ramos - L. F. Linares-Ferrando


FRI0664 INFLUENCE OF JOINT PATHOLOGY ON OPTICAL SPECTRAL TRANSMISSION IMAGING, ASSESSING INFLAMMATION IN HAND AND WRIST JOINTS OF RHEUMATOID ARTHRITIS PATIENTS / N. Besselink* - P. van der Meijde - A. Marijnissen - P. Meijer - W. Rensen - J. van Laar - F. Labefer - J. Jacobs

FRI0665 ANTI-HETEROGENOUS NUCLEAR RIBONUCLEOPROTEINS (ANTI- HNRNP) AND OTHER AUTOANTIBODIES FOR DETECTION OF EROSIIVE ARTHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH JOINT INVOLVEMENT IN COMPARISON BY JOINT X-RAY / S. Y. Hussein - N. A. Fathi* - S. H. Goma - N. A. Mohammed - E. Mosad


FRI0668 EULAR TASK FORCE / I. Janta* - P. Collado Ramos - J. Vojinovic - E. Naredo - L. Carmona - Belgian Group of Ultrasonography in Rheumatology

FRI0669 STANDARDIZED PROCEDURES FOR ULTRASOUND IMAGING IN PAEDIATRIC RHEUMATOLOGY: PROGRESS OF A EULAR TASK FORCE / I. Janta* - P. Collado Ramos - J. Vojinovic - E. Naredo - L. Carmona


FRI0672 ASSESSMENT OF THE NAIL BED IN PSORIATIC ARTHRITIS (PSA) BY ULTRASOUND (US) AND MRI / S. Paramalingam* - A. Taylor - H. Keen

* Presenting author
142 / SCIENTIFIC POSTER SESSION 2 / FRIDAY 16 JUNE 2017


FRIO676 A PROPOSAL FOR A SIMPLE ULTRASOUND METHOD FOR THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS / T. Serban* - I. Satulu - O. Vucanaru - M. Milicescu - C. M. Mihai - M. Bojinca


FRIO682 FOLLOW-UP OF TREATMENT RESPONSE WITH DYNAMIC DOPPLER ULTRASOUND IN RAYNAUD'SPHENOMENON / U. Toprak - Z. Ozbalkan* - M. Edugan - S. Parliak - S. G. Sandkci - T. Kaya - S. Sayilsoy

Epidemiology, risk factors for disease or disease progression


FRIO689 LIPID PEROXIDATION AS RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION IN ANTI PHOSPHOLIPID SYNDROME (APS) PATIENTS / L. Stojanovich* - N. Stanisavljevic - A. Djokovic - M. Zdravkovic


* Presenting author
FRA0697 FRENCH NATIONWIDE SURVEY OF CHRONIC PAIN PERCEPTION IN 1739 PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM / A.-P. Trouvin* - C. Beller - P. Preiss - S. Perrot


FRA0701 DOES PARITY INFLUENCE JOINT DAMAGE PROGRESSION IN WOMEN WITH RHEUMATOID ARTHRITIS? / D. Polatcan Rodriguez* - F. Berger - D. Courvoisier - C. Gaby - A. Finch on behalf of Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis


FRA0703 NEW INCIDENT CASES OF RHEUMATOID ARTHRITIS, PSORIATRIC ARTHRITIS AND POLYMYALGIA RHEUMATICA IN A CITY OF CENTRAL ITALY: RESULTS OF THE CAMPO-RE STUDY / A. De Socio - F. M. Perrotta* - E. Lubrano


FRA0705 PROGRESSION OF CHRONIC DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AFTER 5-YEAR FOLLOW-UP, DATA FROM A LARGE MONOCENTRIC COHORT / I. Lecese* - F. Ceccarelli - C. Perricone

FRA0706 HLA-DRB1 ALLELES ARE ASSOCIATED WITH MARKERS OF ENDOTHelial INJURY IN FIRST-DEGREE RELATIVES OF RHEUMATOID ARTHRITIS PATIENTS / J. M. Hughes-Austin* - M. Corr - G. S. Firestein - V. M. Holers - K. D. Deane - J. M. Norris - J. H. Ix


FRA0708 HLA-DRB1 ALLELES ARE ASSOCIATED WITH MARKERS OF ENDOTHELIAL INJURY IN FIRST-DEGREE RELATIVES OF RHEUMATOID ARTHRITIS PATIENTS / J. M. Hughes-Austin* - M. Corr - G. S. Firestein - V. M. Holers - K. D. Deane - J. M. Norris - J. H. Ix

FRA0709 NEUROPATHIC PAIN IS A WEAK PREDICTOR OF NEW ONSET CHRONIC WIDESPREAD PAIN / J. McBeth* - M. Muvey - A. Rashid - J. Anderson - K. Duce


FRA0711 GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (AGAPSS) / M. Radin* - K. Schreiber - P. Costanzo - I. Cecchi - D. Roccatello - S. Baldovino - M. Bazzan - M. Cuadrado - S. Sciaccia

FRA0712 DRIVERS OF UNREFRESHING SLEEP IN PEOPLE WITH MUSCULOSKELETAL PAIN / K. L. Druce* - J. McBeth


FRA0716 RISK STRATIFICATION IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION USING THE ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (AGAPSS) / M. Radin* - K. Schreiber - P. Costanzo - I. Cecchi - D. Roccatello - S. Baldovino - M. Bazzan - M. Cuadrado - S. Sciaccia

FRA0717 POSITIVE CONVERSION OF TUBERCULOSIS SCREENING RESULTS AND INCIDENCE OF ACTIVE TUBERCULOSIS INFECTION IN PATIENTS RECEIVING BIOLOGIC TREATMENT / M.-C. Park* - H. W. Kim - S. H. Han


FRA0720 CHARACTERISTICS OF PATIENTS WITH GOUT TREATED TO SUA TARGET THAT CONTINUE TO EXPERIENCE FLARES: DATA FROM FRANCE, GERMANY, ITALY, SPAIN, UK AND US / R. Morlock* - D. C. Taylor - S. Baumgartner


* Presenting author

FRI0724 PREDICTORS OF PRESENTEEISM AND ABSENTEEISM IN PATIENTS COMMENCING TREATMENT WITH METHOTREXATE MONOTHERAPY OR BIOLOGIC THERAPY FOR RHEUMATOID ARTHRITIS / S. Leggett* - M. Lunt - A. Barton - K. Hycroch - K. Walker-Bone - S. M. Verstappen on behalf of RAMS and BRAGGSS co-investigators


FRI0726 LONG-TERM USE OF ANALGESICS AND NSAIDS IN EARLY RA: LESSONS FROM THE CARERA STUDY / S. Pazmino* - R. Westhoens - V. Stouten - J. Joly - K. van der Elst - P. Verschueren on behalf of CareRA study group

FRI0727 IMPACT OF MATERNAL SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES ON NEONATAL OUTCOMES: A POPULATION-LEVEL ANALYSIS / S. O. Keeling* - A. Savu - P. Kaul

FRI0728 OSTEOARTHRITIS AND GOUT: REAL-WORLD EVIDENCE EVALUATING PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTHCARE UTILIZATION / S. Krasnokutsky Samuels* - M. Pillinger - S. Kabadi - D. C. Taylor - R. Morlock

FRI0729 DEFINITION OF REMISSION AND MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / T. Gudz* - R. Ionescu

FRI0730 THE NEED FOR HOSPITAL ADMISSION FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN WESTERN AUSTRALIA LEADS TO A DOUBLING OF THE ALL-CAUSE MORTALITY RISK AS SEEN IN CONTROLS, ESPECIALLY FOR MEDICARE RELIANT AND MALE PATIENTS / W. D. Raymond* - D. Preen - C. Inderjeeth - H. Keen - J. Nossent

FRI0749-HPR  THE EFFECT OF A SUPPORTED OSTEOARTHRITIS SELF-MANAGEMENT PROGRAM ON PHYSICAL ACTIVITY, PAIN, QUALITY OF LIFE AND SELF-EFFICACY. AN INTERVENTION STUDY WITH A REFERENCE GROUP / T. S. J. Jönsson* - C. A. Thorstensson - E. Ekvall Hansson - L. Dahlberg

FRI0750-HPR  CONSTRUCT VALIDITY OF THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE - LONG FORM IN PATIENTS WITH AXIAL SPONDYLOARTHITIS / T. W. Swinnen* - S. Willemijns - W. Dankaerts - R. Westhovens - K. de Vlam

HPR: Epidemiology and public health (including prevention)

FRI0751-HPR  SAFETY PROFILE OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS - A REAL WORLD EXPERIENCE WITH GOOD RESULTS / A. Malpica* - P. Santos-Moreno - K. Mendez - D. Buitrago-Garcia


FRI0753-HPR  PAIN SPREAD AND PAIN INTENSITY IMPROVE OVER TIME IN WOMEN WITH FIBROMYALGIA AND CHRONIC WIDESPREAD PAIN. A 12 YEAR FOLLOW UP STUDY / A. Bergenheim* - S. Johannesson - L. Nordeman - M. Joelsson - K. Männerkorp

FRI0754-HPR  IMPACT OF CORTICOSTEROID UTILIZATION ON BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG INITIATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / C. A. Spivey* - J. Griffith - C. Kaplan - A. Postlethwaite - A. Ganguli - J. Wang

FRI0755-HPR  POTENTIAL BENEFITS OF BIOLOGICS ON CARDIOVASCULAR DISEASES AND ORTHOPEDIC SURGERIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE POPULATION-BASED COHORT STUDY IN TAIWAN / D.-Y. Chen* - C.-H. Tang - F. Yu - C.-Y. Huang


FRI0758-HPR  COMORBIDITY PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM RHEUMATOID ARTHRITIS REGISTRY IN QATAR / F. Alam* - M. Hammoudeh - S. Al Emadi

FRI0759-HPR  COLLABORATION BETWEEN GENERAL PRACTITIONERS AND RHEUMATOLOGISTS TO MANAGE CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS PATIENTS / J. Weijers* - S. Rongen-van Dartel - M. Hulscher - P. van Riel

FRI0760-HPR  BIOSIMILAR USE AMONG EUROPEAN RHEUMATOID ARTHRITIS PATIENTS AND IMPACT ON PATIENT OUTCOMES / L. Chanroux* - F. Mboge - A. Wadiwalla


FRI0764-HPR  MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND END STAGE RENAL DISEASE / S. Paudyal* - J. Waller - A. Oliver - B. Le - N. Zieik - N. S. Nahman - L. Carbone

FRI0765-HPR  PREVALENCE OF SARCOPENIA IN ELDERLY WITH OSTEOARTHRITIS OF LARGE JOINTS / Y. Safonova* - V. Tsurko

HPR: Professional education, training and competencies

FRI0766-HPR  DOWN’S ARTHROPATHY - CLINICAL AND RADIOLOGICAL FEATURES OF ARTHRITIS IN CHILDREN WITH TRISOMY 21 / C. Foley* - E. J. MacDermott - O. G. Killeen

FRI0767-HPR  PARTICIPATING IN A MUSCULOSKELETAL RANDOMISED CONTROLLED TRIAL: IDENTIFICATION OF EDUCATION TRAINING NEEDS BY OCCUPATIONAL THERAPISTS AND PHYSIOTHERAPISTS IN THE UK / J. Adams* - P. Barratt - S. Bradley - S. Barbosa-Bouças - K. Hislop Lennie - P. White on behalf of OTTER II Trial working group


FRI0770-HPR  A BETTER WAY TO DECREASE KNEE SWELLING IN PATIENTS WITH KNEE OSTEOARTHRITIS: INTERMITTENT PNEUMATIC COMPRESSION - A RANDOMIZED CONTROLLED CLINICAL TRIAL / Z. San - O. Aydoğdu* - I. Demirbüken - U. S. Yurdalan - G. M. Polat

FRI0771-HPR  WORK - RELATED LUMBAR PAIN IN PHYSIOTHERAPISTS WHO WORK IN DIFFERENT FIELDS - A PILOT STUDY / B. Karakoc - Z. Sar - O. Aydoğdu* - U. S. Yurdalan

FRI0772-HPR  FORMAL RHEUMATOLOGY TRAINING FOR GENERAL PRACTITIONERS / S. Khan* - A. Mohammad - K. P. O’Rourke - C. Sheehy

* Presenting author
Scientific Programme

08:00 - 15:00  Registration area (Hall 2)

08:30 - 10:00  Hall 6

What is New (WIN) & How to Treat/Manage (HOT) session

WIN session: The Lancet session - pathogenesis and treatment of rheumatoid arthritis

Chairperson(s):
Juan J. Gomez-Reino Carnota (Spain)
Mary K. Crow (United States)
Jennifer Sargent (United States)
Iain B. McInnes (United Kingdom)
Gerd R. Burmester (Germany)

08:30 - 10:00  Hall 8

Clinical Science session

Reverse translation - learning from clinical trials in SLE, Sjögren’s and APS

Learning objectives:
To address the past and current challenges of clinical trials in SLE, APS and Sjögren’s

Chairperson(s):
Joachim R. Kalden (Germany)
Salvatore de Vita (Italy)
David Isenberg (United Kingdom)

08:35

Abstract N° SP0152
The learnings from SLE trials

Raphaele Seror (France)

08:53

Abstract N° SP0153
Lessons from APS trials

B. Chen (United States)

08:35

Abstract N° OP0331
A novel humanized effector-deficient FcyRIIa antibody inhibits immune complex mediated proinflammatory responses

08:30 - 10:00  Hall 7A

Challenges in Clinical Practice session

Myositis

Learning objectives:
- How to manage different aspects of the pharmacological and physical treatment of acute myositis
- How to recognise signs and symptoms of cardiac impairment early on and how to choose the more appropriate imaging techniques

Chairperson(s):
Andrea Doria (Italy)
Jiri Vencovsky (Czech Republic)

08:35

Case 1 presentation: Severe autoimmune myositis

Robert Cooper (United Kingdom)

08:45

Case 1 discussion: Management of autoimmune myositis in 2017
Mariele Gatto (Italy) 09:15
Case 2 presentation: Severe dermatomyositis with cardiac manifestations

Louise Diederichsen (Denmark) 09:25
Case 2 discussion: Imaging on cardiac involvement in myositis

08:30 - 10:00  Hall 7B
From Bench to Bedside
Genomic imprinting and post-translational modifications

Learning objectives:
To address the interrelationship of basic insights and data obtained from big data analyses for improved diagnostic and therapeutic approaches

Chairperson(s):
Martin Herrmann (Germany)
Andreas Radbruch (Germany)
Hyun-Dong Chang (Germany) 08:35
Abstract N° SP0154
Rationale to target immune memory residing in inflamed tissues

Rene Toes (Netherlands) 08:55
Abstract N° SP0155
The role of post-translational modification and autoreactivity

Peter Lipsky (United States) 09:15
Abstract N° OP0332
How big data help US to understand new and old therapy targets

G. Bertsias (Greece) 09:35
Abstract N° OP0332
The genomic architecture of systemic lupus erythematosus (SLE) by RNA-seq: distinct disease susceptibility, activity and severity signatures and extensive genetic effects on whole blood gene expression

P. K. Schulz-Knappe (Germany) 09:45
P. Budde, H.-D. Zucht, D. Wirtz, K. Marquardt, R. Thomas, T. Witte, M. Schneider, K. Sivils, A. Rasmussen
Abstract N° OP0333
Discovery and validation of novel autoantigens in Sjögren’s syndrome with potential for subgrouping of disease

08:30 - 10:00  N103/N104
Clinical Science session
Optimising treatment for osteoarthritis. Take the phenotype in account: "one size does not fit all"

Learning objectives:
• What is the evidence that different OA phenotypes exist?
• Which phenotypes can be distinguished?
• What are the therapeutic consequences?

Chairperson(s):
Abishek Abishek (United Kingdom)
Sita Bierma-Zeinstra (Netherlands)

Francis Berenbaum (France) 08:35
Abstract N° SP0157
Metabolic phenotype: the two faces of obesity in OA

Tonia Vincent (United Kingdom) 08:55
Abstract N° SP0158
Post-traumatic phenotype: resulting in new insight's in OA pathogenesis

Abishek Abishek (United Kingdom) 09:15
Abstract N° SP0158
Pain phenotype: can we take advantage of the placebo effect

J. Tian, D. Aitken, F. Cicuttini, C. Ding, G. Jones
Abstract N° OP0334
Predictors and MRI-detected structural pathology with trajectories of knee pain severity: a 10.7-year prospective study

M. J. Minten (Netherlands) 09:45
Abstract N° OP0335
Exploring associations between histologically assessed inflammation and pain and fatigue in knee osteoarthritis

08:30 - 10:00  South Auditorium
Basic and Translational Science session
Targeting adipose tissue inflammation

Learning objectives:
• To learn about adipose tissue alterations in inflammation and adipose tissue-derived factors released
• To learn about the role of adipose tissue and its factors in (chronic) inflammation
• To learn how to target adipose tissue inflammation: how to treat?

Chairperson(s):
Andreea Ioan-Facsinay (Netherlands)
Maria Bokarewa (Sweden)
Maria Bokarewa (Sweden) 08:35
Adipose tissue - bystander or therapeutical target?

Andreas Schäffler (Germany) 08:53
Is diabetes type 2 an inflammatory disease and should it be treated like that?

Andreea Ioan-Facsinay (Netherlands) 09:11
Role of adipose tissue in osteoarthritis

Oreste Gualillo (Spain) 09:29
Adipokines in the pathophysiology of cartilage

I. Arias de la Rosa (Spain) 09:47
Role of systemic inflammation associated with rheumatoid arthritis in the glucose and lipid metabolism: humans, CIA mouse model and in vitro studies

Paediatric Rheumatology session
Outcome in juvenile idiopathic arthritis

V. Ahluwalia (Canada) 09:47
M. Movahedi, E. Rampakakis, A. Cesta, X. Li, S. Couto, J. Sampalis, C. Bombardier on behalf of OBRI investigators
Abstract N° OP0337-HPR
Predictors of patient reported decision to discontinue anti-rheumatic medication in rheumatoid arthritis patients: data from a rheumatoid arthritis cohort

08:30 - 10:00  N101/N102
Health Professionals session
Trials and tribulations of medication adherence

Learning objectives:
To learn how to engage patients in treatment decisions and understand the impact of illness beliefs on medication adherence

Chairperson(s):
Yeliz Prior (United Kingdom)
Annette Sverker (Sweden)

Jo Adams (United Kingdom) 08:35
Health literacy and its impact on accessing, understanding and using medication information

Joke Vriezekolk (Netherlands) 08:53
Interventions to improve medication adherence in patients with inflammatory arthritis

Katerina Koutsogianni (Greece) 09:11
Barriers and facilitators to adherence to medication in patients with inflammatory arthritis

Kanta Kumar (United Kingdom) 09:29
Can musculoskeletal ultrasound inform health beliefs and play a role for medication adherence?

08:30 - 10:00  N111/N112
Educational session
Getting financial support to research in RMDs through Horizon 2020: opportunities, good practices, and successful experiences

Learning objectives:
To address important issues in setting research priorities for RMDs and how to obtain the necessary funds on the EU level

Chairperson(s):
Neil Betteridge (United Kingdom)
Rik Lories (Belgium)

Soeren Haar (Belgium) 08:35
EULAR’s service to the research community
Scientific Programme / Saturday 17 June 2017

Juan E. Riese (Spain) 08:53
Abstract no SP0167
Horizon 2020: characteristics and opportunities for medical research and innovation

Christian Jorgensen (France) 09:11
Successful experiences in applying for Horizon 2020 calls in the RMD scientific community: Dos and Don’ts

Iain B. McInnes (United Kingdom) 09:29
RheumaMap: a roadmap for research and innovation in RMDs for the next decade

Faculty 09:47
Q&A

08:30 - 10:00  N117/N118
EULAR Projects in Education and Training
Challenging projects in education and training

Learning objectives:
To illustrate and discuss the ongoing projects in education and training

Chairperson(s):
Annamaria Iagnocco (Italy)
Nemanja Damjanov (Serbia)

Maarten Boers (Netherlands) 08:35
Abstract N° SP0168
Theory of poster design and presentation**

Johannes W. J. Bijlsma (Netherlands) 09:10
Abstract N° SP0169
The EULAR School of Rheumatology. A challenging educational EULAR Project. Where are we now?

Catherine Haines (United Kingdom) 09:25
Abstract N° SP0170
Assessing rheumatology skills

08:30 - 10:00  N107/N108
Practical skills session*

MRI II

Learning objectives:
To learn how to use MRI for assessment of inflammation and damage in spondyloarthritis and rheumatoid arthritis in clinical practice

Chairperson(s):
Kay-Geert Hermann (Germany)
Mikkel Østergaard (Denmark)

Iris Eshed (Israel) 08:35
Abstract N° SP0128
MRI of enthesitis - by conventional and wholebody MRI - including patient cases

Daniel Glinatsi (Denmark) 08:55
Are MRI findings important to the rheumatoid arthritis patient - relation to patient reported outcomes - including patient cases

Mikkel Østergaard (Denmark) 09:15
Classification, diagnosis and differential diagnosis of axial spondyloarthritis by MRI - including patient cases

Kay-Geert Hermann (Germany) 09:35
MRI of the sacroiliac joint - lessons learnt from comparisons with CT - including patient cases

08:30 - 10:00  N109/N110
Practical skills session*

Capillaroscopy II

Chairperson(s):
Vanessa Smith (Belgium)
Ariane L. Herrick (United Kingdom)

Vanessa Smith (Belgium) 08:35
Abstract N° SP0098
The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease

Alberto Sulli (Italy) 08:45
Scoring the capillaroscopic images: manual versus (semi) automatic systems

Ariane L. Herrick (United Kingdom) 08:55
How to distinguish the major capillaroscopic patterns in connective tissue diseases

Maurizio Cutolo (Italy) 09:05
Abstract N° SP0099
Why capillaroscopy can predict disease severity and prognosis

Francesca Ingegnoli (Italy) 09:15
Abstract N° SP0171
How to select the most appropriate capillaroscopic device: pros and cons

Faculty 09:25
Live practical sessions with patients and case discussion

10:15 - 11:45  N115/N116
PARE session

Workshop: Strengthening your organisation - how to manage volunteers

Learning objectives:
• How to gain and motivate volunteers
• How to train and accompany volunteers
• How voluntary work can be valued and appreciated

Clare Jacklin (United Kingdom) 10:20
Abstract N° SP0172
How to manage volunteers - setting the scene

Marija Kosanovic (Serbia) 10:35
Abstract N° SP0173
The challenges of a small organisation

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
** Session followed by a poster tour on poster design led by Maarten Boers, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Poster tour

S1: Innate mediators and autoantibodies in rheumatic disease
Chairperson(s): Martin Herrmann (Germany), Mary Canavan (Ireland)
Abstracts N° SAT0010 - SAT0019

Poster tour

S2: How B and T cells contribute to rheumatic disease
Chairperson(s): Leonie Taams (United Kingdom), Hans-Ulrich Scherer (Netherlands)
Abstracts N° SAT0027 - SAT0036

Poster tour

S3: RA - risk factors and consequences
Chairperson(s): Ingemar Petersson (Sweden), Suzanne Verstappen (United Kingdom)
Abstracts N° SAT0037 - SAT0046

Poster tour

S4: From the heart of rheumatology
Chairperson(s): Zoltán Szekanecz (Hungary), Joao Madruga Dias (Portugal)
Abstracts N° SAT0088 - SAT0097

Poster tour

S5: Trends in non-TNF alpha biologicals for RA II
Chairperson(s): Johannes W. J. Bijlsma (Netherlands), W. Erwin van Spil (Netherlands)
Abstracts N° SAT0176 - SAT0187

Poster tour

S6: New treatment options in SLE, Sjögren’s and APS
Chairperson(s): Martin Aringer (Germany), Hendrika Bootsma (Netherlands)
Abstracts N° SAT0219 - SAT0230

Poster tour

S7: SSc, myositis and rare diseases: etiology and animal models
Chairperson: Gabriela Riemekasten (Germany), Jens Humrich (Germany)
Abstracts N° SAT0312 - SAT0321

Poster tour

S8: Last news on systemic sclerosis and myositis
Chairperson(s): Maurizio Cutolo (Italy), Alberto Sulli (Italy)
Abstracts N° SAT0372 - SAT0381

Poster tour

S9: A walk through PsA progress
Chairperson(s): Iain B. McInnes (United Kingdom), George E. Fragoulis (Greece)
Abstracts N° SAT0433 - SAT0441

Poster tour

S10: Steps forward in osteoarthritis research
Chairperson(s): Margreet Kloppenburg (Netherlands), Jeremie Sellam (France)
Abstracts N° SAT0483 - SAT0494

Poster tour

S11: Infection related rheumatic disease: clinical and epidemiologic aspects
Chairperson(s): Leonard Calabrese (United States), Konstantinos Thomas (Greece)
Abstracts N° SAT0556 - SAT0565

Poster tour

S12: Imaging advances in vasculitis, crystal and connective tissue disease
Chairperson(s): Lene Terslev (Denmark), Berit Dalsgaard Nielsen (Denmark)
Abstracts N° SAT0609 - SAT0618

Poster tour

S13: Comorbidities and outcomes in RMDs
Chairperson(s): Axel Finckh (Switzerland), Merete Hetland (Denmark)
Abstracts N° SAT0669 - SAT0678
Poster tour HPR

**S14: Nursing and daily practice**

**Chairperson(s):** Annette de Thurah (Denmark), Jenny de la Torre-Aboki (Spain)
Abstracts N° SAT0717-HPR - SAT0725-HPR

---

**Special poster tour**

**S16: Poster design and presentation**

**Chairperson:** Maarten Boers

---

**Attendance of the session EULAR Projects - challenging projects in education and training, 08:30 - 10:00, Room N117/N118 is required in order to participate in this special poster tour.**

---

**What is New (WIN) & How to Treat/Manage (HOT) session**

**WIN session**

**Chairperson(s):** Raimon Sanmarti (Spain)
Meghna Jani (United Kingdom)

**Josef S. Smolen (Austria)**
WIN: Rheumatoid arthritis treatment

**Nico Wulffraat (Netherlands)**
Abstract N° SP0175
WIN: Juvenile idiopathic arthritis

---

**Clinical Science session**

**Systemic sclerosis**

**Learning objectives:**
- To learn about novel therapeutic approaches
- To identify most promising therapies in SSc
- To identify therapeutic targets

**Chairperson(s):**
Madelon Vonk (Netherlands)
Elise Siegert (Germany)

**Maurizio Cutolo (Italy)**
Abstract N° SP0176
Targeting vasculopathy from the beginning

**Christopher Denton (United Kingdom)**
Abstract N° SP0177
New approaches by targeting soluble mediators

**Jacob M. van Laar (Netherlands)**
Advances in immunosuppressive therapeutic approaches

**Oliver Distler (Switzerland)**
Addressing most promising antifibrotic and epigenetic targets

---

**Challenges in Clinical Practice session**

**The challenges of MRI in axSpA**

**Learning objectives:**
- To learn the specificities of SpA-associated oedema in the SIJ, and how to differentiate from other diagnosis
- To gain insight into the potential of MRI in the diagnosis of axSpA, but also its pitfalls

**Chairperson:**
Victoria Navarro-Compán (Spain)
Fernando Pimentel dos Santos (Portugal)

**Anna Moltó (France)**
Case 1 presentation: A partum sacral fissure mimicking saccroluthritis

**Kay-Geert Hermann (Germany)**
Case 1 discussion: A positive MRI is not always axSpA

**Xenophon Baraliakos (Germany)**
Case 2 presentation: When MRI makes the difference

**Martin Rudwaleit (Germany)**
Case 2 discussion: The value of a positive MRI in axSpA

---

**From Bench to Bedside**

**How diet influences musculoskeletal diseases**

**Learning objectives:**
To highlight recent advances in research on nutrition and its impact on MSD

**Chairperson(s):**
Alexander So (Switzerland)
Pascal Richette (France)

**Hyon Choi (United States)**
Fructose, obesity and health

**Charles R. Mackay (Australia)**
Gut microbiota and its effects on immune mediated diseases

**Pascal Richette (France)**
Drastic weight loss and its effects on health
S. M. Nielsen (Denmark) 13:20
E. M. Bartels, M. Henriksen, H. Gudbergsen,
H. Bliddal, A. Astrup, F. K. Knop, L. Carmona,
W. Taylor, J. A. Singh, F. Perez-Ruiz,
L. E. Kristensen, R. Christensen
Abstract N° OP0340
Weight loss for overweight and obese individuals with
gout: a systematic review of longitudinal observational
studies

12:00 - 13:30  N103/N104
Clinical Science session
Can targeting disease activity in hand osteoarthritis improve our
treatment in the 21st century?

Learning objectives:
• What are the underlying mechanisms involved in
  pain and structural damage in finger and thumb base
  osteoarthritis?
• What is the clinical relevance of synovitis and
  subchondral bone activity?
• What are the treatment options?

Chairperson(s):
Johannes W. J. Bijlsma (Netherlands)
W. Erwin van Spil (Netherlands)
Ruth Wittoek (Belgium) 12:05
Abstract N° SP0179
What is disease activity in finger OA?

Xavier Chevalier (France) 12:25
Abstract N° SP0180
Biologics and other inflammatory therapies in finger
OA. What have we learned?

Margreet Kloppenburg (Netherlands) 12:45
Thumb base OA requires a different approach than finger
OA, but why and how?

A. L. Tan (United Kingdom) 13:05
M. A. D’Agostino, E. Hensor, A. Grainger, P. Emery,
D. Mcgonagle
Abstract N° OP0341
Can pain in hand osteoarthritis be associated with MRI
collateral ligament abnormalities?

S. van Beest (Netherlands) 13:15
F. P. Kroon, W. Damman, R. Liu, M. Kloppenburg
Abstract N° OP0342
Assessment of structural damage of the thumb base in
patients with hand osteoarthritis: comparing the newly
developed OMERACT magnetic resonance imaging
scoring system with standard radiography

12:00 - 13:30  South Auditorium
Basic and Translational Science session
Why we do develop autoimmunity

Learning objectives:
• To gain insight into novel strategies about autoimmunity
• To learn current knowledge in specific drivers for
  rheumatic diseases
• To understand the role of environmental factors

Chairperson(s):
Tom Huizinga (Netherlands)
Hans-Ulrich Scherer (Netherlands)
Otavio Marques (Germany) 12:05
Failure of natural regulatory autoantibody network as
cause of autoimmunity

Hans-Ulrich Scherer (Netherlands) 12:23
Abstract N° SP0182
Alterations in the antibody repertoire and sugar
modulation as a cause for autoimmunity

Jens Humrich (Germany) 12:41
Abstract N° SP0183
Failure of Treg control to understand autoimmunity

Peter Lamprecht (Germany) 12:59
Abstract N° SP0184
Role of microenvironment and endogenous pathways
to break tolerance

G. Natalello (Italy) 13:17
S. L. Bosello, F. Paroni Sterbini, A. Palladini,
G. B. Canestrari, F. Parisi, E. De Lorenzis,
G. Berardi, B. Posteraro, M. Sanguinetti,
G. Ferraccioi
Abstract N° OP0343
The intestinal involvement in systemic sclerosis is
characterized by a peculiar gut microbiota

12:00 - 13:30  N101/N102
Health Professionals session
Closing the gap between objective
measures and self-report in
fibromyalgia

Learning objectives:
To understand the factors associated with the
discrepancy between subjective and objective
measurements in fibromyalgia

Chairperson(s):
Rinie Geenen (Netherlands)
Milena Gobbo Montoya (Spain)
Marius Henriksen (Denmark) 12:05
Abstract N° SP0185
Divergences between objective and self-reported physical
function in fibromyalgia
Brian Walitt (United States) 12:23
Abstract N° SP0186
Cognitive fog: subjective and objective understandings of the symptom of dyscognition

Fernando Estévez-López (Spain) 12:41
Abstract N° SP0187
Pain catastrophizing and self-efficacy in women with fibromyalgia: the al-Ándalus project

Louise Piggott (United Kingdom) 12:59
Abstract N° SP0188
Self-management of fibromyalgia from a patient perspective

V. Vervoort (Netherlands) 13:17
Abstract N° OP0344-HPR
Development of responder criteria for multicomponent non-pharmacological treatment in fibromyalgia

12:00 - 13:30 N111/N112
The Young Rheumatologist
Interactive cases from the HOT and WIN sessions

Learning objectives:
To discuss interactively clinical aspects and clinical cases from the HOT/WIN sessions

Chairperson(s):
Vasco C. Romao (Portugal)
Annamaria Iagnocco (Italy)
Margreet Kloppenburg (Netherlands) 12:05
WIN: Interactive clinical aspects and cases on osteoarthritis

Pedro Machado (United Kingdom) 12:25
WIN: Interactive clinical aspects and cases on axial and peripheral spondyloarthritis

Raashid Luqmani (United Kingdom) 12:45
HOT: Interactive clinical aspects and cases on vasculitis treatment

Iain B. McInnes (United Kingdom) 13:05
WIN: Interactive clinical aspects and cases on rheumatoid arthritis - what have therapeutics taught us

12:00 - 13:30 N115/N116
Joint session PARE/HPR
Suffering in silence. Optimizing the management of psychological well-being for people with RMDs

Learning objectives:
• To gain insights of the extend and features of psychological impact of RMDs on daily life from different angles
• To learn how health professionals and patients can help to break the vicious circle of suffering in silence

Chairperson(s):
Souzi Makri (Belgium)
Heidi A. Zangi (Norway)
Emma Dures (United Kingdom) 12:05
Abstract N° SP0190
Facts and figures: how mental health care addresses the psychological burden of RMD’s in Europe

Anja Marchal (Belgium) 12:25
A personal account of learning to disclose: how psychological support can help to break the vicious circle of hiding and ignoring

Vasiliki Christodoulou (Cyprus) 12:45
Mindfulness and acceptance - how to use your body and mind to manage your life with a rheumatic disease

K. Cattelaens (Germany) 13:10
Abstract N° OP0345-PARE
Growing up with arthritis - yes we can!
A project of Deutsche Rheuma-Liga in co-operation with the German arthritis research center. With financial support by the German Federal Ministry of Health

S. Mingolla (Italy) 13:20
F. Riondino, I. Cinieri, C. Assalve on behalf of fibromyalgia group APMAR Onlus
Abstract N° OP0346-PARE
“Listening to pain - un dolore da ascoltare” multidisciplinary support for women with fibromyalgia

12:00 - 13:30 N117/N118
EULAR Projects in Health Professionals
Showcasing the EULAR Online Course for Health Professionals

Learning objectives:
To be informed on the online course for health professionals

Chairperson(s):
Els van den Ende (Netherlands)
Karin Niedermann (Switzerland)
Peter Oesch (Switzerland)

Iain B. McInnes (United Kingdom) 13:05
WIN: Interactive clinical aspects and cases on osteoarthritis

Pedro Machado (United Kingdom) 12:25
WIN: Interactive clinical aspects and cases on axial and peripheral spondyloarthritis

Raashid Luqmani (United Kingdom) 12:45
HOT: Interactive clinical aspects and cases on vasculitis treatment

Iain B. McInnes (United Kingdom) 13:05
WIN: Interactive clinical aspects and cases on rheumatoid arthritis - what have therapeutics taught us

12:00 - 13:30 N115/N116
Joint session PARE/HPR
Suffering in silence. Optimizing the management of psychological well-being for people with RMDs

Learning objectives:
• To gain insights of the extend and features of psychological impact of RMDs on daily life from different angles
• To learn how health professionals and patients can help to break the vicious circle of suffering in silence

Chairperson(s):
Souzi Makri (Belgium)
Heidi A. Zangi (Norway)
Emma Dures (United Kingdom) 12:05
Abstract N° SP0190
Facts and figures: how mental health care addresses the psychological burden of RMD’s in Europe

Anja Marchal (Belgium) 12:25
A personal account of learning to disclose: how psychological support can help to break the vicious circle of hiding and ignoring

Vasiliki Christodoulou (Cyprus) 12:45
Mindfulness and acceptance - how to use your body and mind to manage your life with a rheumatic disease

K. Cattelaens (Germany) 13:10
Abstract N° OP0345-PARE
Growing up with arthritis - yes we can!
A project of Deutsche Rheuma-Liga in co-operation with the German arthritis research center. With financial support by the German Federal Ministry of Health

S. Mingolla (Italy) 13:20
F. Riondino, I. Cinieri, C. Assalve on behalf of fibromyalgia group APMAR Onlus
Abstract N° OP0346-PARE
“Listening to pain - un dolore da ascoltare” multidisciplinary support for women with fibromyalgia

12:00 - 13:30 N117/N118
EULAR Projects in Health Professionals
Showcasing the EULAR Online Course for Health Professionals

Learning objectives:
To be informed on the online course for health professionals

Chairperson(s):
Els van den Ende (Netherlands)
Karin Niedermann (Switzerland)
Peter Oesch (Switzerland)
M. K. Nisar (United Kingdom) 13:17
J. Begum
Abstract N° OP0347-HPR
Training rheumatology nurse specialists: what does the future hold?

12:00 - 13:30  N107/N108

Practical skills session*
Ultrasound, clinical, diagnostic and therapeutic skills II

Chairperson(s):
Dario Roccatello (Italy)
Nemanja Damjanov (Serbia)

Peter Mandl (Austria) 12:05
Abstract N° SP0101
Diagnostic and therapeutic ultrasound-guided procedures

Michael Doherty (United Kingdom) 12:23
Abstract N° SP0102
How to perform a quick and efficient physical examination

Roberto Caporali (Italy) 12:41
How to read and interpret imaging tools: X-Ray

Hilde Berner Hammer (Norway) 12:59
Abstract N° SP0103
How to assess US competency skills

Faculty 13:17
Q&A

13:45 - 14:45  Hall 6

Highlight session
Clinical Basic Translational Highlight session

Chairperson(s):
João E. Fonseca (Portugal)
Robert B. M. Landewé (Netherlands)

Thomas Dörner (Germany) 13:50
Basic and translational highlights

Loreto Carmona (Spain) 14:15
Clinical highlights

13:45 - 14:45  N101/N102

Highlight session
Health Professionals Highlight session

Chairperson(s):
Lurdes Barbosa (Portugal)
Yeliz Prior (United Kingdom)

Ricardo Ferreira (Portugal) 13:50
Highlights from the Health Professional sessions

Muditha Samaranayaka (United Kingdom) 14:08
Highlights from the Scientific programme

Carol Rhodes (United Kingdom) 14:26
Highlights from the PARE programme

13:45 - 14:45  N115/N116

Highlight session
PARE Highlight session

Learning objectives:
To provide an overview of learning and outcomes from the 2017 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates

Chairperson(s):
Nele Caeyers (Belgium)
Marios Kouloumas (Cyprus)
Jette Primdahl (Denmark) 13:50
Highlights from the PARE programme

Daniel Aletaha (Austria) 14:15
Highlights from the Scientific programme

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Guided Poster Tours

Saturday 17 June 2017 10:20 - 12:00

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis on the day of the poster tour.

**Poster Tour S1: Innate mediators and autoantibodies in rheumatic diseases**

Chairperson(s): Martin Herrmann (Germany), Mary Canavan (Ireland)

**SAT0010**
THE DAMP PROTEIN S100A8/A9 IS CRUCIAILY INVOLVED IN MYELOID-DERIVED SUPPRESSOR CELL (MDSC) DIFFERENTIATION AND FUNCTION IN COLLAGEN-INDUCED ARTHRITIS / M. Kuhlenroder - Y. Kusche* - S. Zenker - T. Vogl - J. Roth

**SAT0011**

**SAT0012**
S100A8/A9 INCREASES THE MOBILIZATION OF LY6C HIGH MONOCYTES TO THE SYNOVIUM DURING EXPERIMENTAL OSTEOARTHRITIS / N. Cremers* - E. Geven - A. Blom - M. van den Bosch - P. van der Kraan - P. van Lent

**SAT0013**

**SAT0014**
THE MUTATED RNA SPlicing PROTEIN HNRNP-A3 IS A NOVEL AUTOANTIGEN IN SYSTEMIC RHEUMATIC DISEASES A LINK TO WARBURG EFFECT IN RA / B. Marklein - M. Hansson - G. Steiner - G. Burmester - K. Skriner*

**SAT0015**

**SAT0016**

**SAT0017**
INVESTIGATING NOVEL AUTOANTIBODIES IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS / M. C. Baker* - N. Lingampalli - W. Robinson

**SAT0018**
EFFECTS OF ANTI-TNF ALPHA THERAPY ON B CELLS IN RHEUMATOID ARTHRITIS (RA) PATIENTS / O. Pala* - A. Diaz - B. Aubourg - E. Greidinger - B. B. Blomberg - D. Frasca

**SAT0019**

**Poster Tour S2: How B and T cells contribute to rheumatic disease**

Chairperson: Leonie Taams (United Kingdom), Hans-Ulrich Scherer (Netherlands)

**SAT0027**

**SAT0028**
AIOLOS OVEREXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS B-CELL SUBTYPES AND BAFF INDUCED MEMORY B-CELL DIFFERENTIATION ARE REDUCED BY CC-220 MODULATION OF CEREBLON ACTIVITY / G. E. Ringheim* - J. Kosek - L. Capone - P. H. Schafer - Y. Nakayama

* Presenting author
SAT0029

SAT0030

SAT0031

SAT0032

SAT0033
SMOKING CONTRIBUTES TO EXHAUSTED STATE OF CD4+ T CELLS IN RHEUMATOID ARTHRITIS / C. Wasén* - M. Turkilla - M. Leth-Larsen - M. P. Andersen - M. Brissel - S. Töyrä Silfverswärd - M. I. Bokarewa

SAT0034

SAT0035

SAT0036
IL-17+CD8+ T CELLS ENRICHED IN THE SYNOVIAL FLUID OF PSA/SPA PATIENTS EXHIBIT A PRO-INFLAMMATORY CYTOKINE PHENOTYPE / K. J. A. Steel* - E. Chan - B. W. Kirkham - L. S. Taams

Poster Tour S3: RA - risk factors and consequences

Chairperson(s): Ingemar Peterssson (Sweden), Suzanne Verstappen (United Kingdom)

SAT0037

SAT0038
SERUM B LYMPHOCYTE CHEMATTRACTANT PROTEIN 13 (CXC13) AND MUSCULOSKELETAL ULTRASONOGRAPHIC FINDINGS IN EARLY RHEUMATOID ARTHRITIS / E. Baraka* - S. EGILA - G. HAMAD - M. KHALIL

SAT0039

SAT0040

SAT0041

SAT0042

SAT0043

SAT0044

SAT0045

SAT0046
IL-17+CD8+ T CELLS ENRICHED IN THE SYNOVIAL FLUID OF PSA/SPA PATIENTS EXHIBIT A PRO-INFLAMMATORY CYTOKINE PHENOTYPE / K. J. A. Steel* - E. Chan - B. W. Kirkham - L. S. Taams

Poster Tour S4: From the heart of rheumatology

Chairperson(s): Zoltán Szekeczec (Hungary), Joao Madruga Dias (Portugal)

SAT0088

SAT0089

SAT0090

SAT0091
IS CLINICAL ARTHRITIS ALWAYS PRECEDED BY SUBCLINICAL INFLAMMATION? A LONGITUDINAL STUDY AT JOINT LEVEL IN PATIENTS WITH ARTHRALGIA THAT DEVELOPED ARTHRITIS / R. M. ten Brinck* - H. W. van Steenbergen - A. H. van der Helm - van Mil

SAT0092

* Presenting author

SAT0094 METABOLIC AND CARDIO- VASCULAR BENEFITS OF HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META- ANALYSIS / C. Rempeaul* - B. Combe - T. Barnetche - C. Gaujoux-Viala - C. Lukas - J. Morel - C. Hua


Poster Tour S6: Trends in non- TNF alpha biologicals for RA II

Chairperson(s): Johannes W. J. Bijlsma (Netherlands), W. Erwin van Spil (Netherlands)


SAT0177 SAFETY EVENTS ARE SIMILAR WITH ABATACEPT vs PLACEBO TREATMENT IN RA: RESULTS FROM INTEGRATED DATA ANALYSIS FROM NINE CLINICAL TRIALS / B. Soule* - M. Hochberg - D. Fleming - A. Torbeys - T. Simon - S. Banerjee - M. Boers


SAT0181 LOW DOSE INTERLEUKIN-2 COMBINED WITH TOCILIZUMAB SELECTIVELY INCREASES REGULATORY T CELLS HELPING REFRATORY RHEUMATOID ARTHRITIS PATIENTS ACHIEVE REMISSION MORE RAPIDLY / Z. Sheng-Xiao* - M. Xiao-Wen - L. Xiao-Qing - M. Miao - W. Xiao-Yan - N. Hong-Qing - W. Cai-Hong - L. Xiao-Feng

SAT0182 SIRUKUMAB LEADS TO SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE THAT MEET OR EXCEED NORMATIVE VALUES IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TNF INHIBITORS IN POST HOC ANALYSES OF A PHASE 3 TRIAL / V. Strand - R. Ganguley - N. Li - K. McQuarrie*

SAT0183 CLINICAL REMISSION IN SUBJECTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER SYNTHEtic DMARDS: A REAL-WORLD CLINICAL TRIAL (TOSPACE) / R. Sammarti* - E. Martin Mola - J. E. Fonseca - D. J. Veale - A. Escudero - C. González on behalf of ToSpace study group

SAT0184 THERAPEUTIC DRUG MONITORING ON RHEUMATOID ARTHRITIS PATIENTS WITH REDUCED DOSES OF INTRAVENOUS TOCILIZUMAB / V. Ruiz-Esquide* - C. Bastida - M. Pascual - J. Aguac - D. Soy - R. Sammarti

SAT0185 BIO-HOLIDAY THERAPY WITH A TIGHT CONTROL STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS WITH CLINICAL DISEASE ACTIVITY INDEX REMISSION ENABLES MAINTENANCE OF BONE METABOLISM STATUS / E. Torikai* - M. Suzuki - Y. Matsuyma


Poster Tour S7: New treatment options in SLE, Sjögren’s and APS

Chairperson(s): Martin Aringer (Germany), Hendrika Bootsm (Netherlands)

SAT0219 EFFICACY AND SAFETY OF ATACICEPT IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II) / J. T. Merrill* - D. J. Wallace - A. Kao - C. Vazquez Mateo - P. A. Fraser - P. Chang - D. Isenberg

SAT0220 EFFECTS OF TYPE I INTERFERON INHIBITION ON BLOOD LEUKOCYTE SUBSETS IN PATIENTS TREATED IN A PHASE IIB CLINICAL STUDY OF ANIPROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / W. White* - K. A. Casey - M. A. Smith - L. Wang - D. Sinbaldi - M. A. Sanjuan - G. Illei


SAT0223  INDIRECT COMPARATIVE CLINICAL EFFECTIVENESS OF INTRAVENOUS AND SUBCUTANEOUS FORMULATIONS OF BELUMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS WITH HIGH DISEASE ACTIVITY / D. Parks - S. Ramachandran* - M. Kurtinecz - Y. Asukai - R. Alfonso-Cristancho

SAT0224  THE ROLE OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION A SINGLE-CENTER COHORT STUDY / Q. Wang* - J. Zhao - J. Qian - Z. Tian - M. Li - X. Zeng


SAT0228  APOPTOTIC EFFECT OF BLYS ON ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IS MEDIATED BY BLYS RECEPTORS AND IS REVERTED BY BELUMUMAB / F. R. Spinelli* - C. Barbati - F. Ceccarelli - T. Colasanti - F. Morello - L. Massaro - V. Orefice - C. Alessandri - F. Conti - G. Valesini


SAT0230  NEW ORAL ANICOAGULANTS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME / M. A. Satybaldyeva* - P. Brunetta - L. Kashnikova - E. Nasonov - T. Reshetnyak

Poster Tour S7: SSc, myositis and rare diseases: etiology and animal models

Chairperson: Gabriela Riemekasten (Germany), Jens Humrich (Germany)


SAT0320  MKP-1 AS A PROTECTIVE FACTOR AND NOVEL DRUG TARGET IN SCLERODERMA: MKP-1 DEFICIENT MICE DEVELOP MORE SEVERE DERMAL FIBROSIS IN A WIDELY USED EXPERIMENTAL MODEL OF SCLERODERMA / M. Scotece* - M. Hämäläinen - T. Leppänen - E. Moilanen

Chairperson(s): Maurizio Cutolo (Italy), Alberto Sulli (Italy)


* Presenting author
EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE (CRISP) INDEX IN THE FASSCINATE TRIAL / D. Khanna* - V. Berrocal - C. Derten - A. Jameris - H. Spotwood - C. Lin - J. Siegel - D. Furst


RELIABILITY OF A NEW AUTOMATED SYSTEM FOR ABSOLUTE CAPILLARY NUMBER COUNTING (AUTOCAP) ON SYSTEMIC SCLEROSIS NAILFOLD VIDEOCAPILLAROSCOPY IMAGES / M. Cutolo - K. Melsens - A. C. Trombetta* - C. Pizzorni - E. Deschepper - A. Sulli - V. Smith


CORRELATION BETWEEN THREE DIFFERENT METHODS TO ASSESS DERMAL THICKNESS IN SYSTEMIC SCLEORSIS PATIENTS WITH DIFFERENT PATTERNS OF NAILFOLD MICROANGIOPATHY / B. Ruaro* - A. Sulli - E. Alessandri - S. Paolino - M. Ghio - A. C. Trombetta - C. Pizzorni - V. Tomatis - M. Cutolo

Chairperson(s): Iain B. Mclnnes (United Kingdom), George E. Fragoulis (Greece)

ANTI-TNF TREATMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IS ASSOCIATED WITH A STRONG INCREASE OF PALMOPLANTAR PUSTULOSIS BUT NOT OF PSORIASIS VULGARIS / J. Ruwaard* - E. van der Vlugt - M. Nurmohamed - T. Rispens - G. J. Wolbink

NETWORK META-ANALYSIS ON THE EFFICACY OF NOVEL THERAPEUTIC AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS / T. T. Cheung - M. F. Tsoi* - Y. Fei - C. S. Lau - B. M. Y. Cheung


PSORIATIC ARTHRITIS AND NODAL OSTEARTHROSIS CAN BE DIFFERENTIATED USING HAND RADIOGRAPHS: A NOVEL METHOD / S. Bahadur* - A. Zavareh - C. Hughes - R. Mandegaran - S. Subesinghe - B. Kirkham

INTEGRATED SAFETY SUMMARY OF TOFACTINIB IN PSORIATIC ARTHRITIS CLINICAL STUDIES / G. Burmester* - R. Mandegaran - S. Subesinghe - B. Kirkham

NOVEL METHOD / S. Bahadur* - A. Zavareh - C. Hughes - R. Mandegaran - S. Subesinghe - B. Kirkham

CORRELATION BETWEEN THREE DIFFERENT METHODS TO ASSESS DERMAL THICKNESS IN SYSTEMIC SCLEORSIS PATIENTS WITH DIFFERENT PATTERNS OF NAILFOLD MICROANGIOPATHY / B. Ruaro* - A. Sulli - E. Alessandri - S. Paolino - M. Ghio - A. C. Trombetta - C. Pizzorni - V. Tomatis - M. Cutolo

Chairperson(s): Margreet Kloppenburg (Netherlands), Jeremie Sellam (France)

OSTEOARTHRITIS (OA) AND SOCIO-ECONOMIC STATUS(SES) PREDICTS THE ONSET OF COMORBIDITIES LINKED TO FREQUENT HEALTHCARE CONSULTATION / R. Hayward* - K. Kaur - R. Wilkie

LOW MAGNESIUM INTAKE IS ASSOCIATED WITH INCREASED PAIN IN SUBJECTS WITH RADIOGRAPHIC KNEE OSTEARTHROSIS; DATA FROM THE OSTEARTHROSIS INITIATIVE / A. Shmagel* - N. Onizuka - T. Vo - L. Langsetmo - K. Ensrud - R. Foley - P. Valen

INCREASED EXPRESSION OF OSTEOPROTEGERIN IN CD271+ MULTIPOTENTIAL STROMAL CELLS FROM FEMORAL HEADS OF PATIENTS WITH HIP OSTEARTHROSIS / D. C. Ilas - S. M. Churchman - J. Aderinto - P. V. Giannoudis - D. McGonnagle - E. Jones

* Presenting author

Chairperson(s): Margreet Kloppenburg (Netherlands), Jeremie Sellam (France)

OSTEOARTHRITIS (OA) AND SOCIO-ECONOMIC STATUS(SES) PREDICTS THE ONSET OF COMORBIDITIES LINKED TO FREQUENT HEALTHCARE CONSULTATION / R. Hayward* - K. Kaur - R. Wilkie

LOW MAGNESIUM INTAKE IS ASSOCIATED WITH INCREASED PAIN IN SUBJECTS WITH RADIOGRAPHIC KNEE OSTEARTHROSIS; DATA FROM THE OSTEARTHROSIS INITIATIVE / A. Shmagel* - N. Onizuka - T. Vo - L. Langsetmo - K. Ensrud - R. Foley - P. Valen

INCREASED EXPRESSION OF OSTEOPROTEGERIN IN CD271+ MULTIPOTENTIAL STROMAL CELLS FROM FEMORAL HEADS OF PATIENTS WITH HIP OSTEARTHROSIS / D. C. Ilas* - S. M. Churchman - J. Aderinto - P. V. Giannoudis - D. McGonnagle - E. Jones

* Presenting author
Poster Tour S11: Infection related rheumatic disease: clinical and epidemiologic aspects

**Chairperson(s):** Leonard Calabrese (United States), Konstantinos Thomas (Greece)

**SAT0556**

**SAT0557**

**SAT0558**

**SAT0559**

**SAT0560**
INTRAMUSCULAR CORTICOSTEROID INJECTION VERSUS PLACEBO INJECTION IN HIP OSTEARTHRITIS: A 12-WEEK BLINDED RANDOMIZED CONTROLLED TRIAL / D. Dorleijn - P. Luijsterburg - M. Reijman - M. Kloppenburg - J. Verhaar - P. Bindels - K. Bos - S. Bierma-Zeinstra

**SAT0561**

**SAT0562**

**SAT0563**
EVALUATION OF ROLE OF SLEEP DISTURBANCE, DEPRESSION, OBESITY, AND PHYSICAL INACTIVITY IN FATIGUE IN CHIKUNGUNYA ARTHRITIS / M. Bhamra

**SAT0564**

**SAT0565**

---

**Poster Tour S12: Imaging advances in vasculitis, crystal and connective tissue disease**

**Chairperson(s):** Lene Terslev (Denmark), Berit Dalsgaard Nielsen (Denmark)

**SAT0609**
GIANT CELL ARTERITIS: ATHEROSCLEROSIS AS PITFALL IN THE HALO SIGN / E. De Miguel* - L. M. Beltran - F. Deodati - I. Monjo - W. A. Schmidt - J. García-Puig

**SAT0610**
TEMPORAL ARTERY ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A COHORT WITH ELEVATED CLINICAL IMPRESSION / P. V. Estrada* - D. Reina - V. Navarro - D. Roig - D. Cerdá - V. Torrente - S. Heredia - H. Corominas

* Presenting author
SAT0611 INTIMA-MEDIA THICKNESS REFERENCE RANGES DEPICTING HALO SIGN FOR THE DIAGNOSING OF LARGE VESSEL GIANT CELL ARTERITIS BY ULTRASOUND / M. Michet* - M. Brzosko

SAT0612 THE USE OF 18F-FDG-PET IN THE DIAGNOSIS OF POLYMYALGIA RHEUMATICA (PMR) - A PROSPECTIVE STUDY OF 99 PATIENTS SUSPECTED OF PMR / L. Henckaerts - O. Hveysens - S. Vanderschueren - K. Goffin - D. Blockmans*


SAT0618 DISTURBANCES OF THE ACRAL PERFUSION DETECTED BY FLUORESCENCE OPTICAL IMAGING ARE ASSOCIATED WITH THE DEVELOPMENT OF ISCHEMIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. Lüders* - S. Friedrich - S. Ohndorf - S. Werner - G. R. Burmester - G. Riemenkasten - M. Backhaus

Poster Tour S13: Comorbidities and outcomes in RMDs

Chairperson(s): Axel Finckh (Switzerland), Merete Hetland (Denmark)


SAT0671 THE IMPACT OF OBESEITY ON TREAT TO TARGET GOALS AND FUNCTIONAL ABILITY IN THE ERAS/ERAN UK PROSPECTIVE COHORTS / E. Nikipherou* - S. Norton - P. Kiely - A. Young on behalf of ERAS/ERAN group


SAT0674 EARLY TREATMENT RESPONSE TO CONVENTIONAL DMARD THERAPY IN RHEUMATOID ARTHRITIS IS A BETTER PREDICTOR OF LOW DISEASE ACTIVITY OR TREATMENT ESCALATION AT 12 AND 24 MONTHS THAN AUTOANTIBODIES OR EROSIONS / A. Richter - A. Strangfeld* - P. Herzer - J. Kaufmann - T. Klopsch - S. Zinke - J. Listing - A. Zink


SAT0677 THE IMPACT OF DISEASE ACTIVITY DURING PREGNANCY IN WOMEN WITH SLE ON THE OCCURRENCE OF PREECLAMPSIA AND PREMATURITY BIRTH / A. G. C. Skorpen* - S. Lydersen - I.-M. Gilboe - K. Å. Salvesen - M. Wallenius

SAT0678 SIGNIFICANTLY INCREASED SEROPOSITIVITY, RHEUMATOID FACTOR TITRES AND RHEUMATOID NODULES IN CORNISH KAOLIN WORKERS / D. Murphy* - E. Fleeming - K. Bellis - D. Hutchinson

Chairperson(s): Annette de Thurah (Denmark), Jenny de la Torre-Aboki (Spain)

SAT0717-HPR PREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHITIS / A. Zbinden* - S. van den Brandt - P. M. Villiger - M. Østensen - F. Förger


* Presenting author


SAT0721-HPR  EXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY / A. K. Hedström - L. Klareskog - L. Alfredsson*


SAT0723-HPR  GENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS - A NATIONWIDE CROSS-SECTIONAL STUDY / B. A. Esbensen* - C. Flurey - K. V. Jensen - L. Andersen - N. M. Hammer

SAT0724-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. PATIENTS' EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY / U. Bergsten* - K. Almeheh - L. Jacobsson

SAT0725-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY / U. Bergsten* - K. Almeheh - L. Jacobsson

* Presenting author
Innate immunity in rheumatic diseases

SAT0001

SAT0002
INNATE LYMPHOID CELLS (ILCs) ARE DIFFERENTIALLY DISTRIBUTED IN INFLAMMATORY AND NON-INFLAMMATORY JOINT DISEASES / I. Meunier - I. Marois - M. Richter - G. Boire*

SAT0003
SINGLE-NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH P2X7R FUNCTION REGULATE THE ONSET OF GOUTY ARTHRITIS / J. Tao* - M. Cheng

SAT0004
NEW AUTOANTIGEN (JKTBP) PART OF SFRITRESS GRANULES CLOSES THE SENSITIVITY GAP IN RHEUMATOID ARTHRITIS / B. Marklein - M. Jenning - K. Muenzer - G. Burmester - K. Skriner*

SAT0005

SAT0006

SAT0007
GROUP 3 INNATE LYMPHOCYTE NUMBERS IN PERIPHERAL BLOOD PREDICT USTEKINUMAB (STELARA) THERAPY RESPONSIVENESS IN PSORIATIC DISEASE CASES WITH SUBCLINICAL IMAGING ENTHESOPATHY / Y. M. El-Sherbiny* - L. Savage - M. Wittmann - P. Emery - M. Goodfield - D. McGonagle

SAT0008
DRUG THERAPY ENHANCES TOLERGENIC PROPERTIES OF DENDRITIC CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Kusche* - S. Zenker - T. Vogl - J. Roth

SAT0009

SAT0010

* Presenting author
Adaptive immunity (T cells and B cells) in rheumatic diseases

SAT0017 INVESTIGATING NOVEL AUTOANTIBODIES IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS / M. C. Baker* - N. Lingampalli - W. Robinson

SAT0018 EFFECTS OF ANTI-TNF ALPHA THERAPY ON B CELLS IN RHEUMATOID ARTHRITIS (RA) PATIENTS / O. Pala* - A. Diaz - B. Aubourg - E. Greigdering - B. B. Blomberg - D. Frasca


SAT0027 AIOLOS OVEREXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS B-CELL SUBTYPES AND BAIFF INDUCED MEMORY B-CELL DIFFERENTIATION ARE REDUCED BY CC-220 MODULATION OF CEREBLON ACTIVITY / G. E. Ringheim* - J. Kosek - L. Capone - P. H. Schafer - Y. Nakayama


SAT0033 SMOKE CONTRIBUTES TO EXHAUSTED STATE OF CD4+ T CELLS IN RHEUMATOID ARTHRITIS / C. Wasén* - M. Turkilla - M. Erlandsson - K. M. Andersson - M. Brisslert - S. Töyrä Silfverswärd - M. I. Bokarewa


SAT0036 IL-17+CD8+ T CELLS ENRICHED IN THE SYNOVIAL FLUID OF PSA/SPA PATIENTS EXHIBIT A PRO-INFLAMMATORY CYTOKINE PHENOTYPE / K. J. A. Steel* - E. Chan - B. W. Kirkham - L. S. Taams

Rheumatoid arthritis - prognosis, predictors and outcome


SAT0038 SERUM B LYMPHOCYTE CHEMOTACTIC PROTEIN 13 (CXCL 13) AND MUSCULOSKELETAL ULTRASONOGRAPHIC FINDINGS IN EARLY RHEUMATOID ARTHRITIS / E. Baraka* - S. Egila - G. Hamard - M. Khalil

SAT0039 LARGE TENDER JOINTS HAVE THE GREATEST IMPACT ON LONGITUDINAL TRAJECTORIES OF FUNCTION IN RHEUMATOID ARTHRITIS / H. Ahmad - M. Maldonado - E. Alemao - J. Ye - M. Schiff


* Presenting author


SAT0044 A 10-YEAR FOLLOW UP STUDY OF EARLY SERONEGATIVE ARTHRITIS DIAGNOSED AT AN ADULT AGE / K. Paalanen* - J. Asikainen - T. Ranno - P. Hannonen - T. Sokka


SAT0046 TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS / M. Cavaco* - F. Araujo - J. Eurico Fonseca - J. Goncalves

SAT0047 PREDICTING MAINTENANCE OF RESPONSE BASED ON DISEASE CLINICAL AND EARLY CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS UPON WITHDRAWAL OF ADA / J. Rönnelid - G. Zanframundo - F. Benaglio - G. Sakellariou - C. Montecucco - R. Caporali


SAT0050 EARLY RESPONSE TO CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PREDICTS OUTCOME: DATA FROM A PROSPECTIVE OBSERVATIONAL STUDY / A. Saraux* - R. M. Filpo - F. Fagnani - J. Massol - B. Combe - P. Huot-Marchand - J. M. Joubert - J. Dunkel - G. Cukierman

SAT0051 CITRULLINATION OF ADENOSINE DEAMINASE ISOFORMS IN RHEUMATOID ARTHRITIS / S. Sharoyan - L. Karapetyan - R. Harutyunyan - S. Mardanyan - A. Antonyan*

SAT0052 HIGH CHANCE OF COMPREHENSIVE DISEASE CONTROL (CDC) IN VERY EARLY AND NORMAL WEIGHT RHEUMATOID ARTHRITIS PATIENTS TREATED ACCORDING TO THE TREAT TO TARGET STRATEGY / A. L. Fedele* - L. Petricca - B. Tolousso - S. Alivennii - C. Di Mario - G. Di Sante - G. Ferraccioli - E. Gremsse


SAT0057 PROSPECTIVE OBSERVATIONAL REAL-LIFE STUDY (STRATEGIE) SHOWS THE EFFICACY OF TREAT-TO-TARGET STRATEGY AND METHOTREXATE MONOTHERAPY OPTIMIZATION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS / R. M. Filpo* - G. Gaujoux-Viala - C. Hudry - E. Zinovieva - H. Herman-Demars on behalf of STRATEGIE study observers


SAT0060 RESPONSE TO CONVENTIONAL SYNTHETIC DMARDs DIFFERS DEPENDING ON RHEUMATOID FACTOR LEVELS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / S. Bugatti* - A. Manzo - G. Zarfamundo - F. Benaglio - G. Sakellariou - G. Montecucco - R. Caporali


SAT0062 14-3-3ETA PREDICTS JOINT DAMAGE PROGRESSION AND FLARING AFTER ADALIMUMAB DISCONTINUATION / S. Hirata* - A. Marotta - K. Hanami - Y. Tanaka


SAT0064 HIGH MMP3 SERUM LEVELS ARE ASSOCIATED WITH EXTENSIVE STRUCTURAL DAMAGE IN PATIENTS WITH EARLY, TREATMENT NAIVE RHEUMATOID ARTHRITIS (RA): TWO YEARS PROSPECTIVE CLINICAL AND ULTRASONOGRAPHIC OBSERVATIONAL STUDY / S. Z. Prodanovic* - G. Radunovic - M. Selfik-Bukilica - M. Zlatanovic - K. Simic-Pasical - S. Seric - N. Damjanov

SAT0065 ACXA AGAINST DIFFERENT CITRULLINATED PEPTIDES IDENTIFY SPECIFIC PHENOTYPES OF RHEUMATOID ARTHRITIS / M. Brink - M. Hansson - L. Mathsson-Alm - M. Corillet - J. Rönnelid - G. Serre - R. Holmdahl - L. Klareskog - S. Rantapää-Dahlqvist

SAT0066 HISTOLOGICAL AND ULTRASOUND SYNOVIAL PREDICTORS OF CLINICAL DIFFERENTIATION TO DEFINED PATIENT SUBGROUPS IN PATIENTS WITH SERONEGATIVE UNDIFFERENTIATED PERIPHERAL INFLAMMATORY ARTHRITIS / A. M. Fenstad - O. N. Furnes - T. W. Nystad

* Presenting author
Rheumatoid arthritis - comorbidity and clinical aspects


SAT0068 THE TIME TO PERFORMING TIGHT CONTROL AS A TREAT-TO-TARGET STRATEGY AND THE TOLERABILITY OF METHOTREXATE STRONGLY INFLUENCE THE ACHIEVEMENT OF CLINICAL REMISSION IN RHEUMATOID ARTHRITIS / T. Hagiwara* - K. Kamada - N. Namura

SAT0069 A RAPID-LIKE INDEX DOCUMENTS SUPERIOR EFFICACY OF BARICITINIB TO ADALUMAB AND PLACEBO, SIMILAR TO BAS28 AND CD4 IN THE RA-BEAM CLINICAL TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS / T. Pincus* - B. Zhu - C. J. Larmore - J. D. Bradley - N. Patel - C. L. Gaich - A. E. Koch


SAT0071 RHEUMATOID ARTHRITIS (RA) REGISTRY IN AKITA PREFECTURE, WHERE AGING IS THE MOST ADVANCED IN JAPAN / T. Aizawa* - T. Kashiwagura - N. Miyakoshi - Y. Shimada


SAT0076 SERUM LEVEL OF SYND6-4 AND ITS CORRELATION WITH CLINICAL PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS / X. Ye* - J. Zhao - Z. Zhang

SAT0077 CLINICAL FEATURES AND PERFORIN A91V GENE ANALYSIS IN SO-JIA CHILDREN WITH MACROPHAGE ACTIVATION SYNDROME / X. Chen* - H. Zeng


SAT0080 CLINICAL SIGNIFICANCE OF SOLUBLE CD163 IN REFRACTORY SYSTEMIC-ONSET IDIOPATHIC ARTHRITIS / Y. Cui* - H. Zeng

SAT0081 RELATIONSHIP BETWEEN RHEUMATOID FACTOR POSITIVITY AND TREATMENT EFFECT WITH A FIRST BIOLOGIC AGENT IN RHEUMATOID ARTHRITIS: MULTICENTER STUDY USING A MIXED-EFFECT MODEL / Y. Ogawa* - N. Takahashi - N. Ishiguro - T. Kojima


SAT0084 CHARACTERISTICS OF PATIENTS WHO RESPOND POORLY TO REDUCTION OF BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RT-4 STUDY POST HOC ANALYSIS / Y. Urata* - S. Abe - B. Devers - Y. Nakamura - H. Takemoto - K.-I. Furukawa


SAT0086 THE ASSOCIATION BETWEEN ELDERLY RHEUMATOID ARTHRITIS PATIENTS USING BIOLOGICS AND ADVERSE EVENTS: RETROSPECTIVE COHORT STUDY / Y. Ikari* - Y. Miwa - N. Yajima


Rheumatoid arthritis - comorbidity and clinical aspects


SAT0091 IS CLINICAL ARTHRITIS ALWAYS PRECEDED BY SUBCLINICAL INFLAMMATION? A LONGITUDINAL STUDY AT JOINT LEVEL IN PATIENTS WITH ARTHRALGIA THAT DEVELOPED ARTHRITIS / R. M. Ten Brinck* - H. W. van Steenbergen - A. H. van der Helm - van Mil

* Presenting author


SAT0094 METABOLIC AND CARDIO-VASCULAR BENEFITS OF HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / C. Rempenault* - B. Combe - T. Barnetche - C. Gaujoux-Viala - C. Lukas - J. Morel - C. Hua


SAT0098 THE ASSOCIATION BETWEEN WORK DISABILITY AND MENTAL HEALTH IN RHEUMATOID ARTHRITIS / A. Houssien* - S. Norton - E. Nikiphourou - F. Matcham - J. Galloway


SAT0100 ACFA AND ABDOMINAL ADIPOSITY ARE INDEPENDENT PREDICTORS OF INCREMENTS IN BASAL INSULIN IN PATIENTS WITH RA / E. Gomez-Bañuelos* - L. R. Harrold - O. Pala - J. M. Kremer

SAT0105 SURVIVAL IN FIRST LINE OF BIOLOGIC AGENTS IN AN APULIAN COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH OCULT HEPATITIS B VIRUS INFECTION / G. Carlino* - M. Fornaro - F. Abal - F. J. Ballina-García - M. Á. González-Gay - A. Suárez

SAT0106 SURVIVAL IN FIRST LINE OF BIOLOGIC AGENTS IN AN APULIAN COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH OCULT HEPATITIS B VIRUS INFECTION / G. Carlino* - M. Fornaro - F. Abal - F. J. Ballina-García - M. Á. González-Gay - A. Suárez

SAT0107 FACTORS THAT INFLUENCE ON PAIN CONTROL DURING TREATMENT FOR RHEUMATOID ARTHRITIS PATIENT / I. Yoshii* - T. Chijwa

SAT0108 CLINICAL SIGNIFICANCE OF ANTI-ACTIN ANTIBODIES IN AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES / I. Ayadi* - L. Laadhar - M. Kallel-Sellami

SAT0109 QUANTITATIVE ESTIMATES OF DAMAGE AND DISTRESS, IN ADDITION TO INFLAMMATION, AND THE PROPORTION EACH OF THE 3 VARIABLES AFFECTS CLINICAL MANAGEMENT DECISIONS (TOTAL=100%) MAY CLARIFY ASSESSMENT OF CLINICAL STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / K. A. Gibson* - I. Castrejon - T. Pincus

SAT0110 THE IMPACT OF PUMMONARY INVOLVEMENT TO THE TREATMENT OF REUMATOID ARTHRITIS / K. Setoguchi* - F. Y. Chen - S. Kamei - M. Ogawa - S. Kobayashi


SAT0112 OBESITY AND METABOLIC SYNDROME INFLUENCE ON N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN RHEUMATOID ARTHRITIS PATIENTS / L. Kondratyeva* - T. Popkova - I. Kirillova - M. Rossini - C. Hua

SAT0113 OBESITY AND METABOLIC SYNDROME INFLUENCE ON N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN RHEUMATOID ARTHRITIS PATIENTS / L. Kondratyeva* - T. Popkova - I. Kirillova - M. Rossini - C. Hua


SAT0115 EFFECT OF BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) ON CARDIO VASCULAR DISEASE (CVD) RISK IN RA PATIENTS: THREE YEARS RESULTS FROM A CANADIAN COHORT / M. Khrashti* - C. Molta - A. Lewis


* Presenting author
SAT0118  SAFETY AND EFFICACY OF ALTERNATE-DAY CORTICOSTEROIDS AS ADJUNCTIVE THERAPY IN RHEUMATOID ARTHRITIS / M. Suda* - S. Ohde - T. Tsuda - M. Kishimoto - M. Okada

SAT0119  PREGNANCY OUTCOMES IN WOMEN WITH AND WITHOUT RHEUMATOID ARTHRITIS / M. E. B. Clowse* - G. McDaniel - A. M. Eudy


SAT0121  COMORBIDITIES AND DISEASE ACTIVITY ARE RELEVANT FOR FUNCTIONAL DISABILITY IN RHEUMATOID ARTHRITIS / N. Andrade* - A. M. Kakehasi - C. Machado - K. Gomes - M. F. Guimarães - S. Krampa - C. Rodrigues - C. Brenol


SAT0123  MULTIDIMENSIONAL EVALUATION OF PAIN IN RHEUMATOID ARTHRITIS / P. Vergne-Salle* - S. Pouplin - A. Bera-Louville - M. Soubrier - C. Richez - R.-M. Javier - S. Perrot - P. Bertin

SAT0124  HIGHER BMI AND SHORTER DISEASE DURATION ARE ASSOCIATED WITH “FIBROMYALGIC” RHEUMATOID ARTHRITIS - EVALUATION USING POWER DOPPLER ULTRASONOGRAPHY / P. Cheung* - M. Lahiri


SAT0126  MENTAL HEALTH BENEFITS ASSOCIATED WITH REDUCTION IN ACTIVITY AMONG RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW OF THE LITERATURE / V. Strand - R. Rendas-Baum - M. Kosinski - D. Brooks - R. Ganguly*

SAT0127  UNFAVORABLE BODY COMPOSITION ALREADY AT THE ONSET OF CLINICAL ARTHRITIS / S. A. Turk* - D. van Schaardenburg - M. Boers - S. de Boer - C. Fokker - W. F. Lemps - M. T. Nurmohamed


SAT0129  EXPLORATION OF COMORBIDITY INDICES IN AN ETHNIC RHEUMATOID ARTHRITIS SUBSET / S. Dowell* - G. Kerr - C. Swearingen - M. Quinones - J. Berrian - M. Hoebig - S. Hochberg on behalf of EMRAC Working Group


SAT0131  MEDIAN NERVE THICKNESS RELATED TO RENAL IMPAIRMENT IN RHEUMATOID ARTHRITIS / S. Hannawi* - I. AlSalmi


SAT0133  SUDOMOTOR DYSFUNCTION IN RHEUMATOID ARTHRITIS PATIENTS IN THE ABSENCE OF TRADITIONAL CARDIOVASCULAR RISK / T. Syngle* - S. Kaur - I. Verma - A. Syngle

SAT0134  DAILY MONITORING OF ARTERIAL STIFFNESS IN WOMEN WITH RHEUMATOID ARTHRITIS / T. A. Romanova* - N. M. Nikitina - A. P. Rebrov

SAT0135  CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS FROM SOUTHERN BRAZIL AND ITS ASSOCIATION WITH SERUM LEVELS AND GENOTYPIC VARIATION OF MANNOSE BINDING LECTIN / B. Stadler - N. M. Nikitina - A. P. Rebrov


Rheumatoid arthritis - anti-TNF therapy

SAT0140  EFFECT OF OBESITY IN RESPONSE TO BILOGICS IN RHEUMATOID ARTHRITIS / A. Khan - S. Sukumaran* - M. Kanitkar - A.-S. Zafar - S. Shah - S. Adnan


SAT0142  PREDICTORS OF INADEQUATE RESPONSE AND RAPID RADIOGRAPHIC PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS RECEIVING METHOTREXATE: A POST HOC ANALYSIS OF 2 RANDOMIZED, CONTROLLED TRIALS OF ADALIMUMAB / A. Kavanaugh* - R. F. van Vollenhoven - B. A. Wolfe - S. Fiorentinus - S. Chen - J. L. Suboticçi - J. S. Smolen

SAT0143  COMPARISON OF TREATMENT WITH GOLIMUMAB AND CERTOLIZUMAB-PEGOL IN ARTHRITIS: RESULTS FROM THE SOUTH SWEDISH ARTHRITIS TREATMENT GROUP (SSATG) REGISTER / C. Roseman* - E. Lindqvist - P. Geborek - M. Cnkic Kapetanovic

* Presenting author


SEVERE LEVELS OF THE ANTI-TNF BIOLOGICS CORRELATE WITH CLINICAL EFFICACY IN PATIENTS WITH INFLAMMATORY ARTHRITIS / C. C. Mok* - B. Fong - L. Y. Ho - C. H. To

RABBIT RISK SCORE FOR SERIOUS INFECTIONS IN A ROMANIAN COHORT OF RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS / C. Ancuta* - C. Pomirleau - R. Maxim - L. Petraiariu - G. Strugariu - A. Kahan - C. Roux - Y. Allanore - M. Dougados


EFFICACY AND SAFETY OF BIOLOGIC THERAPY IN ELDERLY RHEUMATOID ARTHRITIS PATIENTS COMPARED TO YOUNG - A SYSTEMATIC REVIEW / D. Dalal* - J. Duran - T. Brar - R. Alqadi - C. Halladay - A. Lakhani - J. Rudolph

REAL-LIFE INFlixIMAB AND ADALIMUMAB TROUGH LEVEL AND ANTI-DRUG ANTIBODY MEASUREMENTS IN RHEUMATOLOGY: THE FINNISH EXPERIENCE / D. Ho* - S. Vattanen - M. Hanna - L. Kröger - K. Eklund - S. Jokiranta

EFFECTIVENESS OF LOW AND HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN A REAL WORLD SETTING: RESULTS FROM THE CORRONA RHEUMATOID ARTHRITIS REGISTRY / D. Pappas* - J. Griffith - C. A. Schlacher - Y. Shan - C. Karki - J. M. Kremer


ADALIMUMAB IN COMBINATION WITH NON-METHTREXATE CONVENTIONAL SYNTHETIC DISEASE MODIFYING RHEUMATIC DRUGS IN A CLINICAL TRIAL SETTING / E. C. Keystone* - J. Suboticki - J. Griffith - Y. Zhang - J. M. Kremer

EXPOSITION TO BIOLOGICAL THERAPY DURING PREGNANCY: A SINGLE-CENTRE STUDY OF PREGNANCY OUTCOME IN MOTHERS WITH RHEUMATIC DISEASES / E. De Stefani* - M. Padovan - A. Bortoluzzi - R. Capucci - M. Govoni

MYCOBACTERIUM TUBERCULOSIS SPECIFIC RESPONSES FROM CD8+ AND CD4+ T CELLS IN PATIENTS WITH LATENT AND ACTIVE FORM OF TUBERCULOSIS / E. Zanova* - D. Kozakov - M. Polanova - I. Soloviov - I. Rybar


IMMUNOGENICITY OF BIOSIMILARS FOR THE TREATMENT OF INFLAMMATORY RHEUMATIC DISEASES: A REVIEW FROM CONFIRMATORY CLINICAL TRIALS / F. Araújo* - J. Gonçalves - J. E. Fonseca


MARKERS OF RESPONSE TO INFlixIMAB IN RHEUMATOID ARTHRITIS - THE PLACE OF ANTINUCLEAR ANTIBODY AND NULEASE SERUM ACTIVITY / M. Volkova* - A. Kundzner - I. Generalov - D. Petrovich
Rheumatoid arthritis - other biologic treatment

**SAT0176**

**SAT0177**
Safety events are similar with abatacept vs placebo treatment in RA: results from integrated data analysis from nine clinical trials / M. C. Genovese* - R. Fleischmann - H. van Hoogstraten - E. K. Mangan - S. Jayawardena - G. R. Burmester

**SAT0178**

**SAT0179**

**SAT0180**
Safety and efficacy of sarilumab 200 mg q2w administered as combination therapy or monotherapy in different patient populations with active RA / M. C. Genovese* - R. Fleischmann - H. van Hoogstraten - E. K. Mangan - S. Jayawardena - G. R. Burmester

**SAT0181**
Low dose interleukin-2 combined with tocilizumab selectively increases regulatory T cells helping refractory rheumatoid arthritis patients achieve remission more rapidly / Z. Sheng-Xiao* - M. Xiao-Wen - L. Xiao-Qing - M. Miao - W. Xiao-Yan - N. Hong-Qing - W. Cai-Hong - L. Xiao-Feng

**SAT0182**
Sirukumab leads to significant and clinically meaningful improvements in health-related quality of life that meet or exceed normative values in patients with rheumatoid arthritis refractory to TNF inhibitors in post hoc analyses of a Phase 3 trial / V. Strand - R. Ganguly - N. Li - K. McQuarrie*

**SAT0183**
Clinical remission in subjects with rheumatoid arthritis treated with subcutaneous tocilizumab as monotherapy or in combination with methotrexate or other synthetic DMARDs: a real-world clinical trial (TOspace) / R. Sammaritai* - E. Martin Mola - J. E. Fonseca - D. J. Veale - A. Escudero - C. González on behalf of ToSpace study group

**SAT0184**
Therapeutic drug monitoring on rheumatoid arthritis patients with reduced doses of intravenous tocilizumab / V. Ruiz-Esquiúde* - C. Bastida - M. Pascal - J. Yagüe - D. Soy - R. Sammarritai

**SAT0185**
Bio-holiday therapy with a tight control strategy in rheumatoid arthritis patients with clinical disease activity index remission enables maintenance of bone metabolism status / E. Torikai* - M. Suzuki - Y. Matsuyama

**SAT0186**

**SAT0187**

* Presenting author

SAT0189  FACTORS INFLUENCING THE PRESCRIPTION OF TOCILIZUMAB ALONE OR IN COMBINATION WITH DMARDS IN RHEUMATOID ARTHRITIS PATIENTS IN A REAL LIFE SETTING. POOLED ANALYSIS OF 3 OBSERVATIONAL STUDIES / A. Saraux - A. Cantagrel - B. Combe - R.-M. Filpo - I. Idier - C. Baffie - J. Tebib


SAT0196  REPEATED RITUXIMAB INFUSIONS FOR THE THERAPY OF RHEUMATOID ARTHRITIS IS NOT ASSOCIATED WITH INCREASED RATES OF SERIOUS INFECTIONS / D. A. Pappas - G. W. Reed - S. Zlotnick - J. Best - R. Magner - G. Persuett - J. Greenberg

SAT0197  TREATMENT OUTCOMES WITH ANTI-TNF AND NON-ANTI-TNF DISEASE-MODIFYING THERAPY BY BASELINE BODY MASS INDEX / E. Alemao - Z. Guo - C. Iannaccone - M. Frits - M. Weinblatt - N. Shadick


SAT0200  BIOLOGIC THERAPY RETENTION IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) ACCORDING TO THE MOSCOW ARTHRITIS REGISTRY REGISTRY (MAR) / G. Lukina - E. Koltsova - E. Schmidt - E. Zhilyaev

SAT0201  ABATCEPT BUT NOT TNF INHIBITORS BLOCK AUTOANTIBODY-MEDIATED CYTOKINE PRODUCTION BY MONOCYTES / A. Bozec - Y. Luo - C. Engdahl - C. Figueiredo - H. Bang - G. Schett


SAT0203  SIGNIFICANCE OF EXTENSION OF TOCILIZUMAB INFUSION INTERVALS FROM 4 WEEKS TO 6 WEEKS IN RA PATIENTS WHO HAD SHOWN GOOD RESPONSE TO 4 WEEK INTERVALS / H. Uda - K. Shigematsu - O. Saiki


SAT0207  LONG-TERM EFFECT OF BIOLOGIC THERAPIES ON BONE MINERAL DENSITY (BMD) FOR RA PATIENTS COMPARED TO PATIENTS TREATED BY SYNTHETIC DMARD OVER AN 8-YEAR FOLLOW-UP / L. Bustamante - V. Breuil - R. Fabre - L. Euler-Ziegler - C. Pradier - C. Roux

SAT0208  CYCLING VERSUS SWAPPING IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO AT LEAST ONE TUMOR NECROSIS FACTOR ALPHA INHIBITOR: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES / M. A. Lopez-Olivo - A. Matusевич - M. E. Suarez-Almazor

SAT0209  OBSERVATIONAL STUDY ON THE EFFECTS OF IL-6 INHIBITOR THERAPY ON MYOSTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. J. Chapman - R. P. Nayarman - A. Cross - R. Moots - J. Wilding - N. Goodson


* Presenting author
SLE, Sjögren's and APS - treatment

SAT0219
EFFECTIVENESS AND SAFETY OF ATAICCIPE IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIb STUDY (ADDRESS II) / J. T. Merrill* - D. J. Wallace - A. Kao - C. Vazquez Mateo - P. A. Fraser - P. Chang - D. Isenberg

SAT0220
EFFECTS OF TYPE I INTERFERON INHIBITION ON BLOOD LEUKOCYTE SUBSETS IN PATIENTS TREATED IN A PHASE IIb CLINICAL STUDY OF ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / W. White* - E. Mateo - P. A. Fraser - P. Chang - D. Isenberg

SAT0221
SIX-MONTH PROTEINURIA MEASUREMENT PREDICTS RENAL RESPONSE AT 18 MONTHS IN LUPUS NEPHRITIS: PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II) / J. T. Merrill* - D. J. Wallace - A. Kao - C. Vazquez Mateo - P. A. Fraser - P. Chang - D. Isenberg

SAT0222

SAT0223

SAT0224
THE ROLE OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION A SINGLE-CENTER COHORT STUDY / Q. Wang* - J. Zhao - J. Qian - Z. Tian - M. Li - X. Zeng

SAT0225

SAT0226

SAT0227

SAT0228

SAT0229

SAT0230
NEW ORAL ANTIACCAULANTS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME / M. A. Satybaldevyeva* - N. Seredavkina - L. Kashnikova - E. Nasonov - T. Reshetnyak

SAT0231

SAT0232

* Presenting author

SAT0234 PROSPECTIVE SINGLE CENTRE STUDY OF EFFECTIVENESS OF UPFRONT RITUXIMAB AND MYCOPHENOLATE WITH MINIMUM STEROID IN SLE / B. G. Dharmannad*" 


SAT0236 SAFETY AND DISEASE ACTIVITY CHANGES IN AN EXTENSION OF A PHASE IIb STUDY OF ATACICEPT IN PATIENTS WITH SLE (ADDRESS II) / D. J. Wallace* - D. Isenberg - S. Wax - A. Kao - P. Chang - P. A. Fraser - J. T. Merrill

SAT0237 BONE MARROW AS A TARGET ORGAN OF SYSTEMIC LUPUS ERYTHEMATOSUS: ANALYSIS OF CASES WITH AUTOIMMUNE MYELOFPBROSIS / D. Ûskûdar - H. Ûskûdar Teke - S. Sâkoncu - C. Korkmaz


SAT0240 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, E. Svenungsson - I. Gunnarsson

SAT0241 EARLY RESPONSE TO BELUMIMAB IN SLE-RELATED JOINT INVOLVEMENT EVALUATED BY ULTRASONOGRAPHIC ASSESSMENT / L. Massaro* - F. Ceccarelli - F. R. Spinelli - F. Morello - C. Perricone - F. Miranda - S. Truglia - C. Perricone - F. Conti

SAT0242 MEASURES OF PERIPHERAL BLOOD B-CELL DEPLETION PREDICT RENAL RESPONSE IN PATIENTS WITH LUPUS NEPHRITIS TREATED WITH RITUXIMAB / L. M. Gomez Mendez* - M. D. Cascino - J. Garg - P. Brunetta - M. Dall’Era - L. Dragone

SAT0243 EXPOSURE--RESPONSE (E-R) ANALYSIS FOR SELECTION OF OPTIMAL DOSAGE REGIMEN OF ANIFROLUMAB IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / L. C. Santiago - B. Wang - P. Brohawn - L. Wang - G. Illlei - L. Roskos*  &

SAT0244 A LONG-TERM FOLLOW-UP STUDY OF ALLOGENEIC MESENCHYMAL STEM CELLS TRANSPLANTATION IN PATIENTS WITH DRUG-RESISTANT SYSTEMIC LUPUS ERYTHEMATOSUS / D. Wang - L. Sun* 

SAT0245 SERUM IFN GAMA MAY PREDICT THERAPEUTIC EFFECT OF MESENCHYMAL STEM CELLS TRANSPLANTATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / D. Wang - L. Sun* 

SAT0246 EXPLORER STUDY: RITUXIMAB USE IN SYSTEMIC LUPUS ERYTHEMATOSUS, A NEW LOOK ON OLD DATA / M. Scherlincer - C. Carcaud - M. E. Truchetet - P. Dufau - L. Couzy - J. Seneschal - T. Barnetche - E. Lazaro - C. Richez*  

SAT0247 EFFICACY AND SAFETY OF MODIFIED-RELEASE PREDNISONE IN MANAGING MODERATE ACTIVITY SYSTEMIC LUPUS ERYTHEMATOSUS DURING PREGNANCY: AN IMPLEMENTED CASE-CONTROL STUDY / M. Meroni* - V. Ramoni - M. Limonta - M. Cutolo


SAT0250 BODY MASS INDEX IS INVERSELY ASSOCIATED WITH RESPONSE TO RITUXIMAB IN LUPUS NEPHRITIS: ANALYSIS OF THE LUNAR TRIAL / M. D. Cascino* - L. M. Gomez Mendez - J. Garg - L. Dragone - M. Dall’Era - P. Brunetta


SAT0253 EFFICACY AND SAFETY OF LEOFUNOMIDE THERAPY IN LUPUS NEPHRITIS: A META-ANALYSIS / Q. Ren* - H. zeng

SAT0254 SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS AND INTRAVENOUS ANIFROLUMAB IN HEALTHY VOLUNTEERS / R. Tummala* - T. Rouse - A. Berglind - L. Santiago


SAT0256 MULTI-TARGET THERAPY WITH MIZORIBINE, TACROLIMUS, AND PREDNISOLONE IN LUPUS NEPHRITIS: ANALYSIS OF 47 CASES / R. Kawato* - R. Rokutanda - M. Kishimoto - M. Okada


* Presenting author
SLE, Sjögren's and APS - clinical aspects (other than treatment)

SAT0262

SAT0263

SAT0264

SAT0265

SAT0266
EFFECT OF THE METABOLIC SYNDROME ON ORGAN DAMAGE AND MORTALITY IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGLATUDINAL ANALYSIS / C. C. Mok* - S. M. Tse - L. Y. Ho

SAT0267

SAT0268

SAT0269

SAT0270

SAT0271

SAT0272
LACK OF ASSOCIATION BETWEEN GLUCOCORTICOID EXPOSURE AND METABOLIC SYNDROME IN SLE / D. Apostolopoulos* - A. Hoi - E. Morand

SAT0273
FACTORS RELATED TO ALEXITHYMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS / D. P. E. Margiotta* - F. Basta - M. Vadacca - G. Dolcini - M. Lo Vullo - A. Rigon - A. Afeltra

SAT0274

SAT0275

SAT0276

SAT0277

SAT0278

SAT0279

SAT0280
A TEN-YEAR SURVIVAL ANALYSIS OF FILIPINO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AT THE NATIONAL KIDNEY AND TRANSPLANT INSTITUTE (PHILIPPINES) / E. M. L. Yap - C. C. Bermudez

SAT0281

* Presenting author


INCIDENCE AND MORTALITY OF PRIMARY SJÖGREN’S SYNDROME: TIME TRENDS OVER A 40-YEAR PERIOD IN A POPULATION-BASED COHORT IN THE UNITED STATES / G. Maciel* - C. Crowson - E. Matteson - D. Cornec


CARDIOVASCULAR RISK STATUS MODIFICATION IN SLE PATIENTS BY MEANS OF CAROTID ULTRASOUND EXAMINATION / H. Sánchez-Pérez* - B. Tejera-Segura - I. Ferrar-Amaro


LONG-TERM PROGNOSIS AND PREDICTING FACTORS OF CHINESE PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME / J. Zhao* - Y. sun - P. Zhang - Q. Wang - M. Li - X. Zeng


"ANTI-RO52/TRIM21 ANTIBODIES ARE ASSOCIATED WITH QT INTERVAL PROLONGATION IN PATIENTS WITH SYSTEMIC LUPUS ERYSHEMATOSUS" / L. F. Perez* - L. H. Silveira - L. Amezua - O. Estevez - M. Moreno

RELATIONSHIP BETWEEN DISEASE ACTIVITY INDEX SCORES AND SUBJECTIVE ASSESSMENTS IN EARLY SYSTEMIC LUPUS ERYSHEMATOSUS / M. Garabajiu* - V. Sadovici-Bobeica - L. Mazur-Nicorici - M. Cebanu - V. Salaru - M. Mazur


AYTICAL ANTIBODIES IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME / M. Fernandez Castro* - J. L. Andreu - C. Sanchez-Piedra - V. Martinez Taboada - A. Olive - J. Rosas on behalf of SJÖGRENSER group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases study group (EASSER)


ASSOCIATION BETWEEN QUALITY OF SLEEP, QUALITY OF LIFE AND DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYSHEMATOSUS / S. Monov* - D. Monova - M. Ivanova

RECURRENT RATE OF THROMBOSIS FOR PATIENTS WITH ANTI-PHOSPHOLIPID ANTIBODIES INITIALLY AND DISAPPEARED LATER AFTER THROMBOSIS / S. M. Kim* - J. Kim - Y. Kim - S. W. Kang - S.-C. Shim - S.-J. Yoo

* Presenting author
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models


SAT0314 A NOVEL HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS / C. Wenglén - L. Pettersson - H. Arzenius - G. Ekström*


SAT0320 SSC- IGG EFFECTS ARE MEDIATED THROUGH DISTINCT PATHWAYS IN THP-1 CELLS / G. Eleftheriadis - M. Wannick - C. Sadik - G. Riemenkasten*

SAT0321 MKP-1 AS A PROTECTIVE FACTOR AND NOVEL DRUG TARGET IN SCLERODERMA: MKP-1 DEFICIENT MICE DEVELOP MORE SEVERE DERMAL FIBROSIS IN A WIDELY USED EXPERIMENTAL MODEL OF SCLERODERMA / M. Scotece* - M. Hämäläinen - T. Leppänen - E. Moilanen


SAT0323 THE ENDOThelial-TO-MESENCHYMAL TRANSITION (ENDOMT) IN SCLERODERMA CAN BE PREVENTED BY THE USE OF DUAL ENDOTHELIN RECEPTOR ANTAGONISTS BOSENTAN AND MACITENTAN / C. Corallo* - M. Cutolo - S. Soldano - A. Montella - C. Chimico - R. Nulti - N. Giordano


Scleroderma, myositis and related syndromes


SAT0326 THE ASSOCIATION OF SERUM TYPE 1 INTERFERON ACTIVITY AND AUTOANTIBODIES IN INFLAMMATORY MYOSITIS / A. Maruyama* - N. Ono - M. Sakai - Y. Sadanaga - S. Koarada - Y. Tada


SAT0328 AN OPEN-LABEL STUDY OF AMBRISIDENTAN WITH ANTI-FIBROTIC AGENT COMBINATION THERAPY IN THE TREATMENT OF DIFFUSE SYSTEMIC SCLEROSIS / A. Schorpion* - M. Shenin - R. Neubauer - C. T. Derk

SAT0329 INTRAVENOUS CYCLOPHOSPHAMIDE ACCORDING TO THE EURO-LUPUS NEPHRITIS PROTOCOL FOR PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH POLYMYOSITIS/DERMATOMYOSITIS / A. Schorpion* - M. Shenin - R. Neubauer - C. T. Derk


SAT0331 AMINAPHTONE INCREASES SKIN BLOOD PERFUSION AND IMPROVES CLINICAL SYMPTOMS IN PATIENTS WITH BOTH PRIMARY AND SECONDARY RAYNAUD’S PHENOMENON: AN OPEN SIX MONTH PILOT STUDY / B. Ruaro* - S. Paulino - C. Pizzorni - E. Alessandri - E. Gotelli - M. Cutolo - A. Sulli

* Presenting author


CORRELATING MULTIPLEX PLASMA CYTOKINE ANALYSIS WITH RIGHT HEART CATHETERISATION FINDINGS IN SCLERODERMA ASSOCIATED PULMONARY ARTERIAL HYPERTENSION / C. H. Ho* - S. Nihtyanova - B. Ahmed Abdi - G. Coghlan - C. Denton - B. Schreiber - V. H. Ong

SERUM KYNURENINE/TRYPTOPHAN (KYN/TRP) RATIO AND NEOTerin (NEO) LEVELS ARE RAISED IN SYSTEMIC SCLEROSIS (SSC) AND ASSOCIATE WITH SPECIFIC CLINICAL AND AETO-PATHOGENETIC FEATURES / C. Campochiaro* - S. D. Lytton - B. Ahmed Abdi - V. H. Ong - C. P. Denton

MALNUTRITION AND SARCOPENIA IN A LARGE COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS / C. Caimmi* - P. Caramaschi - A. Venturini - E. Bertoldo - M. Ferrari - M. Rossini

IMPACT OF ORGAN INVOLVEMENT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH IDIOPATHIC MYALPATHIES / D. Huscher* - K. Albrecht - J. Richter - J. Henes - T. Alexander - A. Zink

SURVIVAL IN A TURKISH IFAMMATORY MYOSITIS COHORT: A SINGLE-CENTRE STUDY / E. Er Gülbezer* - F. Yargucu Zihni - G. Karabulut - G. Keser - Y. Kabasakal


SCREENING OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS USING DETECT ALGORITHM - VALIDATION IN THE COHORT OF JAPANESE SINGLE CENTER / H. Yasuoka* - Y. Shirai - Y. Tamura - T. Takeuchi - M. Kuwana

DISEASE RELATED MALNUTRITION IN SYSTEMIC SCLEROSIS AND ASSOCIATED FACTORS: A CROSS-SECTIONAL STUDY / I. Türk* - N. Cuzdan Coskun - V. Ciftçi - D. Arslan Taş - M. C. Doğan - I. Unal

THE IMPACT OF GASTROINTESTINAL INVOLVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS / J. Caetano* - J. Branco - S. Oliveira - J. Delgado Alves

SYSTEMIC SCLEROSIS’S EARLY STAGES AND ITS SIGNIFICANCE IN DAILY PRACTICE / J. P. Abreu* - I. Almeida - A. Marinho - C. Vasconcelos

DECREASED BODY FAT, LEAN BODY MASS AND BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND ASSOCIATE WITH SPECIFIC CLINICAL AND AETIO-PATHOGENETIC FEATURES / C. Campochiaro - M. C. Doğan - I. Unal - V. Ciftci - D. Arslan Taş - M. C. Doğan - I. Unal

MORTALITY IN IDIOPATHIC INFLAMMATORY MYOPATHY- RESULTS FROM A SWEDISH NATIONWIDE POPULATION-BASED COHORT STUDY / C. Dooblug - J. Svensson - I. Lundberg - M. Holmqvist*


SAT0362 RISK FACTORS AND OUTCOME OF THAI PATIENTS WITH SCLERODERMA RENAL CRISIS (SRC): A DISEASE DURATION-MATCHED CASE CONTROL STUDY / S. Wangkaew* - S. Lertthanaphok - S. Puntana - K. Noppakun


SAT0365 MUSCULOSKELETAL US AND MRI FINDINGS IN JUVENILE SCLERODERMA / M. Tsinti - V. Dermentzoglou* - on behalf of OPERA study group

SAT0366 SMOKE AND THE PROGRESSION OF ORGAN MANIFESTATIONS IN SYSTEMIC SCLEROSIS: E. Tsitsami

SAT0367 TREATING SMOKE AND ITS EFFECT ON THE PROGRESSION OF ORGAN MANIFESTATIONS IN SYSTEMIC SCLEROSIS: E. Tsitsami


SAT0372 CLINICAL AND SEROLOGICAL ASSOCIATIONS OF AUTOANTIBODIES TO BICD2 AS A NOVEL MARKER FOR RESEMBLANCES TO RHEUMATOID ARTHRITIS / Z. Griger* - A. Vincze - K. Szabó - J. Gaál - K. Dankó

SAT0373 METABOLOMICS OF SERA REVEALS POTENTIAL BIOMARKERS OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS THAT CORRELATE WITH PRO-FIBROTIC GENE EXPRESSION IN SKIN BIOPSY / M. K. Rai - D. Dubey - A. Rawat - D. P. Misra - D. Kumar - V. Agarwal


SAT0375 RELIABILITY OF A NEW AUTOMATED SYSTEM FOR ABSOLUTE CAPILLARY NUMBER COUNTING (AUTOCAPI) ON SYSTEMIC SCLEROSIS NAILFOLD VIDEOCAPILLAROSCOPIC IMAGES / M. Cutoio - K. Meliens - A. C. Trombetta* - C. Pizzorni - E. Deschepper - A. Sulli - V. Smith

SAT0376 METABOLOMICS OF SERA REVEALS POTENTIAL BIOMARKERS OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS THAT CORRELATE WITH PRO-FIBROTIC GENE EXPRESSION IN SKIN BIOPSY / S. Ahmed* - M. K. Rai - D. Dubey - A. Rawat - D. P. Misra - D. Kumar - V. Agarwal


* Presenting author
Spondyloarthritis - clinical aspects (other than treatment)

**SAT0382**

**SAT0383**

**SAT0384**

**SAT0385**

**SAT0386**

**SAT0387**

**SAT0388**

**SAT0389**
COMPARISON OF ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIS SPONDYLARTHITIS IN A MULTI-ETHNIC ASIAN POPULATION OF SINGAPORE / C. Hong* - Y. H. Kwan - W. Fong

**SAT0390**
DIFFUSION WEIGHTED IMAGING (DWI) IS MORE USEFUL THAN SHORT TAU INVERSION RECOVERY (STIR) SEQUENCE IN DIAGNOSIS OF NON-RADIOGRAPHIC AXIS SPONDYLARTHITIS (SPA) AND BOTH SEQUENCES ARE PARTICULARLY USEFUL IN EARLY DISEASE STAGE / C. W. S. Chan* - H. Y. Chung

**SAT0391**

**SAT0392**
THE DIAGNOSTIC ACCURACY OF EXISTING GRADING CRITERIA OF SACROILIAC JOINT CT IN ANKYLOSING SPONDYLITIS / D. Gao* - K. Li - Y. Wang - J. Zhu - J. Zhang - F. Huang

**SAT0393**
PROTEIN FINGERPRINTING SCREENING SPECIFIC PROTEINS IN SERUM OF PATIENTS WITH ANKYLOSING SPONDYLITIS / D. Ma* - L. Zhang

**SAT0394**

**SAT0395**

**SAT0396**
INVESTIGATION OF IRON DEFICIENCY ANEMIA IN ANKYLOSING SPONDYLITIS PATIENTS / Y. Bulut - D. Arslan Tas* - O. Goruroglu Ozturk - U. Karaogullaridan

**SAT0397**
RISK FACTORS FOR DEVELOPMENT AND PERSISTENCE OF CHRONIC WIDESPREAD PAIN, IN ANKYLOSING SPONDYLITIS AND UNDIFFERENTIATED SPONDYLARTHITIS / E. Mogard* - E. Lindqvist - A. Bremander - S. Bergman

**SAT0398**
PREGNANCY OUTCOMES IN KOREAN WOMEN WITH ANKYLOSING SPONDYLITIS / E. H. Park* - J. K. Jun - S. M. Lee - Y. W. Song - E. B. Lee

**SAT0399**
HEADACHE AS A CLINICAL COMPLAINT AT INITIAL PRESENTATION AND DURING THE DISEASE COURSE IN PATIENTS WITH SPONDYLARTHITIS INDICATES CONCOMITANT / SECONDARY FIBROMYALGIA / E. Roussou* - M. Karela - A. Georgiou

**SAT0400**

**SAT0401**
PREVALENCE OF ULTRASONOGRAPHIC LOWER AND UPPER ENTHESITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE / G. Cuomo* - S. Ono - R. Hara - M. Yasumura - T. Muramatsu - S. Suzuki

**SAT0402**

**SAT0403**

**SAT0404**
RELATIONSHIP OF SCLEROSTIN AND DICKKOPF-1 SERUM LEVELS WITH DISEASE ACTIVITY AND INFLAMMATORY MRI LESIONS IN PATIENTS WITH SPONDYLARTHITIS / I. Shynkaruk* - O. Iaremenko - D. Fedkov - K. Iaremenko

* Presenting author
SAT0405  CLINICAL, BIOLOGICAL AND GENETIC FACTORS, PREDICTORS OF TREATMENT NONRESPONSE TO TNF INHIBITORS (TNFi), INankylosing Spondylitis (AS) AND Psoriatic Arthritis (PsA) / J. Polo y La Borda* - J. Campos - J. Sanz - J. Mulero - A. Sánchez

SAT0406  PREVALENCE OF VERTEBRAL FRACTURES IN AXIAL SPONDYLOARTHRITIS. A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES / J. C. Nieto-González* - R. Cubero - S. Castañeda - J. Ramírez - L. Carmona


SAT0410  HLA-B27 ROLE IN ANKYLOSING SPONDYLITIS PHENOTYPE: RESULTS FROM THE REGISPONSER DATABASE / M. A. Alzate* - P. Font - M. Moreno - D. Ruiz - M. Castro - P. Carreto - M. Larrosa - E. Collantes - J. Gratacos on behalf of REGISPONSER group


SAT0413  INFECTIOUS PROFILE IN A TUBERCULOSIS-ENDEMIC POPULATION WITH SPONDYLOARTHROPATHIES / M. A. Alzate* - F. Ramirez - F. Vargas - D. Hernandez-Parras - J. C. Salazar-Uribe - P. Ortiz-Salazar - R. Pineda on behalf of Artmedica IPS, Medellin, Colombia

SAT0414  DIFFERENCES IN CLINICAL PRESENTATION BY GENDER IN COLOMBIAN PATIENTS WITH SPONDYLOARTHROPATHIES / M. A. Alzate - F. Vargas - F. Ramirez - D. Hernandez-Parras - J. C. Salazar-Uribe - P. Ortiz-Salazar - R. Pineda on behalf of Artmedica IPS, Medellin, Colombia

SAT0415  HIGH PREVALENCE OF HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF INHIBITORS / M. Konsta* - M. T. Nurmohamed - A. Iliopoulos - J. C. van Denderen - I. Visman - P. P. Sfikakis - I. E. van der Horst-Bruinsma


SAT0417  GRADUAL PROGRESSIVE CHANGE TO EQUAL PREVALENCE OF ANKYLOSING SPONDYLITIS AMONG MALES AND FEMALES IN SWITZERLAND: DATA FROM THE SWISS ANKYLOSING SPONDYLITIS SOCIETY (SVMB) / H. Baumberger - M. A. Khan*


SAT0420  RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS, IN PATIENTS WITH ANKYLOSING SPONDYLITIS / P. Chiochwanwisawakit* - V. Srinonprasert - W. Katchamart

SAT0421  FAT MASS NEGATIVELY AFFECTS THE RESPONSE TO TNF ALPHA BLOCKERS IN ANKYLOSING SPONDYLITIS PATIENTS / S. E. Ibáñez Vodnizza* - M. T. Nurhammad - I. M. Visman - J. C. van Denderen - W. F. Lems - I. E. van der Horst-Bruinsma

SAT0422  EFFECTS OF VITAMIN D REPLACEMENT ON THE DISEASE ACTIVITY AND INFLAMMATORY PARAMETERS SUCH AS IL-1, IL-6, TNF-A, ASYMOMETRIC DIMETHYLA... / M. C. Cooper - B. Davidson - N. Harvey - E. Dennison - R. Seth - K. E. Walker-Bone - S. Bennett - C. J. Edwards


SAT0424  AXIAL DISEASE IN PSORIATIC ARTHRITIS: BURDEN OF UNDERDIAGNOSED DISEASE AND RISK FACTORS IN REAL LIFE / S. Z. Aydin* - U. Kalyoncu on behalf of the PsART study group

SAT0425  SYMPTOMOLOGY, DISEASE STATUS, AND REMISSION RATES OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ANKYLOSING SPONDYLOARTHRITIS PATIENTS IN EUROPE / T. M. Hunter* - D. Sandoval - S. Lobosco - R. Moon - J. Birt - G. Miligan


* Presenting author
Psoriatic arthritis

SAT0433  ANTI-TNF TREATMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IS ASSOCIATED WITH A STRONG INCREASE OF PALMOPLANTAR PUSTULOSIS BUT NOT OF PSORIASIS VULGARIS / J. Ruwaard* - E. van der Vlugt - M. Nurmohamed - T. Rispens - G. J. Wolbink

SAT0434  NETWORK META-ANALYSIS ON THE EFFICACY OF NOVEL THERAPEUTIC AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS / T. T. Cheung - M. F. Tsolo - Y. Fei - C. S. Lau - B. M. Y. Cheung


SAT0441  COMPARISON OF DIFFERENT REMISSION TARGETS IN PATIENTS WITH PSORIATIC ARTHRITIS AND EVALUATION OF THEIR PROGNOSTIC VALUE / L. C. Coates* - L. Aikman - A. Szumski - A. Chhabra


SAT0448  APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND J. Birt - D. H. Adams - O. Benichou - C. -Y. Lin - P. Nash

SAT0449  SEX, METABOLIC COMORBIDITIES AND LINE OF THERAPY PREDICT TNF-INHIBITOR THERAPY PERSISTENCE IN PSORIATIC ARTHRITIS / T. T. Cheung - M. F. Tsoi* - Y. Fei - C. S. Lau - B. M. Y. Cheung

SAT0450  CORRELATION BETWEEN THE SPINAL MRI FINDINGS AND NEW BONE FORMATION FACTOR (DKK-1) IN PATIENTS WITH PSONDYLOARTHRITIS / Z. Zhao* - G. Wang - Y. Y. Wang - J. S. Yang - J. Zhu - F. Huang

* Presenting author

SAT0454  Finger flexor tendon pulley complex involvement in psa: an high resolution ultrasonographic study / I. Tinazzi* - A. Marchetta - D. Chessa - D. M. Mac Gonagle - P. Macchioni

SAT0455  impact of psoriatic arthritis in the workplace: results of the french survey psopro / P. Claudepierre - I. Bonnet* - Y. Roquelaure - P. Levy - R. Aubert - H. Bachelez

SAT0456  Therapy modifications among patients with psoriatic arthritis treated with a biological in the united states—descriptive analyses from an administrative claims database / J. A. Walsh* - O. Adejoro - B. Chaste - G. Chun - J. B. Palmer

SAT0457  Mixed anxiety-depressive disorder (madd) in patients with psoriatic arthritis treated with biological therapy / C. Garcia-Porrua - J. A. Mosquera-Martinez - F. J. Maceiras-Pan - L. Fernandez-Dominguez - L. Guerra-Vazquez - J. Pinto-Tasende*


SAT0459  Low dose il-2 restores imbalance between th17 and regulatory t cells in patients with psoriatic arthritis / K. Qin* - Q. Chen - J. FAN - D. Xu - X. Li - C. Wang - C. Gao


SAT0465  An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriomn's disease, and arthritis, and psoriasis / L. S. Gensler* - E. Hsia - C. Gasinsk - B. Randazzo - D. Parenti - S. Fakharzadeh - L.-L. Gao - S. D. Chakravarty

SAT0466  Pregnancy in women with psoriatic arthritis: pregnancy outcomes and changes in disease activity / M. E. B. Clowse* - G. McDaniel - A. M. Eudy

SAT0467  All 10-year Cardiovascular risk scores are similar in patients with psoriatic arthritis and psoriasis / N. Ikumi* - F. Farkas - A. Szentpetery - B. Kirby - O. FitzGerald


SAT0474  Very low disease activity and impact of disease in a spanish population with psoriatic arthritis / R. Queiro* - J. D. Cañete - C. Montilla - M. A. Abad - S. Gómez - A. Cabeza


SAT0476  Demographic, clinical, and laboratory characteristics of elderly onset psoriatic arthritis / S. Kobak* - M. Orman


* Presenting author
Osteoarthritis

SAT0483  RAPID3 QUESTIONNAIRE HAS HIGH DISCRIMINATING ABILITY IN MINIMAL DISEASE ACTIVITY ATTAINMENT IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS TREATED ACCORDING TO TIGHT CONTROL STRATEGY IN DAILY CLINICAL PRACTICE (RESULTS OF ONE-YEAR OPEN-LABEL REMARCA STUDY) / T. Korotaeva* · E. Loginova · A. Koltakova · L. Denisov · M. Chamurileva · D. Karateev · E. Nasonov

SAT0479  INCREASED CAROTID INTIMA-MEDIA THICKNESS CAN DISCRIMINATE SIGNIFICANT CORONARY ARTERY STENOSIS BY CORONARY CT ANGIOGRAM IN PATIENTS WITH PSORIATIC ARTHRITIS / T. H. Cheng* · Q. Shang · E. K. M. Li · K. T. Wong · A. P. W. Lee · C. C. Szeto · L. S. Tam

SAT0480  COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND INFILXIMAB IN PSORIATIC ARTHRITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE 3 CLINICAL TRIAL DATA / V. Strand* · L. B. Molnes · P. Mease · E. Choy · P. Nash · H. Thom · C. Kalyvas · K. Ghandi · L. Pricop · S. Jug

SAT0481  THE RELATIONSHIP BETWEEN THE PATIENT ACCEPTABLE SYMPTOM STATE (PASS) AND DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) / J. Z. Fei · A. Perruccio · Y. Ye · D. D. Gladman · V. Chandran*

SAT0482  SUBCLINICAL ENTHESOPATHY IN PSORIATIC PATIENTS AND ITS RELATION TO OTHER DISEASE PARAMETERS: AN ULTRASOUND STUDY / W. Gouda* · M. Ismail · M. Doma

**Presenting author**

---

SAT0483  OSTEOARTHRITIS (OA) AND SOCIO-ECONOMIC STATUS (SES) PREDICTS THE ONSET OF COMORBIDITIES LINKED TO FREQUENT HEALTHCARE UTILIZATION / R. Hayward* · K. Kaur · R. Wilkie

SAT0484  LOW MAGNESIUM INTAKE IS ASSOCIATED WITH INCREASED PAIN IN SUBJECTS WITH RADIOGRAPHIC OSTEOARTHRITIS (OA) / A. Shmagel* · N. Onizuka · T. Vo · L. Langsetmo · K. Ensrud · R. Foley · P. Valen

SAT0485  INCREASED MAGNESIUM INTAKE IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN SUBJECTS WITH RADIOGRAPHIC OSTEOARTHRITIS / T. Korotaeva* · E. Loginova · A. Shmagel · N. Onizuka · T. Vo · L. Langsetmo · K. Ensrud · R. Foley · P. Valen

SAT0486  CATASTROPHIZING IN OSTEOARTHRITIS OF THE KNEE: DOES THE LEQUESNE SCORE TAKE IT IN COUNT? A PROSPECTIVE STUDY / J. Lecorney · M. Chouk · X. Guillot · C. Prati · D. Wendling · F. Verhoeven*

SAT0487  A RANDOMIZED, BLINDED, COMPARATOR-CONTROLLED TRIAL INVESTIGATING A 4-WEEK COURSE OF LYRICA IN SUBJECTS WITH KNEE OSTEOARTHRITIS WHO EXHIBIT NEUROPATHIC PAIN, COMPARED WITH A 4-WEEK COURSE OF PARACETAMOL / A. Wright* · P. Moss · H. A. Benson · R. Will · P. Chowalloor

SAT0488  COMPARATIVE EFFECTIVENESS OF AYURVEDIC AND CONVENTIONAL CARE IN KNEE OSTEOARTHRITIS: A CROSS-SECTIONAL ANALYSIS OF OSTEOARTHRITIS INITIATIVE (OAI) DATA / I. Shirinsky* · P. M. Welsing · C. Fellows · F. P. Lafeber · W. E. Van Spil

SAT0489  INTRAMUSCULAR CORTICOSTEROID INJECTION VERSUS PLACEBO INJECTION IN HIP OSTEOARTHRITIS: A 12-WEEK RANDOMIZED CONTROLLED TRIAL / D. Dorleijn · P. Luijsterburg · M. Reijman · M. Kloppenburg · J. Verhaar · P. Bindels · K. Bos · S. Bierma-Zeinstra*

SAT0490  MAINTAINING SUFFICIENT SERUM VITAMIN D LEVELS OVER TWO YEARS IS ASSOCIATED WITH IMPROVED KNEE STRUCTURAL AND SYMPTOMATIC OUTCOMES IN PEOPLE WITH KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL / C. S. Kessler* · K. Dhiman · A. Kumar · T. Ostermann · S. Gupta · A. Morandi · M. Mittwede · E. Stapelfeldt · M. Spoo · K. Icke · A. Michalsen · C. Witt

SAT0491  EARLY TOLL-LIKE RECEPTOR 4 BLOCKADE IMPEDES THE BEHAVIOURAL AND HISTOLOGICAL CHARACTERISTICS OBSERVED IN A MIA-INDUCED ANIMAL MODEL OF OSTEOARTHRITIC PAIN / M. M. Garcia · D. Aitken · L. Blizzard · G. Jones · C. Ding · B. Antony

SAT0492  INTRAOPERATIVE PAIN MANAGEMENT IN KNEE OSTEOARTHRITIS PATIENTS UNDERGONE TOTAL KNEE Replacement SURGERY: A SYSTEMATIC REVIEW / A. Abogamal* · H. Aly · S. Ghanem · H. Saad on behalf of AL-Azhar MSUS school

SAT0493  MELANIN-CONTAINING NEURONS AND THEIR RELATION TO OSTEOARTHRITIS IN PATIENTS WITH KNEE OSTEOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / L. D. Bhanot · V. Singh

SAT0494  WHAT ARE THE PATIENTS’ EXPERIENCE, NEEDS AND EXPECTATIONS IN HAND OSTEOARTHRITIS? A QUALITATIVE EVALUATION / M.-A. Offroy · A. Frazier-Mironer*

SAT0495  THE PERFORMANCE OF URINARY COLLAGEN TYPE II C-TELOPEPTIDE (UCTX-II) IN KNEE OSTEOARTHRITIS: A META-ANALYSIS / M.-A. Offroy · F. A. Frazer-Mironer*

SAT0496  IDENTIFICATION OF BIOCHEMICAL PHENOTYPES IN KNEE OSTEOARTHRITIS: LONGITUDINAL DATA FROM THE FNIH OA BIOMARKER CONSORTIUM / B. Jeremiasse* · P. M. Welsing · C. Fellows · F. P. Lafeber · W. E. Van Spil

SAT0497  SLEEP DISTURBANCE, KNEE INFLAMMATION, AND SYMPTOMS IN KNEE OSTEOARTHRITIS / C. K. Kwoh* · E. Ashbeck · A. Guermazi · F. W. Roemer · S. Parthasarathy

SAT0498  KNEE FUNCTION AND ENTHESITIS IN LONG STANDING OSTEOARTHRITIS, WHAT ULTRASOUND COULD TELL US? / A. Abogamal* · H. Aly · S. Ghanem · H. Saad on behalf of AL-Azhar MSUS school

SAT0499  SAFETY OF DIACEREIN IN PATIENTS WITH OSTEOARTHRITIS: A REAL WORLD EXPERIENCE WITH UNEXPECTED OUTCOMES / M. M. Garcia · D. Aitken · L. Blizzard · G. Jones · C. Ding

SAT0500  KNEE FUNCTION AND ENTHESITIS IN LONG STANDING OSTEOARTHRITIS, WHAT ULTRASOUND COULD TELL US? / A. Abogamal* · H. Aly · S. Ghanem · H. Saad on behalf of AL-Azhar MSUS school

SAT0501  EARLY TOLL-LIKE RECEPTOR 4 BLOCKADE IMPEDES THE BEHAVIOURAL AND HISTOLOGICAL CHARACTERISTICS OBSERVED IN A MIA-INDUCED ANIMAL MODEL OF OSTEOARTHRITIC PAIN / M. M. Garcia · D. Aitken · L. Blizzard · G. Jones · C. Ding

SAT0502  THE SAFETY OF DIACEREIN IN PATIENTS WITH OSTEOARTHRITIS: A REAL WORLD EXPERIENCE WITH UNEXPECTED OUTCOMES / M. M. Garcia · D. Aitken · L. Blizzard · G. Jones · C. Ding

SAT0503  WHAT ARE THE PATIENTS’ EXPERIENCE, NEEDS AND EXPECTATIONS IN HAND OSTEOARTHRITIS? A QUALITATIVE EVALUATION / M.-A. Offroy · A. Frazier-Mironer*

SAT0504  THE PERFORMANCE OF URINARY COLLAGEN TYPE II C-TELOPEPTIDE (UCTX-II) IN KNEE OSTEOARTHRITIS: A META-ANALYSIS / B. Jeremiasse* · F. P. Lafeber · W. E. Van Spil

SAT0505  IDENTIFICATION OF BIOCHEMICAL PHENOTYPES IN KNEE OSTEOARTHRITIS: LONGITUDINAL DATA FROM THE FNIH OA BIOMARKER CONSORTIUM / B. Jeremiasse* · P. M. Welsing · C. Fellows · F. P. Lafeber · W. E. Van Spil

SAT0506  SLEEP DISTURBANCE, KNEE INFLAMMATION, AND SYMPTOMS IN KNEE OSTEOARTHRITIS / C. K. Kwoh* · E. Ashbeck · A. Guermazi · F. W. Roemer · S. Parthasarathy

SAT0507  PREVALENCE OF HAND OSTEOARTHRITIS IN A MODEL OF AUTO-IMMUNE DISEASE, SJÖGREN SYNDROME: RESULTS OF A PROSPECTIVE STUDY / C. Glanowski* · J. Z. Fei · A. Perruccio · Y. Ye · D. D. Gladman · V. Chandran*

SAT0508  CLINICAL PRACTICE (RESULTS OF ONE-YEAR OPEN-LABEL REMARCA STUDY) / T. Korotaeva* · E. Loginova · A. Koltakova · L. Denisov · M. Chamurileva · D. Karateev · E. Nasonov

SAT0509  SAT0478  INCREASED CAROTID INTIMA-MEDIA THICKNESS CAN DISCRIMINATE SIGNIFICANT CORONARY ARTERY STENOSIS BY CORONARY CT ANGIOGRAM IN PATIENTS WITH PSORIATIC ARTHRITIS / T. H. Cheng* · Q. Shang · E. K. M. Li · K. T. Wong · A. P. W. Lee · C. C. Szeto · L. S. Tam


SAT0509 DYNAMICS IN THE LEVELS OF ADIPOKINES AND CYTOKINES IN PARALLEL WITH WEIGHT LOSS AND THEIR RELATIONSHIP WITH CLINICAL MANIFESTATIONS OF KNEE OSTEOARTHRITIS / E. Strebkova* - I. Solovyova - A. M. Mkrtumyan - L. Alekseeva

SAT0510 EFFECT OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL THERAPY ON THE CLINICAL MANIFESTATIONS OF OSTEOARTHRITIS / E. Strebkova* - L. Alekseeva

SAT0511 THUMB BASE OSTEOARTHRITIS: ASSOCIATIONS BETWEEN SYNOVITIS ON ULTRASOUND AND PAIN / S. Ermurat - F. Kroon* - M. Kortekaas - M. Reijnierse - M. Kloppenburg

SAT0512 MRI PROVIDING INSIGHTS IN ASSOCIATION OF SYNOVITIS AND BONE MARROW LESIONS (BMLS) WITH PAIN IN THUMB BASE OSTEOARTHRITIS (OA) / F. Kroon* - S. van Beest - W. Damman - R. Liu - M. Reijnierse - M. Kloppenburg


SAT0516 INFLUENCE OF ETHNICITY ON CLINICAL PAIN IN PATIENTS WITH OSTEOARTHRITIS VERSUS RHEUMATOID ARTHRITIS: CONTRIBUTION OF LEVEL OF EDUCATION AND DEPRESSION / I. Castrejon* - J. Chua - J. A. Block - L. A. Bradley - Y. Yazici - N. Shakoor

SAT0517 FACTORS RELATED TO ANALGESIC USE IN PATIENTS WITH KNEE AND/OR HIP OSTEOARTHRITIS REFERRED TO AN OUTPATIENT CENTER: RESULTS FROM THE AMSTERDAM OSTEOARTHRITIS COHORT / J. Knoop* - J. van Tunen - M. van der Esch - L. D. Roorda - J. Dekker - M. van der Leeden - W. F. Lems


SAT0520 MARKED REDUCTION OF OSTEOARTHRITIS PAIN WITH A HYDROGEN SULFIDE-RELEASENING NAPROXEN DERIVATIVE / J. L. Wallace* - D. Vaughan


SAT0522 SEARCHING FOR THE OPTIMAL TIMING FOR PREVENTIVE WEIGHT REDUCTION STRATEGIES FOR KNEE OSTEOARTHRITIS DEVELOPMENT / J. Runhaar* - M. Landsmeer - M. van Middelkoop - S. M. Bierma-Zeinstra


SAT0525 THE EFFICACY OF PELOID THERAPY IN MANAGEMENT OF HAND OSTEOARTHRITIS / M. Aksoy Kasapoğlu - L. Altan* - R. Eröksüz - B. ÖkmenMetin

SAT0526 POSSIBILTY OF CARCILAGE REPAIR WITH PLATELET AUTOLOGOUS PLASMA (PAP) / L. V. Khimion* - O. A. Burianov - L. O. Smolina - H. Havryliuk - T. Omelchenko


SAT0530 Central sensitisation in hand osteoarthritis: the anterior cingulate cortex is involved in pain processing / M. Russell* - F. Howe - T. Barrick - N. Sofat

SAT0531 Matrix assisted laser desorption ionization imaging mass spectrometry applied to human osteoarthritic cartilage reveals the intra-tissue metabolic heterogeneity / M. Eveque-Mouroux* - P. Emans - T. Welting - A. Boonen - R. Heeren - B. Cillero-Pastor


SAT0534 Effect of sustained-release symptomatic drugs on progression of knee joint osteoarthritis in patients with less than 5 years disease duration in a 5-year prospective study / N. Kashevarova* - E. Taskina - L. Alekseeva


SAT0537 Influence of meloxicam in orodispersible form on platelet aggregation and von Willebrand factor in patients with osteoarthritis / O. S. Khmel* - V. V. Rodionova

SAT0538 Progression of pain, number of clinically swollen joints and ultrasound detected synovitis and osteophyte formation in patients with hand osteoarthritis over two years / O. Slegova* - O. Ruzickova - K. Pavelka - L. Senolt

SAT0539 Differential profile of endogenous peptides detected by targeted proteomics in hip and knee cartilage secretomes from osteoarthritis patients / P. Fernandez-Puente* - L. Gonzalez-Rodriguez - V. Calamia - L. Lourido - M. Carnacho - C. Ruiz-Romero - F. J. Blanco

SAT0540 The reduction in adrenergic and inflammatory serum markers in osteoarthritic patients after treatment with chondroitin sulfate/glucosamine hydrochloride and celecoxib is different according to the presence of bacterial DNA in blood / P. Zapater* - M. Herrero - H. Martinez - R. Francois - J. Vergés - J. F. Horga

SAT0541 Inhibiting AVB3 integrin and CD47 signaling ameliorates the progression of osteoarthritis / Q. Wang* - K. Onuma - R. Mao - H. Wong - W. H. Robinson

SAT0542 Subclinical crystal arthropathy might influence functional disability in patients with knee osteoarthritis? An Egyptian cross sectional study / R. A. Mohammed*

SAT0543 Clinical predictors and radiographic evidences of occult crystal deposition disease with knee osteoarthritis / R. H. A. Mohammed*


SAT0546 Total osteophyte score is a biomarker of current and persistent pain in knee osteoarthritis subjects / S. Feng* - M. C. Levesque

SAT0547 The influence of osteoarthritis on clinical, laboratory and ultrasonographic parameters of patients with early rheumatoid arthritis / T. Serban* - I. Satulu - O. Vultcanu - M. Milicescu - C. M. Mihai - M. Bojinca


SAT0549 Anti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis / V. Deshmukh* - C. Barroga - M. Ibanez - T. Seo - S. KC - Y. Yazici

SAT0550 Neurogenic pain among patients with primary knee osteoarthritis: results of a cross sectional study from a tertiary care centre in southern India / V. Narayan R* - M. M. Thabah - M. Poduval

SAT0551 Increased serum and synovial levels of midkine are associated with radiological progression in knee osteoarthritis patients / W. A. Hassan* - A. I. Mansour


SAT0553 Detection of serum level changes of matrix metalloproteinase-13 and inter leukin-1 beta during remission and flare-ups of primary osteoarthritis of the knees / Y. Hussein Gazar* - H. Bassioumi


SAT0555 MRI-detected knee osteoarthritis: natural history and structural risk factors affecting change / Z. Zhu* - W. Han - S. Zheng - T. Winzenberg - F. Cicuttini - C. Ding - G. Jones on behalf of Musculoskeletal Unit, Menzies Institute for Medical Research

* Presenting author
Infection-related rheumatic diseases


SAT0568  RHEUMATOLOGICAL MANIFESTATIONS IN A SERIES OF PATIENTS WITH CHIKUNGUNYA FEVER / A. M. Sapag Duran - A. M. Beron* - S. Sapag Duran - C. Coral Cristado - G. Medina - G. Nasswetter - D. Dubinsky


SAT0570  AN IGNORED DISEASE IN ADULTS: ACUTE RHEUMATIC FEVER / B. Bitik* - O. Kucuksahin - N. Karahan Yesil - H. Yesil - S. Ertan

SAT0571  PERFORMING SEPTIC ARTHRITIS DIAGNOSIS IN SCENARIOS WHERE SYNOVIAL FLUID IS NOT AVAILABLE: MULTIVARIATE LOGISTIC REGRESSION ANALYSIS / C. A. Guillen-Astete* - G. A. Gabilondo-Alvarez

SAT0572  LEVELS OF SERUM PROCALCITONINE AS DIAGNOSIS DISCERNING TOOL BETWEEN GOUT AND SEPTIC ARTHRITIS / C. A. Guillen-Astete* - M. Terán-Tinedo


SAT0577  MUSCULOSKELETAL MANIFESTATIONS OF TUBERCULOSIS: AN OBSERVATIONAL STUDY / N. Gupta* - A. Bhatnagar

SAT0578  LEFLUNOMIDE INHIBITS THE APOTOPSIS OF HUMAN EMBRYONIC LUNG FIBROBLASTS INFECTED BY HUMAN CYTOMEGALOVIRUS / Q. Ren* - H. Zeng

SAT0579  LOW DOSE IL-2 RESTORES IMBALANCE BETWEEN TH17 AND REGULATORY T CELLS IN PATIENTS WITH CONNECTIVE DISEASE COMBINED EBV/CMV VIREMIA / G. Wang* - C. Wang

SAT0580  OSTEARTICULAR TUBERCULOSIS: A RETROSPECTIVE STUDY OF 119 CASES / R. Sonia* - S. Boussaid - I. Abdelkafi - S. Hela - C. Ilhem - E. Mohamed* Presenting author

17 June 2017
Non-tuberculous mycobacterial (NTM) infection in patients with rheumatic diseases: possible importance of pulmonary barrier function rather than systemic immune state in the development and exacerbation of NTM infection / S. Takenaka - H. Kameda - T. Ogura - H. Oshima - K. Izuami - A. Hirata - H. Itó - Y. Fujisawa on behalf of Department of Connective Tissue Diseases, National Tokyo Medical Center


Back pain, mechanical musculoskeletal problems, local soft tissue disorders


The role of MRI interpretation in patients with rotator cuff disease / S. Albina - A.-M. Ramazan* - E. V. Ionescu - M. G. Iliescu

Is it safe to perform joint punctures in patients treated with dabigatran? / C. A. Guillen-Astete - J. R. Quíñones-Torres

Relationship between core stabilization and low back pain in young people / E. Mete* - V. Akduman - I. Demirbuken - G. Ogren

School bags weight is not more at risk to low back pain than other occupations / F. Kemta Lekpa - M. S. Doualla - H. Namme Luma

Healthcare workers are not at more risk to low back pain than other occupations / F. Kemta Lekpa - M. S. Doualla - H. B. Ngaiane Mbatchou - A. S. Mkoh - H. Namme Luma


Local steroid injection versus wrist splinting for carpal tunnel syndrome: a randomized clinical trial / H. Soo - V. Chung - J. Cheng - M. L. Yip


The effect of radial extracorporeal shock wave therapy (RESWT) in the treatment of trigger finger / M. Dogru - S. Narin* - M. Erduran


Efficacy of epidural steroid injection in lumbar spinal stenosis is not related to the degree of severity by MRI / E. S. Elsayad - M. A. Mortada* - T. Abd El Samad Elhawala - E. S. A. Abd El Hady - A. Hijab

Relationship between lumbar disc herniation and benign joint hypermobility syndrome / M. R. Albeer - F. K. Abd Alrazaq - M. H. Alosami*


Low back pain in medical students linked to poor sleep quality: results from the PAX-I study / N. R. Ziade* - F. Fayad - B. Badra


Treatment of carpal tunnel syndrome (CTS) with ESWT: a sham controlled double blinded randomized study / O. Karatay* - S. Catal - E. A. Gökmem - N. Samanci


An innovative treatment modality for acute ilio-tibial band syndrome in runners: local hyaluronate + botulinum toxin in a prospective cohort of 45 athletes / R. Petrella* - A. Decruze - J. Darcia

Autoologous blood and corticosteroid local injection in treatment of plantar fasciitis (randomized, controlled multicenter clinical trial) / A. Karimzadeh - S. A. Raeissadat* - S. Erfani Fam - L. sedighipour

Local progesterone injection: new option for management of carpal tunnel syndrome / S. A. Raeissadat - L. Sedighipour - S. Shahraeeni*
SAT0609
GIANT CELL ARTERITIS: AHEROSCLEROSIS AS PITFALL IN THE HALO SIGN / E. De Miguel* - L. M. Beltran - F. Deodati - I. Monjo - W. A. Schmidt - J. Garcia-Puig

SAT0610
TEMPORAL ARTERY ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A COHORT WITH ELEVATED CLINICAL IMPRESSION / P. V. Estrada* - D. Reina - V. Navarro - D. Roig - D. Cerdà - V. Torrente - S. Heredia - H. Corominas

SAT0611
INTIMA-MEDIA THICKNESS REFERENCE RANGES DEPICTING HALO SIGN FOR THE DIAGNOSING OF LARGE VESSEL GIANT CELL ARTERITIS BY ULTRASOUND / M. Milchert* - M. Brzosko

SAT0612
THE USE OF 18F-FDG-PET IN THE DIAGNOSIS OF POLYMYALGIA RHEUMATICA (PMR) - A PROSPECTIVE STUDY OF 99 PATIENTS SUSPECTED OF PMR / L. Henckaerts - O. Gheysens - S. Vanderschueren - K. Goffin - D. Blockmans*

SAT0613

SAT0614

SAT0615

SAT0616

SAT0617

SAT0618
DISTURBANCES OF THE ACRAL PERFUSION DETECTED BY FLUORESCENCE OPTICAL IMAGING ARE ASSOCIATED WITH THE DEVELOPMENT OF ISCHEMIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. Lüders* - S. Friedrich - S. Ohndorf - S. Werner - G.-R. Burmester - G. Riemekasten - M. Backhaus

SAT0619
ANKLE EVALUATION IN ACTIVE RHEUMATOID ARTHRITIS BY ULTRASOUND: A CROSS SECTIONAL STUDY / A. M. Elsaman* - E. S. Mostafa - A. R. Radwan

SAT0620
POTENTIAL ROLE OF METACARPOPHALANGEAL JOINTS ULTRASOUND IN THE DIFFERENTIAL DIAGNOSIS BETWEEN EARLY RHEUMATOID ARTHRITIS AND EARLY SPONDYLOARHTITIS / A. Batticciotto* - G. Prato - M. Antivalle - M. C. Ditto - M. C. Gerardi - R. Talotta - F. Atzeni - P. Sarzi-Puttini

SAT0621

SAT0622

SAT0623

SAT0624

SAT0625

SAT0626

SAT0627

SAT0628

SAT0629

SAT0630
EXTRA-ARTICULAR MUSCULOSKELETAL INVOLVEMENT IN JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL AND ULTRASONOGRAPHIC FINDINGS / V. Ravagnani - F. Licciardi* - D. Montin - F. Santarelli - S. Martino - C. Cirone

* Presenting author

Diagnostics and imaging procedures


SAT0634 MUSCULOSKELETAL ULTRASOUND IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM POST-CHIKUNGUNYA / I. Monjo Henry* - F. De la Calle - E. Trigo - E. Fernandez - D. Benavent - E. De Miguel - A. Balsa


SAT0640 DIAGNOSTIC UTILITY OF DETECTING ENTHESITIS BY ULTRASOUND IN PERIPHERAL SPONDYLOARTHRITIS / K. Fujikawa* - Y. Endo - A. Mizokami - M. Mine - A. Kawai-ami

SAT0641 THE DIAGNOSTICS OF OSTEOPOROSIS IN MALE REUMATOID PATIENTS / K. Aminov*


SAT0643 VALUE OF POWER DOPPLER ULTRASONOGRAPHY FOR PREDICTION OF TREATMENT FOR RHEUMATOID ARTHRITIS (RA) IN EARLY ARTHRITIS DURING THE FIRST 12 MONTHS OF FOLLOW-UP / L. Mayordomo* - M. L. Vellos - C. Jurado - P. González-Moreno - C. Gomez-Canó - J. L. Marenco - C. Almeida

SAT0644 IS ANKLE INVOLVEMENT IMPORTANT IN RHEUMATOID ARTHRITIS? / L. Enache* - M. Parvu - C. Popescu - E. M. Vital

SAT0645 MAGNETIC RESONANCE IMAGING AND HISTOPATHOLOGICAL CORRELATION IN DERMATOMYOSITIS / M. V. Collado* - J. C. Milisenda - X. Tomás - A. I. García - M. Faruch - J. M. Grau on behalf of Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona, Universidad de Barcelona and CIBERER


SAT0648 ULTRASONOGRAPHY FINDINGS IN SYMPTOMATIC AND ASYMPTOMATIC JOINTS IN PATIENTS WITH GOUT / M. M. Basaric* - G. Radunovic - N. Damjanov - M. Radak Perovic


SAT0651 QUANTIFICATION OF DYNAMIC MRI EXAMINATIONS IN JUVENILE IDIOPATHIC ARTHRITIS / N. Tzairbachev* - R. Hagou - P. Louka - J. Islam - M. Hinton - O. Kubassova - M. Boesen


* Presenting author
**Epidemiology, risk factors for disease or disease progression**

**SAT0654**

**SAT0655**

**SAT0656**

**SAT0657**

**SAT0658**

**SAT0659**
Comparison between eight different ultrasonographic scores for hand assessment in rheumatoid arthritis - a cross-sectional study / S. Hussain* - P. Sivakumaran - L. Attipoe - C. Curtin

**SAT0660**

**SAT0661**

**SAT0662**

**SAT0663**
Two-step algorithm for early diagnosis of osteoarthritis based on plasma damaged amino acids provides simple and low cost screening test / N. Rabbani - U. Ahmed* - P. J. Thornalley

**SAT0664**

**SAT0665**
Does patients' opinion of remission in rheumatoid arthritis overlap us "true" remission? / V. Vlad* - F. Bergeha - M. Popescu - V. Iorgoveanu - D. Predateanu - R. Ionescu

**SAT0666**

**SAT0667**
Presepsin and procalcitonin are of diagnostic value for bacterial infection in patients with connective tissue diseases / Y. Ichimura* - Y. Kawaguchi - A. Tochimoto - T. Higuchi - M. Tochihara - Y. Katsumata - H. Yamanaka

**SAT0668**
Assessment of intracranial vessels and vascular lesions in rheumatoid arthritis. A detailed study / Y. Katsumata - H. Yamanaka

**SAT0669**

**SAT0670**

**SAT0671**
The impact of obesity on treat to target goals and functional ability in the ERAS/ERAN UK prospective cohorts / E. Nikiphorou* - S. Norton - P. Kiely - A. Young on behalf of ERAS/ERAN group

**SAT0672**

**SAT0673**

**SAT0674**
Early treatment response to conventional DMARD therapy in rheumatoid arthritis is a better predictor of low disease activity or treatment escalation at 12 and 24 months than autoantibodies or erosions / A. Richter - A. Strangfeld* - P. Herzer - J. Kaufmann - T. Klopsch - S. Zinke - J. Listing - A. Zink

**SAT0675**

**SAT0676**

**SAT0677**

* Presenting author
SAT0678  SIGNIFICANTLY INCREASED SEROPositivity: rheumAtoid factor titres and rheumAtoid nODULES in cornish kaolin workers / d. murphy* - e. plowman - k. bellis - d. hutchinson

SAT0679  ARE ADULT TRAJECTORIES OF WEIGHT OVER A LIFE TIMe LINKED TO FOOT problems years later? / A. B. Dufour* - E. Losina - H. B. Merz - M. P. LaValley - M. T. Hannan

SAT0680  THE IMPACT OF DISEASE ACTIVITY DURING PREGNANCY IN women with SLE ON THE BIRTH weight of the ChILd / A. C. G. Skorpen* - S. Lydersen - I.-M. Gilboe - K. A. Salvesen - M. Wallenius


SAT0683  PREVALENCE OF OSTEOPOROSIS IN ALBANIAN POSTMENOPAUSAL women and the role of risk factors in osteopORosIs / A. Kollaku* - J. Kollaku - V. Duraj


SAT0689  PREVALENCE OF and temporal trends in hyperuricAemia among adult patients with chronic kidney disease in ireland / F. Adeeb* - A. A. Udayakumar - D. Ryan - X. Li - A. D. Fraser - A. G. Stack on behalf of health Research Institute, University of Limerick

SAT0690  RISK OF HOSPITALIZED INFECTION in CANCER patients with autoIMMUNE diseases: a sinGle-CenTer cohOrt study / H.-H. Chen* - D.-Y. Chen


SAT0692  PREDICTORS AND PERSISTENCE OF UNACCEPTABLE PAIN DURING THE FIRST YEAR of rheumAtoid arthritis in Sweden / H. Westerlind - M. E. Schelin - R. Altawil - L. Klareskog - L. Alfredsson - J. Lampa*

SAT0693  SERUM uric ACId levels and hormone replacement therapy type: a retrospective case-control study of postmenopausal women / j. H. Jung* - j.-H. Kim - Y. H. Lee - G. G. Song - S. J. Choi

SAT0694  subgroupING of early ra-patients identified cluster of patients with high levels of pain, fatigue and psychosocial distress 3 years after diagnosis / j. Lindqvist* - H. Westerlind - L. Klareskog - L. Alfredsson - J. Lampa

SAT0695  no association between vitamin d levels and cardiovascular diseases in inflammatory joint diseases and systemic autoimmune diseases - a systematic review / j. E. S. Ling* - M. Ter Wee - W. Lems - M. Nummohamed - H. Raterman

SAT0696  endotheLial nitric oxide SYNthase t-786c gene promoter polymorphisM is a potenTial predictor of low response to therapy in patients with rheumAtoid arthritis, ukraiNe populAtion / K. zaichko* - M. Stasiulavicius - I. Shapoval


SAT0698  disease activity during and after pregnancy in women with axial Spondyloarthritis / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius


SAT0702  local and systemic inflammation in patients with early rheumAtoid arthritis with Chlamydia trachomatis infection / M. Natalia* - K. Svettiana


* Presenting author


SAT0707 EFFICACY AND SAFETY OF PROPYLTHIOURACIL TREATMENT ON ACTIVATION OF LATENT TUBERCULOSIS DURING GLUCOCORTICOID THERAPY IN PATIENTS WITH RHEUMATIC DISEASES / R. Wu


SAT0710 RENAL FUNCTION CONTRIBUTE TO RISK OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS / S. Ahmed - S. A. Haq - A. Z. Al-qadir - M. M. Rahman - S. Paul

SAT0711 CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH ADVANCED MALIGNANCIES AND PREEXISTING RHEUMATOMIC DISEASE: THE MAYO CLINIC EXPERIENCE / U. Thanarajasingam* - O. Pinkston - L. Kottschade - H. Firmes - S. Markovic

SAT0712 SELF-REPORTED SEDENTARY BEHAVIOUR IS ADVERSELY ASSOCIATED WITH MICROSULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. A. M. Fenton* - J. J. Veldhuijen van Zanten - A. Sandoo - J. L. Duda - G. S. Metsios - G. D. Kitsa


SAT0715 CLINICAL SIGNIFICANCE OF FIBROMYALGIA SYNDROME IN DIFFERENT RHEUMATIC DISEASES: RELATION TO DISEASE ACTIVITY AND QUALITY OF LIFE / T. A. Gheita* - S. M. El-Rabat & N. K. Mahmoud

SAT0716 A FIRST TIME HOSPITAL ADMISSION FOR COMORBID CONDITIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS MORE FREQUENTLY DUE TO CARDIOVASCULAR AND RENAL COMPLICATIONS THAN IN CONTROLS AND SUBSEQUENTLY INCREASES THE RISK FOR DEATH / W. D. Raymond* - D. Preen - C. Inderjeeth - H. Keen - J. Nossent

HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

SAT0717-HPR PREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHHRITIS / A. Zbinden - S. van den Brandt - P. M. Villiger - M. Østensen

HPR: Measuring health (development and measurement properties of PROs, tests, devices)


HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)


HPR: Service developments, innovation and economics in healthcare


HPR: Epidemiology and public health (including prevention)

SAT0721-HPR EXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY / A. K. Hedström - L. Klareskog


* Presenting author
HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

SAT0723-HPR  GENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS - A NATIONWIDE CROSS-SECTIONAL STUDY / B. A. Estbensen* - C. Flurey - K. V. Jensen - L. Andersen - N. M. Hammer

SAT0724-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. PATIENTS’ EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS / U. Bergsten* - A.-S. Sjö

HPR: Interventions (educational, physical, social and psychological)

SAT0725-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY / U. Bergsten* - K. Almehed - L. Jacobsson

HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

SAT0726-HPR  FUNCTIONAL IMPAIRMENT IN PATIENTS WITH RA IN AN EIGHT YEAR PERSPECTIVE / A. Bremlander* - K. Forslind - K. Eberhardt - M. Andersson


SAT0729-HPR  PSYCHOLOGICAL PROFILE OF PATIENTS WITH FIBROMYALGIA SYNDROME / D. Xhaxho* - J. Lauri - M. A. Lauri - J. Fleri Soler - A. Borg - C. Mercieca


SAT0731-HPR  SYMPTOMS OF PAIN, FATIGUE AND SELF-EFFICACY IN YOUNG PATIENTS WITH SPONDYLOARTHITIS - A COMPARISON BETWEEN WOMEN AND MEN / A. Torell - A. Bremlander - S. Bergman - E. Haglund

SAT0732-HPR  RESILIENCE AND POSITIVE AFFECT ARE RELATED TO THE EXPERIENCE OF FATIGUE IN PATIENTS WITH A RHEUMATIC DISEASE / E. Taal* - K. Schreurs - L. Guddeff - C. Bode - M. van de Laar

SAT0733-HPR  A QUALITATIVE STUDY ON OBSTACLES AND MOTIVATIONS TO VACCINATIONS IN RHEUMATOID ARTHRITIS / F. Fayet* - C. Savel - M. Rodere - M. Soubrier - S. Mathieu


SAT0736-HPR  "LIKE A BAG OF LIQUORICE ALLSORTS - EVERYBODY’S GOT DIFFERENT FLAVOURS": A QUALITATIVE FOCUS GROUP STUDY TO EXPLORE SYMPTOMS OF FATIGUE, SLEEP DISTURBANCES AND PAIN IN PRIMARY SJÖGREN’S SYNDROME PATIENTS AND TO DEVELOP A FUTURE MODEL OF CARE / K. L. Hackett* - V. Deary - K. Deane - J. L. Newton - W.-F. Ng - T. Rapley


SAT0738-HPR  EXPERIENCES OF TELE-HEALTH FOLLOW-UP IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE INTERVIEW STUDY / L. R. Knudsen* - A. de Thura - K. Lomberg


SAT0740-HPR  SIGNIFICANT OTHERS AS BOTH BARRIERS AND FACILITATORS FOR PARTICIPATION IN DAILY ACTIVITIES IN PERSONS WITH EARLY RHEUMATOID ARTHRITIS - AN INTERVIEW STUDY WITHIN THE SWEDISH TIRA PROJECT / M. Bergström - A. Sverker - Å. Larsson Ranada - E. Valtersson - G. Östlund - M. Björk


SAT0742-HPR  THE EFFECT OF A NEOPRENE KNEE SLEEVES ON KNEE JOINT PROPRIOCEPTION IN PATIENTS WITH TOTAL KNEE PROSTHESIS / M. Eymir* - S. Narin - V. Karatosun

SAT0743-HPR  RISK FACTORS FOR FEAR OF FALLING IN PATIENTS WITH KNEE OSTEOARTHRITIS LIVING IN THE COMMUNITY / M. Karapinar* - A. Abd Kocaman - N. Kirdi

SAT0744-HPR  THE USE OF HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) IN GIVING A PICTURE OF PATIENT EVERYDAY LIFE WITH RHEUMATOID ARTHRITIS / P. Toftegaard* - I. M. J. Hansen

SAT0745-HPR  IMPACT OF AN INTERDISCIPLINARY INTERVENTION ON RA PATIENTS / I. Fortin - H. Sylvain - F. Banville - B. Lovisi - S. V. Rochefort*

SAT0746-HPR  TOWARDS MEASUREMENT OF PERSON-CENTERED CARE OUTCOMES IN OUTPATIENT NURSE-LED CLINICS / V. Bala - B. Fridlund - K. Forslind - B. Svensson - P. Hagell


* Presenting author

SAT0749-HPR  THE RELATIONSHIP BETWEEN SPINAL MOBILITY AND STATIC AND DYNAMIC BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS / B. Unver* - H. Yilmaz - F. Unver


SAT0752-HPR  THE MEASUREMENT OF PATIENTS' EXPECTATIONS OF A MULTIDISCIPLINARY AND DEDICATED FIBROMYALGIA PROGRAM / D. Xhaxho* - A. A. Borg - C. Mercieca

SAT0753-HPR  AWARENESS OF POSSIBLE SIDE EFFECTS OF NSAIDS AMONG THE ALBANIAN PATIENT POPULATION / E. Pistja* - A. Themeli

SAT0754-HPR  "A NECESSARY INVESTMENT IN FUTURE HEALTH": PERCEPTIONS OF PHYSICAL ACTIVITY MAINTENANCE AMONG PEOPLE WITH RA PARTICIPATING IN AN OUTSOURCED HEALTH-ENHANCING PHYSICAL ACTIVITY PROGRAM / E. Swärd* - B. Nordgren - C. H. Opava - I. Demmelmaier

SAT0755-HPR  VARIATION IN SLE-RELATED PAIN: A SEVEN YEAR FOLLOW-UP STUDY / E. Waldheim* - S. Ajeganova - S. Bergman - J. Frostegård - E. Welin Henriksson

SAT0756-HPR  DEPRESSION BUT NOT CORE SYMPTOMS PREDICT CAREGIVER STRAIN IN ADULTS SHARING A HOME WITH PRIMARY SJÖGREN'S SYNDROME PATIENTS / K. Hackett* - D. Lendrem - V. Ripley - V. Deary - K. Deane - J. Newton - W. Ng

SAT0760-HPR  FUNCTIONAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE BACKGROUND CORRECTION OF PROGESTERONE INSUFFICIENCY / M. Salokhiddinov* - M. A. Rongen - A. Fernandez-Nebro


SAT0762-HPR  THE ACCESSIBILITY AND USABILITY OF AN AUSTRALIAN WEB-BASED SELF-MANAGEMENT PROGRAMME FOR PEOPLE WITH LOWER HEALTH LITERACY AND JOINT PAIN IN THE UK / L. B. Parsons* - J. Adams

SAT0763-HPR  PHYSICAL ACTIVITY MAINTENANCE AND DIGITAL HEALTH INTERVENTIONS IN PEOPLE WITH RHEUMATOID ARTHRITIS: PATIENT AND HEALTHCARE PROFESSIONALS' PERSPECTIVES / R. Simmons* - H. Lempp - J. Galloway - L. Bearne

SAT0764-HPR  SUBJECTIVE COGNITIVE DYSFUNCTION AND COMPUTERIZED NEUROPSYCHOLOGICAL PERFORMANCE IN KOREAN ADULTS WITH RHEUMATOID ARTHRITIS / S. Y. Shin* - J. H. Lee - B. Yoon


WEDNESDAY, 14 JUNE 2017

13:30 - 14:30  N101/N102

Health Professionals session
Health Professionals Welcome session

Learning objectives:
To gain a historic perspective on the development of the role of health professionals in rheumatology and an understanding of future possibilities and challenges

Chairperson(s):
Christina H. Opava (Sweden)
Milena Gobbo Montoya (Spain)
Thea Vliet Vlieland (Netherlands)

Thea Vliet Vlieland (Netherlands) 13:35
Abstract N° SP0005
Looking back at 70 years of EULAR and 30 years of HP involvement: a rehabilitation perspective

Jackie Hill (United Kingdom) 13:50
Abstract N° SP0006
Looking back at 70 years of EULAR and 30 years of HP involvement: a nursing perspective

Johannes W. J. Bijlsma (Netherlands) 14:05
Abstract N° SP0007
70 years past and a view of the future

Annette de Thurah (Denmark) 14:15
Abstract N° SP0008
The future for HPs in rheumatology

14:30 - 15:00  N101/N102

Exhibition (Hall 10)

Break

15:00 - 16:30  N115/N116

Joint session Clinical/HPR/PARE
EULAR Campaign: Don’t Delay, Connect Today

Learning objectives:
• To experience how access to early diagnosis is enabled
• To learn how tight control optimises therapies targeting remission
• To understand what markers signify illness progression
• To comprehend how lifestyle factors (smoking, obesity, alcohol, inactivity) influence the progression of rheumatic diseases

Chairperson(s):
Gerd R. Burmester (Germany)
Ailsa Bosworth (United Kingdom)
Andreas Schwarting (Germany)

15:00 - 16:30  N101/N102

Health Professionals session
Wearable technologies in 21st century healthcare

Learning objectives:
To understand the current state-of-the-art in wearables and the applications and implications of wearables in clinical practice and research

Chairperson(s):
Thijs Swinnen (Belgium)
Jette Primdahl (Denmark)

Alex Clarke-Cornwell (United Kingdom) 15:05
Abstract N° SP0023
Review of wearable technologies - the state of the art

Marie McCarthy (Ireland) 15:23
Abstract N° SP0024
Wearable technologies in research and clinical trials

Alma Leora Culén (Norway) 15:41
Ethics and politics of the use and the design of technology in health care

Mitchell Silva (Belgium) 15:59
Patients’ perspective on wearables

D. Bayraktar (Turkey) 16:17
S. Savci, O. Altug-Gucenmez, E. Manci, B. Makay, N. Ilcin, S. E. Unsal
Abstract N° OP0009-HPR
The effect of an 8-week water exercise program on anaerobic exercise capacity in children with juvenile idiopathic arthritis
Health Professionals session

Rehabilitation and modern drug treatment - needs and challenges

Learning objectives:
• To identify current rehabilitation needs in patients with RMDs
• To describe challenges and experiences with rehabilitation complementing modern pharmacological treatment
• To gain insight into how and why physical activity and work rehabilitation are important cornerstones of rehabilitation

Chairperson(s):
Norelee Kennedy (Ireland)
Hana Smucrova (Czech Republic)

Mathilda Björk (Sweden) 17:05
Abstract N° SP0041
Current needs for rehabilitation

Florin Catrina (Romania) 17:23
Abstract N° SP0042
The art of juggling - a patient’s perspective

Nina Brodin (Sweden) 17:41
Physical activity: subjective and objective outcome

Yeliz Prior (United Kingdom) 17:59
Abstract N° SP0043
Work retention rehabilitation in practice

B. A. Esbensen (Denmark) 18:17
N. M. Hammer, C. Flurey, K. V. Jensen, L. Andersen
Abstract N° OP0055-HPR
Preferences for self-management and support services in patients with inflammatory arthritis: a Danish nationwide cross-sectional study

17:00 - 18:30 N101/N102

18:45 - 20:00 Hall 6

EULAR 2017 Opening Plenary session

20:00 - 22:00 Esplanade (Hall 6)
Networking Platform

THURSDAY, 15 JUNE 2017

10:15 - 11:45 N101/N102

HPR Abstract session

Mind over matter - patients perspectives

Chairperson(s):
Yeliz Prior (United Kingdom)
Andrea Domjan (Hungary)

E. M. Selten (Netherlands) 10:20

Abstract N° OP0138-HPR
Do patients’ treatment beliefs affect treatment choices in knee and hip osteoarthritis?

S. Hewlett (United Kingdom) 10:30

Abstract N° OP0139-HPR
Reducing arthritis fatigue - clinical teams (RAFT) using cognitive-behavioural approaches: an RCT

N. Nealon Lennox (Ireland) 10:40

S. O'Neill, A. Hannigan

Abstract N° OP0140-HPR
Acceptance and commitment therapy: a retrospective study of outcomes from a hospital-based, group, pain rehabilitation programme in rheumatology services in the South East of Ireland

W. Peter (Netherlands) 10:50

Abstract N° OP0141-HPR
An innovate measurement instrument to assess activity limitations in hip and knee osteoarthritis: the computerized animated activity questionnaire (AAQ) and its psychometric properties

R. Geenen (Netherlands) 11:00

N. Cameron, M. B. Kool, F. Estévez-López, I. López-Chicheri

Abstract N° OP0142-HPR
The potential buffering role of self-efficacy and pain acceptance against invalidation in rheumatic diseases
M. Björk (Sweden) 11:10
I. Thyberg, E. Valtersson, G. Östlund, B. Stenström, A. Sverker
Abstract N° OP0143-HPR
Disability in the feet related to participation in daily life in patients with early RA - an interview study in the Swedish TIRA project

M. Henriques (Portugal) 11:20
C. Duarte, M. Ndosi, A. Marques, J. A. P. da Silva, R. J. O. Ferreira
Abstract N° OP0144-HPR
“It can’t be zero”: a qualitative study of patients’ perspective on patient global assessment in rheumatoid arthritis

E. Mathijssen (Netherlands) 11:30
J. Vriezekolk, A. Eijsbouts, B. van den Bemt
Abstract N° OP0145-HPR
Rheumatoid arthritis patients’ support needs regarding medication use and their perspectives on the applicability of eHealth interventions to address those needs: a focus group study

11:45 - 13:30 Exhibition (Hall 10)
Poster viewing & lunch

11:50 - 13:30 Poster area (Hall 10)
Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour.
For full details regarding the guided poster tour on Thursday please refer to page 201.

Poster tour HPR
T15: From top to toe; health professional practice
Chairperson(s): Rikke H. Moe (Norway)
Branka Rimac (Croatia)
Abstracts N° THU0750-HPR - THU0759-HPR

13:30 - 15:00 N101/N102
Joint session HPR/PARE/Paediatric Rheumatology
To be and to become: transition from paediatric to adult care
Learning objectives:
• To understand the patient perspective
• To learn about the scientific evidence and comprehend the clinical implementation of the transition process
Chairperson(s):
Tadej Avcin (Slovenia)
Erik Taal (Netherlands)

Wendy Olserde (Netherlands) 13:35
Abstract N° SP0064
To be and to become: reflections on my transition

Kirsten Minden (Germany) 13:53
Abstract N° SP0065
Are we asking the right questions in transition research?

Line Raunsbaek - Knudsen (Denmark) 14:11
Abstract N° SP0066
Implementation of a brief transition programme for adolescents with juvenile idiopathic arthritis

Janjaap van der Net (Netherlands) 14:29
Growing into a healthy lifestyle

I. Pontikaki (Italy) 14:47
L. M. Argolini, C. Artusi, P. L. Meroni
Abstract N° OP0195
What is the impact of juvenile idiopathic arthritis in adulthood? The monocentric experience of 240 patients followed in a transition tertiary clinic of rheumatology

15:00 - 15:30 Exhibition (Hall 10)
Coffee break

15:30 - 17:00 N101/N102
Health Professionals session
What to do about comorbidity?
Learning objectives:
To obtain knowledge on impact of comorbidity on individuals and society, and on treatment approaches and their outcome
Chairperson(s):
Rikke H. Moe (Norway)
Joost Dekker (Netherlands)

Arja H. Häkkinen (Finland) 15:35
Abstract N° SP0088
New drugs, but still comorbidity

Martin Neovius (Sweden) 15:53
Costs of comorbidity

Hanne Dagfinrud (Norway) 16:11
Abstract N° SP0089
How to prevent and treat cardiovascular comorbidity with exercise?

Mariette de Rooij (Netherlands) 16:29
Abstract N° SP0090
Comorbidity-adapted exercise for patients with knee osteoarthritis

M. A. Martin Martinez (Spain) 16:47
Abstract N° OP0209-HPR
Incidence of first cardiovascular event in Spanish patients with chronic inflammatory rheumatic diseases: prospective data from the CARMA project
10:15 - 11:45  N101/N102

Abstract session HPR

Move to improve

Chairperson(s):
Peter Oesch (Switzerland)
Francoise Alliot (France)
K. Ellegaard (Denmark)

C. von Bülow, A. Repke, C. Bartholdy, I. S. Hansen, S. Rifbjerg, R. Christensen, M. Henriksen, E. Waehrens

Abstract N° OP0254-HPR
Hand exercise for women with rheumatoid arthritis and decreased ADL ability: an exploratory randomised controlled trial

G. Berdal (Norway)


Abstract N° OP0255-HPR
An add-on programme improved the short-term, but not the long-term effect of rehabilitation in patients with rheumatic diseases: results from a pragmatic multi-centre stepped-wedge cluster randomized controlled trial

C. Boström (Sweden)

F. Russ, F. Eriksson, S. Pettersson, I. Gunnarsson, E. Svenungsson

Abstract N° OP0256-HPR
Physical activity and inactivity in patients with systemic lupus erythematosus

L. Villarreal (Colombia)

S. Henao, D. Buitrago-Garcia, P. Santos-Moreno

Abstract N° OP0257-HPR
Relationship between sleep disorders and disease activity in patients with rheumatoid arthritis

E. Lange (Sweden)

D. Kucharski, K. Svensson, S. Svedlund, I. Gjertsson, K. Mannerkorpi

Abstract N° OP0258-HPR
Intensive physical exercise for elderly persons with rheumatoid arthritis improves physical capacity

S. T. Miyamoto (Brazil)


Abstract N° OP0259-HPR
Supervised walking improves aerobic capacity, exercise tolerance, fatigue and perceived improvement in women with primary Sjögren’s syndrome: a randomized controlled trial

K. Mannerkorpi (Sweden) 11:20

A. Larsson, A. Palstam, M. Ernberg, B. Gerdle, E. Kosek

Abstract N° OP0260-HPR
Higher satisfaction with activity-related symptoms after 15-week resistance exercise in women with fibromyalgia

K. Risum (Norway) 11:30

A. M. Selvaag, B. Molberg, H. Dagfinrud, H. Sanner

Abstract N° OP0261-HPR
Physical activity level measured by accelerometer is comparable between juvenile idiopathic arthritis patients and controls, but patients spend less time in vigorous physical activity

11:45 - 13:30  Exhibition (Hall 10)

Poster viewing & lunch

13:30 - 15:00  N101/N102

Health Professionals session

Fighting osteoporosis fragilities

Learning objectives:
To get an overview of:
• osteoporosis and osteoporotic fracture socio-economic impact
• non-pharmacological prevention strategies
• future perspectives

Chairperson(s):
Ricardo Ferreira (Portugal)
Jo Adams (United Kingdom)
John Kanis (United Kingdom)

Sonya M. Stephenson (United Kingdom) 13:53

Abstract N° SP0118
Establishing and implementing fracture liaison services

Andrea Marques (Portugal) 14:11

Abstract N° SP0119
Predicting fracture risk: accuracy and feasibility of tools

Debra J. Rose (United States) 14:29

Abstract N° SP0120
Predicting the risk of falls and promoting balance in older adults

K. Niedermann (Switzerland) 14:47

B. Zindel, A. Meichtry, V. Krafft

Abstract N° OP0314-HPR
A home-based fall prevention programme reduces fear of falling in seniors

15:00 - 15:30  Exhibition (Hall 10)

Coffee break
HEALTH PROFESSIONALS / FRIDAY 16 JUNE AND SATURDAY 17 JUNE 2017 / 199

15:30 - 17:00  N101/N102

Health Professionals session

Patient engagement in research: best practices, benefits, and challenges

Learning objectives:
• To describe best practices for engaging patients in research at different levels during research and how the engagement plans match expectations of the funding agencies
• To demonstrate the benefits and challenges for researchers and patient research partners

Chairperson(s):
Elizabeth A. Schlenk (United States)
Thea Vliet Vlieland (Netherlands)
Maarten de Wit (Netherlands)

Abstract N° SP0138
The challenges of patient involvement in scientific research

Antony Redmond (United Kingdom)

Abstract N° SP0139
Meaningful patient and public involvement in planning research

Janet L. Poole (United States)

Abstract N° SP0140
Patient engagement in research: a PCORI exemplar

K. Cresswell (United Kingdom)

S. Parsons, S. Stones, J. E. McDonagh,
W. Thomson, L. Lunt

Abstract N° OP0327-PARE
Your Rheum - giving young people a voice in rheumatology research

Chairperson(s):
Joke Vriezefolok (Netherlands)

Abstract N° SP0163
Interventions to improve medication adherence in patients with inflammatory arthritis

Katerina Koutsogianni (Greece)

Abstract N° SP0164
Barriers and facilitators to adherence to medication in patients with inflammatory arthritis

Kanta Kumar (United Kingdom)

Abstract N° SP0165
Can musculoskeletal ultrasound inform health beliefs and play a role for medication adherence?

V. Ahluwalia (Canada)

Abstract N° OP0337-HPR
Predictors of patient reported decision to discontinue anti-rheumatic medication in rheumatoid arthritis patients: data from a rheumatoid arthritis cohort

10:15 - 11:45  Exhibition (Hall 10)
Poster viewing & coffee break

10:20 - 11:45  Poster area (Hall 10)

Guided Poster tours

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour.

For full details regarding the guided poster tour on Saturday please refer to page 161.

Poster tour HPR

S14: Nursing and daily practice

Chairperson(s):
Annette de Thurah (Denmark),
Jenny de la Torre-Aboke (Spain)

Abstracts N° SAT0717-HPR - SAT0725-HPR

12:00 - 13:30  N101/N102

Health Professionals session

Closing the gap between objective measures and self-report in fibromyalgia

Learning objectives:
To understand the factors associated with the discrepancy between subjective and objective measurements in fibromyalgia

Chairperson(s):
Rinie Geenen (Netherlands)
Milena Gobbo Montoya (Spain)
**Marius Henriksen (Denmark)** 12:05  
Abstract N° SP0185  
Divergences between objective and self-reported physical function in fibromyalgia

**Brian Walitt (United States)** 12:23  
Abstract N° SP0186  
Cognitive fog: subjective and objective understandings of the symptom of dyscognition

**Fernando Estévez-López (Spain)** 12:41  
Abstract N° SP0187  
Pain catastrophizing and self-efficacy in women with fibromyalgia: the al-Ándalus project

**Louise Piggott (United Kingdom)** 12:59  
Abstract N° SP0188  
Self-management of fibromyalgia from a patient perspective

**V. Vervoort (Netherlands)** 13:17  
Abstract N° OP0344-HPR  
Development of responder criteria for multicomponent non-pharmacological treatment in fibromyalgia

---

**12:00 - 13:30 N115/N116**

**Joint session PARE/HPR**

**Suffering in silence. Optimizing the management of psychological well-being for people with RMDs**

**Learning objectives:**
- To gain insights of the extend and features of psychological impact of RMDs on daily life from different angles
- To learn how health professionals and patients can help to break the vicious circle of suffering in silence

**Chairperson(s):**  
Souzi Makri (Belgium)  
Heidi A. Zangi (Norway)  
Emma Dures (United Kingdom)

**Emma Dures (United Kingdom)** 12:05  
Abstract N° SP0190  
Facts and figures: how mental health care addresses the psychological burden of RMD’s in Europe

**Anja Marchal (Belgium)** 12:25  
A personal account of learning to disclose: how psychological support can help to break the vicious circle of hiding and ignoring

**Vasiliki Christodoulou (Cyprus)** 12:45  
Mindfulness and acceptance - how to use your body and mind to manage your life with a rheumatic disease

**K. Cattelaens (Germany)** 13:10  
Abstract N° OP0345-PARE  
Growing up with arthritis - yes we can!  
A project of Deutsche Rheuma-Liga in co-operation with the German arthritis research center. With financial support by the German Federal Ministry of Health

**S. Mingolla (Italy)** 13:20  
F. Riondino, I. Cinieri, C. Assalve on behalf of fibromyalgia group APMAR Onlus  
Abstract N° OP0346-PARE  
“Listening to pain - un dolore da ascoltare” multidisciplinary support for women with fibromyalgia

---

**12:00 - 13:30 N117/N118**

**EULAR Projects in Health Professionals**

**Showcasing the EULAR Online Course for Health Professionals**

**Learning objectives:**  
To be informed on the online course for health professionals

**Chairperson(s):**  
Peter Oesch (Switzerland)  
Thea Vliet Vlieland (Netherlands)  
M. K. Nisar (United Kingdom)  
J. Begum

**Peter Oesch (Switzerland)** 12:05  
Abstract N° SP0191  
Principles of non-pharmacological management of regional musculoskeletal disorders

**Thea Vliet Vlieland (Netherlands)** 12:23  
Abstract N° SP0192  
Principles of non-pharmacological management of rheumatic diseases

**Joke Vriezekolk (Netherlands)** 12:41  
Abstract N° SP0193  
Principles of non-pharmacological management of fibromyalgia

**Roger Hilfiker (Switzerland)** 12:59  
Abstract N° SP0194  
Principles of assessment in clinical practice

**3:45 - 14:45 N101/N102**

**Highlight session**

**Health Professionals Highlight session**

**Chairperson(s):**  
Lurdes Barbosa (Portugal)  
Yeliz Prior (United Kingdom)  
Ricardo Ferreira (Portugal)  
Muditha Samaranayaka (United Kingdom)

**Ricardo Ferreira (Portugal)** 13:50  
Abstract N° SP0195  
Highlights from the Health Professional sessions

**Muditha Samaranayaka (United Kingdom)** 14:08  
Highlights from the Scientific programme

**Carol Rhodes (United Kingdom)** 14:26  
Highlights from the PARE programme
HPR Poster Tours
Health Professionals in Rheumatology

Thursday, 15 June 2017

Poster Tour T15: HPR: From top to toe; health professional practice

Chairperson(s): Rikke H. Moe (Norway), Branka Rimac (Croatia)

THU0750-HPR
THE EFFECTIVENESS OF THERAPEUTIC FOOTWEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / M. Tenter-Diepenmaat* - M. Leeden van der - T. Vliet Vlieland - L. D. Roorda - J. Dekker

THU0751-HPR
EFFECTIVENESS OF FOOT ORTHOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS RELATED TO QUALITY OF LIFE AND PAIN. A SYSTEMATIC REVIEW AND META-ANALYSIS / G. Gijon-Nogueron* - L. Ramos-Petersen - S. Garcia-Mayor - J. M. Morales-Añasceno

THU0752-HPR

THU0753-HPR

THU0754-HPR
WORK STATUS IN WOMEN WITH FIBROMYALGIA - A 12-YEAR FOLLOW UP STUDY / S. Johannesson* - L. Nordesemn - M. Juelsson - M. Mannerkorpi - A. Bergenheim

THU0755-HPR

THU0756-HPR

THU0757-HPR

THU0758-HPR
APPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND / K. Niedermann* - C. Madelaine-Bonjour - M. Roffler - A. Kocher on behalf of Health Professionals in Rheumatology Switzerland

THU0759-HPR
DOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS? / M. Karapinar* - T. Firat - N. Kirdi

Saturday, 17 June 2017

Poster Tour S14: HPR: Nursing and daily practice

Chairperson(s): Annette de Thurah (Denmark), Jenny de la Torre-Aboki (Spain)

SAT0717-HPR
PREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHITIS / A. Zbinden* - S. van den Brandt - P. M. Villiger - M. Östensen - F. Förger

SAT0718-HPR

SAT0719-HPR

SAT0720-HPR
LONGITUDINAL ANALYSIS OF RESPONSE, COSTS AND RESOURCE USE OF PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) IN TAIWAN USING THE NATIONAL HEALTH INSURANCE RESEARCH DATABASE / Q. Shi* - T. Treuer - B. C. Wang - C. L. Gaich - Q. Shi - T. Treuer - B. C. Wang - C. L. Gaich

SAT0721-HPR
EXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY / A. K. Hedström - L. Klareskog - L. Alfredsson*" NateS

SAT0722-HPR
FAMILIAL RISKS OF RHEUMATOID ARTHRITIS: EVIDENCE FROM THE MALAYSIAN EPIDEMIOLOGICAL INVESTIGATION OF RHEUMATOID ARTHRITIS (MICKAR): A CASE-CONTROL STUDY / C. L. Too - L. K. Tan - N. M. Hammer

SAT0723-HPR
GENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFANTILMARI ARTHRITIS - A NATIONWIDE CROSS-SECTIONAL STUDY / B. A. Esbensen* - C. Flurey - K. V. Jensen - L. Andersen - N. M. Hammer

SAT0724-HPR
GOETHENBURG NURSE LED TIGHT CONTROL STUDY - GONTET. PATIENTS’ EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS / U. Bergsten* - A-S. Sjö

SAT0725-HPR
GOETHENBURG NURSE LED TIGHT CONTROL STUDY - GONTET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY / U. Bergsten* - K. Almehed - L. Jacobsson

* Presenting author
HPR Posters
Health Professionals in Rheumatology

Thursday, 15 June 2017

HPR: Interventions (educational, physical, social and psychological)

THU0720-HPR PHYSICAL ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES / A. López Esteban* - I. Janta - J. C. Nieto Gonzalez - F. Garcia - C. Garaballu - T. del Rio - C. Barbero - C. Gonzalez - J. Lopez Longo - I. Monteagudo

THU0721-HPR MULTIDISCIPLINARY EDUCATIONAL PROGRAM FOR PATIENTS WITH HIP- OR KNEE-OA: RESULTS OF A PILOT STUDY / A. Claassen* - H. Schers - S. Koëter - J. Botman - W. Rijnen - W. Noort-van der Laan - C. van den Ende on behalf of project team "towards a regional approach of osteoarthritis"

THU0722-HPR THE EFFECTS OF KINESIO TAPING ON PAIN, JOINT RANGE OF MOTION, MUSCLE STRENGTH AND DISABILITY IN IMPINGEMENT SYNDROME / A. Yıldız* - Y. Buyuktepe


THU0724-HPR SELF-MANAGEMENT EXERCISE PROGRAM ASSOCIATED TO SPA THERAPY INCREASED THE PHYSICAL ACTIVITY LEVEL OF PEOPLE WITH SYMPTOMATIC KNEE OSTEOARTHRITIS: A QUASI-RANDOMIZED CONTROLLED TRIAL / C. Gay* - C. Auclair-Boisseau - L. Gr. de Caunes - A. Król-Couderye

THU0725-HPR COST EFFECTIVENESS ANALYSIS OF ABATAcept COMPARED WITH TNF INHIBITORS IN PATIENTS WHO ARE POSITIVE FOR ANTI-CITRULLINATED PROTEIN AntibODIES BASED ON RESULTS FROM AN OBSERVATIONAL TRIAL / S. Johel - E. Alemo*


THU0729-HPR PATIENTS AND CAREGIVERS PREFERENCES RELATED WITH THE USE OF INFORMATIC TECHNOLOGY TOOLS FOR EDUCATION IN RHEUMATOID ARTHRITIS / S. Henao - F. Rodriguez* - L. Villarreal - P. Santos-Moreno - M. Cabrera - D. Buitrago-Garcia - C. Caicedo


THU0731-HPR CAN A THREE WEEKS PROGRAM IN A REHABILITATION CENTER IMPROVE SYMPTOMS AND EXERCISE-FREQUENCY FOR RHEUMATIC PATIENTS? / G. Jarret* - A. Orpiana


THU0733-HPR REHABILITATION IN WARM CLIMATE FOR YOUNG ADULTS WITH INFLAMMATORY RHEUMATIC DISEASE. A 12 MONTHS RANDOMIZED CONTROLLED TRIAL / I. R. Nilssen* - H. Koksvik - K. Gremming - A. Steinsbekk

THU0734-HPR ASSESSMENT OF LOCAL DISEASE ACTIVITY AFTER AN INTENSIVE HAND EXERCISE PROGRAM IN PATIENTS WITH RHEUMATOID ARTHRITIS MEASURED BY ULTRASOUND IMAGING: AN EXPLORATORY RANDOMIZED CONTROLLED TRIAL / C. Bartholdy - M. Henriksen - E. Waehrens - K. Hellegaard


THU0737-HPR EXPERIENCES AND APPRECIATION OF SHARED MEDICAL APPOINTMENT OF YOUNG ADULTS WITH A RHEUMATIC DISEASE, IN TRANSITION FROM CHILD TO ADULT CARE / L. Gossens* - J. Ammerlaan - L. Cazemier - W. Bouwens - B. Formmisse - J. van Laar - J. van Laar - D. van Laar

THU0738-HPR PROMOTING PHYSICAL ACTIVITY IN RHEUMATOID ARTHRITIS: DEVELOPING A THEORY-BASED BEHAVIOUR CHANGE INTERVENTION / L. Larkin* - A. Fraser - S. Gallagher - N. Kennedy

THU0739-HPR THE PHENOMENON OF ALEXITHYMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / M. Ramkhalawon* - R. A. Grekhoff - G. Suleymanova

THU0740-HPR INFLUENCE OF BIOFEEDBACK THERAPY ON THE MICRO-CIRCULATION IN SYSTEMIC SCLEROSIS / M. Ramkhalawon* - R. A. Grekhoff - G. Suleymanova - S. A. Kharchenko


THU0743-HPR A NEW AND ALTERNATIVE TREATMENT IN SCLERODERMIC DIGITAL ULCERS / M. Muratore* - D. Carati - L. Quarta - A. Grimaldi - E. Quarta - M. Garzya - D. Longo - O. Casilli - F. Calcagnile


THU0745-HPR A COMPARISON THE EFFECTIVENESS OF wholeBODY VIBRATION, PROGRESSIVE RESISTive EXERCISE AND home-BASED EXERCISE IN PATIENTS WITH KNEE OSTEOARTHRITIS / M. Pekesen Kurtça* - U. Baş Aslan - E. Kuyucu

* Presenting author
THU0749-HPR
RECOMMENDATIONS ON PHYSICAL THERAPY PRESCRIPTION FOR AXIAL SPONDYLOARTHITIS IN THE NETHERLANDS / S. van Weely* - F. van der Giesen - N. Lopuhaa - F. van Gaalen - T. Vliet Vlieland

THU0750-HPR
THE EFFECTIVENESS OF THERAPEUTIC FOOTWEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / M. Tenter-Diepenmaat* - M. Leeden van der - T. Vliet Vlieland - L. D. Roorda - J. Dekker

THU0751-HPR
EFFECTIVENESS OF FOOT ORTHOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS RELATED TO QUALITY OF LIFE AND PAIN. A SYSTEMATIC REVIEW AND META-ANALYSIS / G. Gijon-Nogueron* - L. Ramos-Petersen - S. Garcia-Mayor - J. M. Morales-Asencio

HPR: Measuring health (development and measurement properties of PROs, tests, devices)

THU0752-HPR

HPR: Epidemiology and public health (including prevention)

THU0753-HPR

THU0754-HPR
DYSK STATUS IN WOMEN WITH FIBROMYALGIA: A 12-YEAR FOLLOW UP STUDY / S. Johannesson* - L. Nordeman - M. Joelsson - K. Mannerkorpi - A. Bergenheim

THU0755-HPR

HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

THU0756-HPR

THU0757-HPR

HPR: Professional education, training and competencies

THU0758-HPR
APPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND / K. Niedermann* - C. Madelaine-Bonjour - M. Roffler - A. Kocher on behalf of Health Professionals in Rheumatology Switzerland

HPR: Interventions (educational, physical, social and psychological)

THU0759-HPR
DOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS? / M. Karapinar* - T. Firat - N. Kirdi

HPR: Service developments, innovation and economics in healthcare

THU0760-HPR
PATIENT ADVICE LINE - THE POTENTIAL CLINICAL AND FINANCIAL BENEFITS TO A RHEUMATOLOGY DEPARTMENT / A. Mason* - C. Beevor - J. Ledingham

THU0761-HPR

THU0762-HPR

THU0763-HPR
ADDRESSING THE ELEPHANT IN THE ROOM: A POSSIBLE NEW AND EFFECTIVE WAY TO INCREASE PATIENT ADHERENCE TO MEDICAL ADVICE / G. Gronhau* - S. Arnesen

THU0764-HPR

THU0765-HPR

THU0766-HPR

THU0767-HPR
ADVANCED PRACTICE MUSCULOSKELETAL PHYSIOTHERAPY SERVICES: A NATIONAL EVALUATION / O. Fennelly* - C. Blake - O. Fitzgerald - R. Breen - A. Brennan - J. Ashton - C. Cunningham on behalf of the National Clinical Programmes for Rheumatology and Orthopaedics

* Presenting author
THU0768-HPR  PHONE FOLLOW-UP PROGRAM ENHANCES TREATMENT SAFETY AND DRUG CONCORDANCE ON DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs) THERAPY FOR RHEUMATOLOGY PATIENTS / P. F. Lee* - Y. S. Cheung - C. K. Lam - M. C. Leung - C. M. Chan - W. L. Ng


THU0770-HPR  COST SAVINGS BY FAVOURING INFILXIMAB BIOSIMILARS IN THE EASTERN REGION OF AUSTRIA / B. Reichardt - G. Reiter - T. Stamm* - V. Nell-Duxneuner

THU0771-HPR  INCORPORATING SENIOR PHARMACIST INPUT IN THERAPIPATIDE PATHWAY ENSURES ADHERENCE TO PRESCRIBING GUIDANCE / AUDIT/QUALITY IMPROVEMENT RESULTS FROM A DISTRICT RHEUMATOLOGY UNIT / W. Gan* - L. Bromilow - S. Vasireddy

THU0772-HPR  VARIATION IN RHEUMATOLOGY NURSING CARE IN THE NETHERLANDS: A SURVEY AMONG NURSES / Y. Van Eijk-Hustings* on behalf of working group Rheumatology Nursing Research

Friday, 16 June 2017

HPR: Measuring health (development and measurement properties of PROs, tests, devices)


FRI0733-HPR  THE EDUCATIONAL NEEDS OF PATIENTS WITH UNDIFFERENTIATED SPONDYLOARTHITIS / A. Bremander* - E. Haglund - S. Bergman - M. Ndosi

FRI0734-HPR  EFFECTS OF VIRTUAL REHABILITATION ON SHOULDER PERIARTHITIS / B. Kapşigay* - Z. Şari - B. Kavlak - I. Aras - A. Tanhan

FRI0735-HPR  ANALYSIS OF LEFT VENTRICULAR FUNCTION WITH ECHOCARDIOGRAM IN PATIENTS WITH PSORIATIC ARTHRITIS AND NOT DIAGNOSED CARDIOVASCULAR DISEASE / P. Egea-Serrano - A. C. Haro-Martinez - A. Vidal - D. Palm-Sánchez*

FRI0736-HPR  VALIDITY AND RELIABILITY OF PERFORMANCE TESTS ASSESSING BALANCE AND FALL RISK IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY / D. C. Sarac* - B. Unver - S. Cekmez - V. Karatosun

FRI0737-HPR  THE SOURCES OF PAIN IN ABDOMEN IN PATIENTS WITH RHEUMATOID ARTHRITIS / H. Palhuyeva* - A. Litviakov - V. Shynkovskiy - N. Podolinisky


FRI0739-HPR  A RHEUMATOLOGY PATIENT PANEL: THE PATIENT IS THE EXPERT, WE ARE THE SPECIALIST / J. E. Voorneveld-Nieuwenhuis* - M. D. Kok - N. Basoski - M. Holtop - D. Lopes Barreto

FRI0740-HPR  ONLINE REMOTE MONITORING OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS OF A PILOT STUDY / L. Renskers* - S. A. A. Rongen - S. Teerenstra - M. E. J. L. Hulscher - P. L. C. M. van Riel

FRI0741-HPR  SCREENING FOR DEPRESSION AND ANXIETY IN AN OUTPATIENT RHEUMATOLOGY CLINIC USING VALIDATED SELF-APPLIED QUESTIONNAIRES / L. F. Perez* - A. Martinez - M. Moreno - L. Silveira


FRI0744-HPR  THE EFFECTIVENESS OF THE LOWER DOSE OF LASER TREATMENT ON KNEE OSTEOARTHRITIS / E. Ekiz - K. Kapaci - M. Korkmaz*

FRI0745-HPR  INVESTIGATION OF ASSOCIATION BETWEEN WRIST PAIN, FUNCTIONAL PERFORMANCE, GRIP AND PINCH STRENGTH IN CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: CROSS-SECTIONAL STUDY / S. N. Arman - E. Tarakci - O. Kasapcopur*

FRI0746-HPR  THE FACTORS AFFECTING STAIR CLIMBING IN PATIENTS WHO HAVE AN AFFECTED KNEE JOINT WITH OLIQARTICULAR JUVENILE IDIOPATHIC ARTHRITIS / S. N. Arman - E. Tarakci - O. Kasapcopur*

FRI0747-HPR  FEASIBILITY OF FOUR QUESTIONNAIRES TO EVALUATE PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS / R. Ree* - K. Gronning - L. R. Eriksson - H. A. Zangi on behalf of the Norwegian patient education expert panel


FRI0749-HPR  THE EFFECT OF A SUPPORTED OSTEOARTHRITIS SELF-MANAGEMENT PROGRAM ON PHYSICAL ACTIVITY, PAIN, QUALITY OF LIFE AND SELF-EFFICACY. AN INTERVENTION STUDY WITH A REFERENCE GROUP / T. S. J. Jönsson* - C. A. Thorstensson - E. Ekvall Hansson - L. Dahlberg

FRI0750-HPR  CONSTRUCT VALIDITY OF THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE - LONG FORM IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / T. W. Swinnen* - S. Willemijns - W. Dankaerts - R. Westhovens - K. de Vlam

HPR: Epidemiology and public health (including prevention)

FRI0751-HPR  SAFETY PROFILE OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS - A REAL WORLD EXPERIENCE WITH GOOD RESULTS / A. Malpica* - P. Santos-Moreno - K. Mendez - D. Buitrago-Garcia


* Presenting author
FR0753-HPR PAIN SPREAD AND PAIN INTENSITY IMPROVE OVER TIME IN WOMEN WITH FIBROMYALGIA AND CHRONIC WIDESPREAD PAIN. A 12 YEAR FOLLOW UP STUDY / A. Bergheim* - S. Johannesson - L. Nordeman - M. Joelsso - K. Mannenkorpi

FR0754-HPR IMPACT OF CORTICOSTEROID UTILIZATION ON BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG INITIATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / C. A. Spivey* - J. Griffith - C. Kaplan - A. Postlethwaite - A. Ganguli - J. Wang

FR0755-HPR POTENTIAL BENEFITS OF BIOLOGICS ON CARDIOVASCULAR DISEASES AND ORTHOPEDIC SURGERIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONALWIDE POPULATION-BASED COHORT STUDY IN TAIWAN / D.-Y. Chen* - C.-H. Tang - F. Yu - C.-Y. Huang


FR0758-HPR COMORBIDITY PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM RHEUMATOID ARTHRITIS REGISTRY IN QATAR / F. Alam* - M. Hammoudeh - S. Al Emadi

FR0759-HPR COLLABORATION BETWEEN GENERAL PRACTITIONERS AND RHEUMATOLOGISTS TO MANAGE CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS PATIENTS / J. Weijers* - S. Rongen-van Dertel - M. Hulscher - P. van Riel

FR0760-HPR BIOSIMILAR USE AMONG EUROPEAN RHEUMATOID ARTHRITIS PATIENTS AND IMPACT ON PATIENT OUTCOMES / L. Chanroux* - F. Mboge - A. Wadiwalla


FR0764-HPR MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND END STAGE RENAL DISEASE / S. Paudyal* - J. Waller - A. Oliver - B. Le - N. Zieik - N. S. Nahman - L. Carbone

FR0765-HPR PREVALENCE OF SARCOPENIA IN ELDERLY WITH OSTEOARTHRITIS OF LARGE JOINTS / Y. Safonova* - V. Tsurko

FR0766-HPR DOWN’S ARTHROPATHY - CLINICAL AND RADIOLOGICAL FEATURES OF ARTHRITIS IN CHILDREN WITH TRISOMY 21 / C. Foley* - E. J. MacDermott - O. G. Killeen

FR0767-HPR PARTICIPATING IN A MUSCULOSKELETAL RANDOMISED CONTROLLED TRIAL: IDENTIFICATION OF EDUCATION TRAINING NEEDS BY OCCUPATIONAL THERAPISTS AND PHYSIOTHERAPISTS IN THE UK / J. Adams* - P. Barratt - S. Bradley - S. Barbosa-Bouças - K. Hislop Lennie - P. White on behalf of OTTER II Trial working group


FR0771-HPR WORK - RELATED LUMBAR PAIN IN PHYSIOTHERAPISTS WHO WORK IN DIFFERENT FIELDS - A PILOT STUDY / B. Karaköç - Z. San - O. Aydoğdu* - U. S. Yurdalan

FR0772-HPR FORMAL RHEUMATOLOGY TRAINING FOR GENERAL PRACTITIONERS / S. Khan* - A. Mohammad - K. P. O’Rourke - C. Sheehy

HPR: Professional education, training and competencies

FR0766-HPR DOWNS ARTHROPATHY - CLINICAL AND RADIOLOGICAL FEATURES OF ARTHRITIS IN CHILDREN WITH TRISOMY 21 / C. Foley* - E. J. MacDermott - O. G. Killeen

FR0767-HPR PARTICIPATING IN A MUSCULOSKELETAL RANDOMISED CONTROLLED TRIAL: IDENTIFICATION OF EDUCATION TRAINING NEEDS BY OCCUPATIONAL THERAPISTS AND PHYSIOTHERAPISTS IN THE UK / J. Adams* - P. Barratt - S. Bradley - S. Barbosa-Bouças - K. Hislop Lennie - P. White on behalf of OTTER II Trial working group


FR0771-HPR WORK - RELATED LUMBAR PAIN IN PHYSIOTHERAPISTS WHO WORK IN DIFFERENT FIELDS - A PILOT STUDY / B. Karaköç - Z. San - O. Aydoğdu* - U. S. Yurdalan

FR0772-HPR FORMAL RHEUMATOLOGY TRAINING FOR GENERAL PRACTITIONERS / S. Khan* - A. Mohammad - K. P. O’Rourke - C. Sheehy

Saturday, 17 June 2017

HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

SAT0717-HPR PREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SpondyloarthritiS / A. Zbinden* - S. van den Brandt - P. M. Villiger - M. Østensen - F. Förger

HPR: Measuring health (development and measurement properties of PROs, tests, devices)

SAT0718-HPR INFLUENCE OF PATIENT GLOBAL ASSESSMENT ON THE DISEASE ACTIVITY ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A METEOR CROSS-SECTIONAL STUDY / R. J. O. Ferreira* - M. Ndosi - C. Duarte - E. M. Badley* - D. Millstone - A. V. Perruccio

HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

HPR: Service developments, innovation and economics in healthcare


HPR: Epidemiology and public health (including prevention)

SAT0721-HPR  EXPOSURE TO PASSIVE SMOKING AND RA RISK: RESULTS FROM THE SWEDISH EIRA STUDY / A. K. Hedström - L. Klareskog - L. Alfredsson*


HPR: Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

SAT0723-HPR  GENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS - A NATIONWIDE CROSS-SECTIONAL STUDY / B. A. Esbensen* - C. Flurey - K. V. Jensen - L. Andersen - N. M. Hammer

SAT0724-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. PATIENTS’ EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS / U. Bergsten* - A.-S. Sjö

SAT0725-HPR  GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY / U. Bergsten* - K. Almehed - L. Jacobsson

SAT0726-HPR  FUNCTIONAL IMPAIRMENT IN PATIENTS WITH RA IN AN EIGHT YEAR PERSPECTIVE / A. Bremander* - K. Forslind - K. Eberhardt - M. Andersson


SAT0729-HPR  PSYCHOLOGICAL PROFILE OF PATIENTS WITH FIBROMYALGIA SYNDROME / D. Xhaxho* - J. Lauri - M. A. Lauri - J. Fleri Soler - A. Borg - C. Mercicca


SAT0731-HPR  SYMPTOMS OF PAIN, FATIGUE AND SELF-EFFICACY IN YOUNG PATIENTS WITH SPONDYLOARTHITIS - A COMPARISON BETWEEN WOMEN AND MEN / A. Torell - A. Breman - S. Bergman - E. Haglund*

SAT0732-HPR  RESILIENCE AND POSITIVE AFFECT ARE RELATED TO THE EXPERIENCE OF FATIGUE IN PATIENTS WITH A RHEUMATIC DISEASE / E. Taal* - K. Schreurs - L. Guddorff - C. Bode - M. van de Laar

SAT0733-HPR  A QUALITATIVE STUDY ON OBSTACLES AND MOTIVATIONS TO VACCINATIONS IN RHEUMATOID ARTHRITIS / F. Fayet* - C. Savel - M. Rodere - M. Soubrier - S. Mathieu


SAT0736-HPR  "LIKE A BAG OF LIQUORICE ALLSORTS - EVERYBODY’S GOT DIFFERENT FLAVOURS": A QUALITATIVE FOCUS GROUP STUDY TO EXPLORE SYMPTOMS OF FATIGUE, SLEEP DISTURBANCES AND PAIN IN PRIMARY SJÖGREN’S SYNDROME PATIENTS AND TO DEVELOP A FUTURE MODEL OF CARE / K. L. Hackett - V. Jolliffe - J. Wood - S. Andrews - S. Capillas - A. Peall


SAT0738-HPR  EXPERIENCES OF TELE-HEALTH FOLLOW-UP IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE INTERVIEW STUDY / L. R. Knudsen* - A. de Thurah - K. Lomborg

SAT0739-HPR  PATIENTS’ PREFERENCES TOWARD CHARACTERISTICS OF TREATMENT WITH BIOLOGICAL AGENTS DIFFER ACCORDING TO EXPERIENCE WITH THEIR RHEUMATIC DISEASE AND TREATMENT RECEIVED OR PRESCRIBED: RESULTS FROM THE CARA STUDY / L. Sinigaglia* - P. Sarzi-Puttini - L. Scalone - C. M. Montecucco - R. Giacomelli - G. Lapadula - L. Olivieri - A. Giardino - P. Cortesi - L. G. Mantovani - M. Mecchia on behalf of CARA study

SAT0740-HPR  SIGNIFICANT OTHERS AS BOTH BARRIERS AND FACILITATORS FOR PARTICIPATION IN DAILY ACTIVITIES IN PERSONS WITH EARLY RHEUMATOID ARTHRITIS - AN INTERVIEW STUDY WITHIN THE SWEDISH TIRA PROJECT / M. Bergström* - A. Sverker - Å. Larsson Ranada - E. Valtersson - I. Thyberg - G. Östlund - M. Björk

SAT0741-HPR  PHYSICAL PERFORMANCE AND GAIT SPEED OF FALLER AND NON-FALLER ELDERLY PEOPLE WITH KNEE OSTEOARTHRITIS LIVING IN THE COMMUNITY / M. Karapinar* - A. Abit Kocaman - N. Kirdi
PARE Programme
People with Arthritis/Rheumatism in Europe

WEDNESDAY, 14 JUNE 2017

15:00 - 16:30  N115/N116

Joint session Clinical/HPR/PARE
EULAR Campaign: Don’t Delay, Connect Today

Learning objectives:
• To experience how access to early diagnosis is enabled
• To learn how tight control optimises therapies targeting remission
• To understand what markers signify illness progression
• To comprehend how lifestyle factors (smoking, obesity, alcohol, inactivity) influence the progression of rheumatic diseases

Chairperson(s):
Gerd R. Burmester (Germany)
Ailsa Bosworth (United Kingdom)
Andreas Schwarting (Germany)

Christian D. Mallen (United Kingdom)
Ways to improve early diagnosis despite limited rheumatologists’ resources

Abstract N° SP0031
How could GPs enhance the early diagnosis of rheumatic diseases?

Paul Kirwan (Ireland)
Abstract N° SP0032
The contribution of physiotherapists to early detection of inflammatory arthritis

John Church (Ireland)
Abstract N° SP0033
The EULAR Campaign and how organisations can get involved

16:30 - 17:00  Exhibition (Hall 10)
Coffee break

17:00 - 18:30  N115/N116

PARE session
Comorbidities: having one RMD is enough - we don’t need anything else

Learning objectives:
• To experience how to prevent comorbidities
• To provide information to patients who are at risk
• How to monitor patients for comorbidities

Chairperson(s):
Jeanette Andersen (United Kingdom)
Kristijonas Mazuras (Lithuania)
Cindy Rusthoven (Netherlands)

Abstract N° SP0044
Screening for comorbidities in daily practice: who and how?

Ailsa Bosworth (United Kingdom)
Abstract N° SP0045
Do patient organisations have a role to play in preventing comorbidities?

Silvia Garcia-Diaz (United Kingdom)
Abstract N° SP0046
Prevention and the protective role of exercise and lifestyle interventions on comorbidities

L. Proulx (Canada)
N. Robertson, D. P. Richards, L. Wilhelm, J. Gunderson, C. Reece, A. Siros, A. McKinnon
Abstract N° OP0072-PARE
Pregnancy and parenting with arthritis - developing an educational resource for patient by patients

18:45 - 20:00  Hall 6
EULAR 2017 Opening Plenary session

20:00 - 22:00  Esplanade (Hall 6)
Networking Platform
THURSDAY, 15 JUNE 2017

10:15 - 11:45  N115/N116

PARE session

Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design

Learning objectives:
To address the most urgent challenges of bringing participatory research to a higher level:
• representativeness education
• support and recognition of patients as collaborative partners
• avoiding unintended forms of tokenism

Chairperson(s):
Jennifer Horonjeff (United States)
Jürgen Clausen (Germany)
Ana-Maria Orbai (United States)

Abstract N° SP0050
Ensuring representativeness of the patients’ perspectives in the final results generated from clinical research - challenges from the perspective of researchers

Elsa Mateus (Portugal)

Abstract N° SP0051
Becoming a patient research partner in the field of rheumatology. My expectations and the challenges of being educated and taken seriously

Heidi Lempp (United Kingdom)

Abstract N° SP0052
Building patient partnerships in health care service design and delivery

S. R. Stones (United Kingdom)

Abstract N° OP0162-PARE
An exploration of lived experiences amongst adults with rheumatoid arthritis using an online research community platform: a pilot study

J. Clausen (Germany)

Abstract N° OP0163-PARE
Invigorating the principle of participatory research in Germany - setup of a training course for patient representatives

11:45 - 13:30 Exhibition (Hall 10)

Poster viewing & lunch

12:00 - 13:30  Poster area (Hall 10)

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tour on Thursday please refer to page 213.

Poster tour PARE

T16 : PARE - Poster tour I

Chairperson(s):
Maarten de Wit (Netherlands)
Kristijonas Mazuras (Lithuania)

Abstracts N° PARE0001 - PARE0011

13:30 - 15:00  N101/N102

Joint session HPR/PARE/Paediatric Rheumatology

To be and to become: transition from paediatric to adult care

Learning objectives:
• To understand the patient perspective
• To learn about the scientific evidence and comprehend the clinical implementation of the transition process

Chairperson(s):
Tadej Avcin (Slovenia)
Erik Taal (Netherlands)
Wendy Olsder (Netherlands)

Abstract N° SP0064
To be and to become: reflections on my transition

Kirsten Minden (Germany)

Abstract N° SP0065
Are we asking the right questions in transition research?

Line Raunsbaek - Knudsen (Denmark)

Abstract N° SP0066
Implementation of a brief transition programme for adolescents with juvenile idiopathic arthritis

Janjaap van der Net (Netherlands)

Growing into a healthy lifestyle

I. Pontikaki (Italy)

L. M. Argolini, C. Artusi, P. L. Meroni

Abstract N° OP0195
What is the impact of juvenile idiopathic arthritis in adulthood? The monocentric experience of 240 patients followed in a transition tertiary clinic of rheumatology
13:30 - 15:00  N115/N116

PARE session
Barrier-free employment for young people with RMDs

Learning objectives:
• To explore barriers to employment that young people with RMDs face
• To look at possible solutions to employ and keep young people with RMDs in the workplace

Chairperson(s):
Andri Phoka (Cyprus)
Alessia Alunno (Italy)

Lembe Kullamaa (Estonia)  13:35
Abstract N° SP0071
Young patients: ready, brilliant and able to work!

Jeanette Andersen (United Kingdom) 13:55
Abstract N° SP0072
Challenges and potential solutions about staying in work as a young person with an RMD

Maureen McAllister (United Kingdom) 14:15
Abstract N° SP0073
Practical employability support for young people with RMDs

G. O’Leary (Ireland) 14:35
Abstract N° OP0198-PARE
Fit for work online: supporting employees with RMDs, employers and healthcare professionals

P. Putrik (Netherlands) 14:45
Abstract N° OP0199-PARE
Support to stay employed and social security arrangements for work disability due to RA - perceptions of patients with RA and rheumatologists in 31 European countries

15:00 - 15:30  Exhibition (Hall 10)

15:30 - 17:00  N115/N116

PARE session
Difficult to reach patient groups

Learning objectives:
• To understand how socio-economic factors influence access to treatment and quality of healthcare
• To realise what barriers exist for people with a migration background and how these barriers can be overcome
• To learn how patient organisations can support disadvantaged people

Chairperson(s):
Boryana Boteva (Bulgaria)
Neil Betteridge (United Kingdom)

Michael Zänker (Germany)  15:35
Abstract N° SP0092
The vicious circle of educational level of rheumatoid arthritis, and risk of poverty - results of a cross-sectional multicentre study in Germany

Kanta Kumar (United Kingdom) 15:55
Abstract N° SP0093
The challenges and solutions for engaging patients from ethnic backgrounds in rheumatology care

Tidiane Diao (Sweden)  16:15
Abstract N° SP0094
The Swedish experience - how a patient organisation could reach out to immigrants and develop through integration

S. R. Stones (United Kingdom) 16:35
S. M. Cruickshank, S. M. M. Verstappen on behalf of MyJIA Expert Advisory group
Abstract N° OP0210-PARE
The development and evaluation of an interactive health communication application to educate and empower young people living with juvenile idiopathic arthritis: a pilot study

A. Bosworth (United Kingdom) 16:45
C. O’Neill, K. R. Martin
Abstract N° OP0211-PARE
Who cares? An investigation of the health and perceived social care needs of people with rheumatoid arthritis living in Scotland

FRIDAY, 16 JUNE 2017

10:15 - 11:45  N115/N116

Abstract session
PARE

Chairperson(s):
Gráinne O’Leary (Ireland)
Karl Cattelaens (Germany)

Stefanie Hulst (Netherlands) 10:20
Edgar Stene Prize 2017: Diagnosis from the perspective of a child

E. F. Mateus (Portugal) 10:30
S. Crisostomo, M. Santos, M. Serapion, A. R. Matos on behalf of MAIS PARTICIPAÇÃO, melhor saúde
Abstract N° OP0276-PARE
More participation, better health - promoting public involvement in health

M. Ekroth (Finland) 10:40
T. Pakkala
Abstract N° OP0277-PARE
Initial information package for children diagnosed with JIA
F15: PARE Poster tour II
Chairperson(s): Dieter Wiek (Germany), Nele Caeyers (Belgium)
Abstracts N° PARE0012 - PARE0022

13:00 - 15:00 N115/N116

PARE session
Health equity and economy - a vital relationship

Learning objectives:
- To define health equity
- To explore the concepts and principles of equity in health
- To explore the link between health equity and health economics

Chairperson(s):
Polina Pchelnikova (Russian Federation)
Elsa Mateus (Portugal)

Neil Betteridge (United Kingdom) 13:35
Mind the gap! EULAR: campaigning for equity in Europe

Polina Putrik (Netherlands) 13:55
Uncovering the equity gap in rheumatic and musculoskeletal diseases

Bruno Fautrel (France) 14:15
Health economics and health equity: two complementary disciplines

A. Bosworth (United Kingdom) 14:35
C. Jacklin, T. Burke, A. Rose, I. Jacob, S. Verstappen
Abstract N° OP0317-PARE
An independent review of people with rheumatoid arthritis (RA) and their caregiver’s lost work time

F. J. Carreira Roca (Spain) 14:45
A. I. Vázquez Lojo, V. Romero Pazos on behalf of LIRE-LRG
Abstract N° OP0318-PARE
Consulting services to employers of people with RMDs

15:00 - 15:30 Exhibition (Hall 10)
Coffee break

15:30 - 17:00 N115/N116

PARE session
Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs

Learning objectives:
- To present latest advances in the management and treatment of psoriatic arthritis
- To explore the potential advantages and safety issues of the use of biosimilars with special attention to the fears and concerns of patients regarding adverse events

Chairperson(s):
Dieter Wiek (Germany)
Simon Stones (United Kingdom)
Laura Coates (United Kingdom) 15:35
Abstract N° SP0143
A new day for people with psoriatic arthritis: a heterogeneous disease that can be treated well?

Faculty: Q&A 16:00

L. M. Thomsen (Denmark) 16:10
Abstract N° OP0328-PARE
Patient safety in relation to biosimilars - how can we act as a patient organization?

Alfons den Broeder (Netherlands) 16:20
Abstract N° SP0144
Biosimilars in rheumatic diseases: society chances versus patient concerns

Faculty: Q&A 16:45

SATURDAY, 17 JUNE 2017

10:15 - 11:45 N115/N116

PARE session

Workshop: Strengthening your organisation - how to manage volunteers

Learning objectives:
• How to gain and motivate volunteers
• How to train and accompany volunteers
• How voluntary work can be valued and appreciated

Clare Jacklin (United Kingdom) 10:20
Abstract N° SP0172
How to manage volunteers - setting the scene

Marija Kosanovic (Serbia) 10:35
Abstract N° SP0173
The challenges of a small organisation

Silke Ssymank (Germany) 10:50
Abstract N° SP0174
Ways of supporting volunteers

Faculty: group discussion and Q&A 11:05

Clare Jacklin (United Kingdom) 11:35
Resume of the group discussions

12:00 - 13:30 N115/N116

Joint session PARE/HPR

Suffering in silence. Optimizing the management of psychological well-being for people with RMDs

Learning objectives:
• To gain insights of the extend and features of psychological impact of RMDs on daily life from different angles
• To learn how health professionals and patients can help to break the vicious circle of suffering in silence

Chairperson(s):
Souzi Makri (Belgium)
Heidi A. Zangi (Norway)

Emma Dures (United Kingdom) 12:05
Abstract N° SP0190
Facts and figures: how mental health care addresses the psychological burden of RMD’s in Europe

Anja Marchal (Belgium) 12:25
A personal account of learning to disclose: how psychological support can help to break the vicious circle of hiding and ignoring

Vasiliki Christodoulou (Cyprus) 12:45
Mindfulness and acceptance - how to use your body and mind to manage your life with a rheumatic disease

K. Cattelaens (Germany) 13:10
Abstract N° OP0345-PARE
Growing up with arthritis - yes we can!
A project of Deutsche Rheuma-Liga in co-operation with the German arthritis research center. With financial support by the German Federal Ministry of Health

S. Mingolla (Italy) 13:20
F. Riondino, I. Cinieri, C. Assalve on behalf of fibromyalgia group APMAR Onlus
Abstract N° OP0346-PARE
“Listening to pain - un dolore da ascoltare” multidisciplinary support for women with fibromyalgia

13:45 - 14:45 N115/N116

Highlight session

PARE Highlight session

Learning objectives:
To provide an overview of learning and outcomes from the 2017 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates

Chairperson(s):
Nele Caeyers (Belgium)
Marios Kouloumas (Cyprus)
Jette Primdahl (Denmark) 13:50
Highlights from the Health Professionals programme
Daniel Aletaha (Austria) 14:15
Highlights from the Scientific programme
PARE Poster tours & Posters
People with Arthritis/Rheumatism in Europe Poster Session

PARE posters Thursday to Saturday & Guided poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis on the day of the poster tour.

Thursday, 15 June 2017 12:00
Poster Tour T16: PARE poster tour I
Chairperson(s): Maarten de Wit (Netherlands), Kristijonas Mazuras (Lithuania)


PARE0004 PATIENT REPORTED LONG-TERM EFFECTS OF SIX WEEK PROGRESSIVE RESISTANCE TRAINING PROGRAMME FOR RHEUMATOID ARTHRITIS / R. Tekkatte* - A. Suarez - B. Berntzen - D. Collins - E. Price - L. Williamson

PARE0005 EDUCATIONAL PROGRAM FOR OLDER ADULTS WITH KNEE OSTEOARTHRITIS / M. R. Espanha* - P. P. Marconcin - P. L. Campos - F. G. Yázigi

PARE0006 PATIENT INVOLVEMENT IN BASIC RESEARCH: A PILOT STUDY / Y. Neijland* - C. van den Ende - F. van den Loo - M. Lieon


PARE0008 TRANSITION: PARTICULARLY DIFFICULT TIME FOR YOUNG PEOPLE WITH AR / U. G. Viora* - E. Fusaro - S. Martino - D. Montin


PARE0010 SIGNIFICANCE OF FOOT PROBLEMS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A PATIENT-LED QUALITATIVE STUDY / S. de Souza* - H. Lempp

PARE0011 ASK THE USERS - ESTABLISHING A DIGITAL USER PANEL / C. R. Ziegler*

Friday, 16 June 2016 12:00
Poster Tour F15: PARE Poster tour II
Chairperson(s): Dieter Wiek (Germany), Nele Caeyers (Belgium)

PARE0012 EDUCATING YOUNG CHILDREN, PARENTS AND DOCTORS THROUGH THE MEDIUM OF AN ILLUSTRATED CHILDREN’S BOOK / T. Egert* - Y. Egert - R. Vitman - W. Costello

PARE0013 BEHIND THE SMILE - RA AWARENESS VIDEOS - RAISING AWARENESS OF THE HIDDEN IMPACT OF RHEUMATOID ARTHRITIS / C. B. Jacklin* - D. Saunders

PARE0014 EXPLORING THE ADDED VALUE OF A BOOSTER SESSION AFTER COMPLETING THE DUTCH SELF-MANAGEMENT TRAINING “CHALLENGING ARTHRITIS” / M. Vos* - R. van den Brink - S. van der Brink - S. de Jong - J. Ammerlaan


PARE0016 KEEP CALM AND TELL ME YOUR STORY!: A NARRATIVE MEDICINE PILOT PROJECT FOR ITALIAN YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES / U. G. Viora* - G. Voltan on behalf of ANMAR Italia - ANMAR Young

PARE0017 EMPOWERING PATIENTS WITH OSTEOARTHRITIS WITH NON-PHARMACOLOGICAL MEASURES / J. Vergés* - J. Monfort - M. Bibas - M. T. Vergés

PARE0018 WE DO THE IMPOSSIBLE, BECAUSE THE POSSIBLE EVERYONE CAN DO WAD AWARENESS CAMPAIGN / H. Bankova* - B. Ivkov - S. Bozhinova - B. Boteva

PARE0019ADHERENCE TO THERAPY: A COMPARISON BETWEEN THREE PATIENTS POPULATIONS WITH AUTOIMMUNE INFLAMMATORY DISEASES / U. G. Viora* - R. Giannelli - M. G. Pisu - G. Voltan on behalf of ANMAR Italia


PARE0021 PUBLIC AND PATIENT INVOLVEMENT AT ARTHRITIS RESEARCH UK: ENSURING BENEFIT FOR ALL / C. Macdonald

PARE0022 ORGANIZATION OF GROUP EXERCISE THERAPY (GET) FOR PATIENTS WITH AXIAL SPONDYLOARTHRITIS (AXS) IN THE NETHERLANDS: A NATIONWIDE SURVEY / F. van der Giesen* - S. Van Weelij - N. Lopuhaa - T. Vliet Vlieland

* Presenting author
# EULAR Related Meetings

**By invitation only**

## Wednesday, 14 June 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>A10.03</td>
<td>EULAR Standing Committee on Health Professionals Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.05</td>
<td>EULAR Standing Committee on Clinical Affairs Business meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A10.01</td>
<td>EULAR Project ScleroID meeting</td>
</tr>
<tr>
<td>09:00 - 13:00</td>
<td>A9.13</td>
<td>Gout Nomenclature Project of the Gout, Hyperuricemia and Crystal-Associated Disease Network</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>A10.01</td>
<td>SLEuro Board meeting</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>S12</td>
<td>GRAPPA Adjacent to EULAR 2017</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>A10.08</td>
<td>EULAR Study Group for Collaborative Research</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>N113/N114</td>
<td>EULAR Standing Committee on PARE Business meeting</td>
</tr>
</tbody>
</table>

## Thursday, 15 June 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>S17</td>
<td>OMERACT Hand Osteoarthritis Working Group meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.01</td>
<td>Clinical Rheumatology - Editorial Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.02</td>
<td>EULAR Standing Committee on Paediatric Rheumatology Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.03</td>
<td>Business meeting for Standing Committee of MSK Imaging</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.04</td>
<td>Steering Committee meeting ATACC-RA</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.05</td>
<td>Steering Committee meeting EULAR-ACR Classification Criteria for SLE</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.06</td>
<td>AGORA meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.08</td>
<td>Educational and Scientific Sub-Committee, ESCHP</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A9.13</td>
<td>EMEUNET Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S12</td>
<td>EUSTAR Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S15</td>
<td>EULAR Myositis Study Group</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S16</td>
<td>UEMS Rheumatology Section and Board meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A10.07</td>
<td>Arthritis Research &amp; Therapy Section/Associate Editor meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>S17</td>
<td>Medication Adherence Special Interest Group</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.01</td>
<td>EULAR Study Group on SLE</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.04</td>
<td>World Scleroderma Foundation</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.06</td>
<td>TICOSPA Investigators meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>S15</td>
<td>ASIF Future Projects Introduction</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>S17</td>
<td>SPECTRA Special Interest Group</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>A10.03</td>
<td>EULAR Standing Committee on Epidemiology and Health Services Research Business meeting</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>A10.05</td>
<td>EULAR Standing Committee on Investigative Rheumatology Business meeting</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>S16</td>
<td>EULAR Lupus Nephritis Trials Network Study Group</td>
</tr>
</tbody>
</table>
Friday, 16 June 2017

08:00 - 09:00 A10.04 EULAR Hand OA Classification Criteria
08:00 - 09:00 S15 Rheumatology Editorial Board meeting
08:00 - 09:30 A10.05 Joint meeting SG EULAR/ACR Microcirculation/Capillaroscopy
08:00 - 10:00 A10.01 Board meeting Scandinavian Society of Rheumatology
08:00 - 10:00 A10.02 EULAR PARE CEO INTERIM meeting
08:00 - 10:00 A10.03 Online Courses Assessments and Updating Tool Use
08:00 - 10:00 A10.07 JSRD meeting
08:00 - 10:00 A10.08 OMERACT Ultrasound Working Group meeting 2017
08:00 - 10:00 S16 ARD Editorial Board meeting
08:30 - 10:00 A10.06 Editorial Board meeting - Rheumatology International
08:30 - 10:00 A9.13 EMEUNET Mentor-Mentee meetings
09:00 - 10:00 S15 Discussion of Proposal for the Development of EULAR Recommendations for the Management of Difficult to Treat RA
09:00 - 10:00 S17 OMERACT Worker Productivity Group meeting
17:00 - 18:00 A10.03 Study Group meeting - Physical Activity and Exercise Therapy Group
17:00 - 18:00 A10.05 Clinical Nurse
17:00 - 18:00 S15 Patient Education Study Group
17:00 - 19:00 A10.02 GLORIA Trial Investigators
17:00 - 19:00 A10.06 EMEUNET Country Liaisons meeting
17:00 - 19:00 A10.07 ESSENTIAL Study Group
17:00 - 19:00 S16 Study Group for Risk Factors for RA
17:30 - 19:00 S12 ASAS meeting
18:00 - 19:00 A10.03 Foot and Ankle Study Group meeting
18:00 - 19:00 A10.05 Psychologists Study Group meeting
18:00 - 19:00 A10.08 Nurses Research & Strategy Study Group meeting
THE 1st BIOSIMILAR RITUXIMAB with proven SWITCHABILITY & LONG-TERM SAFETY.

Truxima

Indispensable evidence pointing to infinite possibilities, priceless opportunities and invaluable engagement.

Before prescribing Truxima®, please read the Summary of Product Characteristics (SmPC). Before prescribing Truxima®, please read the Important Safety Information available at the above link.

Truxima® (rituximab): Filling concentrate for solution for infusion.

Precautionary Information: Please read the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Clear Type 1 glass vial with rubber stopper containing 100 mg of Truxima in 5 ml. Indications: Non-Hodgkin's lymphoma (NHL). Truxima is indicated for the treatment of patients with previously untreated diffuse large B-cell lymphoma in combination with chemotherapy. Truxima maintenance therapy is indicated for the treatment of follicular lymphoma in patients responding to induction therapy. Truxima monotherapy is indicated for treatment of patients with low-grade follicular lymphoma in combination with chemotherapy for patients with previously untreated diffuse large B-cell lymphoma. Truxima is indicated for the treatment of patients with CLL for the following indications: CLL in combination with chemotherapy for patients with previously untreated CLL and for combination with chemotherapy for patients with previously untreated CLL and for combination with chemotherapy and obinutuzumab for patients with previously untreated CLL.

Combination therapy: Truxima is not recommended in combination with methotrexate and is not indicated for the treatment of patients with active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs.

Clinical trials: A total of 24 clinical trials evaluating the efficacy and safety of Truxima have been conducted, including 10 Phase I studies, 7 Phase II studies, and 7 Phase III studies. The information presented in the Summary of Product Characteristics is based on data from these clinical trials.

Adverse effects: Adverse events should be reported. Reporting forms and information can be found at www.medicines.org.uk/ADRs. Adverse events should also be reported to Celgene Healthcare Limited.
Satellite Symposia

Status as of 1 May 2017

**WEDNESDAY, 14 JUNE 2017**

**Hall 8**

**AbbVie**

*Optimizing long-term therapy: How can we deliver the outcomes patients need?*

**Chairperson:**
Paul Emery (United Kingdom)

**Paul Emery (United Kingdom)** 13:00
Introduction

**Paul Emery (United Kingdom)** 13:05
The importance of detecting patients at risk of imminent RA; overcoming the obstacles

**Daniel Aletaha (Austria)** 13:20
Taking the patient from target to goal
How do we implement the most effective approach?

**Filip van den Bosch (Belgium)** 13:35
Delivering the long-term treatment aspirations of the patient and the clinician
What are the latest data?

**John Isaacs (United Kingdom)** 13:55
In a changing world, how do we select the right therapy for the long-term benefit of the patient?

**Maxime Dougados (France)** 14:10
Closing remarks and wrap-up

---

**Hall 7A**

**Pfizer**

*Time for a paradigm shift in RA? Patient and physician journeys when treatment is not to target*

**Chairperson:**
Maxime Dougados (France)

**Maxime Dougados (France)** 13:00
Welcome and introduction

**Peter C. Taylor (United Kingdom)** 13:05
Understanding the DMARD-intolerant/inadequate responder journey for patients and physicians

**All** 13:25
Question and answer session

**Roy Fleischmann (United States)** 13:30
JAK inhibition: deep dive into efficacy and safety data

**All** 13:50
Question and answer session

**Janet Pope (Canada)** 13:55
RA data in the real world

**All** 14:15
Question and answer session

**Maxime Dougados (France)** 14:20
Closing remarks and wrap-up

---

**N103/N104**

**Novartis Pharmaceuticals**

*IL-17A inhibition: meeting patient needs and achieving new treatment goals in PsA*

**Chairperson:**
Peter Nash (Australia)

**Peter Nash (Australia)** 13:00
Welcome and introduction

**Georg Schett (Germany)** 13:05
The role of IL-17A in the immunobiology of early and established PsA

**Laura Coates (United Kingdom)** 13:25
Treatment targets in PsA: the rheumatologists’ perspective

**Tore K. Kvien (Norway)** 13:45
Treatment targets in PsA: the patients’ priorities
Peter Nash (Australia) 14:00
Does IL-17A inhibition meet these treatment targets?

Peter Nash (Australia) and all 14:20
Panel discussion and conclusions

13:00 - 14:30 N105/N106

Pearls supported by Janssen

Considering patients' needs - action and reaction of IL-6 blockade

Chairpersons:
Josef S. Smolen (Austria)
Costantino Pitzalis (United Kingdom)

Costantino Pitzalis (United Kingdom) 13:00
Welcome and introduction

Josef S. Smolen (Austria) 13:05
IL-6 blockade: a clinical update

Costantino Pitzalis (United Kingdom) 13:30
The role of IL-6 in RA pathophysiology and structural damage

Ernest Choy (United Kingdom) 13:55
The biology behind patient-reported outcomes in RA

Josef S. Smolen (Austria) 14:15
Q&A, conclusions and closing remarks

THURSDAY, 15 JUNE 2017

08:15 - 09:45 Hall 6

AbbVie

Non-infectious uveitis: Beyond the joints - a vision for all

Chairperson:
James T. Rosenbaum (United States)

James T. Rosenbaum (United States) 08:15
Welcome and introduction: how do we create a vision for all?

Andrew D. Dick (United Kingdom) 08:25
A dual perspective, from fundamental science to the clinic: the uveitis specialist’s view

Athimalaipet V. Ramanan (United Kingdom) 08:40
Keeping an eye on our paediatric patients: the rheumatologist’s view

Antoine P. Brézin (France) 08:55
Near and distant vision: treatment goals in adult non-infectious uveitis

James T. Rosenbaum (United States) 09:10
Establishing the evidence base for the management of non-infectious uveitis: the importance of co-management

All 09:25
Roundtable discussion: optimizing the care of rheumatologic patients with ocular manifestations

08:15 - 09:45 Hall 8

Novartis Pharmaceuticals

IL-17A Inhibition: a paradigm shift in the management of axial spondyloarthritis

Chairperson:
Denis Poddubnyy (Germany)

Denis Poddubnyy (Germany) 08:15
Welcome and introductions

Denis Poddubnyy (Germany) 08:20
Marco Garrido-Cumbreira (Spain)
Axial spondyloarthritis: the physician versus patient perspective

Dirk Elewaut (Belgium) 08:35
Pathophysiology of axial spondyloarthritis: the role of IL-17A in inflammation, enthesitis, and new bone formation

Xenofon Baraliakos (Germany) 08:55
An update on IL-17A inhibitors in clinical trials: latest data

Atul Deodhar (United States) 09:15
Remission in axial spondyloarthritis: a realistic treatment target?

All 09:35
Panel discussion: what does this mean for our patients?
15 June 2017

**SATELLITE SYMPOSIA / THURSDAY 15 JUNE 2017 / 219**

### Lilly

**Redefining expectations for patients living with rheumatoid arthritis: the role of JAKs inhibition and baricitinib**

**Chairperson:**
José M. Álvaro-Gracia Álvaro (Spain)

- **José M. Álvaro-Gracia Álvaro (Spain)** 08:15
  Welcome and introduction

- **Paul Emery (United Kingdom)** 08:20
  Perceptions of the burden for a rheumatoid arthritis patient: is it really all about inflammation?

- **Peter Taylor (United Kingdom)** 08:35
  An unconventional journey to the center of the cell

- **Maxime Dougados (France)** 08:50
  The current evidence of the efficacy/safety profile of baricitinib in rheumatoid arthritis

- **Josef S. Smolen (Austria)** 09:05
  EULAR updated rheumatoid arthritis management recommendations: what’s new?

- **José M. Álvaro-Gracia Álvaro (Spain)** 09:20
  Panel discussion and Q&A

**Symposium close** 09:45

---

### Pfizer

**The biologic conversation: talking originators and biosimilars**

**Chairperson:**
Robert J. Moots (United Kingdom)

**Panel:**
Eduardo Mylser (Argentina)
Mark Genovese (United States)
Ronald Van Vollenhoven (the Netherlands)

- **Robert J. Moots (United Kingdom)** 08:15
  Welcome and introduction

**Talking originator biologics and biosimilars** 08:30

- How can the critical roles of the physician and patient as treatment decision makers be maintained?
- What do physicians need to know with respect to biologic and biosimilar clinical data?
- How can real-world data support decision making?
- What factors need to be considered when making switching decisions?

**Unanswered questions** 09:30

**Robert J. Moots (United Kingdom)** 09:40
Summary and close

---

### Bristol-Myers Squibb

**Role of co-stimulation in adaptive immunity and autoimmune diseases**

**Chairperson:**
Juan Gómez-Reino (Spain)

- **Juan Gómez-Reino (Spain)** 08:15
  Welcome and introduction

- **Tom Huizinga (Netherlands)** 08:17
  Co-stimulation and pathophysiologic drivers of clinical outcomes in RA

- **Georg Schett (Germany)** 08:42
  The molecular pathophysiology underlying erosive arthritis

- **Gregg Silverman (United States)** 09:07
  The impact of co-stimulation in autoimmune diseases with unmet needs

**All** 09:32
Panel discussion and Q&A

---

### medac

**Current trends and future perspectives of MTX - do you really know it all?**

**Ulf Müller-Ladner (Germany)** 08:15
Welcome and introduction

**Ulf Müller-Ladner (Germany)** 08:20
Optimizing the current RA treatment paradigm and the benefit in daily practice

**Carter Thorne (Canada)** 08:40
Implementing clinical guidelines and optimizing outcomes in RA - learning from CATCH

**Pavla Dolezalova (Czech Republic)** 09:00
Is there a place for conventional disease modifying drugs in the treatment of paediatric rheumatic diseases in biologic era?

**Jaime Calvo-Alén (Spain)** 09:20
New recommendations for the optimal use of parenteral MTX
Expanding the knowledge in **Systemic Sclerosis (SSc)**
**Interstitial Lung Disease (ILD)** with the

**SENSCIS™ Trial**

To discover more about this study please visit us at:

**BOOTH #09** or **ClinicalTrials.gov (ID:NCT02597933)**

Nintedanib is not approved for Systemic Sclerosis Associated Interstitial Lung Disease
Amgen

Biosimilars in rheumatology: are we comfortable or cautious?

Chairperson:
Thomas Dörner (Germany)

Thomas Dörner (Germany)
Welcome and introduction

Ferdinand Breedveld (the Netherlands)
Are we reassured by the current regulatory approval approach to biosimilars?

Tore K. Kvien (Norway)
Are we confident about switching to biosimilars in our patients?

Jonathan Kay (United States)
Are we comfortable with indication extrapolation of biosimilars in clinical practice?

Thomas Dörner (Germany)
Concluding comments and close

GSK

Optimising SLE disease management: a patient-centric case-based workshop

Chairperson:
Roger Levy (Brazil)

Roger Levy (Brazil)
Chairman’s welcome

Roger Levy (Brazil)
Introduction

Ioannis Parodis (Sweden)
Detailed examination of case study

Roger Levy (Brazil)
Summing up and concluding remarks

Grunenthal

Time to control gout and make it crystal clear

Chairpersons:
Fernando Perez Ruiz (Spain)
Thomas Bardin (France)
Alexander So (Switzerland)

Do you think you know gout? Time to rethink
Chairperson: Fernando Perez Ruiz (Spain)

Tillman Uhlig (Norway)
Epidemiology and pathogenesis: a common disease with genetic predisposition
17:30 - 19:00  Hall 7A

**AbbVie**

**Deep dive into SpA: the way to an integrative approach**

**Chairperson:**
Walter P. Maksymowych (Canada)

**Walter P. Maksymowych (Canada)**  17:30
Welcome and introduction - the many faces of SpA

**Ernest Seidman (Canada)**  17:40
Gut inflammation in SpA: significance and treatment implications

**Miguel Cordero-Coma (Spain)**  17:55
Integrative management of anterior uveitis in the patient with SpA

**Wolf-Henning Boehncke (Switzerland)**  18:10
The dematologist’s perspective on collaborative care in patients with PsA

**Walter P. Maksymowych (Canada)**  18:25
How can integrative management enhance the care of patients with SpA?

**All**  18:40
Participant engagement and panel response

---

17:30 - 19:00  Hall 7B

**Roche**

**A new era for giant cell arteritis**

**Chairperson:**
John H. Stone (United States)

**John H. Stone (United States)**  17:30
Opening patient video ‘Living with GCA’

**John H. Stone (United States)**  17:35
Introduction

**John H. Stone (United States)**  17:40
Future GCA treatment options

**All faculty address key topics, using slides where necessary to back up opinion**  18:00
Discussion: What do these data mean for clinical practice?

**Yara Banz (Switzerland)**  18:10
Exploring the diagnosis landscape

**Andreas Diamantopoulos (Norway)**  18:19
Harnessing innovation to guide diagnosis and management

**Georg Schett (Germany)**  18:32
Navigating the route to better outcomes for patients

**John H. Stone (United States)**  18:45
Summary: Towards a brighter horizon for GCA

**All,**  18:50
Moderated by John H. Stone (United States)
Question and answer session

---

17:30 - 19:00  N103/N104

**Celltrion Healthcare**

**Expanding the horizon of rheumatic disease treatment through compelling biosimilars**

**Chairperson:**
Tore K. Kvien (Norway)

**Tore K. Kvien (Norway)**  17:30
Perceptual evolution in the biosimilar landscape

**Tore K. Kvien (Norway)**  17:40
Another step towards evidence based switching N OR-SWITCH

**DaeHyun Yoo (Korea)**  18:00
Taking the first step with the 1st biosimilar rituximab

**Balsa Alejandro (Spain)**  18:20
A new level of evidence seen through therapeutic drug monitoring

**All**  18:40
Panel discussion

---

17:30 - 19:00  N101/N102

**Celgene**

**Translating the latest knowledge in PsA into daily practice**

**Chairperson:**
Jaime Calvo-Alén (Spain)

**Jaime Calvo-Alén (Spain)**  17:30
Introduction to the complexity of PsA

**Carlo Selmi (Italy)**  17:35
Clinical challenges of PsA in daily practice

**Kurt de Vlam (Belgium)**  18:00
Partnering with patients to guide therapy decisions

**Dennis McGonagle (England)**  18:25
Real-world clinical experience

**Question-and-answer panel**  18:45

---

17:30 - 19:00  N105/N106

**MSD**

**Shaping long-term outcomes: how to ensure durable disease control in rheumatic diseases**

**Chairperson:**
Josef S. Smolen (Austria)

**Josef S. Smolen (Austria)**  17:30
Welcome and Introductions

**Josef S. Smolen (Austria)**  17:35
Long-term management of patients with rheumatic diseases: achievements from the past and lookout for the future
Choosing the right treatment for our patients: making our first choice count

Integrating patients’ needs and therapeutic strategies

Panel discussion & Question-and-answer session

Biosimilars in rheumatoid arthritis: common questions and application to practice

Speakers:
Roy Fleischmann (United States)
Stanley Cohen (United States)
Jürgen Braun (Germany)

Introduction
Biosimilar Fundamentals
Biosimilars in RA
Individualized management - case studies
Conclusion

Optimising SLE disease management: a patient-centric case-based workshop

Chairperson:
Roger Levy (Brazil)

Roger Levy (Brazil) 17:30
Chairman’s welcome

Roger Levy (Brazil) 17:35
Introduction

Ioannis Parodis (Sweden) 17:55
Detailed examination of case study

Roger Levy (Brazil) 18:55
Summing up and concluding remarks

Breaking the fragility fracture cycle: can we step up to the challenge?

Serge Ferrari (Switzerland) 17:30
Welcome and introduction

Piet Geusens (Belgium) 17:35
Who manages patients with a recent fragility fracture?

Bente Langdahl (Denmark) 18:00
How can we do better to heed the warning of the first fragility fracture?

Stepping up to the challenge - are there learnings from rheumatoid arthritis?

Questions, summary and close

Innovations in rheumatology: where is the new frontier?

Welcome and introduction

Who manages patients with a recent fragility fracture?

Optimising outcomes for mother and baby during pregnancy

Postpartum flares and breastfeeding

Wrap-up and conclusion

Question and answer session moderated by the symposium chairperson
**Pfizer**

**Biosimilar infliximab: building a switching dialogue**

**Chairperson:**
Miguel Abad Hernández (Spain)

**Miguel Abad Hernández (Spain)** 08:15
Welcome and learning objectives

**Miguel Abad Hernández (Spain)** 08:20
The evidence for switching stable patients to biosimilar infliximab

**Silvio Danese (Italy)** 08:50
Arnold Vulto (Netherlands)
Scenario 1: Conducting the switching dialogue

**All** 09:00
Panel discussion

**Guro Goll (Norway)** 09:15
**Jorge Mestre-Ferrandiz (Spain)**
Scenario 2: Best practice considerations for switching

**All** 09:25
Panel discussion

**Miguel Abad Hernández (Spain)** 09:40
Summary and close

---

**Roche**

**From evolution to revolution in treatment of RA patients**

**Chairperson:**
José M. Álvaro-Gracia (Spain)

**José M. Álvaro-Gracia (Spain)** 08:17
Introduction

**Leslie Harrold (United States)** 08:22
What can we learn from real world data approaches with biologics?

**Moderator: José M. Álvaro-Gracia (Spain)** 08:42
**Andrea Rubbert-Roth (Germany)**
Ernest Choy (United Kingdom)
Debate: What RA treatment-related challenges do patients still face?

**David Lee (Switzerland)** 08:58
Making further advances in the treatment of RA

**José M. Álvaro-Gracia (Spain)** 09:28
Summary

**Moderated by José M. Álvaro-Gracia (Spain)** 09:33
Audience questions to the faculty
Question and answer session

---

**Biogen**

**Switching patients from originator to biosimilar medications in rheumatoid arthritis - limiting the ‘nocebo’ effect**

**Chairperson:**
Chris Edwards (United Kingdom)

**Chris Edwards (United Kingdom)** 08:15
Welcome and introduction

**Chris Edwards (United Kingdom)** 08:20
RCT extensions - what clinical trial transition data can tell

**Merete Lund Hetland (Denmark)** 08:30
DANBIO - switching insights from registries

**Lars Erik Kristensen (Denmark)** 08:40
PARKER institute research in rheumatology - ways to avoid the ‘nocebo’ effect

**Sharing best practice** 08:50
Chris Edwards (United Kingdom)
The Southampton case

**Maria Cuadrado (United Kingdom)**
The Guy’s and St Thomas’ case

**Moderated by Chris Edwards (United Kingdom)** 09:10
Q&A

**Chris Edwards (United Kingdom)** 09:40
Closing remarks

---

**Pfizer**

**The patient’s perspective on PsA: what more can rheumatologist do to optimise disease management?**

**Chairperson:**
Juan Gómez-Reino (Spain)

**Speakers:**
Juan J. Gomez-Reino (Spain)
Laure Gossec (France)
Ana-Maria Orbai (United States)

**08:15**
Welcome and Introduction

**08:25**
Understanding PsA from the patient’s perspective

**08:45**
Optimising PsA care sin clinical practice

**09:10**
Rising to the challenge: patient case studies

**09:30**
Closing remarks and wrap-up
08:15 - 09:45  N111/N112

Boehringer Ingelheim
Systemic sclerosis-associated interstitial lung disease (SSc-ILD): current and future perspectives

Chairperson:
Oliver Distler (Switzerland)

Oliver Distler (Switzerland) 08:15
Welcome and introduction

Christopher Denton (United Kingdom) 08:25
Systemic sclerosis - a journey through diagnosis and treatment

Aryeh Fischer (United States) 08:45
Can we improve the management of SSc-ILD?

Annelise Rønnow (Denmark) 09:05
A patient’s journey

All 09:20
Questions and answers

Oliver Distler (Switzerland) 09:40
Summary and close

17:30 - 19:00  Hall 7

Boehringer Ingelheim
How do we manage rheumatoid arthritis - in 2037?

Chairperson:
Leonard Calabrese (United States)

Leonard Calabrese (United States) 17:30
Introduction

Theme 1: Which new scientific technologies will have revolutionised the management of RA in the year 2037

Georg Schett (Germany) 17:45
Presentation: Upcoming advances in medical science that are relevant to the diagnosis, treatment, and prevention of RA. Focus on advances that are now at the translational stage.

Leonard Calabrese (United States) 18:00
Moderated interactive panel discussion including the question Will we still be treating RA but in new ways or will we also be preventing RA?

Theme 2: How will patients interact with physicians and other healthcare providers in 2037?

Marie Ennis-O’Connor (Ireland) 18:10
Presentation: The disruptive forces in medicine and how patient empowerment may grow through technology including the use of advanced communication technology (may also include some thoughts about wearable sensors to monitor, diagnose and prevent/treat disease).

Leonard Calabrese (United States) 18:25
Moderated interactive panel discussion including the question Will doctors or the patients monitor their disease activity and prevent complications?

Theme 3: What will be the role of life style modification in immunologic health in 2037?

Fulvio D’Acquisto (United Kingdom) 18:35
Presentation: The emotional side of rheumatic inflammatory diseases: a new venue for treatment?

Leonard Calabrese (United States) 18:45
Presentation: Similar efforts are being investigated in the areas of exercise and stress modification. This discussion will explore how our behaviour can influence our immune function, inflammatory disease states, and immunologic aging through modifying diet, exercise, and mindful spiritual health based on individualised data mining.

Leonard Calabrese (United States) 18:55
Moderated interactive panel discussion

Leonard Calabrese (United States) 19:00
Moderated panel discussion that brings the themes back to reality (including touching on resources) and closure

17:30 - 19:00  Hall 7B

AbbVie
Rheum for improvement?
The increasing role of real-world evidence in decision making

Chairperson:
Deborah Marshall (Canada)

Deborah Marshall (Canada) 17:30
What is the role of RWE in evidence based medicine?

Martin Rudwaleit (Germany) 17:50
How has RWE informed treatment recommendations and guidelines? An example from rheumatology

Denis Choquette (Canada) 18:05
What is the current value of RWE in daily clinical practice? A rheumatologist’s perspective

Wouter Bos (the Netherlands) 18:25
How can RWE contribute to transforming patient care in rheumatology?

All 18:40
Interactive panel discussion

17:30 - 19:00  N101/N102

Pearls supported by Janssen
IL-23: the common link between the joint, the gut and the skin?

Chairpersons:
Frank Bethreus (Germany)
Dennis McGonagle (United Kingdom)

Dennis McGonagle (United Kingdom) 17:30
Welcome and introduction
Frank Behrens (Germany) 17:35
Comparing IL-12/23 and anti-TNF “real-world” registry data in psoriasis and PsA

Dennis McGonagle (United Kingdom) 18:00
Immunological similarities and differences between psoriasis and PsA

Silvio Danese (Italy) 18:25
The link between the joint and the gut: a gastroenterologist’s view

Chaired by Frank Behrens (Germany) 18:45
Interactive discussion: how far does the spectrum of psoriatic disease reach?

17:30 - 19:00 N105/N106
Sandoz
Biosimilars and switching: what's your perspective?

Chairperson:
John Isaacs (United Kingdom)

John Isaacs (United Kingdom) 17:30
Welcome and introductions

Part I: Physician's perspective 17:35
John Isaacs (United Kingdom)
Clinical aspects of biosimilars and switching

Guro Løvik Goll (Norway)
The NOR-SWITCH study

Part II: Pharmacist's perspective 18:15
João Gonçalves (Portugal)
Safety and immunogenicity in switching

Part III: Patient's perspective 18:40
Ailsa Bosworth (United Kingdom)
Decision-making process in prescribing biosimilars

17:30 - 19:00 Room Retiro
Rheumatology Today
Highlights of EULAR 2017
Satellite symposium in German

Moderator:
Matthias Schneider

Speakers:
Peer M. Aries (Germany)
Xenofon Baraliakos (Germany)
Frank Behrens (Germany)
Christof Iking-Konert (Germany)
Christof Specker (Germany)
Torsten Witte (Germany)

Round table experts:
Frank Buttgereit (Germany)
Jens Gert Kuipers (Germany)
Ulf Müller-Ladner (Germany)
Andrea Rubbert-Roth (Germany)

Title of each presentation given during the symposium:
Axial spondyloarthritis
Biologica monotherapy
Collagenoses
Novelties in RA treatment
Psoriatic arthritis
Vasculitis

17:30 - 19:00 N117/N118
Samsung Bioepis
Biosimilars from patients' perspectives

Chairperson:
Josef S. Smolen (Austria)

Josef S. Smolen (Austria) 17:30
Introduction

Josef S. Smolen (Austria) 17:35
Biosimilars from A to Z

Tore K. Kvien (Norway) 17:50
Biosimilars: clinical evidence

Sofia Georgopoulou (United Kingdom) 18:05
Physicians’ role in patient-physician interactions when discussing biosimilars

Diana Skingle (United Kingdom) 18:15
A patient’s perspective on biosimilars

All speakers 18:25
Panel discussion

All speakers 18:45
Q&A session

Josef S. Smolen (Austria) 18:55
Closing

17:30 - 19:00 N111/N112
Fidia
The world has it: an international clinical in OA management

Chairperson:
Leonardo Punzi (Italy)

Leonardo Punzi (Italy)
Introduction: Welcome

Raveendhara R. Bannuru (United States)
Overview: “Is the world ready to endorse IAHA therapy in OA management?”

Y. Henrotin (Belgium)
Specific case: “HA and biomarkers: the future of personalized OA management is now”

Pascal Richette (France)
Clinical experience: “The science and experience behind hymovis clinical success”
In Rheumatoid Arthritis (RA), as IL-6 elevates, the effects go beyond the joints.  

1-3

Learn more about the role of IL-6 in RA at Booth 41. For more information, please visit www.arthritis-IL6.es*


*For Spanish healthcare professionals only.
Company Profiles

Status as of 1 May 2017

Booth N° 29A + 31 + 32

ABBVIE

1 North Waukegan Road
North Chicago, IL 60064
United States
www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs approximately 29,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Booth N° V25

AGORA

1 Kamelias str
3110, Limassol
Cyprus
www.agora-platform.eu /
www.agora-pait.com

Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since 2011. Agora aims to raise awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives.

Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as promote supportive attitudes towards RMDs and enable patients to live independently and participate fully in society.

Booth N° 20 + 21

AMERICAN COLLEGE OF RHEUMATOLOGY (ACR)

2200 Lake Boulevard, NE
Atlanta, GA 30319
United States
www.rheumatology.org

The American College of Rheumatology is a professional membership society that serves over 9,500 physicians, health professionals and scientists worldwide and is committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Stop by the ACR stand for information on:

• The Annual Meeting, November 3-8, 2017, San Diego, CA
• Educational programs and products, such as SessionSelect; the Rheumatology Image Library
• Arthritis & Rheumatology, Arthritis Care & Research, The Rheumatologists
• The benefits of membership
AMGEN

One Amgen Center Drive
Thousand Oaks, CA 91320
United States
www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

APLAR

1 Scotts Road #24-10
Shaw Centre
Singapore 228208
www.aplar.org

Established in 1963, APLAR, Asia Pacific League of Associations for Rheumatology, through IJRD and APLAR Congress, brings together rheumatologists, internists, orthopedic surgeons, clinical immunologists, physiatrists, physical and occupational therapists, paediatricians and researchers from allied disciplines on common platform to provide best forum in the region.

ARAB LEAGUE AGAINST RHEUMATISM (ARLAR)

Park Rotana Complex,
Two Four 54
P.O. BOX 77893, Abu Dhabi
United Arab Emirates
www.arlar.org

ARLAR, re-established in 2014 from the biennial meeting of Pan Arab Rheumatology, in its current iteration, has organizational roots reaching back to 1995. The goals of the ARLAR include advancing professional camaraderie, research and training to improve the health of Arabs with rheumatic diseases. The ARLAR is composed of over 500 members throughout all 22 Arab League countries. As of today, ARLAR comprises seventeen Rheumatology Associations.

Mission

ARLAR is the voice for Arab rheumatologists in the world arena as one of the top regional rheumatology leagues in patient care, research, and education. The ARLAR mission is to promote joint and bone health and care through:

- Knowledge transmission, including dissemination of research and encouragement of best practices
- Professional development and leadership in health policy

ASSOCIATION OF WOMEN IN RHEUMATOLOGY

2125 Valleygate Drive, Suite 201
28304 Fayetteville NC
United States
www.awirgroup.org

Mission statement:

To promote the science and practice of rheumatology, foster the advancement and education of women in rheumatology, and advocate access to the highest quality health care and management of patients with rheumatic diseases.

BIOGEN

Landis Gyr Strasse 3
6300 Zug
Switzerland
www.biogen.ch

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is the world’s oldest independent biotechnology company. In 2012, Biogen entered into a joint venture with Samsung Biologics to form Samsung Bioepis to develop, manufacture and market biosimilars of advanced biologics. Biogen has commercialization rights for three anti-TNF biosimilar candidates in Europe, Japan, Turkey and Russia. These therapies will be manufactured in the company’s large-scale manufacturing facility in Hillerød, Denmark, which is one of the largest in the world.

BMJ

BMA House, Tavistock Square
London WC1H 9JR
United Kingdom
www.bmj.com/company

Annals of the Rheumatic Diseases (ARD), a collaboration between EULAR and BMJ, is the #1 ranked journal in the field of rheumatology (impact factor 12.384) and the flagship in the Essential Rheumatology portfolio. It is supported by RMD Open, an Open Access journal expanding the breadth of rheumatic and musculoskeletal diseases, and Lupus Science & Medicine - the world’s first lupus specific open access journal. The package also comprises the newest edition of the EULAR Textbook on Rheumatic Diseases, the EULAR textbook on Systemic Sclerosis and the latest EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology.
### BOEHRINGER INGELHEIM

**Binger Strasse 173**  
55216 Ingelheim  
Germany  
www.boehringer-ingelheim.com

Boehringer Ingelheim is one of the 20 leading pharmaceutical companies worldwide. Its activities focus on the research, development, production and marketing of new medicines with high therapeutic value for human and veterinary medicine. The Group consists of 145 companies and employs around 47,500 people across the world. In 2015, the research-driven pharmaceutical company achieved net sales of around 14.8 billion euros. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and is family-owned to this day. The international headquarters and the company’s traditional home are based in Ingelheim am Rhein, Germany.

### BRISTOL-MYERS SQUIBB

**3401 Princeton Pike**  
Lawrenceville, NJ  
United States  
www.bms.com

Bristol-Myers Squibb is a global BioPharma company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

### BRITISH SOCIETY FOR RHEUMATOLOGY

**Bride House**  
18 - 20 Bride Lane  
London EC4Y 8EE  
United Kingdom  
www.rheumatology.org.uk

British Society for Rheumatology is the leading UK membership society for rheumatology and musculoskeletal care health professionals. We are member driven, supporting them in delivering the best care, at all stages of the care pathway, improving the lives of children and adults with rheumatic and musculoskeletal disease.

Visit us at stand V23 to learn more about the society, including our conferences, courses, academic journal and the benefits of membership.

Tweet us @Rheumatologyuk

### CELGENE

**86 Morris Avenue**  
Summit, New Jersey 07901  
United States  
www.celgene.com

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

### CELLTRION HEALTHCARE

**4F, 19, Academy-ro**  
51 beon-gil Yeonsu-gu  
22014 Incheon  
Republic of Korea  
www.celltrionhealthcare.com

Celltrion Healthcare is a global biopharmaceutical company which conducts worldwide marketing and distribution of Celltrion, Inc.’s biosimilars and biologics. Celltrion Healthcare endeavors to offer high-quality, cost-effective and advanced therapeutics for patients in rheumatology, gastroenterology, immunology and oncology.

Celltrion Healthcare has two products approved by EMA, Remsima®, the world’s first biosimilar mAb medication for treatment of a number of autoimmune diseases and Truxima®, the first bisimilar rituximab for treatment of lymphoma, leukemia and autoimmune diseases.

### CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

**Via Santa Maria 31**  
56126 Pisa  
Italy  
www.clinexprheumatol.org

Clinical and Experimental Rheumatology is an international journal focused on the latest developments in rheumatology. Every issue contains original articles, editorials, reviews, case reports and articles on paediatric rheumatology, aimed at updating readers in this complex and growing field.

The journal also publishes regular annual supplements on monothematic topics, facing the most new and controversial aspects in rheumatology, such as Contemporary Advances in Clinical Rheumatology, Vasculitis, Behçet’s disease and Autoinflammatory conditions, Systemic Sclerosis, Fibromyalgia.
CRESCENDO BIOSCIENCE

Crescendo Bioscience (a subsidiary of Myriad Genetics) focuses on enabling more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience’s current products are: Vectra® DA, the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity, and MyRA, a free mobile app designed to empower people living with RA to regularly track multiple aspects of their RA and easily share the information with their physician. www.Vectra-DA.com www.TrackMyRA.com

CYTORI THERAPEUTICS INC

Cytori Therapeutics Inc is developing regenerative therapies from its proprietary cell therapy platform for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products.

DNAlytics develops innovative data-driven precision medicine solutions (diagnosis, prognosis, treatment guidance) through partnerships with healthcare players such as pharmaceutical, biotechnological or In Vitro Diagnostic (IVD) companies. DNAlytics wants its solutions to have a major impact on patients, healthcare practitioners and Society as a whole. DNAlytics is a Belgian company founded in 2012 as a UCLouvain Spin-Off that bases its activities on a data mining technology platform. Aside from product (co)development, DNAlytics also proposes its expertise in the form of a data mining consultancy service. DNAlytics received various awards, namely from IBM, Microsoft, the European Commission or the MIT, both for its technology and its business model.

DS MEDICA SRL

Viale Monza 133
20125 Milan
Italy
www.dsmedica.info

Since 1979 DS Medica has been involved in project development, production, distribution and marketing of medical technologies (hardware and software) as well as in the pharmaceutical advertising.

ELI LILLY AND COMPANY

Indianapolis, IN 46285
United States
www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.
How do we manage rheumatoid arthritis - in 2037?

17:30-19:00, Friday 16 June 2017
Hall 7A, Feria de Madrid

Presentations and panel discussions on the following topics:

Which new scientific technologies will have revolutionised the management of RA in the year 2037?

How will patients interact with physicians and other healthcare providers in 2037?

What will be the role of lifestyle modification in immunologic health in 2037?

Discusants:

Chair: Leonard Calabrese
Professor of Medicine
Cleveland, OH, USA

Georg Schett
Professor of Internal Medicine
Erlangen, Germany

Marie Ennis-O'Connor
Digital Communications Strategist
Dublin, Ireland

Fulvio D'Acquisto
Professor of Immunopharmacology
London, UK

Boehringer Ingelheim
EMEUNET, the EMerging EULAR NETwork, is a EULAR network of young clinicians and researchers in rheumatology promoting education, research, widening collaborations and integrating younger members within EULAR activities. The main objectives of EMEUNET include the development of a European-wide network of young emerging rheumatologist and rheumatology-oriented researchers, enabling continued excellence in research and promoting and facilitating a comprehensive higher educational platform for all rheumatology trainees across Europe.

Esaote is a top-10 diagnostic imaging company offering innovative clinical solutions from prevention to therapy. It focuses exclusively on ultrasound and office-based MRI, boasting an extended range of products specifically tuned to rheumatology applications and able to satisfy any clinical need.

The ultrasound MyLab family boasts a complete range of rheuma-dedicated systems, from portable to premium-end products. Whilst the dedicated MRI line represents an optimal solution for excellent rheuma images with low installation requirements and costs per exam.

The EULAR Standing Committee of PARE gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for the more than 120 million people in Europe living with these conditions. The committee’s vision is of people with rheumatic and musculoskeletal diseases (RMDs) in Europe being empowered to lead full and independent lives. To achieve this, the committee organises a range of high-quality activities and programmes. Activities may include lobbying at the national level, e.g. raising awareness of the disease, defending the civil rights of people with RMDs, or having access to the latest and most appropriate treatments.

The EULAR Standing Committee of Health Professionals in Rheumatology (ESCHPR) represents nurses, physiotherapists, occupational therapists, podiatrists and psychologists/social workers in the field of rheumatology across Europe. Our main aim is to improve the standard of care for people with rheumatic and musculoskeletal diseases (RMDs), with them as active and empowered individuals. The ESCHPR collaborates across Europe to improve the quality of education and research to be implemented by health professionals in their clinical practice, and participates in activities to raise the awareness of how health professionals can contribute to the health and well-being of patients with RMDs.

EULAR Study Groups are focus groups in the sphere of one of EULARs Standing Committee who received EULAR endorsement. These groups promote activities/scientific networking under their own guidance without any financial support of EULAR. They are open for participation to anyone who is interested in the field in question and who brings background knowledge.
**Booth N° V2**

**EUROPEAN LUPUS SOCIETY**

Via G. Ripamonti, 129  
20141, Milan  
Italy  
www.sleuro.org

The European Lupus Society is a non-profit association and pursues the following goals:

- Building up a community of clinicians and researchers interested in SLE at a European and international level, with special focus to engage younger physicians in the field
- Promoting and coordinating the organisation of research and educational meetings on SLE and related syndromes
- Promoting equal access to best standard of care for SLE patients across Europe
- Facilitating research projects and clinical trials in SLE

To learn more about SLEuro, please visit us at www.sleuro.org

**Booth N° 3**

**EXPANSCIENCE**

10 Avenue de l’Arche  
92400 Courbevoie  
France  
www.expanscience.com

In 2016, Expanscience generated a turnover of €277.8 million, 54.9% of which was through exports, and employed 1044 people.

Over more than 60 years, we have built up a solid international reputation as an innovator and expert. Our products, which include two leading brands - Piasclédine 300 and Mustela - are distributed in almost 100 countries (including 14 subsidiaries).

The whole value chain is an integral part of the business - from research to production and distribution. Our CSR policy was introduced more than 10 years ago and has been recognized as exemplary by the AFAQ 26000 assessment.

**Booth N° V7**

**EYELLED – HELP POINT FOR SMARTPHONES AND MOBILES DEVICES**

Science Park 1  
66123 Saarbrücken  
Germany  
www.eyeled.de

Eyeled - the mobile IT specialists

With our knowledge and experience from more than 250 mobility projects, we offer our customers comprehensive advice, implement mobile solutions and provide long-term support for them.

On site, we offer battery recharge, support for troubleshooting smartphones and other mobile devices as well as assistance for downloading the EULAR Congress App. Visit us at booth V7 in the EULAR Village.

**Booth N° 7 + 8**

**FIDIA FARMACEUTICI**

Via Ponte della Fabbrica 3/A  
35031 Abano Terme PD  
Italy  
www.fidiapharma.com

Fidia Pharma Group is an Italian company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronan (HA) in Joint Care, Wound Care, Eye Care and Aesthetics. Over 50 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of MW. Manufacturing operations are FDA-approved, and comply international regulations and safety standards. Fidia extends its global reach through local partners in 100 countries worldwide, and wholly-owned subsidiaries in United States, Kazakhstan, Germany, Spain, Russia, Middle East, Czech and Slovak Republics.

**Booth N° V15 + V16**

**FOREUM FOUNDATION FOR RESEARCH IN RHEUMATOLOGY**

Seestrasse 240  
8802 Kilchberg  
Switzerland  
www.foreum.org

FOREUM Foundation for Research in Rheumatology is an independent non-profit organisation, devoted to promote research in rheumatic and musculoskeletal diseases (RMDs). FOREUM seeks to initiate research of the highest quality and periodically announces calls for research proposals.

FOREUM seeks to raise funds from donors sharing FOREUM's vision and goals: recognising that research and innovation in this field are crucial for improving prevention and management of RMDs and, hence, the living, working and socio-economic conditions of the more than 120 million people in Europe afflicted by RMDs.
GE HEALTHCARE

Beethovenstrasse 239
42665 Solingen
Germany
www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

GILEAD SCIENCES

333 Lakeside Drive
Foster City, CA 94404
United States
www.gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead's dedicated Research and Development team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions, including rheumatoid arthritis. With the help of dedicated clinicians who manage these conditions, we are pursuing a comprehensive clinical trial program evaluating novel agents with the goal of advancing the care of patients suffering from inflammatory and autoimmune diseases.

GRIFOLS

Av. De la Generalitat 153-150
08174 Sant Cugat
Barcelona
Spain
www.grifols.com

Grifols is a global healthcare company with more than 75-year legacy of improving people's health and well-being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products. Health commitment drives our activity organized into three divisions: Bioscience, Diagnostic, and Hospital, which develop, produce and market innovative products to medical professionals in more than 100 countries worldwide.

GRÜNENTHAL GMBH

Zieglerstrasse 6
52078 Aachen
Germany
www.grunenthal.com

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value adding products to markets.

Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,300 employees work for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of €1.2 bn.


HEEL

Dr.-Reckeweg-Str. 2-4
76532 Baden-Baden
Germany
www.heel.com

Heel is a pharmaceutical company that develops, manufactures and distributes medicines based on natural substances for a wide range of indications. The company is a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of Integrative Medicine. Traumeel and Zeel are two of the company's leading products. They will both be featured at the Heel booth.
HEMICS

Torenallee 20
5617 BC Eindhoven
Netherlands
www.hemics.com

Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics developed the Hemics® HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, perfectly fitting the workflow in the rheumatologist’s office.

HITACHI MEDICAL SYSTEMS EUROPE

Sumpfstrasse 13
6300 Zug
Switzerland
www.hitachi-medical-systems.com

We are the European headquarter of Hitachi Healthcare, a business unit of Hitachi Ltd. in Japan. Hitachi’s diagnostic imaging systems include MRI, CT, Ultrasound, Bone Densitometry and Optical Topography. Our ultrasound portfolio offers a unique combination of specialist transducers for MSK application, together with advanced modalities and analysis tools, for a non-invasive assessment of the kinetic function of ligaments, muscles, tendons, etc. and joints, or for monitoring a patient’s response to therapy. Visit our booth 46B and discover our latest developments!

IBSA INSTITUT BIOCHIMIQUE SA

Via del Piano
6915 Pambio Noranco
Switzerland
www.ibsa-international.com

IBSA is an international pharmaceutical company based in Lugano, Switzerland, active in different therapeutic areas. For OA and related syndromes, IBSA’s portfolio includes a wide range of pharmaceutical options such as pharmaceutical-grade chondroitin sulphate for oral intake (Condrosulf®, Chondrosulf®), a highly purified intra-articular hyaluronic acid of biofermentative origin (Sinovial®, Yaral®, Intragel®, Gelsyn-3™), topical and oral forms of diclofenac epolamine (Flector®) and an innovative low-dosage subcutaneous injection of diclofenac (Akis®, Dicloin®).

INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS

Gustavslundsvägen 143, 5th floor
167 51 Bromma
Sweden
www.ifpa-pso.com

The International Federation of Psoriasis Associations (IFPA) is a non-profit organization uniting national and regional psoriasis associations from around the world. As the key global psoriasis advocacy organization, IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis. People with psoriasis or psoriatic arthritis may struggle to get a correct diagnosis or adequate treatment, have limited access to care or face persistent stigma and discrimination. Since its founding in 1971, IFPA have worked to resolve these challenges facing the international psoriasis community. Our goals are to empower our members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis and cooperate with fellow stakeholders.

JANSSEN PHARMACEUTICA NV

Turnhoutseweg 30
2340 Beerse
Belgium
www.janssen-emea.com

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world.

The JCR publishes its official journal, Modern Rheumatology, which provides information on the latest developments in rheumatic diseases.

Since the founding in 1873, Konica Minolta has always focused on innovation and continuously strives to create products and services that bring real benefit to our customers’ lives. Our healthcare portfolio includes Digital Flat Panel Detectors, Integrated and Retrofit X-ray rooms, Ultrasound, CR, Laser Imagers, and Medical Film.

LCA Pharmaceutical is expert in osteoarthritis with sodium hyaluronate joint injections of high molecular weight and high concentration:

- ARTHRUM H 2%, 3 weekly intra-articular injections;
- ARTHRUM VISC 75, single injection for knee osteoarthritis;
- COXARTHROM, single injection for hip osteoarthritis;
- RHIZARTHROM for small joints injection;

Two other innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis: pain relief and joint function recovery.

- SYNOVIVUM HCS single injection;
- ARTHRUM HCS 3 weekly intra-articular injections.

LIRE stands for Spanish League Against Rheumatism. LIRE is formed of over 60 RMDs Patient Associations in Spain in order to take care of people with any of the more than 200 types of RMDs. At the same time it is part of the biggest nationals and internationals patient associations, physical and organic disability organizations, as well as chronic diseases such as EULAR, COCEMFE, General Patients’ Partnership (AGP) and Patients’ Forum (FEP).

Our goals are to improve RMDs treatments, prevention and rehabilitation, and therefore to reduce the negative impact of RMDs in Spain.
The International League of Associations for Rheumatology’s mission is to advance rheumatology in developing countries.

The ILAR Executive Committee consists of the Presidents and Presidents-Elect of ACR, EULAR, PANLAR, APLAR and AFLAR. The collaboration of the leaders of these international organizations has resulted in a renewed commitment to support programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need.

LUPUS EUROPE

St. James House
27-43 Eastern Road
RM1 3NH,
Romford, Essex
United Kingdom
www.lupus-europe.org

Since 1989, LUPUS EUROPE is the umbrella organisation federating national lupus self-help organisations all over Europe. Today it unites 26 members representing 24 countries in Europe.

Our Vision is “a fulfilling life for all people with lupus in Europe until we have reached a world without lupus”.

Our Mission is to be the voice of lupus in Europe and to empower the national organisations for people living with lupus. Since 2013, we pursue 3 fundamental Strategic Drivers:

- People with lupus in Europe participate in and benefit from research in lupus
- Enthusiasm and empowerment to member organizations.
- LUPUS EUROPE is heard & acting

MDT Int’l SA is dedicated fully to the development of medical devices based on Hyaluronic Acid in a number of specialised therapeutic areas such as orthopaedics and sports medicine (musculoskeletal).

Established in Geneva, Switzerland, since 2007, we continuously cater to the market by providing customers with a portfolio of innovative and quality patented medical devices, and we pride ourselves in being creative and proactive in new concepts and approaches.

medac Gesellschaft für klinische Spezialpräparate mbH
medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems.

Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof.

You can find further information about the company and its products at www.medac.de.

medi GmbH & Co. KG has become one of the world’s leading manufacturers of medical aids. Our orthopaedic assortment consists of supports and braces for the treatment of joint conditions and injuries for all parts of the human body such as back, shoulder/spine, hip, knee, ankle, wrist, elbow or foot. Our full range of premium-quality products are the first choice of many renowned healthcare professionals all across the globe especially for indications like osteoarthritis, osteoporosis, cruciate ligament rupture, post-operative shoulder immobilization and much else besides.
MEDICINE MATTERS – SPRINGER HEALTHCARE

236 Grays Inn Road
UK WC1X 8HB
London
United Kingdom
www.rheumatology.medicinematters.com

Medicine Matter rheumatology is provided by Springer Healthcare part of the Springer Nature group. Medicine Matters is a free to access professional rheumatology resource for healthcare professionals working with patients with rheumatology.

Guided by our Advisory Board, Medicine Matters rheumatology will:
• Be a trusted online source of daily news, medical information, and expert opinion
• Provide regularly updated, peer-reviewed content
• Serve as an access point to the foremost sources of rheumatology information on the web
• Deliver educational tools and (CME) to support professional development

MSD

2000 Galloping Hill Road
Kenilworth, NJ 07033
United States
www.msd.com

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

NOVARTIS PHARMA AG

Novartis Campus Basel
CH-4002 Basel
Switzerland
www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. www.novartis.com

NORDIC PHARMA GROUP

254, Bd Saint-Germain
75007 Paris
France
www.nordicpharmagroup.com

The Nordic Group is a privately owned, fully integrated, pharmaceutical company with a direct presence in 17 countries. Nordic’s strategy is to focus on creating Added Value for specific unmet medical needs and for the true benefit of the patient and the healthcare stakeholders. With the patient in mind, Nordic has developed products which offer more autonomy and comfort in rheumatic disease management.

OXFORD UNIVERSITY PRESS

Great Clarendon Street
Oxford, OX2 6DP
United Kingdom
www.oup.com

Oxford University Press is a leading publisher in rheumatology, publishing the official journals of the British Society for Rheumatology (BSR) and some of the most respected online resources, and books, including the Oxford Textbook of Rheumatology, the Oxford Handbook of Rheumatology, and Oxford Case Histories in Rheumatology. Visit us to enter our prize draw, pick up a free copy of Rheumatology, find out more about our exciting new journal Rheumatology Advances in Practice, and browse our extensive collection of books, available to buy with an exclusive 20% conference discount.

PAN AMERICAN LEAGUE OF ASSOCIATIONS OF RHEUMATOLOGY

2200 Lake Boulevard NE
30319 Atlanta, GA
United States
www.panlar.org

The Pan American League of Associations of Rheumatology (PANLAR), founded in 1943, gathers the scientific societies of rheumatology, health professionals related to rheumatic illnesses and rheumatic patient associations of all countries in the Americas.

The mission of PANLAR is to stimulate, promote and support research, prevention, treatment and rehabilitation of the rheumatic illnesses. The rheumatology field includes the rheumatic illnesses of the connective tissue, locomotive apparatus and musculoskeletal system.

Follow us in Facebook, Twitter and LinkedIn: #WearePanlar #YosoyPanlar
Booth N° 37+38+40B

PFIZER

Via Valbondione 113, Rome 00188 Italy
www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Booth N° 41

REGENERON

777 Old Saw Mill River Road Tarrytown, NY 10591 United States
www.regeneron.com

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Booth N° V19

RHEUMATOLOGY NEWS

7 Century Drive Parsippany NJ 07054 United States
www.rheumatologynews.com

Rheumatology News® is the leading independent newspaper for the practicing rheumatologist. Readers rely on Rheumatology News® for breaking news and insightful commentary - in a clear, concise, accessible format - that can be used daily in practice.

Rheumatology News® is published 18X/year by Frontline Medical Communications (www.FrontlineMedCom.com) and circulates to over 7,500 rheumatologists and selected primary care physicians.

All articles - researched, written, and produced by a full-time staff of professional medical journalists -can be found at www.RheumatologyNews.com.

Booth N° 39

ROCHE

Grenzacherstrasse 124 CH-4070 Basel Switzerland
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

For more information, please visit roche.com.

Booth N° V6

ROMANIAN SOCIETY OF RHEUMATOLOGY (SRR)

37-39 Ion Mihalache Blvd, St. Mary Hospital, 1st floor 011172 Bucharest Romania
www.srreumatologie.ro

Is the professional medical association that brings together all Romanian rheumatologists. SRR roots can be found in the late 70’of the last century but a modern structure was adopted after 1989 and further adjusted in 2016. From 2016, we adopted an internal structure very similar EULAR to facilitate an easier cooperation: President is Prof. Ruxandra Ionescu, the elected president is Assoc. Prof. Catalin Codreanu; we have a scientific committee, a professional committee and a council of ethics. SRR is open for cooperation with all scientific organization with similar objectives in rheumatology.
**SAMUMED LLC**

9381 Judicial Drive  
92121, San Diego, CA  
United States  
www.samumed.com

Samumed, LLC is a pharmaceutical platform company that has made groundbreaking advances in the biology of tissue regeneration. Our platform is rooted in its discoveries of new targets and biological processes in the Wnt pathway, an essential component of cellular biology of tissue regeneration. Samumed researchers are developing and testing drug therapies that regulate tissue regeneration and/or target other causes of diseases such as systemic inflammation. Samumed is currently conducting clinical trials in osteoarthritis, androgenetic alopecia, cancer and idiopathic pulmonary fibrosis.

**SANDOZ**

Industriestrasse 25  
83607 Holzkirchen  
Germany  
www.sandoz.com

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules covers all major therapeutic areas. In 2016, we had sales of USD 10.1 billion and reached well over 500 million patients – we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, Germany.

**SANOFI GENZYME**

500 Kendall Street  
Cambridge, MA 02142  
United States  
www sanofi.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

**SCANDINAVIAN JOURNAL OF RHEUMATOLOGY**

Aarhus University Hospital,  
Nørrebrogade 44  
8000 Aarhus  
Denmark  
scandjrheumatol@editorialoffice.dk  
www.scandjrheumatol.dk

The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology. Subscriptions include print, online access, and supplements to the Journal. Published since 1955 by the Scandinavian Society for Rheumatology. Detailed information is available on our website www.scandjrheumatol.dk

**TURKISH LEAGUE AGAINST RHEUMATISM**

Dumlupinar Cad.  
40/3 Dortyol Cebeci  
06100 Ankara  
Turkey  
www.tjr.org.tr

The Fight Against Rheumatism is in its 70th Year  
The first association on rheumatology in Turkey is the Turkish League Against Rheumatism (TLAR). It was established in 2 May 1947 in the same year as EULAR and it became a member of EULAR in 1947. In 1959, TLAR has organized the fourth EULAR Congress in Istanbul and it marks the first rheumatology congress in Turkey. We have 1240 members. We are honored to celebrate the 70th anniversary of our Association which has served considerably in the field of rheumatic diseases in our country, and which meticulously strives to uphold this mission. We aim to continue to serve, as we have done so to date, whilst maintaining our presence in this field.
UCB BIOPHARMA SPLR

Allée de la Recherche 60
1070 Brussels
Belgium
www.ucb.com

UCB is a global biopharmaceutical company, with a focus on neurology and immunology.

Our business is strong. Total revenue grew to €4.2 billion in 2016. We are more than 7,700 people in all four corners of the globe, inspired by patients and driven by science.

Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.

WISEPRESS MEDICAL BOOKSHOP

15 Lyon Road
Merton
London SW19 2RL
United Kingdom
marketing@wisepress.com
www.wisepress.com

Wisepress are Europe’s principal conference bookseller. We exhibit the leading books, sample journals and digital content relevant to this meeting. Books may be purchased at the booth, and we offer a postal service. Visit our online bookshop for special offers and follow us on Twitter for the latest news @WisepressBooks.

Acknowledgements

The EULAR 2017 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following partners:
VISIT BOOTH 38
FOR AN IMMERSIVE JOURNEY INTO OUR STORY

BOOTH HIGHLIGHTS INCLUDE:

• XELJANZ data and information – our booth is packed with compelling content so you can check out the big picture or study the small details

• XELJANZ augmented reality – use cutting-edge technology to explore the impact XELJANZ has on patients’ quality of life

• XELJANZ virtual reality – put on the headset to take an interactive tour of our mode of action and inhibition

• Expert videos – take a seat and get comfortable while key opinion leaders discuss the latest topics in RA.

Our booth team is waiting to meet you...

Join us at booth 38 for an experience to remember!

*This drug is centrally authorised in the EU but not yet marketed in Spain pending pricing and reimbursement approval.

Este medicamento está autorizado por procedimiento centralizado en la Unión Europea pero aún no está comercializado en España a la espera de la aprobación de precios y reembolso.
Plan - Overview

Hospitality suites
Overflow area
Mezzanine 9
Hospitality suites A09.01-A09.14

Sessions
Mezzanine 7
First aid
Hospitality suites A07.01-A07.02
Speakers preview

North convention centre

South convention centre

South Auditorium
S12-S22
Related meetings
Sessions
Prayer rooms
Catering, exhibition, posters
Cyber café @
EULAR Village
Mezzanine 10
Hospitality suites A10.11-A10.15
Related meetings A10.01-A10.10
Room Retiro

Sessions
Mezzanine 6
Hospitality suites A06.01-A06.02

Press centre
Mezzanine 4
Hospitality suite A04.02

Cloakroom
Registration area

Goya
Exhibitors’ List

Status as of 1 May 2017

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>29A+31+32</td>
</tr>
<tr>
<td>AMGEN</td>
<td>45</td>
</tr>
<tr>
<td>BIOGEN</td>
<td>64</td>
</tr>
<tr>
<td>BMJ</td>
<td>17</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>9+34</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>26+27</td>
</tr>
<tr>
<td>CELGENE</td>
<td>28+29B</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>66+67</td>
</tr>
<tr>
<td>CRESCEBIO BOSCIENCE</td>
<td>46C</td>
</tr>
<tr>
<td>CYBER</td>
<td>06</td>
</tr>
<tr>
<td>CYTIZED THERAPEUTICS INC</td>
<td>47</td>
</tr>
<tr>
<td>DNALYICS</td>
<td>15</td>
</tr>
<tr>
<td>DS MEDICA SRL</td>
<td>49</td>
</tr>
<tr>
<td>ECHOLIGHT</td>
<td>48</td>
</tr>
<tr>
<td>ELI LILLY AND COMPANY</td>
<td>01+30</td>
</tr>
<tr>
<td>ESAOTE S.P.A</td>
<td>20</td>
</tr>
<tr>
<td>EXPANSCIENCE</td>
<td>03</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>07+08</td>
</tr>
<tr>
<td>FUTURE EVENTS</td>
<td>58B</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>58C</td>
</tr>
<tr>
<td>GILEAD SCIENCES</td>
<td>61</td>
</tr>
<tr>
<td>GRÜENTHAL GMBI</td>
<td>65</td>
</tr>
<tr>
<td>GLAXOSMITHKLINE</td>
<td>23+24</td>
</tr>
<tr>
<td>HEEL</td>
<td>13+14</td>
</tr>
<tr>
<td>HEMICS</td>
<td>58A</td>
</tr>
<tr>
<td>HITACHI MEDICAL SYSTEMS EUROPE</td>
<td>46B</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE SA</td>
<td>68</td>
</tr>
<tr>
<td>JANSSEN PHARMAUETICA NV</td>
<td>43+44</td>
</tr>
<tr>
<td>KONICA MINOLTA MEDICAL &amp;</td>
<td>54</td>
</tr>
<tr>
<td>GRAPHIC IMAGING EUROPE BV</td>
<td></td>
</tr>
<tr>
<td>LA LETTRE DU RHUMATOLOGUE</td>
<td>50</td>
</tr>
<tr>
<td>LCA PHARMACEUTICAL</td>
<td>57</td>
</tr>
<tr>
<td>MDT INTL. SA</td>
<td>16</td>
</tr>
<tr>
<td>MEDAC</td>
<td>40A</td>
</tr>
<tr>
<td>MEDI GMB &amp; CO</td>
<td>22</td>
</tr>
<tr>
<td>MERCK &amp; CO, INC.</td>
<td>25</td>
</tr>
<tr>
<td>NORDIC PHARMA GROUP</td>
<td>05</td>
</tr>
<tr>
<td>NOVARTIS PHARMA AG</td>
<td>02+33+36</td>
</tr>
<tr>
<td>OXFORD UNIVERSITY PRESS</td>
<td>46E</td>
</tr>
<tr>
<td>PFIZER</td>
<td>37+38+40B</td>
</tr>
<tr>
<td>PROGENIKA (GRIFOLS)</td>
<td>46A</td>
</tr>
<tr>
<td>ROCHE</td>
<td>39</td>
</tr>
<tr>
<td>SAMUMED LLC</td>
<td>04</td>
</tr>
<tr>
<td>SANDOZ</td>
<td>35</td>
</tr>
<tr>
<td>SANOVI GENZYME</td>
<td>41</td>
</tr>
<tr>
<td>SPRINGER HEALTHCARE</td>
<td>46D</td>
</tr>
<tr>
<td>UCB BIOPHARMA SPRL</td>
<td>42</td>
</tr>
<tr>
<td>WISEPRESS MEDICAL BOOKSHOP</td>
<td>10</td>
</tr>
</tbody>
</table>

**EULAR Village Exhibitor's List**

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGORA</td>
<td>V25</td>
</tr>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY</td>
<td>V20+V21</td>
</tr>
<tr>
<td>APLAR</td>
<td>V24</td>
</tr>
<tr>
<td>ARAB LEAGUE AGAINST RHEUMATISM (ARLAR)</td>
<td>V1</td>
</tr>
<tr>
<td>ASSOCIATION OF WOMEN IN RHEUMATOLOGY</td>
<td>V12</td>
</tr>
<tr>
<td>BRITISH SOCIETY FOR RHEUMATOLOGY</td>
<td>V23</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>V4</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>E26</td>
</tr>
<tr>
<td>EULAR</td>
<td>EULAR CAMPUS</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY</td>
<td>E27</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>E29+V8</td>
</tr>
<tr>
<td>EULAR STUDY GROUPS</td>
<td>V13+V14</td>
</tr>
<tr>
<td>EUROPEAN LUPUS SOCIETY</td>
<td>V2</td>
</tr>
<tr>
<td>FORUM: FOUNDATION FOR RESEARCH IN RHEUMATOLOGY</td>
<td>V15+V16</td>
</tr>
<tr>
<td>HELP DESK FOR MOBILE DEVICES</td>
<td>V7</td>
</tr>
<tr>
<td>INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS (IFPA)</td>
<td>V3</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V22</td>
</tr>
<tr>
<td>LETTER TO EDITOR RHEUMATOLOGY</td>
<td>V18</td>
</tr>
<tr>
<td>LIGA RHEUMATOLOGICA ESPAÑOLA (LIRE)</td>
<td>V10</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V9</td>
</tr>
<tr>
<td>PAN AMERICAN LEAGUE OF ASSOCIATION OF RHEUMATOLOGY (PANLAR)</td>
<td>V11</td>
</tr>
<tr>
<td>RHEUMATOLOGY NEWS</td>
<td>V19</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF RHEUMATOLOGY (SRR)</td>
<td>V6</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>V17</td>
</tr>
<tr>
<td>TURKISH LEAGUE AGAINST RHEUMATISM</td>
<td>V5</td>
</tr>
<tr>
<td>TURKISH SOCIETY OF RHEUMATOLOGY</td>
<td>V18</td>
</tr>
</tbody>
</table>
Exhibition Plan

Status as of 1 May 2017
It’s time to shine a light on the true impact of structural damage. From how they feel, to what they can do, to how they interact with loved ones—the structural damage of rheumatoid arthritis (RA) has wide-ranging impact on the everyday lives of patients. With so much at stake, isn’t it time to expand our view of RA?1-4

EULAR Online Courses: Learn and qualify anywhere!

Shape your future with EULAR’s Online Courses:

- Regular quality control by appointed experts
- Six online courses of between one to two years duration
- Flexible learning approach - no extra or hidden costs
- Internationally recognised
- Low and middle income countries receive 25% discount

Expand your knowledge with the EULAR Textbook:

Published by leading medical publisher, BMJ, the EULAR textbooks are heavily subsidised by EULAR. Individuals in low and middle income countries qualify for a 25% discount.

Learn more at eular.org/education
Follow EULAR on Twitter and Facebook at @eular_org
WHY WE INVENT

AT MSD, WE ARE INVENTING FOR LIFE.

For more than a century, MSD has been inventing medicines and vaccines for many of the world’s most challenging diseases. We have always been and always will be inventing, and we do it for the single greatest purpose: Life.

MSD. Inventing for Life.

JOIN US IN THE MAIN EXHIBITION HALL AT BOOTH 25.

To explore our commitment to invention, visit www.msd.com and connect with us on Twitter.
WHEN MTX IS NOT ENOUGH FOR YOUR RA PATIENTS, YOU CAN PRESCRIBE XELJANZ®†1-3

RAPID AND SUSTAINED EFFICACY4-8
PROVEN IN COMBINATION THERAPY4,5 AND IN MONOTHERAPY16,7

PRESCRIBED IN MORE THAN 55,000 PATIENTS WORLDWIDE9

FOR MORE DETAILS ABOUT XELJANZ INCLUDING THE PRESCRIBING INFORMATION, PLEASE FIND US AT BOOTH 38

XELJANZ has a well-established safety profile1,8-11
XELJANZ is recommended as a treatment option after failure of csDMARDs in the 2016 EULAR recommendations for the management of RA.‡3

* This drug is centrally authorised in the EU but not yet marketed in Spain pending pricing and reimbursement approval
Este medicamento está autorizado por procedimiento centralizado en la Unión Europea pero aún no está comercializado en España a la espera de la aprobación de precios y reembolso

† XELJANZ in combination with MTX is indicated for the treatment of moderate to severe active RA in adult patients who responded inadequately to, or who are intolerant to, one or more DMARDs.
XELJANZ can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. ‡ Where poor prognostic factors are present.

SMALL PILL  BIG IMPACT4-12

This medicinal product is subject to additional monitoring, any suspected adverse reactions should be reported. / Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.